[
    {
        "text": "other drugs drug interactions have been reported with concomitant administration of ddrug0 and other medications , including ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "the coadministration of ddrug0 decreases the biologic half-life of ddrug1 because of an increase in metabolic clearance that results in a greater amount of ddrug2 in the urine .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the potential effects of increased plasma concentrations of ddrug0 or other ddrug1 metabolized via cyp3a4 { ddrug2 , ddrug3 } should be considered when coadministering these agents with ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 including coumarin derivatives , indandione derivatives , and ddrug1 such as ddrug2 { ddrug3 } , and ddrug4 may increase the risk of bleeding when administered concomitantly with ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "agents causing renin release : the antihypertensive effect of ddrug0 and ddrug1 iv is augmented by ddrug2 that cause renin release { e , g , , ddrug3 } .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "before taking ddrug0 , tell your doctor if you are taking any of the following medicines : - ddrug1 or another ddrug2 such as ddrug3 { ddrug4 } , ddrug5 { ddrug6 , others } , ddrug7 { ddrug8 } , ddrug9 { ddrug10 } , or ddrug11 { ddrug12 } ;",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug12"
            ]
        ]
    },
    {
        "text": "ddrug0 may be active in inhibiting cryptosporidium parvum growth in vitro upon combination with either ddrug1 or ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "drugs that lower seizure threshold : concurrent administration of ddrug0 and agents { e , g , , ddrug1 , other ddrug2 , ddrug3 , systemic ddrug4 , etc , } that lower seizure threshold should be undertaken only with extreme caution .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 may increase the clearance of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : coadministration of ddrug1 and ddrug2 can decrease plasma levels of ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 , ddrug2 , ddrug3 , or ddrug4 may interfere with the bactericidal effect of ddrug5 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "severe hypoglycemia has been reported in patients concomitantly receiving ddrug0 and oral ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : in vitro data indicate that ddrug1 and ddrug2 markedly inhibit the metabolism of ddrug3 which can result in an increase in plasma ddrug4 levels and prolongation of the qt interval on the ecg .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 decreases urinary excretion of ddrug1 and may enhance the magnitude and duration of their effect .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of ddrug0 such as ddrug1 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 like other ddrug2 , has been shown to affect bleeding parameters in patients receiving ddrug3 , and serious clinical bleeding has been reported .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 should be used with caution , if at all , when potent inhalational ddrug1 such as ddrug2 are employed because of potential to sensitize the myocardium to effects of ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , certain ddrug7 , ddrug8 , ddrug9 and ddrug10 , thereby delaying elimination and increasing blood levels of these drugs .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : coadministration of ddrug1 and ddrug2 resulted in a 32 % decrease in ddrug3 plasma auc and a 207 % increase in ddrug4 plasma a , c.",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "these results suggest that both ddrug0 and ddrug1 , and possibly other ddrug2 and ddrug3 , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of ddrug4 and ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "- ddrug0 or ddrug1 { with hepatotoxic potential } must not be administered together with ddrug2 or ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "interactions with other ddrug0 : significant decreases in the auc of ddrug1 { 20 % } and ddrug2 { 84 % } occurred following simultaneous administration of these agents with ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 reduces the clearance of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in vitro mixing of an ddrug0 with beta-lactamtype ddrug1 { ddrug2 or ddrug3 } may result in a significant mutual inactivation .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : in a single dose study { n = 6 } , ingestion of an ddrug1 containing # - gram of ddrug2 with 500-mg of ddrug3 increased the cmax and auc of ddrug4 by 125 % and 36 % , respectively , a number of compounds are inhibitors of cyp2c9 including ddrug5 , ddrug6 and ddrug7 .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the ddrug0 of drugs may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , the ddrug6 , ddrug7 and ddrug8 , ddrug9 and the ddrug10 , and by other ddrug11 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : the effects of ddrug1 and ddrug2 on gi bleeding are synergistic , such that users of both drugs together have a risk of serious gi bleeding higher than that of users of either drug alone .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the use of ddrug0 wwox injection in combination with ddrug1 is not recommended due to the risk of severe pulmonary toxicity .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 should not be administered concomitantly with potent ddrug1 such as ddrug2 and ddrug3 as the potential for ototoxicity is enhanced by the combination .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "- drugs whose efficacy is impaired by ddrug0 include : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , oral ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug10"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 may provoke vasoconstriction in some patients , predisposing to a greater ischemic response to ddrug2 therapy .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "coadministration of ddrug0 tablets with ddrug1 or ddrug2 has resulted in elevated plasma concentrations of the latter two drugs .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "elevated plasma levels of ddrug0 have been reported with concomitant use of some ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 / ddrug1 / ddrug2 / ddrug3 : co-administration of ddrug4 with ddrug5 , ddrug6 , ddrug7 , and ddrug8 is likely to lead to an enhancement of effects .",
        "triple_list": [
            [
                "ddrug4",
                "effect",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 } { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 } have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with ddrug6 .",
        "triple_list": [
            [
                "ddrug4",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "synergism between ddrug0 { e , g , , ddrug1 } , ddrug2 , and other ddrug3 has been reported .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "concomitant treatment with ddrug0 { ddrug1 , ddrug2 } , ddrug3 , or ddrug4 may potentiate any hypokalemic effect of ddrug5 .",
        "triple_list": [
            [
                "ddrug4",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 , ddrug2 , and possibly ddrug3 } : concomitant administration with ddrug4 may increase the risk of gastrointestinal ulceration .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "therefore , co-administration of ddrug0 with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index , including certain ddrug1 { ddrug2 -lsb- ddrug3 -rsb- , such as ddrug4 , ddrug5 , and ddrug6 } , ddrug7 and ddrug8 { e , g , , ddrug9 , ddrug10 } , should be approached with caution .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "avoid the concomitant use of ddrug0 and ddrug1 { ddrug2 } .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the use of ddrug0 may result in additive cns depressant effects when coadministered with ddrug1 , ddrug2 , ddrug3 or other drugs that produce cns depression .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : when coadministered with ddrug1 , ddrug2 , a drug which increases gastrointestinal motility , lowers the serum concentration and urinary excretion of ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "-lsb- the gaba-ergic system and brain edema -rsb- it has been shown in rats with experimental toxic and traumatic edemas that ddrug0 { 1 mg/kg } removes the antiedematous action of ddrug1 , ddrug2 , ddrug3 and ddrug4 and reduces the action of ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "when used in therapeutic doses , ddrug0 had a modest effect on the pharmacokinetics of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { intravenous and oral } , ddrug12 , ddrug13 / ddrug14 or ddrug15 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug11"
            ]
        ]
    },
    {
        "text": "although there was no effect of ddrug0 on the plasma auc of ddrug1 or ddrug2 determined on day 3 , there was a 34 % decrease in ddrug3 { a cyp2c9 substrate } trough concentration accompanied by a 14 % decrease in the prothrombin time { reported as international normalized ratio or inr } # days after completion of dosing with ddrug4 .",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug15"
            ]
        ]
    },
    {
        "text": "co-administration of ddrug0 and ddrug1 or other agents interfering with neuromuscular transmission { e , g , , ddrug2 } should only be performed with caution as the effect of the ddrug3 may be potentiated .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "after multiple dosing , ddrug0 { ddrug1 # mcg im once weekly } reduced ddrug2 clearance by approximately 30 % .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "therefore , it is theoretically possible that ddrug0 may interfere with the absorption of drugs where gastric ph is an important determinant of bioavailability { e , g , ddrug1 , ddrug2 esters , ddrug3 salts , ddrug4 } .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "nonetheless , individual patients may require additional titration of their ddrug0 dosage when ddrug1 is started or stopped to ensure clinically effective blood levels .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "epidemiological studies of the case-control and cohort design that have demonstrated an association between use of ddrug0 that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an ddrug1 or ddrug2 potentiated the risk of bleeding .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 may exacerbate the rebound hypertension which can follow the withdrawal of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 and other ddrug1 can reduce the antihypertensive effect of ddrug2 and other ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 , and ddrug2 : drugs such as ddrug3 , ddrug4 , and ddrug5 may increase the risk of developing peripheral_neuropathies or other ddrug6 - associated adverse events by interfering with the renal clearance of ddrug7 { thereby raising systemic exposure } .",
        "triple_list": [
            [
                "ddrug4",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug10"
            ]
        ]
    },
    {
        "text": "consequently , concomitant administration of ddrug0 with strong cyp3a4 inhibitors { e , g , , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } should be approached with caution .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 salts may reduce the bioavailability of ddrug1 and ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in normal volunteers receiving ddrug0 , the administration of ddrug1 decreased the renal clearance and significantly increased the plasma levels of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "data from in vitro studies of ddrug0 suggest a possible drug interaction with ddrug1 for the following : ddrug2 and ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "int",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "reports suggest that ddrug0 may diminish the antihypertensive effect of ddrug1 , including ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : in vitro and/or in vivo data show that ddrug1 , ddrug2 , and ddrug3 markedly inhibit the metabolism of ddrug4 , which can result in an increase in plasma ddrug5 levels and prolongation of the qt interval on the ecg .",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose ddrug0 and ddrug1 , specifically , ddrug2 , ddrug3 , ddrug4 and ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "use of ddrug0 with ddrug1 { e , g , , ddrug2 , ddrug3 , or ddrug4 } , ddrug5 supplements , or potassium-containing salt substitutes may lead to significant increases in serum potassium .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "literature reports suggest that oral ddrug0 may be used in combination with ddrug1 when heart function is normal , but should be avoided in patients with impaired cardiac function .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "as with some other ddrug0 , the time of onset of neuromuscular block induced by ddrug1 is lengthened and the duration of block is shortened in patients receiving ddrug2 or ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 reversible increases in serum ddrug1 concentrations and toxicity have been reported during concomitant administration of ddrug2 with ddrug3 , and with some ddrug4 .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "these results suggest that both ddrug0 and ddrug1 , and possibly other ddrug2 and ddrug3 , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of ddrug4 and ddrug5 .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "the antihypertensive effects of ddrug0 , ddrug1 , ddrug2 , and ddrug3 may be reduced by ddrug4 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug27"
            ]
        ]
    },
    {
        "text": "there have been reports of interactions of ddrug0 with ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug10"
            ]
        ]
    },
    {
        "text": "ddrug0 : administration of ddrug1 concomitantly with ddrug2 has been associated with an increase in ddrug3 - induced toxicity , possibly due to decreased synthesis of renal prostacyclin .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 should not be used concomitantly with other drugs known to prolong the qt interval : certain ddrug1 , including those of class ia { such as ddrug2 and ddrug3 } and class iii { such as ddrug4 } ;",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "this antagonistic effect of ddrug0 on ddrug1 natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "therefore , the potential exists for a drug interaction between ddrug0 and drugs that affect the cyp2b6 isoenzyme { e , g , , ddrug1 and ddrug2 } .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : as with other ddrug1 , ddrug2 inhibits the renal excretion of ddrug3 , resulting in an approximate doubling in a , c , a 54 % increase in peak ddrug4 plasma levels , and a 50 % prolongation in the apparent elimination half-life .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 given concomitantly with ddrug1 has been reported to increase the serum concentration and prolong the half-life of ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 } : increase the metabolism of ddrug6 and/or some ddrug7 , leading to possible decrease in contraceptive effectiveness .",
        "triple_list": [
            [
                "ddrug5",
                "mechanism",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "therefore , if ddrug0 is co-administered with ddrug1 , its dose should be reduced to one third of the usual daily maintenance dose and plasma concentrations of ddrug2 should to monitored .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in addition , most ddrug0 are contraindicated in patients receiving ddrug1 therapy who have pre-existing cardiac abnormalities { arrhythmia , bradycardia , qt c interval prolongation , ischemic heart disease , congestive heart failure , etc , } or electrolyte disturbances .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 , a ddrug1 , may antagonize the bactercidal effect of ddrug2 and concurrent use of these drugs should be avoided .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 may have additive effects with ddrug1 and other ddrug2 , e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 / ddrug1 : the coadministration of ddrug2 or ddrug3 will not affect plasma concentrations of ddrug4 , but may reduce endogenous plasma levels of ddrug5 / ergocalcitriol by accelerating metabolism .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 : a relationship of functional antagonism exists between ddrug1 analogues , which promote calcium absorption , and ddrug2 , which inhibit calcium absorption .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "interactions for ddrug0 { ddrug1 , ddrug2 , ddrug3 , and ddrug4 } : ddrug5 : ddrug6 has been reported to reduce intestinal absorption of ddrug7 ;",
        "triple_list": [
            [
                "ddrug6",
                "mechanism",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "ddrug0 : clinical studies , as well as post-marketing observations , have shown that ddrug1 can reduce the natriuretic effect of ddrug2 and ddrug3 in some patients .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "in patients with mild to moderate hypertension , administration of # mg daily of ddrug0 with the ddrug1 ddrug2 , # to # mg for # weeks , was associated with an average increase in mean arterial pressure of about # mm hg compared to ddrug3 alone .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the actions of the ddrug0 may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 or other ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "some ddrug0 , including ddrug1 , have also been shown to interfere with the metabolism of ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "delayed adverse reactions to ddrug0 : a review of the literature revealed that # % { range 11-28 % } of # patients treated with various ddrug1 containing regimens who were subsequently administered ddrug2 experienced acute , atypical adverse reactions .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "concurrent administration of drugs possessing nephrotoxic { e , g , , ddrug0 , ddrug1 } , myelotoxic { e , g , , ddrug2 chemotherapy } , cardiotoxic { e , g , , ddrug3 } or hepatotoxic { e , g , , ddrug4 , ddrug5 } effects with ddrug6 may increase toxicity in these organ systems .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 { 2 } , ddrug7 , ddrug8 , and ddrug9 thus , if a patient has been titrated to a stable dosage on ddrug10 , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for ddrug11 may be necessary .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 should be avoided by patients with a history of serious reaction to any ddrug1 , including ddrug2 and ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "a potential interaction between oral ddrug0 and oral ddrug1 leading to severe hypoglycemia has been reported .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "coadministration of ddrug0 and ddrug1 as compared to a non-matched historicalcontrol group resulted in a 30 % , 27 % , and 25 % decrease in serum ddrug2 auc , cmax , andcmin , respectively .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "patients who are applying ddrug0 gel should not concurrently use products that contain ddrug1 { n , ddrug2 } , a common component of insect repellent products .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 should be taken at least # minutes before any oral medications containing multivalent cations { including ddrug1 , supplements or ddrug2 } .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 { e , g , , ddrug1 , ddrug2 , ddrug3 , ddrug4 , etc , } : in vitro and animal studies with the combination of ddrug5 and ddrug6 suggest that ddrug7 may induce fungal resistance to ddrug8 .",
        "triple_list": [
            [
                "ddrug7",
                "effect",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "ddrug0 { eg , ddrug1 } and other drugs , including ether , ddrug2 , ddrug3 , ddrug4 and ddrug5 , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with ddrug6 parenteral .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "the oral bioavailability of ddrug0 is reduced by 60 % with coadministration of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "although there was a slight reduction in blood sugar concentrations during concomitant administration of ddrug0 and ddrug1 , there were no signs or symptoms of hypoglycemia .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 prolong and intensify the anticholinergic effects of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : based on reports of profound hypotension and loss of consciousness when ddrug1 was administered with ddrug2 , the concomitant use of ddrug3 with drugs of the ddrug4 { including , for example , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 } is contraindicated .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 { e , g , , ddrug1 } and ddrug2 containing carbohydrate-splitting enzymes { e , g , , ddrug3 , ddrug4 } may reduce the effect of ddrug5 and should not be taken concomitantly .",
        "triple_list": [
            [
                "ddrug4",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 : as with other ddrug1 , co-administration of ddrug2 with ddrug3 resulted in an increase in the plasma exposure of ddrug4 , with a 49 % increase in mean cmax , a 122 % increase in mean auc , and a 53 % increase in half-life .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 / ddrug1 : ddrug2 inhibits the enzymatic oxidation of ddrug3 and ddrug4 to ddrug5 .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "in patients receiving nonselective ddrug0 { ddrug1 } { e , g , , ddrug2 } in combination with ddrug3 { e , g , , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 } , there have been reports of serious , sometimes fatal , reactions .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 : studies in normal volunteers have shown that ddrug1 like other ddrug2 , can interfere with the effects of ddrug3 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 prolong and intensify the anticholinergic effects of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : coadministration of ddrug1 and ddrug2 resulted in an 82 % decrease in ddrug3 plasma a , c.",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "exert particular caution in combining ddrug0 with other ddrug1 { ddrug2 and ddrug3 } : particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 supplements , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "co-administration of ddrug0 reduced ddrug1 cmax up to 50 % after multiple dosing .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : coadministration of ddrug1 { using an experimental soft-gelatin capsule formulation of ddrug2 1200mg } with ddrug3 resulted in an 18 % increase in ddrug4 plasma auc and a 4-fold increase in ddrug5 plasma a , c.",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "concomitant use of ddrug0 and drugs that inhibit cyp3a4 { eg , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 } may increase exposure to ddrug12 and should be avoided .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "also , concomitant administration of ddrug0 with products containing ddrug1 , ddrug2 containing ddrug3 , or ddrug4 { ddrug5 } chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "use with ddrug0 : the use of ddrug1 to control hypertension in patients on ddrug2 has been reported to induce severe leukopenia .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the doses of ddrug0 required to antagonize the effects of ddrug1 were more than # times higher than those required to antagonize the effects of ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 have been reported to cause a significant decrease in ddrug2 clearance .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the concurrent use of two or more drugs with anticholinergic activity -- such as an ddrug0 { eg , ddrug1 } , an ddrug2 { eg , ddrug3 } , and/or a ddrug4 { eg , ddrug5 } -- commonly results in excessive anticholinergic effects , including dry mouth and associated dental complications , blurred vision , and , in patients exposed to high temperature and humidity , hyperpyrexia .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 : may increase ppig metabolism of ddrug1 leading to possible decrease in contraceptive effectiveness .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 may enhance the effects of : other ddrug3 s , ddrug4 , general ddrug5 , ddrug6 such as ddrug7 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 , ddrug2 , etc , } increase the concentration of the ionized species of the ddrug3 molecule , thereby increasing urinary excretion .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "based on the chemical resemblance of ddrug0 and ddrug1 , coadministration of ddrug2 with ddrug3 is contraindicated .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : elevated serum levels of ddrug1 have been reported with concomitant use of ddrug2 with other members of the ddrug3 .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 , porpranolol , ddrug2 } may exacerbate rebound hypertension when ddrug3 is withdrawn .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "drug interactions with ddrug0 administration of # mg of ddrug1 { 2 x # mg capsule } within # minutes of an ddrug2 and ddrug3 containing ddrug4 { ddrug5 } decreased ddrug6 auc by 41 % and cmax by 43 % .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "based on adult data , lower doses of ddrug0 may be needed following coadministration of drugs which are reported to decrease ddrug1 elimination { e , g , , ddrug2 and ddrug3 } and higher ddrug4 doses may be needed following coadministration of drugs that increase ddrug5 elimination { e , g , , ddrug6 and ddrug7 } .",
        "triple_list": [
            [
                "ddrug4",
                "advise",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "the consumption of ddrug0 during treatment with ddrug1 should be minimized or avoided { also see a href = bupropz_od , htm #ci contraindications }",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "coadministration of ddrug0 and strong cyp3a4 inhibitors , such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , and ddrug5 has not been evaluated but should be undertaken with caution because of similar potential drug interactions .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "administration of ddrug0 with ddrug1 in # healthy male subjects increased plasma ddrug2 concentrations approximately 20 % .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "therefore , co-administration of ddrug0 with other drugs that are metabolized by this isoenzyme , including other ddrug1 , ddrug2 , ddrug3 , and ddrug4 { eg , ddrug5 , ddrug6 , and ddrug7 } , or that inhibit this enzyme { eg , ddrug8 } , should be approached with caution .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "a two-way interaction between the ddrug0 , ddrug1 , and the ddrug2 s has been suggested .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 is contraindicated in patients using ddrug1 or who may need to use ddrug2 , because the combination may cause a sharp fall of the blood pressure .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "hepatic enzyme inducers , inhibitors and substrates : drugs which induce cytochrome p450 3a4 { cyp 3a4 } enzyme activity { e , g , , ddrug0 , ddrug1 , ddrug2 , ddrug3 } may enhance the metabolism of ddrug4 and require that the dosage of the ddrug5 be increased .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "tablets , injection , and oral solution one study in six subjects demonstrated that the combination of ddrug0 and ddrug1 temporarily reduced creatinine clearance in patients with chronic renal insufficiency .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "a rare , but serious , constellation of symptoms , termed serotonin syndrome , has been reported with the concomitant use of ddrug0 { ddrug1 } and agents for migraine therapy , such as ddrug2 { ddrug3 } and ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 : clinical studies , as well as post-marketing observations , have shown that ddrug1 can reduce the natriuretic effect of ddrug2 and ddrug3 in some patients .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of ddrug0 such as ddrug1 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "data from in vitro studies of ddrug0 other than ddrug1 suggest a possible drug interaction for the following : ddrug2 , ddrug3 , ddrug4 , ddrug5 , and ddrug6 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 can interact with ddrug1 or other ddrug2 { may potentiate the cns depressant effects of either these medications or ddrug3 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and ddrug6 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "although trough ddrug0 plasma levels were unaffected , given the enzyme-inducing properties of ddrug1 , the possibility that ddrug2 might increase the clearance of ddrug3 should be considered if the two drugs are coadministered .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "when ddrug0 are given to patients receiving ddrug1 , hypertensive reactions , including hypertensive crises , may occur .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the hypoglycemic action of ddrug0 may be potentiated by certain drugs including ddrug1 and other drugs that are highly protein bound , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , and ddrug8 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "our data suggest that ddrug0 significantly potentiates the reduction in cell number induced by ddrug1 alone .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "therefore , ddrug0 may interfere with the absorption of drugs where gastric ph is an important determinant of bioavailability { eg , ddrug1 , ddrug2 salts and ddrug3 } .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "in vivo studies : ddrug0 : the blood pressure lowering effects of sublingual ddrug1 { # mg } taken # and # hours after ddrug2 and increases in heart rate when taken at 1 , # and # hours were potentiated by a # mg dose of ddrug3 in healthy middle-aged subjects .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "abased on reports of narcotic withdrawal syndrome in patients treated with ddrug0 and ddrug1 concurrently , and evidence of decreased plasma concentrations of ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "high-dose ddrug0 resulting in concentrations above # ng/ml administered with oral ddrug1 has led to an 80 % increase in ddrug2 exposure with a 38 % decrease in total body clearance of ddrug3 compared to ddrug4 alone .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "agents with increased levels in the presence of ddrug0 : ddrug1 increases the plasma levels of the following agents : ddrug2 , ddrug3 { 6 } , and ddrug4 thus , if a patient has been titrated to a stable dosage on one of the agents in this category , and then begins a course of the treatment with ddrug5 , it is reasonable to expect that a dose decrease for the concomitant agent may be necessary .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "cyclosporine , digoxin , methotrexate ddrug0 , like other ddrug1 , through effects on renal prostaglandins , may cause changes in the elimination of these drugs leading to elevated serum levels of ddrug2 , ddrug3 , ddrug4 , and increased toxicity .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 should not be used together with ddrug1 { ddrug2 , ddrug3 } , another arthritis medication .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "presumably , ddrug0 acts as a stimulator of ddrug1 metabolism and has been reported to cause decreased serum levels of the ddrug2 and increased prothrombin-proconvertin concentrations .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "as with other ddrug0 , it should be noted that ddrug1 may be capable of potentiating ddrug2 such as ddrug3 , ddrug4 , and ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : in some patients , the administration of a ddrug1 can reduce the diuretic , natriuretic , and antihypertensive effects of ddrug2 , ddrug3 and ddrug4 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "therefore , cyp3a4 substrates known to have a narrow therapeutic index such as ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , or ddrug10 { ddrug11 , ddrug12 } should be administered with caution in patients receiving ddrug13 .",
        "triple_list": [
            [
                "ddrug3",
                "advise",
                "ddrug13"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 , and ddrug2 may decrease ddrug3 plasma levels , resulting in a decrease in effectiveness of a previously effective ddrug4 dose .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "the action of the ddrug0 may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , or other drugs that produce cns depression .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 supplements , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug11"
            ]
        ]
    },
    {
        "text": "in some patients , the administration of a ddrug0 can reduce the diuretic , natriuretic , and antihypertensive effects of ddrug1 , ddrug2 and ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "- the action of ddrug0 and ddrug1 may be enhanced by ddrug2 or ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "therefore , co-administration of ddrug0 with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index , including certain ddrug1 { ddrug2 -lsb- ddrug3 -rsb- , such as ddrug4 , ddrug5 , and ddrug6 } , ddrug7 and ddrug8 { e , g , , ddrug9 , ddrug10 } , should be approached with caution .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "total body clearance of ddrug0 was reduced by an average 22 % and 51 % when ddrug1 and ddrug2 , respectively , were added to a regimen consisting of ddrug3 , usp { modified } and ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : coadministration of a single dose of ddrug1 and ddrug2 { 10 and # mg , respectively } resulted in a 15 % decrease in maximal plasma concentrations of ddrug3 , but no change in the area under the plasma concentration-time curve .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 should not be administered concomitantly with ddrug1 , ddrug2 , ddrug3 , ddrug4 , or ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : the concomitant use of ddrug1 { ddrug2 transdermal system } with other ddrug3 , including but not limited to other ddrug4 , ddrug5 , ddrug6 , ddrug7 { e , g , , ddrug8 } , general ddrug9 , ddrug10 , ddrug11 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug11"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 may delay intestinal absorption of ddrug2 ;",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "reciprocal interactions may occur with concomitant use of ddrug0 and drugs that increase or inhibit the cytochrome cyp2b6 system { e , g , , ddrug1 , ddrug2 , ddrug3 , ddrug4 } , though this has not been studied",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 should not be used concomitantly with other ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 / ddrug1 / ddrug2 / ddrug3 : co-administration of ddrug4 with ddrug5 , ddrug6 , ddrug7 , and ddrug8 is likely to lead to an enhancement of effects .",
        "triple_list": [
            [
                "ddrug4",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as ddrug0 include certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 } , ddrug10 salts , ddrug11 , local ddrug12 , ddrug13 , and ddrug14 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "the concomitant use of transdermal ddrug0 with ddrug1 or other potent 3a4 inhibitors such as ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and nefazadone may result in an increase in ddrug7 plasma concentrations .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "the hypoglycemic action of ddrug0 may be potentiated by certain drugs including ddrug1 and other drugs that are highly protein bound , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , and ddrug8 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 may delay intestinal absorption of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 causes increase { by about 80 % } in the free fraction of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "in addition to bleeding associated with ddrug0 and ddrug1 , drugs that alter platelet function { such as ddrug2 , ddrug3 and ddrug4 } may increase the risk of bleeding if administered prior to , during , or after ddrug5 therapy .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 augments the action of ddrug1 s and the muscle relaxant effects of ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug42"
            ]
        ]
    },
    {
        "text": "in these patients whose hypertension was controlled with ddrug0 , ddrug1 # mg produced mean additional supine systolic/diastolic blood pressure reductions of 6/5 mm hg compared to placebo .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the concurrent use of two or more drugs with anticholinergic activity -- such as an ddrug0 { eg , ddrug1 } , an ddrug2 { eg , ddrug3 } , and/or a ddrug4 { eg , ddrug5 } -- commonly results in excessive anticholinergic effects , including dry mouth and associated dental complications , blurred vision , and , in patients exposed to high temperature and humidity , hyperpyrexia .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "in patients taking an ddrug0 { eg , ddrug1 , ddrug2 , ddrug3 or ddrug4 } , the concomitant use of ddrug5 may reduce seizure control by lowering the plasma levels of the ddrug6 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "however , high doses of ddrug0 may reduce the efficacy of intrathecally administered ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "human pharmacokinetic data indicate that oral ddrug0 markedly inhibits the metabolism of ddrug1 , resulting in a mean eight-fold increase in auc of ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 , as with other ddrug1 , should be administered with extreme caution to patients being treated with ddrug2 , ddrug3 , or drugs known to prolong the qtc interval because the action of ddrug4 on the cardiovascular system may be potentiated by these agents .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "this interaction should be given consideration in patients taking ddrug0 concomitantly with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "oral ddrug0 may be less effective while you are taking ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the administration of local ddrug0 containing ddrug1 or ddrug2 to patients receiving ddrug3 or ddrug4 may produce severe , prolonged hypertension .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit ddrug0 binding to serum proteins or alter the concentrations of serum binding proteins : ddrug1 and related ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug12"
            ]
        ]
    },
    {
        "text": "ddrug0 : combination ddrug1 may increase the clearance of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "potential for reduction in ddrug0 and/or ddrug1 plasma levels ;",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "suppression by ddrug0 of ddrug1 - enhanced peritoneal metastasis of intestinal adenocarcinomas induced by ddrug2 in wistar rats .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "other drugs drug interactions have been reported with concomitant administration of ddrug0 and other medications , including ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the use of ddrug0 or ddrug1 with ddrug2 preparations may increase the effect of either the ddrug3 or ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "in addition , deaths have been reported rarely with concomitant administration of ddrug0 and ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : ddrug1 ; ddrug2 ; ddrug3 ; certain ddrug4 , especially the ddrug5 and ddrug6 ; ddrug7 ; ddrug8 salts ; ddrug9 ; and ddrug10 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "although the magnitude of changes in ddrug0 plasma exposure when coadministered with ddrug1 were not sufficient to warrant dosage adjustments , patients may experience enhanced sedative side effects caused by increased exposure of ddrug2 under this circumstance .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : in vitro data indicate that ddrug1 and ddrug2 markedly inhibit the metabolism of ddrug3 which can result in an increase in plasma ddrug4 levels and prolongation of the qt interval on the ecg .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug10"
            ]
        ]
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug14"
            ]
        ]
    },
    {
        "text": "ddrug0 or ddrug1 increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered ddrug2 , such as ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "drugs that may alter ddrug0 plasma concentrations drugs that may increase ddrug1 plasma concentrations : caution is recommended when administering ddrug2 with inhibitors of the cyp3a4 family { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 } .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 diminishes the effect of ddrug1 and ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may enhance the effects of ddrug1 , ddrug2 , and other ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 should not be used together with ddrug1 { ddrug2 , ddrug3 } , another arthritis medication .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "synergism was observed when ddrug0 was combined with ddrug1 against bacillus subtilis and klebsiella oxytoca .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug12"
            ]
        ]
    },
    {
        "text": "a potential interaction between oral ddrug0 and oral ddrug1 leading to severe hypoglycemia has been reported .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : coadministration { n = 18 } of ddrug1 capsules { 250 mg } with ddrug2 { 125 mg } appears to increase the amount of ddrug3 absorbed by 12 % to 15 % .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 : ddrug2 , when given as a regimen of 125mg with ddrug3 coadministered orally as # mg on day 1 , and ddrug4 when given as # mg/day with ddrug5 coadministered orally as # mg on days # through 5 , increased the auc of ddrug6 , a cyp3a4 substrate by # - fold , on days # and 5 .",
        "triple_list": [
            [
                "ddrug4",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "administration of ddrug0 with other cyp3a4 inhibitors { e , g , , ddrug1 # mg bid , ddrug2 # mg qd , ddrug3 # mg tid , ddrug4 # mg qd } resulted in increases in cmax of ddrug5 ranging from # - to # - fold and auc from # - to # - fold .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "administration of ddrug0 may potentiate ddrug1 - induced neuromuscular block .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 { 2 } , ddrug7 , ddrug8 , and ddrug9 thus , if a patient has been titrated to a stable dosage on ddrug10 , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for ddrug11 may be necessary .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "therefore , use of ddrug0 in combination with ddrug1 is not recommended",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "organic ddrug0 - ddrug1 supplements theoretically may potentiate the effects of organic ddrug2 if taken concomitantly .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "- drugs whose efficacy is impaired by ddrug0 include : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , oral ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "there have been reports of interactions of ddrug0 with ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "dosage adjustment of ddrug0 may be necessary when coadministered with cyp2d6 inhibitors , e , g , , ddrug1 , ddrug2 , and ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 may delay intestinal absorption of ddrug2 ;",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "because of the pronounced intersubject variability in the extent of the ddrug0 - ddrug1 interaction , whole blood ddrug2 concentrations should be monitored closely in patients treated with the two drugs .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "patients receiving other ddrug0 , ddrug1 , ddrug2 , or other ddrug3 { including ddrug4 } concomitantly with ddrug5 and ddrug6 tablets may exhibit an additive cns depression .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "certain drugs , including ddrug0 { ddrug1 } , ddrug2 , ddrug3 , and ddrug4 may potentiate the hypoglycemic action of ddrug5 and other oral ddrug6 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 generally should not be given with ddrug1 because they reduce its renal clearance and add a high risk of lithium toxicity .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "therefore , a slower onset can be anticipated if ddrug0 is administered concomitantly with , or immediately following , a ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with ddrug1 or other ddrug2 , causing increased sedative effects .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "appropriate laboratory testing should be considered prior to initiating combination therapy with ddrug0 and ddrug1 and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "co-administration of ddrug0 resulted in about a 50 % increase in ddrug1 cmax and auc after multiple dosing .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "two of # subjects dosed simultaneously with ddrug0 # mg and ddrug1 # mg experienced a standing systolic blood pressure below # mm hg .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 inhibited ddrug1 phosphorylation at high concentration ratios { 10 and 100 } ;",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "caution should be used when administering or taking ddrug0 with ddrug1 and other strong cyp3a4 inhibitors such as , but not limited to , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { ddrug12 } , and ddrug13 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and ddrug7 raise the serum ddrug8 concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that ddrug9 intoxication may result .",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 - pectin , ddrug2 , ddrug3 , ddrug4 , certain anticancer drugs , and ddrug5 may interfere with intestinal ddrug6 absorption , resulting in unexpectedly low serum concentrations .",
        "triple_list": [
            [
                "ddrug5",
                "mechanism",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 { and possibly other ddrug2 } and ddrug3 may increase ddrug4 absorption in patients who inactivate ddrug5 by bacterial metabolism in the lower intestine , so that ddrug6 intoxication may result .",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 significantly decreases clearance of ddrug1 and ddrug2 , and the combination is poorly tolerated .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "if a ddrug0 is also used , it may increase the risk of ddrug1 toxicity .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as ddrug1 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain ddrug2 such as ddrug3 , the ddrug4 and other ddrug5 , ddrug6 , certain ddrug7 such as the ddrug8 salts , and ddrug9 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "in diabetic patients , the metabolic effects of ddrug0 may decrease blood glucose and therefore , ddrug1 requirements .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : the concomitant use of ddrug1 { ddrug2 transdermal system } with other ddrug3 , including but not limited to other ddrug4 , ddrug5 , ddrug6 , ddrug7 { e , g , , ddrug8 } , general ddrug9 , ddrug10 , ddrug11 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug10"
            ]
        ]
    },
    {
        "text": "when other ddrug0 or ddrug1 are used concomitantly , there is the potential for ddrug2 to increase the risk of bleeding .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "caution should be used when administering or taking ddrug0 with ddrug1 and other strong cyp3a4 inhibitors such as , but not limited to , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { ddrug12 } , and ddrug13 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "caution is advised when ddrug0 is coadministered with other medications that can prolong the qt interval { e , g , certain ddrug1 or ddrug2 } or lead to electrolyte abnormalities { such as ddrug3 or ddrug4 } .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "for this reason , the dose of the ddrug0 should be reduced by # - 50 % at the start of treatment with ddrug1 or ddrug2 retard and then titrated according to the blood clotting parameters",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "although specific drug interaction studies have not been conducted with ddrug0 , the possibility of an additive or potentiating effect with ddrug1 { ddrug2 , ddrug3 , ddrug4 , ddrug5 , or ddrug6 } should be considered .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 depresses tubular secretion of certain weak acids such as ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : clinical studies , as well as post-marketing observations , have shown that ddrug1 can reduce the natriuretic effect of ddrug2 and ddrug3 in some patients .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "drug interactions : ddrug0 may interact with some drugs , like ddrug1 { ddrug2 } : ddrug3 could theoretically affect ddrug4 pharmacodynamics - ddrug5 - jzqyavbxjcqsok_uhfffaoysa_n - ddrug6 : ddrug7 and ddrug8 cause additive cns depression - ddrug9 : ddrug10 increases the effect of ddrug11",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "however , other published reports describe modest elevations { less than two-fold } of ddrug0 and metabolite concentrations when ddrug1 was taken with ddrug2 , ddrug3 , and ddrug4 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 may enhance the effects of ddrug1 , ddrug2 , and other ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "since ddrug0 may raise the serum uric_acid level , dosage adjustment of ddrug1 may be necessary",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the increase of ddrug0 level , however , is small { 15 % } when given with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 administered # hours before ddrug1 resulted in a slower absorption { mean c max decreased by 30 % and mean t max increased by # hour } and a lesser extent of absorption { mean auc decreased by approximately 25 % } .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "when combined with ddrug0 , ddrug1 exhibited strong synergistic activity while only additive effects were observed with the combination of ddrug2 { or ddrug3 } and ddrug4 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "treatment with ddrug0 once weekly for # weeks in healthy subjects was associated with an inhibition of cyp2b6 1a2 and a 25 % increase in ddrug1 auc .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 , or other products containing ddrug1 or ddrug2 , ddrug3 or ddrug4 should not be administered concomitantly with , or within # hours of , the administration of ddrug5 , because they may interfere with absorption resulting in lower serum and urine levels of ddrug6 .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 : hallucinations have been reported when ddrug1 was used in patients taking ddrug2 { ddrug3 , ddrug4 , ddrug5 } .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "experience with ddrug0 { ddrug1 } suggests the potential for interactions with ddrug2 and ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "other depressasnts such as ddrug0 , ddrug1 , and ddrug2 may enhance cns depression when administered with ddrug3 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 : concomitant treatment with ddrug3 , ddrug4 , or ddrug5 may potentiate a possible hypokalemic effect of ddrug6",
        "triple_list": [
            [
                "ddrug4",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 : since ddrug1 may bind other drugs given concurrently , patients should take ddrug2 at least # hour before or 4-6 hours after a ddrug3 to avoid impeding its absorption .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "caution should be used if ddrug0 is administered concomitantly with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may enhance the nephrotoxicity of ddrug1 parenteral .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 - and/or ddrug1 - containing ddrug2 , products containing ddrug3 { ddrug4 } , ddrug5 containing ddrug6 or other metal cations , or ddrug7 { ddrug8 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after ddrug9 .",
        "triple_list": [
            [
                "ddrug3",
                "advise",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "ddrug0 should not be administered concurrently with d2-antagonists , such as ddrug1 , ddrug2 , ddrug3 , or ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in case of ddrug0 toxicity and/or elevated serum ddrug1 levels , the dose of ddrug2 should be reduced while the patient is receiving concomitant ddrug3 therapy .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 injection and potassium-depleting agents : when ddrug1 are administered concomitantly with potassium-depleting agents { e , g , , ddrug2 , ddrug3 } , patients should be observed closely for development of hypokalemia .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "oral ddrug0 may potentiate the hypoglycemic action of ddrug1 , eg , ddrug2 and ddrug3 , by inhibiting their metabolism in the liver .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "consequently , concomitant administration of ddrug0 with strong cyp3a4 inhibitors { e , g , , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } should be approached with caution .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "ddrug0 diminished binding of ddrug1 by a net change of # % { percentage increase in fdf , # % } at # micromol/l .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "therefore , co-administration of ddrug0 with drugs that are metabolized by cyp2d6 isoenzyme including certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } , ddrug8 { e , g , , ddrug9 , ddrug10 , ddrug11 } , ddrug12 { e , g , , ddrug13 } , and ddrug14 { e , g , , ddrug15 , ddrug16 } , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "ddrug0 may decrease the effectiveness of oral ddrug1 , certain ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and ddrug7 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "when ddrug0 dosing was separated from ddrug1 # mg by # hours , # of # subjects who received # mg of ddrug2 experienced a decrease in standing systolic blood pressure below # mm hg .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "serious toxicity may result if ddrug0 is coadministered with ddrug1 { ddrug2 } .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "when ddrug0 is co-administered with inducers of drug clearance , such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , or ddrug5 , use of a daily dose of # mg of ddrug6 should be considered",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the use of ddrug0 may result in additive cns depressant effects when coadministered with ddrug1 , ddrug2 , ddrug3 or other drugs that produce cns depression .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 may add to or potentiate the action of other ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "physicians are provided this information to increase awareness of the potential for serious interactions when ddrug0 and certain ddrug1 are administered concomitantly .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 causes an approximate 50 % increase in the clearance of ddrug2 at steady state and , therefore , the addition of ddrug3 results in an approximate 40 % decrease in the steady-state trough concentrations of ddrug4 as compared to the same dose of ddrug5 given as monotherapy .",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "consequently , ddrug0 should be avoided in patients receiving ddrug1 and ddrug2 , which are very potent inhibitors of cyp3a .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 potentiates the muscle relaxant effect of all ddrug1 , most notably ddrug2 , and mac { minimum alveolar concentration } is reduced by concomitant administration of n 2o .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "inhibitors of this isoenzyme { e , g , , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , grapefruit juice , ddrug7 , ddrug8 , ddrug9 , ddrug10 } should be cautiously coadministered with ddrug11 as they can potentially increase ddrug12 levels .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug11"
            ]
        ]
    },
    {
        "text": "ddrug0 : sporadic cases of seizures have been reported during concomitant use of ddrug1 and ddrug2 { ddrug3 , ddrug4 } .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 are all metabolized by the cytochrome p450iiia4 isozyme , and it has been demonstrated that ddrug3 , a potent inhibitor of iiia4 , blocks the metabolism of these drugs , resulting in increased plasma concentrations of parent drug .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 with ddrug1 or ddrug2 and possibly other ddrug3 cause striking and sustained increases in the concentration of ddrug4 in the brain ;",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "reciprocal interactions may occur with concomitant use of ddrug0 and drugs that increase or inhibit the cytochrome cyp2b6 system { e , g , , ddrug1 , ddrug2 , ddrug3 , ddrug4 } , though this has not been studied",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : use of ddrug1 with ddrug2 and other ddrug3 may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "co-medications that induce cyp 3a4 { e , g , , ddrug0 , ddrug1 , ddrug2 , ddrug3 , or st , john s wort } may significantly decrease exposure to ddrug4 .",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 absorption : the following agents may bind and decrease absorption of ddrug1 from the gastrointestinal tract : ddrug2 , ddrug3 resin , ddrug4 , ddrug5 , ddrug6 , soybean flour { e , g , , infant formula } , ddrug7 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "the ecg changes and/or hypokalemia that may result from the administration of ddrug0 { such as ddrug1 or ddrug2 } can be acutely worsened by ddrug3 , especially when the recommended dose of the ddrug4 is exceeded .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 is reported to reduce hepatic metabolism of certain ddrug1 , thereby delaying elimination and increasing steady-state concentrations of these ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "therefore , cyp3a4 substrates known to have a narrow therapeutic index such as ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , or ddrug10 { ddrug11 , ddrug12 } should be administered with caution in patients receiving ddrug13 .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug13"
            ]
        ]
    },
    {
        "text": "potentiation of the hypotensive effects of ddrug0 for patients with ischemic_heart_disease has not been evaluated , and concomitant use of ddrug1 and ddrug2 is contraindicated .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "studies showed that ddrug0 increased the auc of ddrug1 and ddrug2 by 3-4 fold and the cmax by 2-fold , compared to placebo .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose ddrug0 and ddrug1 , specifically , ddrug2 , ddrug3 , ddrug4 and ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "animal experience indicates that ddrug0 prolongs the sleeping time after ddrug1 or after ddrug2 , increases the inhibitory effects of ddrug3 , but does not exhibit maoa inhibition .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "because ddrug0 may interfere with the absorption of ddrug1 , simultaneous use of these drugs should be avoided .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in vitro studies have shown that the metabolism of ddrug0 may be modified by the concomitant administration of compounds that induce , inhibit , or are metabolized by cytochrome p450 3a4 , such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , and ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "as with other ddrug0 , it should be noted that ddrug1 may be capable of potentiating ddrug2 such as ddrug3 , ddrug4 , and ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "exogenous ddrug0 also appeared to influence the percentage of ddrug1 - induced deaths in a dose-dependent manner .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "although the interactions observed in these studies do not appear to be of major clinical importance , ddrug0 should be titrated with caution in patients being treated concurrently with ddrug1 , ddrug2 , ddrug3 or ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : combination ddrug1 may inhibit the metabolism of ddrug2 , leading to increased plasma concentrations ;",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the effects of ddrug0 are antagonized by ddrug1 such as ddrug2 and ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "there have been reports of interactions of ddrug0 with ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "limited clinical experience indicates that requirements for ddrug0 are reduced by # to 50 % for the first sixty { 60 } minutes following ddrug1 induction the concomitant use of ddrug2 with ddrug3 can significantly inhibit ddrug4 clearance and may increase the risk of prolonged or delayed respiratory depression .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "studies in humans show that the absorption of ddrug0 as reflected in urinary excretion is markedly decreased even when administered one hour before ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug13"
            ]
        ]
    },
    {
        "text": "ddrug0 : animal studies wshow that ddrug1 given with ddrug2 , including ddrug3 , yields a net decrease in anti-inflammatory activity with lowered blood levels of the non-aspirin drug .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 or ddrug1 substantially interfere with the absorption of some ddrug2 , resulting in low urine levels .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 is a competitive inhibitor of the metabolism of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "particular caution is recommended when administering ddrug0 with cyp3a4 substrates that have a narrow therapeutic window { e , g , , ddrug1 or ddrug2 } .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "on the basis of the metabolism of ddrug0 by cytochrome p450 3a4 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , grapefruit juice , and other inhibitors of cyp3a4 would be expected to lead to an increase in plasma ddrug5 concentrations .",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "it is believed that the toxicity may have resulted from a previously unrecognized interaction between ddrug0 and ddrug1 and a molecular basis for this interaction has been proposed .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : in patients with mild to moderate hypertension , administration of ddrug1 once daily , as a tablet formulation comparable to # mg of the capsule formulation , with ddrug2 # mg # times daily for # days , resulted in a 2-fold increase of ddrug3 auc and a simultaneous # - fold increase of ddrug4 auc .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "nevertheless , caution is indicated in the co-administration of ddrug0 with any of the ddrug1 and also in switching from one class to the other .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 is not recommended for use in patients who have received ddrug2 within # days because severe and unpredictable potentiation by ddrug3 has been reported with ddrug4",
        "triple_list": [
            [
                "ddrug3",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "however , it has been established that ddrug0 interferes with the contraceptive effect of microdosed ddrug1 minipill preparations .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "drugs that reduce the number of blood platelets by causing bone marrow depression { such as ddrug0 } or drugs which inhibit platelet function { eg , ddrug1 and other ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 } may increase the bleeding tendency produced by ddrug7 without altering prothrombin time determinations .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "ddrug0 produced only minor changes in the levels of ddrug1 and its metabolites .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may augment the activity of other ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "because oral ddrug0 may interfere with the hepatic metabolism of ddrug1 , toxic levels of the ddrug2 may occur when an oral ddrug3 and ddrug4 are administered concurrently .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "effects of other ddrug0 on ddrug1 ddrug2 : ddrug3 causes an approximate doubling of the clearance of ddrug4 { ddrug5 } at steady state and , therefore , the addition of ddrug6 causes an approximate 45 % decrease in the steady-state trough concentrations of ddrug7 as compared to the same dose of ddrug8 given as monotherapy .",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 may enhance the effects of : other ddrug3 s , ddrug4 , general ddrug5 , ddrug6 such as ddrug7 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "thus , concomitant administration of ddrug0 and ddrug1 should be avoided .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 preparations are incompatible with ddrug1 preparations .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 exposure was significantly decreased by ddrug1 ;",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "when ddrug0 is given to patients receiving ddrug1 , the plasma levels of ddrug2 are likely to be increased .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 { e , g , ddrug1 and ddrug2 } : agents of the ddrug3 , of which ddrug4 { ddrug5 } injection , usp is a member , have been shown to interact with ddrug6 of the ddrug7 , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "if treatment with inhibitors of cyp3a4 activity { such as ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , etc , } is indicated , reduction of the ddrug6 dose should be considered .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "other depressasnts such as ddrug0 , ddrug1 , and ddrug2 may enhance cns depression when administered with ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "in vitro studies have shown that the metabolism of ddrug0 may be modified by the concomitant administration of compounds that induce , inhibit , or are metabolized by cytochrome p450 3a4 , such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , and ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "therefore , co-administration of ddrug0 with other drugs that are metabolized by this isozyme , including ddrug1 , ddrug2 , ddrug3 , and ddrug4 { e , g , , ddrug5 , ddrug6 and ddrug7 } , or that inhibit this enzyme { e , g , , ddrug8 } , should be approached with caution .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 , by decreasing gut motility , may increase ddrug2 absorption .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 has been shown to increase plasma levels of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in ewes given # mg of ddrug0 / kg for # days intraperitoneally { ip } , the anticholinesterase effect of # mg of ddrug1 / kg was significantly reduced and signs of toxicity were not present .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "certain drugs , including ddrug0 { ddrug1 } , ddrug2 , ddrug3 , and ddrug4 may potentiate the hypoglycemic action of ddrug5 and other oral ddrug6 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 may antagonize the effects of the drugs that alter gastrointestinal motility , such as ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "antagonism between ddrug0 and ddrug1 in vitro has been demonstrated .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "interactions with other cns agents : concurrent use of ddrug0 with all ddrug1 { eg , ddrug2 , ddrug3 , ddrug4 , other ddrug5 , general ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 and ddrug12 } may result in additive central nervous system depressant effects .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 reduce the renal clearance of ddrug1 and add a high risk of ddrug2 toxicity .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 / ddrug1 : ddrug2 inhibits the enzymatic oxidation of ddrug3 and ddrug4 to ddrug5 .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "patients receiving other ddrug0 , ddrug1 , ddrug2 , or other ddrug3 { including ddrug4 } concomitantly with ddrug5 and ddrug6 tablets may exhibit an additive cns depression .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving ddrug0 metabolized similarly to ddrug1 or on the basis of in vitro studies with ddrug2 or other ddrug3 { caution is recommended during coadministration with ddrug4 } : available data from clinical studies of ddrug5 other than ddrug6 suggest a possible drug interaction with ddrug7 for the following : ddrug8 , ddrug9 , ddrug10 such as ddrug11 and ddrug12 , and grapefruit juice .",
        "triple_list": [
            [
                "ddrug7",
                "int",
                "ddrug10"
            ]
        ]
    },
    {
        "text": "however , prudent medical practice dictates careful monitoring of prothrombin time in all patients treated with ddrug0 and ddrug1 concomitantly .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the effectiveness of ddrug0 - only pills is reduced by hepatic enzyme-inducing drugs such as the ddrug1 ddrug2 , ddrug3 , and ddrug4 , and the ddrug5 ddrug6 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "although the interaction between ddrug0 and other potent cyp3a4 inhibitors { e , g , , ddrug1 , ddrug2 , and ddrug3 } has not been studied , increased exposures to ddrug4 may be expected when ddrug5 is used concomitantly with these medications .",
        "triple_list": [
            [
                "ddrug3",
                "advise",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 : increased inr { international normalized ratio } when ddrug1 and ddrug2 were co-administered has been rarely reported .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 should be withdrawn at least # hours before conducting an ddrug1 - mediated stress test .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 supplements , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug13"
            ]
        ]
    },
    {
        "text": "therefore , co-administration of ddrug0 with drugs that are metabolized by cyp2d6 isoenzyme including certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } , ddrug8 { e , g , , ddrug9 , ddrug10 , ddrug11 } , ddrug12 { e , g , , ddrug13 } , and ddrug14 { e , g , , ddrug15 , ddrug16 } , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug13"
            ]
        ]
    },
    {
        "text": "ddrug0 has additive effects with ddrug1 and other ddrug2 { ddrug3 , ddrug4 , ddrug5 , etc } .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a ddrug0 , including ddrug1 , with multivalent cation-containing products such as ddrug2 or ddrug3 ddrug4 , ddrug5 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , ddrug8 , or ddrug9 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 } chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with , or within # hours of , the administration of ddrug2 , because these products may interfere with absorption resulting in lower serum and urine levels of ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 and other ddrug1 can reduce the antihypertensive effect of ddrug2 and other ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with ddrug1 , ddrug2 s , ddrug3 { allergy , cold , and sinus medicines } , diabetic drugs , ddrug4 , ddrug5 , ddrug6 like ddrug7 or ddrug8 , and high blood pressure medications .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "agents with increased levels in the presence of ddrug0 : ddrug1 increases the plasma levels of the following agents : ddrug2 , ddrug3 { 6 } , and ddrug4 thus , if a patient has been titrated to a stable dosage on one of the agents in this category , and then begins a course of the treatment with ddrug5 , it is reasonable to expect that a dose decrease for the concomitant agent may be necessary .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ddrug0 is administered in combination with other ddrug1 such as ddrug2 , ddrug3 , ddrug4 , or inhalation general ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may prevent the urinary antiseptic effect of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the action of the ddrug0 may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , or other drugs that produce cns depression .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "because ddrug0 is highly bound to serum protein , the administration of ddrug1 to patients taking other drugs that are highly bound to protein { e , g , , ddrug2 , ddrug3 } may cause an increase in plasma concentrations of these drugs , potentially resulting in adverse effects .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the concomitant administration of ddrug0 including ddrug1 with ddrug2 { a ddrug3 } has , on rare occasions , resulted in severe hypoglycemia .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "because there is a theoretical basis that these effects may be additive , use of ddrug0 - containing or ddrug1 { like ddrug2 or ddrug3 } and ddrug4 within # hours of each other should be avoided .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "- ddrug0 or ddrug1 { with hepatotoxic potential } must not be administered together with ddrug2 or ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "co-administration of ddrug0 with ddrug1 has been shown to increase the mean half-life and the area under the concentration-time curve .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "if ddrug0 is to be combined with other ddrug1 such as ddrug2 or ddrug3 / ddrug4 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of ddrug5 and ddrug6 { e , g , , ddrug7 or ddrug8 } are additive .",
        "triple_list": [
            [
                "ddrug5",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "concomitant treatment with ddrug0 { ddrug1 , ddrug2 } , ddrug3 , or ddrug4 may potentiate any hypokalemic effect of ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "additional ddrug0 significantly inhibited the absorption of ddrug1 in both dietary ddrug2 treatments .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "this appears to be the only clinically relevant interaction of this kind with ddrug0 , although theoretically , coadministration of other drugs known to alter cardiac conduction { eg , ddrug1 or ddrug2 , ddrug3 , ddrug4 or ddrug5 , ddrug6 and ddrug7 } might also contribute to a prolongation of the qtc interval .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "although a causal mechanism and a cause-and-effect relationship have not been established , current evidence suggests that renal function should be monitored in patients on ddrug0 and ddrug1 even in the absence of renal failure , and dosage levels should be even more conservatively adjusted in those patients on such combined therapy if diminished renal function is detected , .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the concurrent use of two or more drugs with anticholinergic activity -- such as an ddrug0 { eg , ddrug1 } , an ddrug2 { eg , ddrug3 } , and/or a ddrug4 { eg , ddrug5 } -- commonly results in excessive anticholinergic effects , including dry mouth and associated dental complications , blurred vision , and , in patients exposed to high temperature and humidity , hyperpyrexia .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "the use of ddrug0 in patients receiving ddrug1 may be rarely associated with ventricular fibrillation .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "drugs decreasing ddrug0 effect : ddrug1 , ddrug2 , ddrug3 , or ddrug4 may partially counteract the anticoagulant action of ddrug5 .",
        "triple_list": [
            [
                "ddrug4",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "in long surgical procedures during ddrug0 or ddrug1 anesthesia , less frequent maintenance dosing , lower maintenance doses , or reduced infusion rates of ddrug2 may be necessary .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "however , co administration of ddrug0 with either ddrug1 or ddrug2 led to increased plasma concentrations of ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 } : ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 } have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with ddrug7 .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "ddrug0 effects are potentiated by ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 at doses of # mg/kg and # mg/kg injected with ddrug1 was found to decrease the antinociceptive effect of ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 { ddrug2 } injection , usp should not be used with ddrug3 because the combination may cause synergistic elevation of blood pressure .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : in a clinical pharmacology study , coadministration of an ddrug1 { ddrug2 , ddrug3 , and ddrug4 } with ddrug5 reduced serum levels and urinary excretion of ddrug6 as compared with ddrug7 administered alone , suggesting that ddrug8 may impair absorption of ddrug9 .",
        "triple_list": [
            [
                "ddrug8",
                "mechanism",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit ddrug0 binding to serum proteins or alter the concentrations of serum binding proteins : ddrug1 and related ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug15"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 { ddrug2 } : may potentiate ddrug3 - induced hypokalemia which may predispose the patient to cardiac dysfunction .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug39"
            ]
        ]
    },
    {
        "text": "the administration of ddrug0 concomitantly with known microsomal enzyme inducer { ddrug1 or ddrug2 } to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "while the effects of chronic ddrug0 or ddrug1 therapy on the action of ddrug2 are unknown , slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "certain drugs including ddrug0 , ddrug1 , ddrug2 , and ddrug3 may reduce the hypoglycemic action of ddrug4 and other oral ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "increasing the ddrug0 dose to # mg/day in six of these subjects increased the steady-state ddrug1 cmin to # 7 micrograms/ml .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "therefore , coadministration of ddrug0 with drugs that strongly induce cyp3a4 activity { e , g , , ddrug1 , ddrug2 , ddrug3 } may result in reduced plasma concentrations of ddrug4 that may result in decreased efficacy of ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "as with other ddrug0 , the antihypertensive effect of ddrug1 may be blunted by the ddrug2 ddrug3",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "pharmacologic studies indicate that there may be additive effects in prolonging av conduction when using ddrug0 or ddrug1 concomitantly with ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "other drugs drug interactions have been reported with concomitant administration of ddrug0 and other medications , including ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "in vitro studies have shown that the metabolism of ddrug0 may be modified by the concomitant administration of compounds that induce , inhibit , or are metabolized by cytochrome p450 3a4 , such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , and ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug40"
            ]
        ]
    },
    {
        "text": "ddrug0 : may increase plasma concentration of ddrug1 , possibly by inhibiting conjugation .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 can interact with ddrug1 or other ddrug2 { may potentiate the cns depressant effects of either these medications or ddrug3 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and ddrug6 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 , and ddrug2 may increase plasma levels of ddrug3 , potentially resulting in adverse effects .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 reduced or eliminated the increases in fi responding produced by intermediate doses of either ddrug1 or ddrug2 in pigeons , but did not antagonize the decreases in fi or fr responding produced by high doses of pgpep1 or either stereoisomer of ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 ddrug2 : absorption of ddrug3 is impaired in the presence of ddrug4 .",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "in the first study , concomitant administration of # mg ddrug0 and # g ddrug1 resulted in decreases of more than 22 % for auc and 40 % for cmax when compared to dosing ddrug2 alone .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "oral ddrug0 may enhance the effect of ddrug1 in ddrug2 by decreasing vitamin k availability .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "in another report , nine patients with breast cancer were reported to have decreased symptoms of ddrug0 - related toxicity when given supplemental ddrug1 at a dose of # gram/kilogram/day .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "co-administration of ddrug0 , a strong inhibitor of cyp3a4 , increased ddrug1 exposure following a single # mg dose of ddrug2 by # fold .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "{ in some patients , the ddrug0 can reduce the diuretic , natriuretic , and antihypertensive effects of ddrug1 , ddrug2 , and ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 , given concomitantly with ddrug2 , produces a reduction in urinary potassium and chloride excretion compared to ddrug3 alone .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the anxiogenic effects of ddrug0 were reduced by pretreatment with ddrug1 , an a2-selective agonist , but not by ddrug2 { ddrug3 } , an a1-selective agonist .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : concomitant administration of ddrug1 containing ddrug2 or ddrug3 with ddrug4 chewable/dispersible buffered tablets or pediatric powder for oral solution may potentiate adverse events associated with the ddrug5 components .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 steady-state cmax , a , c , and cmin were decreased by 22 % , 38 % , and 27 % , respectively , by concomitant ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "most of the above effects concerning ddrug0 have been attributed , at least in part , to mechanisms involving inhibition of prostaglandin synthesis by ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in some patients , combined use of ddrug0 and ddrug1 has been associated with fatal gastrointestinal hemorrhage .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 may enhance the effects of : other ddrug3 s , ddrug4 , general ddrug5 , ddrug6 such as ddrug7 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 { eg , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , and ddrug15 } may have elevated plasma concentrations when coadministered with ddrug16 ;",
        "triple_list": [
            [
                "ddrug14",
                "mechanism",
                "ddrug16"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 , and ddrug2 may decrease ddrug3 plasma levels , resulting in a decrease in effectiveness of a previously effective ddrug4 dose .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "-lsb- the gaba-ergic system and brain edema -rsb- it has been shown in rats with experimental toxic and traumatic edemas that ddrug0 { 1 mg/kg } removes the antiedematous action of ddrug1 , ddrug2 , ddrug3 and ddrug4 and reduces the action of ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : combination ddrug1 may decrease the clearance of some ddrug2 { ddrug3 , ddrug4 , ddrug5 } and increase the clearance of others { ddrug6 , ddrug7 , ddrug8 } .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "patients receiving other ddrug0 s , general ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 or other ddrug6 { including ddrug7 } concomitantly with ddrug8 may exhibit an additive cns depression .",
        "triple_list": [
            [
                "ddrug6",
                "effect",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "caution should be observed when ddrug0 is coadministered with other ddrug1 , ddrug2 , ddrug3 , or ddrug4 , as these agents may increase respiratory and circulatory depression .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 is a potent inhibitor of the cyp4f3 isozymes responsible for the metabolism of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 may also interfere with the absorption of oral ddrug1 supplements and ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "agents increasing serum potassium : ddrug0 and ddrug1 iv attenuate potassium loss caused by ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "- drugs that may either increase or decrease plasma ddrug0 concentrations include : ddrug1 , vaiproic acid , and ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 administration to three cancer patients over a dose range of # mg to # mg led to a dose-dependent inhibition of ddrug1 elimination # the effect of alternate-day administration of # mg of ddrug2 on drug metabolism in ms patients is unknown .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "therefore , ddrug0 may interfere with the absorption of drugs where gastric ph is an important determinant of bioavailability { eg , ddrug1 , ddrug2 salts and ddrug3 } .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : in hypercholesterolemic patients , steady-state ddrug1 auc and cmax increased approximately 50 % and 24 % respectively after # days with co-administration of ddrug2 , a known inhibitor of cytochrome p450 3a4 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : in vitro and/or in vivo data show that ddrug1 , ddrug2 , and ddrug3 markedly inhibit the metabolism of ddrug4 , which can result in an increase in plasma ddrug5 levels and prolongation of the qt interval on the ecg .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "patients who have been treated with ddrug0 within two to three weeks prior to the administration of ddrug1 should receive initial doses of ddrug2 no greater than one-tenth { 1/10 } of the usual dose .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : drugs such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 and others that interfere with platelet-aggregation reactions { the main hemostatic defense of heparinized patients } may induce bleeding and should be used with caution in patients receiving ddrug8 .",
        "triple_list": [
            [
                "ddrug5",
                "effect",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "other drugs drug interactions have been reported with concomitant administration of ddrug0 and other medications , including ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug10"
            ]
        ]
    },
    {
        "text": "the antihypertensive effects of ddrug0 , ddrug1 , ddrug2 , and ddrug3 may be reduced by ddrug4 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "therefore , the potential exists for a drug interaction between ddrug0 and drugs that affect the cyp2b6 isoenzyme { e , g , , ddrug1 and ddrug2 } .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 and other ddrug2 can inhibit the activity of ddrug3 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "consequently , concomitant administration of ddrug0 with strong cyp3a4 inhibitors { e , g , , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } should be approached with caution .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "patients in a clinical study who were on established therapy with ddrug0 , to which ddrug1 was added , were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ddrug2 ci or ddrug3 alone .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "caution should be taken when ddrug0 is used concomitantly with medications that are predominantly metabolized by cyp2d6 and which have a narrow therapeutic window , such as ddrug1 , ddrug2 and ddrug3 { see clinical pharmacology } .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 { e , g , , ddrug1 , ddrug2 , ddrug3 } and ddrug4 may reduce the therapeutic effects of ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 alone was found to have no effect on cas , but can completely block ddrug1 - induced phosphorylation of this protein in mda-mb-435 cells .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 increases ddrug1 s serum concentrations .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 } : ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 } have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with ddrug7 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "transient delirium has been reported in patients who were treated with one gram of ddrug0 and # - # mg of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "as the primary effect of ddrug0 is to decrease conduction through the a-v node , higher degrees of heart block may be produced in the presence of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "interactions may occur between ddrug0 supplements and ddrug1 and other ddrug2 and herbs such as garlic { allium sativum } and ddrug3 { ddrug4 } .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "therefore , co-administration of ddrug0 with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index , including certain ddrug1 { ddrug2 -lsb- ddrug3 -rsb- , such as ddrug4 , ddrug5 , and ddrug6 } , ddrug7 and ddrug8 { e , g , , ddrug9 , ddrug10 } , should be approached with caution .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug10"
            ]
        ]
    },
    {
        "text": "ddrug0 : combination ddrug1 may decrease the clearance of some ddrug2 { ddrug3 , ddrug4 , ddrug5 } and increase the clearance of others { ddrug6 , ddrug7 , ddrug8 } .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "injection : ddrug0 injection , like other injectable ddrug1 , produces depression of the central nervous system when administered with ddrug2 , ddrug3 , ddrug4 , ddrug5 , and other ddrug6 , when ddrug7 is used concomitantly with injectable ddrug8 , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug29"
            ]
        ]
    },
    {
        "text": "since ddrug0 { ddrug1 } may interact with concurrently administered ddrug2 , periodic serum level determinations of these drugs may be necessary { eg , ddrug3 may elevate ddrug4 serum levels and ddrug5 has been reported to both increase and decrease ddrug6 levels } .",
        "triple_list": [
            [
                "ddrug1",
                "int",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "although no clinical studies have been conducted , it is likely that the metabolism of ddrug0 may be affected by the known cyp3a4 inducers { such as ddrug1 , ddrug2 , ddrug3 } , cyp3a4 inhibitors { azole antimycotics e , g , , ddrug4 ;",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "however , the systemic administration of some ddrug0 has been shown to elevate plasma concentrations of ddrug1 , interfere with the metabolism of ddrug2 , and enhance the effects of the oral ddrug3 ddrug4 and its derivatives , and has been associated with transient elevations in serum creatinine in patients receiving systemic ddrug5 concomitantly .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the use of ddrug0 may result in additive cns depressant effects when coadministered with ddrug1 , ddrug2 , ddrug3 or other drugs that produce cns depression .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "avoid the use of preparations such as ddrug0 and local ddrug1 which contain any ddrug2 { e , g , , ddrug3 , ddrug4 } , since it has been reported that ddrug5 can potentiate the effects of catecholamines .",
        "triple_list": [
            [
                "ddrug4",
                "advise",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "avoid the concomitant use of ddrug0 and ddrug1 { ddrug2 } .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "drug interactions : ddrug0 may interact with some drugs , like ddrug1 { ddrug2 } : ddrug3 could theoretically affect ddrug4 pharmacodynamics - ddrug5 - jzqyavbxjcqsok_uhfffaoysa_n - ddrug6 : ddrug7 and ddrug8 cause additive cns depression - ddrug9 : ddrug10 increases the effect of ddrug11",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "in one controlled clinical study , the ureidopenicillins , including ddrug0 , were reported to prolong the action of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "when concomitant administration of ddrug0 with ddrug1 occurs , ddrug2 dose should be reduced to one-half of its normal dose .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 , like other ddrug2 , may cause changes in the elimination of ddrug3 leading to elevated serum levels of the drug and increased toxicity .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "catecholamine-depleting drugs , e , g , , ddrug0 , may have an additive effect when given with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "data from in vitro studies of ddrug0 other than ddrug1 suggest a possible drug interaction for the following : ddrug2 , ddrug3 , ddrug4 , ddrug5 , and ddrug6 .",
        "triple_list": [
            [
                "ddrug1",
                "int",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "drugs that induce hepatic enzymes such as ddrug0 , ddrug1 and ddrug2 may increase the clearance of ddrug3 and may require increases in ddrug4 dose to achieve the desired response .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "although ddrug0 have been shown to reduce ddrug1 - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with ddrug2 may reduce the antitumor effectiveness of ddrug3 and thus should be avoided , # ddrug4 and other ddrug5 may potentiate the hypotension seen with ddrug6 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may affect gastrointestinal absorption of various drugs , such as slowly dissolving dosage forms of ddrug1 ;",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 : concomitant treatment with ddrug3 , ddrug4 , or ddrug5 may potentiate a possible hypokalemic effect of ddrug6",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "nephrotoxicity has been reported following concomitant administration of ddrug0 with ddrug1 or potent ddrug2 such as ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "the auc of ddrug0 was decreased an average of 15-fold in # healthy subjects given ddrug1 and ddrug2 - placebo tablets concurrently .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the effects of ddrug0 may be potentiated by ddrug1 which inhibits the metabolism of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 may increase the plasma-level of concomitantly given ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in clinical trials , ddrug0 was used with ddrug1 , ddrug2 , ddrug3 , oral ddrug4 , and supplemental ddrug5 , in a pharmacokinetic substudy in patients with congestive heart failure receiving ddrug6 or ddrug7 in whom therapy with ddrug8 was initiated , apparent oral clearance values for ddrug9 { n = 23 } and ddrug10 { n = 30 } were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .",
        "triple_list": [
            [
                "ddrug7",
                "mechanism",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 is not recommended for use in patients who have received ddrug2 within # days because severe and unpredictable potentiation by ddrug3 has been reported with ddrug4",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "it is , however , possible that concomitant use of other known ddrug0 such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 might increase the photosensitivity reaction of actinic_keratosis treated with the ddrug7 for topical solution .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "ddrug0 usually does not alter the plasma levels of ddrug1 , however , serum ddrug2 levels should be evaluated after concomitant therapy with ddrug3 is initiated .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 is known to interact with the metabolism or renal tubular excretion of many drugs { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 agents , ddrug14 , and ddrug15 } .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "ddrug0 , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , certain ddrug7 , ddrug8 , ddrug9 and ddrug10 , thereby delaying elimination and increasing blood levels of these drugs .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "ddrug0 may increase the action of ddrug1 , ddrug2 , ddrug3 , and ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "interactions with other cns agents : concurrent use of ddrug0 with all ddrug1 { eg , ddrug2 , ddrug3 , ddrug4 , other ddrug5 , general ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 and ddrug12 } may result in additive central nervous system depressant effects .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "therefore , co-administration of ddrug0 with other drugs that are metabolized by this isoenzyme , including other ddrug1 , ddrug2 , ddrug3 , and ddrug4 { eg , ddrug5 , ddrug6 , and ddrug7 } , or that inhibit this enzyme { eg , ddrug8 } , should be approached with caution .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 { eg , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , and ddrug15 } may have elevated plasma concentrations when coadministered with ddrug16 ;",
        "triple_list": [
            [
                "ddrug4",
                "mechanism",
                "ddrug16"
            ]
        ]
    },
    {
        "text": "when used in therapeutic doses , ddrug0 had a modest effect on the pharmacokinetics of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { intravenous and oral } , ddrug12 , ddrug13 / ddrug14 or ddrug15 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "concomitant administration of ddrug0 with ddrug1 has been reported to result in elevated serum levels of ddrug2 { 40 % to 72 % increase } , resulting in toxicity in some cases .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "coadministration of oral ddrug0 increased the maximum plasma concentration of ddrug1 by 18 % , decreased clearance by 22 % , and increased half-life by 29 % .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "co-administration of ddrug0 with ddrug1 produced a 25 % increase in auc and a 33 % increase in the cmax of ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : concomitant treatment with ddrug1 and ddrug2 should be avoided because ddrug3 use has been associated with a number of cases of idiopathic_intracranial_hypertension { benign intracranial hypertension } , some of which involved concomitant use of ddrug4",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 : because ddrug1 can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine , and because renal excretion is the primary elimination route of ddrug2 including ddrug3 , there is a risk that an interaction will lead to deterioration .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "drugs that reduce the number of blood platelets by causing bone marrow depression { such as ddrug0 } or drugs which inhibit platelet function { eg , ddrug1 and other ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 } may increase the bleeding tendency produced by ddrug7 without altering prothrombin time determinations .",
        "triple_list": [
            [
                "ddrug4",
                "effect",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "ddrug0 : in post-marketing experience , there have been reports of both increases and decreases in ddrug1 levels with ddrug2 co-administration , leading to alterations in seizure control .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "this interaction should be given consideration in patients taking ddrug0 concomitantly with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "other ddrug0 should be used with caution in patients taking ddrug1 , since the effects may be additive .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "concomitant administration of other ddrug0 may potentiate the undesirable effects of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the concurrent use of ddrug0 injection with other ddrug1 or medications with anticholinergic activity , such as ddrug2 , ddrug3 , or ddrug4 , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "the hypoglycemic action of ddrug0 may be potentiated by certain drugs including ddrug1 and other drugs that are highly protein bound , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , and ddrug8 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 / ddrug1 : an increase in the frequency of skin rash has been reported among patients receiving ddrug2 or ddrug3 concurrently with ddrug4 compared to patients who are not receiving both drugs .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "although not studied with ddrug0 , inhibition of n-acetyltransferase may have clinically relevant consequences for drugs such as ddrug1 , ddrug2 , and ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "when the ddrug0 was administered # minutes after the ddrug1 nasal spray , the auc of ddrug2 increased 11 % and cmax decreased 18 % .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 , and ddrug3 the in vitro binding of ddrug4 to plasma proteins is only slightly reduced by ddrug5 { # % control vs # % } when ddrug6 plasma concentrations reach # to10 m g/ml .",
        "triple_list": [
            [
                "ddrug4",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "it is recommended that if ddrug0 is started in patients already receiving ddrug1 , prothrombin times should be closely monitored and adjustment of the ddrug2 dose may be necessary .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "substances that are potent inhibitors of cyp3a4 activity { eg , ddrug0 and ddrug1 } decrease ddrug2 metabolism and increase ddrug3 plasma concentrations .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "as with most psychoactive medications , patients should be advised to avoid ddrug0 while taking ddrug1",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in addition , drugs that are actively secreted via this route { e , g , , ddrug0 , ddrug1 and ddrug2 } should be co-administered with care as they might increase ddrug3 levels .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "therefore , cyp3a4 substrates known to have a narrow therapeutic index such as ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , or ddrug10 { ddrug11 , ddrug12 } should be administered with caution in patients receiving ddrug13 .",
        "triple_list": [
            [
                "ddrug5",
                "advise",
                "ddrug13"
            ]
        ]
    },
    {
        "text": "ddrug0 : concomitant administration of ddrug1 and some ddrug2 has been reported to reduce the clearance of ddrug3 , enhancing the toxicity of ddrug4 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 attenuated the heart rate increase following administration of immediate release ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "therefore , cyp3a4 substrates known to have a narrow therapeutic index such as ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , or ddrug10 { ddrug11 , ddrug12 } should be administered with caution in patients receiving ddrug13 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug13"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug37"
            ]
        ]
    },
    {
        "text": "the interaction is a consequence of blocking hepatic metabolism of ddrug0 by ddrug1 , a highly potent cyp3a4 inhibitor , which also inhibits cyp2c9 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "increased nephrotoxicity has been reported following concomitant administration of ddrug0 and ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "tablets : the ddrug0 , including ddrug1 , produce cns-depressant effects when administered with such medications as ddrug2 or ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 - concomitant intake of ddrug1 and ddrug2 may reduce the absorption of ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "concurrent administration of ddrug0 and ddrug1 , which competes for tubular secretion , has been shown to increase the plasma half-life of ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in patients receiving ddrug0 { ddrug1 } or ddrug2 { ddrug3 } , the concomitant administration of 300-600 mg of ddrug4 per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of ddrug5 or ddrug6 .",
        "triple_list": [
            [
                "ddrug4",
                "advise",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "concomitant administration of ddrug0 and other related compounds { eg , ddrug1 , ddrug2 and ddrug3 } may produce electrocardiographic abnormalities and increase the risk of convulsions .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "even when an ddrug0 and a ddrug1 - type drug are administered separately by different routes , a reduction in ddrug2 serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "a rare , but serious , constellation of symptoms , termed serotonin syndrome , has been reported with the concomitant use of ddrug0 { ddrug1 } and agents for migraine therapy , such as ddrug2 { ddrug3 } and ddrug4 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "this decrease in bioavailability was about 5 % when ddrug0 was administered # hours after ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 and other ddrug1 can reduce the antihypertensive effect of ddrug2 and other ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 , such as ddrug1 , may have an additive effect when given with ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "the plasma concentration of ddrug0 may increase when the drug is given concomitantly with hepatic enzyme inhibitors { e , g , , ddrug1 , ddrug2 } and decrease by concomitant administration of hepatic enzyme inducers { e , g , , ddrug3 , ddrug4 } , and adjustment of the dosage of ddrug5 may therefore be necessary .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 may enhance the effects of : other ddrug3 s , ddrug4 , general ddrug5 , ddrug6 such as ddrug7 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "because there is a theoretical basis that these effects may be additive , use of ddrug0 - containing or ddrug1 { like ddrug2 or ddrug3 } and ddrug4 within # hours of each other should be avoided .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "because ddrug0 may enhance the serotonergic effects of ddrug1 , caution should be exercised when ddrug2 and ddrug3 are coadministered .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "it is concluded that ddrug0 modulates in an opposite way the function of the enkephalinergic neurons and the central action of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 should be used with caution in patients receiving other local ddrug1 or agents structurally related to amide-type local anesthetics since the toxic effects of these drugs could be additive .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "dose reduction of ddrug0 to # mg every # hours should be considered when taking ddrug1 # mg three times a day .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "therefore , cyp3a4 substrates known to have a narrow therapeutic index such as ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , or ddrug10 { ddrug11 , ddrug12 } should be administered with caution in patients receiving ddrug13 .",
        "triple_list": [
            [
                "ddrug8",
                "advise",
                "ddrug13"
            ]
        ]
    },
    {
        "text": "since ddrug0 is extensively metabolized by cyp4f3 isoenzymes , caution should be exercised when ddrug1 is coadministered with inhibitors of c , p , a , such as ddrug2 and ddrug3 or inhibitors of cyp2c19 such as ddrug4 .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "a rare , but serious , constellation of symptoms , termed serotonin syndrome , has been reported with the concomitant use of ddrug0 { ddrug1 } and agents for migraine therapy , such as ddrug2 { ddrug3 } and ddrug4 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "cyclosporine , digoxin , methotrexate ddrug0 , like other ddrug1 , through effects on renal prostaglandins , may cause changes in the elimination of these drugs leading to elevated serum levels of ddrug2 , ddrug3 , ddrug4 , and increased toxicity .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "inhibitors of cyp3a4 { eg , ddrug0 } or cyp2d6 { eg , ddrug1 , ddrug2 , or ddrug3 } can inhibit ddrug4 elimination and cause increased blood levels .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "plasma concentrations of ddrug0 should therefore be closely monitored , and its dosage reduced accordingly , in patients treated with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "although neither ddrug0 nor ddrug1 affected the proliferation of prostatic epithelium in rpmi1640 containing ddrug2 alone , they modify the mitogenic effect of ddrug3 and ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "similarly , the effects of ddrug0 on ddrug1 , ddrug2 and sodium plasma ddrug3 concentrations are unpredictable",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as ddrug0 include certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 } , ddrug10 salts , ddrug11 , local ddrug12 , ddrug13 , and ddrug14 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug10"
            ]
        ]
    },
    {
        "text": "ddrug0 : a literature article reported that when a 60-mg controlled-release ddrug1 capsule was administered # hours prior to a 600-mg ddrug2 capsule { n = 12 } , mean ddrug3 auc increased by 44 % compared to ddrug4 administered without ddrug5 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 { 600 mg b , i , d , } co-administered with ddrug1 # mg resulted in a 49-fold increase in ddrug2 auc and a 13-fold increase in ddrug3 cmax .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 containing ddrug1 and ddrug2 reduce the oral absorption of ddrug3 by 75 % .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "preliminary studies indicate that the concomitant use of ddrug0 and ddrug1 results in a higher cardiac output and , usually , a lower pulmonary wedge pressure than when either drug is used alone .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "interaction of ddrug0 and ddrug1 in anaesthetised horses .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "injection of ddrug0 # min before a nonlethal dose of ddrug1 changed the serum sex steroid hormone response of male rats to ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 is known to interact with the metabolism or renal tubular excretion of many drugs { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 agents , ddrug14 , and ddrug15 } .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "concomitant single dose administration of ddrug0 # mg with multiple doses of ddrug1 and ddrug2 produced a significant increase in exposure of ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "poor metabolizers of ddrug0 : interactions of ddrug1 with strong inhibitors of cyp2d6 { such as ddrug2 , ddrug3 , ddrug4 , and ddrug5 } have not been studied , but these drugs would be expected to increase blood levels of the r { + } enantiomer of ddrug6 .",
        "triple_list": [
            [
                "ddrug4",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "pharmacological/pharmacodynamic interactions with ddrug0 concomitant administration of ddrug1 and ddrug2 may increase the risk of neurotoxic side effects .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "interactions with other cns agents : concurrent use of ddrug0 with all ddrug1 { eg , ddrug2 , ddrug3 , ddrug4 , other ddrug5 , general ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 and ddrug12 } may result in additive central nervous system depressant effects .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug11"
            ]
        ]
    },
    {
        "text": "experience with ddrug0 { ddrug1 } suggests the potential for interactions with ddrug2 and ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "int",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 should be used with caution , if at all , when potent inhalational ddrug1 such as ddrug2 are employed because of potential to sensitize the myocardium to effects of ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "other potentially important drug interactions : ddrug0 : ddrug1 metabolized by hepatic oxidation { e , g , , ddrug2 , ddrug3 , ddrug4 elc , } should be used with caution because the clearance of these drugs is likely to be reduced by ddrug5 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "thus , when ddrug0 and ddrug1 are administered concurrently , subjects should be observed carefully for signs of ddrug2 toxicity .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : as with other ddrug1 , the renal excretion of ddrug2 is inhibited by ddrug3 .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "coadministration of ddrug0 with other ddrug1 , ddrug2 , and ddrug3 may cause hypokalemia .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "effects of other ddrug0 on ddrug1 ddrug2 : ddrug3 causes an approximate doubling of the clearance of ddrug4 { ddrug5 } at steady state and , therefore , the addition of ddrug6 causes an approximate 45 % decrease in the steady-state trough concentrations of ddrug7 as compared to the same dose of ddrug8 given as monotherapy .",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "among the risk factors studied , two appear to increase the risk of are : the prescription of ddrug0 to treat strongyloidiasis during the ddrug1 cure and the bad general clinical conditions of patients .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "conversely , ddrug0 may interfere with ddrug1 { i , e , , ddrug2 , ddrug3 } .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "patients who begin taking ddrug0 or who increase their ddrug1 dose or any other ddrug2 while taking ddrug3 , ddrug4 , or ddrug5 may develop toxicity characteristics for these drugs .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "several ddrug0 have been reported to block the pharmacologic effects of ddrug1 , ddrug2 , or similar agents , and such an effect may be anticipated with ddrug3 because of its structural similarity to other ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "concomitant administration of ddrug0 with ddrug1 tablets reduces the blood levels of the latter .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "certain drugs , including ddrug0 { ddrug1 } , ddrug2 , ddrug3 , and ddrug4 may potentiate the hypoglycemic action of ddrug5 and other oral ddrug6 .",
        "triple_list": [
            [
                "ddrug4",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 increase the rate of absorption of ddrug1 , while ddrug2 decreases it .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the possibility of hypotensive effects with ddrug0 can be minimized by either discontinuing the ddrug1 or increasing the salt intake approximately one week prior to initiation of treatment with ddrug2 { ddrug3 tablets , usp } or initiating therapy with small doses { # or # mg } .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in rats , simultaneous ingestion of ddrug0 and ddrug1 in the diet for # weeks has been reported to cause tumors , and it has been suggested that ddrug2 may react with ddrug3 in the rat stomach to form a nitrosamine , which is tumorigenic .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "as with some other ddrug0 , the time of onset of neuromuscular block induced by ddrug1 is lengthened and the duration of block is shortened in patients receiving ddrug2 or ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : concomitant administration of ddrug1 may reduce plasma levels of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "therefore concomitant administration of ddrug0 tablets with ddrug1 is contraindicated .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "there are case reports of patients who developed increased bun , serum creatinine and serum potassium levels , and weight gain when ddrug0 was used in conjunction with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in vitro mixing of an ddrug0 with beta-lactamtype ddrug1 { ddrug2 or ddrug3 } may result in a significant mutual inactivation .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "cardiac effects of ddrug0 are antagonized by ddrug1 , such as ddrug2 and ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "considerable caution should be exercised if ddrug0 is administered concurrently with ddrug1 { ddrug2 } since paranoid symptoms have been reported during therapy with this combination .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : a study in # healthy volunteers has shown a significant increase in peak ddrug1 plasma levels { 80 % } and area-under-the-curve { 74 % } after a # week course of ddrug2 at # mg per day and ddrug3 at # mg per day .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 or ddrug1 : concomitant administration of ddrug2 or ddrug3 decreases the elimination of ddrug4 , most likely by inhibition of renal tubular secretion of ddrug5 .",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "if the ddrug0 dose is adjusted upward , the dose will need to be reduced upon discontinuation of ddrug1 or other inducers .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "therefore , cyp3a4 substrates known to have a narrow therapeutic index such as ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , or ddrug10 { ddrug11 , ddrug12 } should be administered with caution in patients receiving ddrug13 .",
        "triple_list": [
            [
                "ddrug11",
                "advise",
                "ddrug13"
            ]
        ]
    },
    {
        "text": "inhibitors of this isoenzyme { e , g , , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , grapefruit juice , ddrug7 , ddrug8 , ddrug9 , ddrug10 } should be cautiously coadministered with ddrug11 as they can potentially increase ddrug12 levels .",
        "triple_list": [
            [
                "ddrug8",
                "advise",
                "ddrug11"
            ]
        ]
    },
    {
        "text": "agents causing renin release : the antihypertensive effect of ddrug0 and ddrug1 iv is augmented by ddrug2 that cause renin release { e , g , , ddrug3 } .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "therefore , co-administration of ddrug0 with drugs that are metabolized by cyp2d6 isoenzyme including certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } , ddrug8 { e , g , , ddrug9 , ddrug10 , ddrug11 } , ddrug12 { e , g , , ddrug13 } , and ddrug14 { e , g , , ddrug15 , ddrug16 } , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 , as well as other ddrug2 , probably reduces the tubular secretion of ddrug3 based on in vitro studies in rabbit kidney slices .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 - containing preparations { eg , ddrug2 } may cause hypermagnesemia and should therefore not be taken during therapy with ddrug3 by patients on chronic renal dialysis .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "concomitant use of ddrug0 with other ddrug1 is not recommended .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 is a potent inhibitor of the cyp4f3 isozymes responsible for the metabolism of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 s : ddrug1 increases the adrenergic effect of catecholamines such as ddrug2 and ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "alternatives to ddrug0 should be considered during the course of pgpep1 treatment with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "other drugs drug interactions have been reported with concomitant administration of ddrug0 and other medications , including ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 : clinical studies , as well as post marketing observations , have shown that ddrug1 can reduce the natriuretic effect of ddrug2 and ddrug3 in some patients .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "in patients who have received ddrug0 , ddrug1 may temporarily mask the residual effects of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 potentiates other ddrug1 such as ddrug2 or ddrug3 and ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "when ddrug0 is co-administered with ddrug1 { 500 mg p , o , every # hours } , ddrug2 competes for active tubular secretion and reduces the renal clearance of ddrug3 .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "in patients taking an ddrug0 { eg , ddrug1 , ddrug2 , ddrug3 or ddrug4 } , the concomitant use of ddrug5 may reduce seizure control by lowering the plasma levels of the ddrug6 .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "consider additive sedative effects and confusional states to emerge , if ddrug0 is given with ddrug1 or ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 - induced oxidative stress in rat brain and liver is prevented by ddrug1 or ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 salts , and ddrug3 may either potentiate or weaken the blood-glucose-lowering effect of ddrug4 .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "drugs metabolized by cytochrome p450 enzymes the drug interaction study evaluating the effect of ddrug0 on ddrug1 indicates that ddrug2 inhibits ddrug3 metabolism , which is mediated by cyp1a2 .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 add some further antihypertensive effect to ddrug1 , but the overall response is less than additive .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the clinical significance of this reduction is not known , hence ddrug0 is not recommended to be ingested simultaneously with ddrug1 / ddrug2 - containing ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the hypoglycemic action of ddrug0 may be potentiated by certain drugs including ddrug1 and other drugs that are highly protein bound , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , and ddrug8 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "therefore , ddrug0 should be taken at least # minutes prior to ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 including ddrug1 , ddrug2 , and ddrug3 hc1 : concomitant use of ddrug4 and non-selective ddrug5 may cause hypertension .",
        "triple_list": [
            [
                "ddrug4",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 , an anionic-binding resin , has a considerable effect in lowering the rate and extent of ddrug1 bioavailability .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "although specific drug interaction studies have not been conducted with ddrug0 , the possibility of an additive or potentiating effect with ddrug1 { ddrug2 , ddrug3 , ddrug4 , ddrug5 , or ddrug6 } should be considered .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the potentiating action of ddrug0 must be considered when the drug is used in conjunction with ddrug1 such as ddrug2 , ddrug3 and ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 should be administered with caution to patients who are taking other ddrug1 or ddrug2 , including ddrug3 , ddrug4 and ddrug5 , or to those with a history of psychiatric disorder { including manic-depressive illness and schizophrenia } .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 may decrease the amount of ddrug1 { ddrug2 , ddrug3 } that gets absorbed into your body .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 - pectin , ddrug2 , ddrug3 , ddrug4 , certain anticancer drugs , and ddrug5 may interfere with intestinal ddrug6 absorption , resulting in unexpectedly low serum concentrations .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "caution should be used when administering or taking ddrug0 with ddrug1 and other strong cyp3a4 inhibitors such as , but not limited to , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { ddrug12 } , and ddrug13 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug10"
            ]
        ]
    },
    {
        "text": "products containing ddrug0 and other multivalent cations { such as ddrug1 , ddrug2 , ddrug3 } are likely to interfere with absorption of ddrug4 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "in an in vitro study in human liver microsomes , inhibition of cyp2a6 hydroxylation of ddrug0 by ddrug1 { 200 m.m. m i , e , , # mg/l } was 17-28 % .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 should be administered with caution to patients receiving ddrug1 { ddrug2 , wyeth-ayerst laboratories } .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : it should be borne in mind that ddrug1 ingestion may increase the danger inherent in any intentional or unintentional ddrug2 overdosage .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "toxicology studies of ddrug0 - related deaths reveal frequent involvement of other ddrug1 , including ddrug2 , ddrug3 such as ddrug4 { ddrug5 } , and , to a rising degree , ddrug6 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "- when ddrug0 or ddrug1 is used concurrently with ddrug2 { e , g , ddrug3 } , an interval of at least # hours should be maintained between the two medicines , since the absorption of ddrug4 or ddrug5 is impaired",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : reports suggest that ddrug1 may diminish the antihypertensive effect of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "drugs that may alter ddrug0 plasma concentrations drugs that may increase ddrug1 plasma concentrations : caution is recommended when administering ddrug2 with inhibitors of the cyp3a4 family { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 } .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug19"
            ]
        ]
    },
    {
        "text": "while the effects of chronic ddrug0 or ddrug1 therapy on the action of ddrug2 are unknown , slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "in patients receiving concurrent therapy with ddrug0 , if therapy is to be discontinued , it is suggested that ddrug1 be discontinued for several days before the withdrawal of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "therefore , co-administration of ddrug0 with other drugs that are metabolized by this isoenzyme , including other ddrug1 , ddrug2 , ddrug3 , and ddrug4 { eg , ddrug5 , ddrug6 , and ddrug7 } , or that inhibit this enzyme { eg , ddrug8 } , should be approached with caution .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 : in a study conducted in healthy subjects , mean steady-state ddrug1 plasma levels increased approximately 17 % in subjects receiving ddrug2 # mg bid with ddrug3 # mg bid as compared to subjects receiving ddrug4 alone .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 should not be administered concurrently with d2-antagonists , such as ddrug1 , ddrug2 , ddrug3 , or ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "caution should be used when administering or taking ddrug0 with ddrug1 and other strong cyp3a4 inhibitors such as , but not limited to , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { ddrug12 } , and ddrug13 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "administration of # - mg/kg { 2 x ed95 } ddrug0 at 10 % or 95 % recovery following an intubating dose of ddrug1 { 1 mg/kg } produced 95 % neuromuscular block .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "serum ddrug0 levels should be monitored frequently if ddrug1 is administered concomitantly with ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "patients receiving other ddrug0 s , general ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 or other ddrug6 { including ddrug7 } concomitantly with ddrug8 may exhibit an additive cns depression .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "ddrug0 - theoretically , ddrug1 supplements taken concomitantly with ddrug2 , may potentiate the effects of the drug .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "certain drugs including ddrug0 , ddrug1 , ddrug2 , and ddrug3 may reduce the hypoglycemic action of ddrug4 and other oral ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "because of the possible additive effects of drugs that may depress the nervous system , ddrug0 or ddrug1 should be used cautiously in combination with ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "because ddrug0 is highly bound to serum protein , the administration of ddrug1 to patients taking other drugs that are highly bound to protein { e , g , , ddrug2 , ddrug3 } may cause an increase in plasma concentrations of these drugs , potentially resulting in adverse effects .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "in a study in which the # mg ddrug0 orally disintegrating tablet was administered with and without ddrug1 { an ddrug2 with multiple effects on the gi tract } to healthy volunteers , the auc of ddrug3 was 10 % lower and the cmax of ddrug4 was 20 % lower when the orally disintegrating tablet was given with ddrug5 compared to when it was given alone .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug26"
            ]
        ]
    },
    {
        "text": "ddrug0 may interfere with the anti-glaucoma action of ddrug1 or ddrug2 ;",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving ddrug0 metabolized similarly to ddrug1 or on the basis of in vitro studies with ddrug2 or other ddrug3 { caution is recommended during coadministration with ddrug4 } : available data from clinical studies of ddrug5 other than ddrug6 suggest a possible drug interaction with ddrug7 for the following : ddrug8 , ddrug9 , ddrug10 such as ddrug11 and ddrug12 , and grapefruit juice .",
        "triple_list": [
            [
                "ddrug7",
                "int",
                "ddrug12"
            ]
        ]
    },
    {
        "text": "there is insufficient experience to assess the safety and efficacy of ddrug0 administered concurrently with ddrug1 , and therefore such use is not recommended .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "however , reports suggest that ddrug0 may diminish the antihypertensive effect of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may enhance the effects of ddrug1 , ddrug2 , ddrug3 , and other ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 and other ddrug2 can inhibit the activity of ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "the concomitant administration of ddrug0 and other ddrug1 have resulted in previous reports of rhabdomyolysis .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "caution should be taken when ddrug0 is used concomitantly with medications that are predominantly metabolized by cyp2d6 and which have a narrow therapeutic window , such as ddrug1 , ddrug2 and ddrug3 { see clinical pharmacology } .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 - ddrug1 and the ddrug2 ddrug3 may have synergistic antidepressant activity if used concomitantly .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of ddrug0 such as ddrug1 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "plasma exposure { auc } to ddrug0 was increased 62 % when coadministered with ddrug1 and 38 % when coadministered with ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "when ddrug0 at an increased dose { 1000 mg every # hours } was given with ddrug1 { 600 mg once daily } , the ddrug2 auc and cmin were decreased on average by 33-46 % and 39-57 % , respectively , compared to when ddrug3 { 800 mg every # hours } was given alone .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving ddrug0 in combination with ddrug1 than those receiving ddrug2 # mg q8h .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as ddrug0 include certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 } , ddrug10 salts , ddrug11 , local ddrug12 , ddrug13 , and ddrug14 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "ddrug0 : in a study in healthy volunteers , a one-week course of ddrug1 at # mg b , i , d , with a single # mg dose of ddrug2 on the sixth day showed an increase in ddrug3 mean peak plasma concentrations { 36 % } and significant increase in area under the curve { 50 % } .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "therefore , ddrug0 should not be administered concurrently with ddrug1 because of the potential for serious and/or life-threatening cardiac arrhythmias .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "coadministration of ddrug0 and strong cyp3a4 inhibitors , such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , and ddrug5 has not been evaluated but should be undertaken with caution because of similar potential drug interactions .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "concomitant use of ddrug0 with other cardioactive compounds that could cause heart failure { e , g , , ddrug1 } , requires close monitoring of cardiac function throughout treatment .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "poor metabolizers of ddrug0 : interactions of ddrug1 with strong inhibitors of cyp2d6 { such as ddrug2 , ddrug3 , ddrug4 , and ddrug5 } have not been studied , but these drugs would be expected to increase blood levels of the r { + } enantiomer of ddrug6 .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 , a ddrug1 , has been reported to inactivate the antifungal activity of ddrug2 by competitive inhibition .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "nephrotoxic agents : concomitant administration of ddrug0 and agents with nephrotoxic potential -lsb- e , g , , intravenous ddrug1 { e , g , , ddrug2 , ddrug3 , and ddrug4 } , ddrug5 , ddrug6 , intravenous ddrug7 , ddrug8 , and ddrug9 -rsb- is contraindicated .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 ddrug2 may enhance the activity of ddrug3 or ddrug4 ;",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "some ddrug0 , including ddrug1 , have been associated with transient elevations in serum creatinine in patients receiving ddrug2 concomitantly .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "spontaneous reports of serotonin syndrome associated with co-administration of ddrug0 and ddrug1 , including ddrug2 such as ddrug3 { ddrug4 } , have been reported .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the effects of medicinal products with similar properties such as inotropes ddrug0 , ddrug1 , ddrug2 , ddrug3 and ddrug4 may be exacerbated by ddrug5 .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "the administration of local ddrug0 containing ddrug1 or ddrug2 to patients receiving ddrug3 or ddrug4 may produce severe , prolonged hypertension .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 blocks dopamine and norepinephrine receptors , thus inhibiting the central stimulant effects of ddrug2 and can be used to treat ddrug3 poisoning .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 decrease the hypotensive effect of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "certain drugs , including ddrug0 { ddrug1 } , ddrug2 , ddrug3 , and ddrug4 may potentiate the hypoglycemic action of ddrug5 and other oral ddrug6 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "although this effect was noted even when ddrug0 was given # hours prior to ddrug1 , this regimen did not result in diminished efficacy .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 causes an increase in steady-state ddrug2 concentrations .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma ddrug0 concentrations include : acute ddrug1 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug15"
            ]
        ]
    },
    {
        "text": "the mechanism for this interaction probably is adsorption of ddrug0 onto the surface of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 has additive effects with ddrug1 and other ddrug2 { ddrug3 , ddrug4 , ddrug5 , etc } .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "effects of ddrug0 are increased with ddrug1 and ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "since ddrug0 is extensively metabolized by cyp4f3 isoenzymes , caution should be exercised when ddrug1 is coadministered with inhibitors of c , p , a , such as ddrug2 and ddrug3 or inhibitors of cyp2c19 such as ddrug4 .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "the concomitant use of ddrug0 and ddrug1 parenteral should be avoided .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "compounds in these categories result in a decreased efficacy of ddrug0 : ddrug1 , ddrug2 , ddrug3 , ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "- concomitant use of ddrug0 may reduce the efficacy of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in clinical trials in patients undergoing ptca/pci , co-administration of ddrug0 with ddrug1 , ddrug2 , ddrug3 or glycoprotein iib/iiia inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with ddrug1 , ddrug2 s , ddrug3 { allergy , cold , and sinus medicines } , diabetic drugs , ddrug4 , ddrug5 , ddrug6 like ddrug7 or ddrug8 , and high blood pressure medications .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "concurrent administration of drugs possessing nephrotoxic { e , g , , ddrug0 , ddrug1 } , myelotoxic { e , g , , ddrug2 chemotherapy } , cardiotoxic { e , g , , ddrug3 } or hepatotoxic { e , g , , ddrug4 , ddrug5 } effects with ddrug6 may increase toxicity in these organ systems .",
        "triple_list": [
            [
                "ddrug4",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "this report describes two cases in which ddrug0 clearance accelerated markedly with concomitant ddrug1 administration .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 reduced or eliminated the increases in fi responding produced by intermediate doses of either ddrug1 or ddrug2 in pigeons , but did not antagonize the decreases in fi or fr responding produced by high doses of pgpep1 or either stereoisomer of ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "preliminary data which suggest that ddrug0 may inhibit the anti-inflammatory activity of ddrug1 have not been confirmed .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , certain ddrug7 , ddrug8 , ddrug9 and ddrug10 , thereby delaying elimination and increasing blood levels of these drugs .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "the possibility of hypotensive effects with ddrug0 can be minimized by either discontinuing the ddrug1 or increasing the salt intake prior to initiation of treatment with ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 { ddrug2 } : may potentiate ddrug3 - induced hypokalemia which may predispose the patient to cardiac dysfunction .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 may decrease vascular response to pressor drugs such as ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "combinations of these drugs have not been studied and coadministration of ddrug0 and ddrug1 is not recommended .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "drugs decreasing ddrug0 effect : ddrug1 , ddrug2 , ddrug3 , or ddrug4 may partially counteract the anticoagulant action of ddrug5 .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 , including ddrug2 , decrease the clearance of ddrug3 , the less active isomer of racemic ddrug4 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "absorption of ddrug0 is impaired by ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : in cases of ddrug1 overdosage , ddrug2 cns stimulation is potentiated and fatal convulsions can occur .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "core temperature was decreased in rats in a dose-dependent manner when ddrug0 was administered to rats treated with ddrug1 # hours before the ddrug2 challenge .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving ddrug0 metabolized similarly to ddrug1 or on the basis of in vitro studies with ddrug2 or other ddrug3 { caution is recommended during coadministration with ddrug4 } : available data from clinical studies of ddrug5 other than ddrug6 suggest a possible drug interaction with ddrug7 for the following : ddrug8 , ddrug9 , ddrug10 such as ddrug11 and ddrug12 , and grapefruit juice .",
        "triple_list": [
            [
                "ddrug7",
                "int",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "ddrug0 : a relationship of functional antagonism exists between ddrug1 , which promote calcium absorption , and ddrug2 , which inhibit calcium absorption .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : in a study of # healthy male volunteers , ddrug1 treatment potentiated the blood glucose lowering effect of ddrug2 { a ddrug3 similar to ddrug4 } in # of the # subjects .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 should not be taken within # hours of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "interactions with other cns agents : concurrent use of ddrug0 with all ddrug1 { eg , ddrug2 , ddrug3 , ddrug4 , other ddrug5 , general ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 and ddrug12 } may result in additive central nervous system depressant effects .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : generally should not be given with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 is known to interact with the metabolism or renal tubular excretion of many drugs { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 agents , ddrug14 , and ddrug15 } .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "plasma levels of several closely related ddrug0 have been reported to be increased by the concomitant administration of ddrug1 or hepatic enzyme inhibitors { e , g , , ddrug2 , ddrug3 } and decreased by the concomitant administration of hepatic enzyme inducers { e , g , , ddrug4 , ddrug5 } , and such an effect may be anticipated with ddrug6 as well .",
        "triple_list": [
            [
                "ddrug4",
                "mechanism",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 inhibits the cyp2c9 catalyzed biotransformation of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : in vitro and/or in vivo data indicate that ddrug1 , ddrug2 , and oral ddrug3 markedly inhibit the metabolism of ddrug4 , which can result in an increase in plasma ddrug5 levels and prolongation of the qt interval on the ecg .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 , including ddrug1 , may enhance the effects of oral ddrug2 , such as ddrug3 or its derivatives .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : in post-marketing experience , there have been rare reports of adverse neuropsychiatric events or reduced ddrug1 tolerance in patients who were drinking ddrug2 during treatment with ddrug3 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "in vitro interaction of ddrug0 and ddrug1 in placental vessels .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "should it be decided to discontinue therapy in patients receiving ddrug0 and ddrug1 concurrently , the ddrug2 should be discontinued slowly over several days before the gradual withdrawal of ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the treatment of ewes with an intravenous { iv } injection of ddrug0 , insufficient to produce significant inhibition of erythrocyte aces_human { ache } activity , appeared to produce additive effects with those produced by subsequent treatment with # mg of ddrug1 / kg/day .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the administration of local ddrug0 containing ddrug1 or ddrug2 to patients receiving ddrug3 , ddrug4 or ddrug5 may produce severe , prolonged hypotension or hypertension .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "the clinical significance of this reduction is not known , hence ddrug0 is not recommended to be ingested simultaneously with ddrug1 / ddrug2 - containing ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 s : ddrug1 should be administered at least # hours after or # hours before dosing with ddrug2 because plasma concentrations of ddrug3 are decreased when administered with ddrug4 containing ddrug5 , ddrug6 , or ddrug7 .",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 : the concomitant administration of ddrug1 and ddrug2 in normal volunteers had no effect on the plasma levels of ddrug3 , but significantly decreased the urinary excretion of ddrug4 and its glucuronide metabolite .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : immediate release capsules : since there have been isolated reports of patients with elevated ddrug1 levels , and there is a possible interaction between ddrug2 and ddrug3 , it is recommended that ddrug4 levels be monitored when initiating , adjusting , and discontinuing ddrug5 to avoid possible over - or under-digitalization .",
        "triple_list": [
            [
                "ddrug4",
                "advise",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 : when ddrug1 # or # mg was given to healthy volunteers either simultaneously or # hours after a # mg dose of ddrug2 , significant hypotension developed in a substantial number of subjects .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 - and/or ddrug1 - containing ddrug2 , products containing ddrug3 { ddrug4 } , ddrug5 containing ddrug6 or other metal cations , or ddrug7 { ddrug8 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after ddrug9 .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "the concurrent use of ddrug0 injection with other ddrug1 or medications with anticholinergic activity , such as ddrug2 , ddrug3 , or ddrug4 , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "close supervision and careful adjustment of the dosage are required when ddrug0 is used with other ddrug1 or ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "catecholamine-depleting agents : patients taking both ddrug0 and a drug that can deplete catecholamines { e , g , , ddrug1 and ddrug2 } should be observed closely for signs of hypotension and/or severe bradycardia .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "increased ectopic pacemaker activity can occur when ddrug0 is used concomitantly with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "there have been reports of increased anticoagulant effects when ddrug0 and oral ddrug1 were used concomitantly .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "based on total ddrug0 concentrations , ddrug1 increased the auc by 25 % and reduced the plasma and renal clearances by 20 % and 35 % , respectively .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "concurrent administration of ddrug0 and ddrug1 may result in elevated serum levels of ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "nephrotoxicity has been reported following concomitant administration of other ddrug0 with potent ddrug1 such as ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "concomitant administration of ddrug0 capsules and ddrug1 resulted in substantial increases in plasma concentrations of ddrug2 , probably at least partially related to cyp3a4 inhibition by ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "patients taking ddrug0 concomitantly with ddrug1 should be monitored regularly for alterations in their coagulation parameters { pt or inr } .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "if ddrug0 and an ddrug1 are used concomitantly , renal function should be carefully monitored , because nephrotoxicity may be potentiated .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : in vitro studies in peripheral blood mononuclear cells , u937 and molt-4 cells revealed that ddrug1 significantly inhibited ddrug2 phosphorylation in a dose dependent manner .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "although specific drug interaction studies have not been conducted with ddrug0 , the possibility of an additive or potentiating effect with ddrug1 { ddrug2 , ddrug3 , ddrug4 , ddrug5 , or ddrug6 } should be considered .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 : as with other ddrug1 , renal excretion of ddrug2 is inhibited by ddrug3 and resulted in an approximate 80 % increase in the auc for ddrug4 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "patients receiving other ddrug0 s , general ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 or other ddrug6 { including ddrug7 } concomitantly with ddrug8 may exhibit an additive cns depression .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 increases ddrug2 plasma levels .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 has been shown to have an additive cns depressant effect when given with either ddrug1 , ddrug2 , ddrug3 or ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in a ten-subject study , coadministration of ddrug0 { 120 mg bid } with ddrug1 resulted in a 3-4 times increase in mean ddrug2 auc and cmax vs , ddrug3 alone ;",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "pretreatment of healthy volunteers with multiple doses of ddrug0 followed by a single dose of ddrug1 , increased ddrug2 oral-dose clearance by # - fold , which significantly { p # } decreased mean cmax and auc { 0-8 } .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 at # microm preferentially blocked the secretory effect of ddrug1 and its synergism with camp , whereas it had no effect on histamine - or camp-stimulated acid secretion within # min .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "therefore , ddrug0 or other ddrug1 { as used for management of angina } or other drugs having vasodilator activity should , if possible , be discontinued before starting ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 may inhibit the intracellular phosphorylation of one another .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "these results suggest that both ddrug0 and ddrug1 , and possibly other ddrug2 and ddrug3 , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of ddrug4 and ddrug5 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "the daily dose of ddrug0 should not exceed # mg when coadministered with potent cyp3a4 inhibitors { e , g , , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 and nefazadone } .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "it is not known whether this potentiation of ddrug0 rashes is due to ddrug1 or the hyperuricemia present in these patients .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the ddrug0 - induced neuronal damage produced a tolerance to the disruptive effects of ddrug1 and a supersensitivity to the disruptive effects of ddrug2 in rats responding in a schedule controlled paradigm .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of ddrug0 such as ddrug1 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "therefore , co-administration of ddrug0 with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index , including certain ddrug1 { ddrug2 -lsb- ddrug3 -rsb- , such as ddrug4 , ddrug5 , and ddrug6 } , ddrug7 and ddrug8 { e , g , , ddrug9 , ddrug10 } , should be approached with caution .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 , or ddrug2 increased metabolic clearance of ddrug3 because of the induction of hepatic enzymes .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "concurrent use of ddrug0 and ddrug1 is therefore not recommended .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "this appears to be the only clinically relevant interaction of this kind with ddrug0 , although theoretically , coadministration of other drugs known to alter cardiac conduction { eg , ddrug1 or ddrug2 , ddrug3 , ddrug4 or ddrug5 , ddrug6 and ddrug7 } might also contribute to a prolongation of the qtc interval .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 - although not reported , ddrug2 , via its metabolism to histamine , might decrease the efficacy of ddrug3 and ddrug4 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 , as with other ddrug1 , should be administered with extreme caution to patients being treated with ddrug2 , ddrug3 , or drugs known to prolong the qtc interval because the action of ddrug4 on the cardiovascular system may be potentiated by these agents .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as ddrug1 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain ddrug2 such as ddrug3 , the ddrug4 and other ddrug5 , ddrug6 , certain ddrug7 such as the ddrug8 salts , and ddrug9 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "oral ddrug0 : coadministration of ddrug1 and an oral ddrug2 increased auc values for ddrug3 and ddrug4 by approximately 30 % and 20 % .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug13"
            ]
        ]
    },
    {
        "text": "nephrotoxicity has been reported following concomitant administration of other ddrug0 with potent ddrug1 such as ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "caution should be observed when ddrug0 is coadministered with other ddrug1 , ddrug2 , ddrug3 , or ddrug4 , as these agents may increase respiratory and circulatory depression .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "particular caution is recommended when administering ddrug0 with cyp3a4 substrates that have a narrow therapeutic window { e , g , , ddrug1 or ddrug2 } .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "this observed increase in the bioavailability of ddrug0 may be due to transport-related effects , such as p-glycoprotein , in vivo animal studies also suggest that in addition to enhancing absorption , ddrug1 decreases ddrug2 gastrointestinal secretion , while ddrug3 may also decrease biliary excretion .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "as with some other ddrug0 , the time of onset of neuromuscular block induced by ddrug1 is lengthened and the duration of block is shortened in patients receiving ddrug2 or ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "although neither ddrug0 nor ddrug1 affected the proliferation of prostatic epithelium in rpmi1640 containing ddrug2 alone , they modify the mitogenic effect of ddrug3 and ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "in vitro data suggest that ddrug0 also markedly inhibits the biotransformation system mainly responsible for the metabolism of ddrug1 ;",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "- drugs whose efficacy is impaired by ddrug0 include : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , oral ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "in long surgical procedures during ddrug0 or ddrug1 anesthesia , less frequent maintenance dosing , lower maintenance doses , or reduced infusion rates of ddrug2 may be necessary .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 may antagonize the hypotensive effects of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in clinical trials in patients undergoing ptca/pci , co-administration of ddrug0 with ddrug1 , ddrug2 , ddrug3 or glycoprotein iib/iiia inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "standard monitoring of ddrug0 - related toxicity should be continued if ddrug1 and ddrug2 are administered concomitantly .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the actions of the ddrug0 may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 or other ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 - containing preparations { eg , ddrug2 } may cause hypermagnesemia and should therefore not be taken during therapy with ddrug3 by patients on chronic renal dialysis .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 increases both free and bound ddrug2 by reducing the plasma clearance of ddrug3 to about one-third , as well as decreasing its protein binding .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as ddrug0 include certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 } , ddrug10 salts , ddrug11 , local ddrug12 , ddrug13 , and ddrug14 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 may inhibit both synthetic and catabolic enzymes of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "in view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by ddrug0 , the physician may wish to withhold ddrug1 during dosing with ddrug2 and , certainly , during periods of active vomiting or diarrhea .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "however , since ddrug0 , ddrug1 , and ddrug2 are all associated with gastrointestinal irritation , caution should be exercised in the concomitant use of ddrug3 or ddrug4 with ddrug5 .",
        "triple_list": [
            [
                "ddrug4",
                "advise",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 may antagonize the hypotensive effects of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 - combined administration of racemic ddrug1 { 40 mg } and ddrug2 { 200 mg } decreased the cmax and auc of ddrug3 by 21 % and 10 % , respectively , and did not significantly affect the pharmacokinetics of ddrug4 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : the concomitant use of ddrug1 { ddrug2 transdermal system } with other ddrug3 , including but not limited to other ddrug4 , ddrug5 , ddrug6 , ddrug7 { e , g , , ddrug8 } , general ddrug9 , ddrug10 , ddrug11 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 administered concurrently with ddrug1 reduced the urine volume in # healthy volunteers .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "conversely , ddrug0 may interfere with ddrug1 { i , e , , ddrug2 , ddrug3 } .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "oral ddrug0 inhibits the gastrointestinal absorption of ddrug1 , oral ddrug2 , ddrug3 and ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "concomitant treatment of four patients in the united kingdom with ddrug0 and intravenous ddrug1 may have caused hypocalcemia ;",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 inhibit the hypotensive effect of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 may increase slightly the effect of ddrug1 , e , g , , ddrug2 , ddrug3 , ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "coadministration of ddrug0 with other ddrug1 , ddrug2 , and ddrug3 may cause hypokalemia .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "taking a ddrug0 while you are taking or within # weeks of taking ddrug1 may increase the risk of central nervous system depression or may cause a severe high blood pressure reaction .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "additive cns depression may occur when ddrug0 are administered concomitantly with other ddrug1 including ddrug2 , ddrug3 , and ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "- drugs that may decrease plasma ddrug0 concentrations include : ddrug1 , chronic ddrug2 abuse , ddrug3",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : acute pulmonary toxicity has been reported in patients receiving intravenous ddrug1 and ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 ddrug2 can antagonize the in vitro antiviral activity of ddrug3 and ddrug4 against hiv .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 - and/or ddrug1 - containing ddrug2 , products containing ddrug3 { ddrug4 } , ddrug5 containing ddrug6 or other metal cations , or ddrug7 { ddrug8 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after ddrug9 .",
        "triple_list": [
            [
                "ddrug7",
                "advise",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "several ddrug0 have been reported to block the pharmacologic effects of ddrug1 , ddrug2 , or similar agents , and such an effect may be anticipated with ddrug3 because of its structural similarity to other ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "coadministration of ddrug0 and strong cyp3a4 inhibitors , such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , and ddrug5 has not been evaluated but should be undertaken with caution because of similar potential drug interactions .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "therefore , it is theoretically possible that ddrug0 may interfere with the absorption of drugs where gastric ph is an important determinant of bioavailability { e , g , ddrug1 , ddrug2 esters , ddrug3 salts , ddrug4 } .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the administration of local ddrug0 containing ddrug1 or ddrug2 to patients receiving ddrug3 , ddrug4 or ddrug5 may produce severe , prolonged hypotension or hypertension .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "a two-way interaction between the ddrug0 , ddrug1 , and the ddrug2 s has been suggested .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 has been reported to decrease the clearance of ddrug1 and ddrug2 and thus may increase the pharmacologic effect of these ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the concomitant use of transdermal ddrug0 with ddrug1 or other potent 3a4 inhibitors such as ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and nefazadone may result in an increase in ddrug7 plasma concentrations .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 may inhibit both synthetic and catabolic enzymes of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 causes an approximate 50 % increase in the clearance of ddrug2 at steady state and , therefore , the addition of ddrug3 results in an approximate 40 % decrease in the steady-state trough concentrations of ddrug4 as compared to the same dose of ddrug5 given as monotherapy .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "in an analysis of the supraventricular arrhythmia and diamond patient populations , the concomitant administration of ddrug0 with ddrug1 was associated with a higher occurrence of torsade de pointes .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 containing ddrug1 , when administered concomitantly with ddrug2 , reduce both the rate and extent of absorption .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the concomitant administration of ddrug0 has been reported to reduce the efficacy of oral ddrug1 and to increase the incidence of breakthrough bleeding .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may potentiate the hypotensive effects of ddrug1 and the anticholinergic effects of ddrug2 - type drugs .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "toxicology studies of ddrug0 - related deaths reveal frequent involvement of other ddrug1 , including ddrug2 , ddrug3 such as ddrug4 { ddrug5 } , and , to a rising degree , ddrug6 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "concurrent administration of ddrug0 { for the treatment of hypotension related to obstetric blocks } and ddrug1 may cause severe , persistent hypertension or cerebrovascular accidents .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug11"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 - pectin , ddrug2 , ddrug3 , ddrug4 , certain anticancer drugs , and ddrug5 may interfere with intestinal ddrug6 absorption , resulting in unexpectedly low serum concentrations .",
        "triple_list": [
            [
                "ddrug4",
                "mechanism",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 : as with other ddrug1 , concomitant administration of ddrug2 and ddrug3 is not generally recommended because of the potential of increased adverse effects .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : the concomitant use of ddrug1 { ddrug2 transdermal system } with other ddrug3 , including but not limited to other ddrug4 , ddrug5 , ddrug6 , ddrug7 { e , g , , ddrug8 } , general ddrug9 , ddrug10 , ddrug11 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "infusion requirements of ddrug0 in patients administered ddrug1 prior to infusions of ddrug2 were comparable to or slightly greater than when ddrug3 was not administered .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "pre-treatment with the cyp3a4 inducer ddrug0 decreased ddrug1 auc by about 2/3 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : the risk of myopathy/rhabdomyolysis is increased by concomitant administration of ddrug1 particularly with higher doses of ddrug2 { see warnings , myopathy/rhabdomyolysis } .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "therefore , it is recommended that ddrug0 tablets not be used in combination with ddrug1 , or within # days of discontinuing treatment with a ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 treatment resulted in a 42 % decrease in the ddrug1 auc 0-24 , but no clinically relevant effect was observed on the pharmacokinetic parameters of ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "thus , the results suggest that ddrug0 exposure of rats results in free radical-mediated tissue damage , as indicated by elevated cerebral and hepatic lipid peroxidation , which was prevented by ddrug1 and ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : concomitant administration of ddrug1 containing ddrug2 or ddrug3 with ddrug4 chewable/dispersible buffered tablets or pediatric powder for oral solution may potentiate adverse events associated with the ddrug5 components .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "two percent of patients treated concurrently with ddrug0 and ddrug1 developed neutropenia { anc # x 109/l } .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may have additive effects with ddrug1 and other ddrug2 , e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "before taking ddrug0 , tell your doctor if you are taking any of the following medicines : - ddrug1 or another ddrug2 such as ddrug3 { ddrug4 } , ddrug5 { ddrug6 , others } , ddrug7 { ddrug8 } , ddrug9 { ddrug10 } , or ddrug11 { ddrug12 } ;",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "patients already stabilized on ddrug0 should be closely monitored for loss of symptom control with ddrug1 coadministration .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "may interact with the following : ddrug0 , ddrug1 { use with ddrug2 may prevent the ddrug3 from working properly ;",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 reduced the blood auc0-12 of ddrug1 by approximately 20 % , peak blood concentration { cmax } by 16 % , and 12-hour blood concentration { c12hr } by 26 % in healthy subjects when ddrug2 { 2 doses of # mg/kg # hours apart } was administered on the 10th day of ddrug3 # mg daily , as compared to results from a control period in which ddrug4 was administered alone .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as ddrug1 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain ddrug2 such as ddrug3 , the ddrug4 and other ddrug5 , ddrug6 , certain ddrug7 such as the ddrug8 salts , and ddrug9 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 dosage must be determined with care in patients undergoing treatment with ddrug2 , as hypercalcemia in such patients may precipitate cardiac arrhythmias .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "if concomitant treatment with ddrug0 and an ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } is clinically warranted , appropriate observation of the patient is advised .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "due to their similar mechanism of action , it is expected that the neuromuscular blockade produced by any of the ddrug0 could be prolonged in the presence of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 have been reported to blunt the hypotensive effect of systemic ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the following drug interactions have been identified involving ddrug0 tablets and other drugs metabolized by the cyp3a4 enzyme system : ddrug1 tablets inhibit the metabolism of ddrug2 , resulting in an increased plasma concentration of ddrug3 and a delay in the elimination of its acid metabolite .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "when ddrug0 is co-administered with ddrug1 , anticoagulation levels should be monitored frequently .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in addition , results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance { ddrug0 , ddrug1 , ddrug2 , ddrug3 , or ddrug4 } with ddrug5 may result in clinically meaningful reductions in ddrug6 concentrations .",
        "triple_list": [
            [
                "ddrug4",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 ddrug1 may delay or reduce the absorption of concomitant oral medication such as ddrug2 , ddrug3 , ddrug4 { acidic } or ddrug5 { basic } , as well as ddrug6 ddrug7 , ddrug8 , thyroid and ddrug9 preparations , ddrug10 and ddrug11 , and ddrug12 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug12"
            ]
        ]
    },
    {
        "text": "the ddrug0 , including ddrug1 , produce additive cns depressant effects when co-administered with other ddrug2 , ddrug3 , ddrug4 , ddrug5 , and other drugs which themselves produce cns depression .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "because of the possible additive effects of drugs that may depress the nervous system , ddrug0 or ddrug1 should be used cautiously in combination with ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "although specific drug interaction studies have not been conducted with ddrug0 , the possibility of an additive or potentiating effect with ddrug1 { ddrug2 , ddrug3 , ddrug4 , ddrug5 , or ddrug6 } should be considered .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "a study in eight healthy volunteers has shown a 50 % increase in mean peak ddrug0 plasma concentrations and a 90 % increase in mean area under the curve , after a one week course of ddrug1 at 1,000 mg/day and ddrug2 at # mg/day .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 increased the auc of ddrug1 by 50 % .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "therefore , when ddrug0 is given with ddrug1 or ddrug2 , a period of at least # hours after the last intravenous dose or # hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in clinical trials in patients undergoing ptca/pci , co-administration of ddrug0 with ddrug1 , ddrug2 , ddrug3 or glycoprotein iib/iiia inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "other strong selective cyp3a4 inhibitors such as ddrug0 can also be expected to increase the exposure of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "drugs that reduce the number of blood platelets by causing bone marrow depression { such as ddrug0 } or drugs which inhibit platelet function { eg , ddrug1 and other ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 } may increase the bleeding tendency produced by ddrug7 without altering prothrombin time determinations .",
        "triple_list": [
            [
                "ddrug6",
                "effect",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma ddrug0 concentrations include : acute ddrug1 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug11"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 similarly inhibit and stimulate ddrug2 - or ddrug3 - induced proliferation of prostatic epithelium .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "in patients receiving nonselective ddrug0 { ddrug1 } { e , g , , ddrug2 } in combination with ddrug3 { e , g , , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 } , there have been reports of serious , sometimes fatal , reactions .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "cyclosporine , digoxin , methotrexate ddrug0 , like other ddrug1 , through effects on renal prostaglandins , may cause changes in the elimination of these drugs leading to elevated serum levels of ddrug2 , ddrug3 , ddrug4 , and increased toxicity .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "immediate and extended release tablets the hypoglycemic action of ddrug0 may be potentiated by certain drugs including ddrug1 , some ddrug2 and other drugs that are highly protein bound , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "caution should be used when administering or taking ddrug0 with ddrug1 and other strong cyp3a4 inhibitors such as , but not limited to , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { ddrug12 } , and ddrug13 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "however , since ddrug0 , ddrug1 , and ddrug2 are all associated with gastrointestinal irritation , caution should be exercised in the concomitant use of ddrug3 or ddrug4 with ddrug5 .",
        "triple_list": [
            [
                "ddrug3",
                "advise",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "the response to ddrug0 may be blunted by ddrug1 and ddrug2 which cause a rise in prolactin .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 have produced an elevation of plasma ddrug2 levels and a reduction in renal ddrug3 clearance .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 : ddrug2 may enhance the activity of ddrug3 or ddrug4 ;",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "concurrent administration of drugs possessing nephrotoxic { e , g , , ddrug0 , ddrug1 } , myelotoxic { e , g , , ddrug2 chemotherapy } , cardiotoxic { e , g , , ddrug3 } or hepatotoxic { e , g , , ddrug4 , ddrug5 } effects with ddrug6 may increase toxicity in these organ systems .",
        "triple_list": [
            [
                "ddrug5",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "additional reductions in blood pressure may occur when ddrug0 is administered with ddrug1 , ddrug2 , or other ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of ddrug0 # % ophthalmic solution , the possibility of an additive or potentiating effect with ddrug1 { ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 } should be considered .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 - concomitant use of ddrug1 and ddrug2 may enhance nutrient absorption in those with severe short bowel syndrome .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "epidural ddrug0 may prolong the duration of pharmacologic effects of epidural local ddrug1 , including both sensory and motor blockade .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may not be effective due to decreased ddrug1 concentrations in patients taking these agents concomitantly .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , certain ddrug7 , ddrug8 , ddrug9 and ddrug10 , thereby delaying elimination and increasing blood levels of these drugs .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "however , the concomitant use of ddrug0 and ddrug1 { 5 # mg initial oral dose followed by # -6 mg/day orally for 6-10 days } results in prolongation of the prothrombin time { pt } and international normalized ratio { inr } .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in patients taking an ddrug0 { eg , ddrug1 , ddrug2 , ddrug3 or ddrug4 } , the concomitant use of ddrug5 may reduce seizure control by lowering the plasma levels of the ddrug6 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "certain drugs including ddrug0 , ddrug1 , ddrug2 , and ddrug3 may reduce the hypoglycemic action of ddrug4 and other oral ddrug5 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "elevated plasma levels of ddrug0 have been reported with concomitant ddrug1 use .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 including coumarin derivatives , indandione derivatives , and ddrug1 such as ddrug2 { ddrug3 } , and ddrug4 may increase the risk of bleeding when administered concomitantly with ddrug5 .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 , including ddrug1 , may enhance the effects of oral ddrug2 , such as ddrug3 or its derivatives .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 or ddrug1 : when ddrug2 is administered immediately following ddrug3 or ddrug4 , the absorption of ddrug5 is slightly enhanced .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "conclusions : single-dose ddrug0 coadministration leads to higher ddrug1 exposure , presumably by inhibition of the first-pass metabolism of ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the daily dose of ddrug0 should not exceed # mg when coadministered with potent cyp3a4 inhibitors { e , g , , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 and nefazadone } .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "inhibitors of cyp3a4 { eg , ddrug0 } or cyp2d6 { eg , ddrug1 , ddrug2 , or ddrug3 } can inhibit ddrug4 elimination and cause increased blood levels .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "therefore , co-administration of ddrug0 with drugs that are metabolized by cyp2d6 isoenzyme including certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } , ddrug8 { e , g , , ddrug9 , ddrug10 , ddrug11 } , ddrug12 { e , g , , ddrug13 } , and ddrug14 { e , g , , ddrug15 , ddrug16 } , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "when taken orally , ddrug0 like ddrug1 may enhance the anticoagulant effect of ddrug2 - like drugs .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "therefore , patients receiving ddrug0 will have erroneously low erpf and tm ddrug1 values .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of ddrug0 such as ddrug1 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as ddrug1 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain ddrug2 such as ddrug3 , the ddrug4 and other ddrug5 , ddrug6 , certain ddrug7 such as the ddrug8 salts , and ddrug9 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 may enhance the effects of : other ddrug3 s , ddrug4 , general ddrug5 , ddrug6 such as ddrug7 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "therefore , when ddrug0 and ddrug1 are used concomitantly , the patient should be observed closely to determine if the desired effect of the ddrug2 is obtained .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 , and ddrug2 : drugs such as ddrug3 , ddrug4 , and ddrug5 may increase the risk of developing peripheral_neuropathies or other ddrug6 - associated adverse events by interfering with the renal clearance of ddrug7 { thereby raising systemic exposure } .",
        "triple_list": [
            [
                "ddrug5",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 : in some patients with compromised renal function who are being treated with ddrug1 , the co-administration of ddrug2 may result in a further deterioration of renal function .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "in em individuals treated with ddrug0 or ddrug1 , the auc of ddrug2 is approximately 6 - to 8-fold and css , max is about 3 - to 4-fold greater than ddrug3 alone .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "however , because some ddrug0 have been reported to enhance the effects of ddrug1 or its derivatives , prothrombin time or other suitable anticoagulation test should be monitored closely if a ddrug2 is administered with ddrug3 or its derivatives .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the peripheral vasoconstriction caused by high doses of ddrug0 is antagonized by ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "because of the potential for ddrug0 levels to continue to increase with multiple dosing , caution should be used if patients are to be receiving both ddrug1 and ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "when ddrug0 hydrochloride is administered concomitantly with an ddrug1 , the risk of hyperkalemia may be increased .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "coadministration of ddrug0 with # mg ddrug1 tablets in epileptic patients lowered the ddrug2 plasma concentrations to undetectable levels .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and ddrug7 raise the serum ddrug8 concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that ddrug9 intoxication may result .",
        "triple_list": [
            [
                "ddrug4",
                "mechanism",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "drug interactions with ddrug0 administration of # mg of ddrug1 { 2 x # mg capsule } within # minutes of an ddrug2 and ddrug3 containing ddrug4 { ddrug5 } decreased ddrug6 auc by 41 % and cmax by 43 % .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "it is possible that the cardiovascular action of other ddrug0 could be enhanced by the addition of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in addition to bleeding associated with ddrug0 and ddrug1 , drugs that alter platelet function { such as ddrug2 , ddrug3 and ddrug4 } may increase the risk of bleeding if administered prior to , during , or after ddrug5 therapy .",
        "triple_list": [
            [
                "ddrug2",
                "int",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "when ddrug0 is withdrawn from the combination therapy , ddrug1 dose should then be reduced .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "nucleoside analogues ddrug0 co-administration of ddrug1 and ddrug2 is not recommended .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 decreased the cmax and auc of sustained-release ddrug1 { ddrug2 } by approximately 31 % and 11 % , respectively .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : coadministration of ddrug1 # mg and ddrug2 # mg produced a decrease in dsst scores .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : coadministration of ddrug1 resulted in a 27 % decrease in ddrug2 clearance and an increase in cmax of approximately 6 % .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "particular caution should be observed with ddrug0 since there are conflicting results for the effect of ddrug1 on the availability of ddrug2 and ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 increases ddrug1 excretion and the ddrug2 may be decreased .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "withdrawal of ddrug0 decreased the ddrug1 requirement by 50 % .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 enhance the renal toxicity of ddrug1 in animals , # ddrug2 interferes with the action of ddrug3 preparations by chelating the ddrug4 , 7",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the actions of the ddrug0 may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 or other ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "rarely ddrug0 toxicity may occur in patients who discontinue ddrug1 after concurrent high-dose ddrug2 therapy .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "monitoring for ddrug0 toxicity and serial measurement of ddrug1 serum concentration during concomitant ddrug2 therapy should be considered .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "similarly , ddrug0 decreased the antinociceptive effect of ddrug1 { only in the tail-flick test } and ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : it appears that ddrug1 may reduce plasma ddrug2 concentrations .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : concomitant treatment with ddrug1 and ddrug2 should be avoided because ddrug3 use has been associated with a number of cases of idiopathic_intracranial_hypertension { benign intracranial hypertension } , some of which involved concomitant use of ddrug4",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "synergism has been shown between ddrug0 anesthesia and intravenously administered ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 { eg , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , and ddrug15 } may have elevated plasma concentrations when coadministered with ddrug16 ;",
        "triple_list": [
            [
                "ddrug11",
                "mechanism",
                "ddrug16"
            ]
        ]
    },
    {
        "text": "also , concomitant administration of ddrug0 with products containing ddrug1 , ddrug2 containing ddrug3 , or ddrug4 { ddrug5 } chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "this interaction should be given consideration in patients taking ddrug0 concomitantly with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "therefore , when using doses of ddrug0 greater than # mg/day during adjunctive therapy , a decrease in the dose of ddrug1 may be required .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "marked symptomatic orthostatic hypotension has been reported when ddrug0 and organic ddrug1 were used in combination .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 significantly decreased the auc { ss } of ddrug1 by 82 % , but ddrug2 had no effect on ddrug3 pharmacokinetics .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 - containing preparations { eg , ddrug2 } may cause hypermagnesemia and should therefore not be taken during therapy with ddrug3 by patients on chronic renal dialysis .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 has been reported to cause coronary artery vasospasm , and its effect could be additive with ddrug2 { ddrug3 } injection , usp .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug11"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and ddrug7 raise the serum ddrug8 concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that ddrug9 intoxication may result .",
        "triple_list": [
            [
                "ddrug5",
                "mechanism",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "1 - adrenergic receptor antagonism , ddrug0 has the potential to enhance the effect of certain ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 blocks dopamine and norepinephrine reuptake , thus inhibiting the central stimulant effects of ddrug2 , and can be used to treat ddrug3 poisoning .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "in some patients the combined use of ddrug0 and ddrug1 has been associated with fatal gastrointestinal hemorrhage .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "therefore , co-administration of ddrug0 with drugs that are metabolized by cyp2d6 isoenzyme including certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } , ddrug8 { e , g , , ddrug9 , ddrug10 , ddrug11 } , ddrug12 { e , g , , ddrug13 } , and ddrug14 { e , g , , ddrug15 , ddrug16 } , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug12"
            ]
        ]
    },
    {
        "text": "ddrug0 may cause an increased prothrombin response by displacing the ddrug1 from protein binding sites or a diminished prothrombin response through increased metabolism of the unbound drug by hepatic enzyme induction , thus leading to inter-patient variation in ultimate prothrombin effect .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ddrug0 is administered in combination with other ddrug1 such as ddrug2 , ddrug3 , ddrug4 , or inhalation general ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 decreased the hyperuricemic effect of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "coadministration of ddrug0 with ddrug1 or any known cyp3a4 inducer should be avoided and alternative ddrug2 therapy should be considered .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "these in vitro studies suggest that concomitant administration of ddrug0 and ddrug1 in humans may result in sub-therapeutic concentrations of active phosphorylated ddrug2 , which may lead to a decreased ddrug3 effect of ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "although ddrug0 have been shown to reduce ddrug1 - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with ddrug2 may reduce the antitumor effectiveness of ddrug3 and thus should be avoided , # ddrug4 and other ddrug5 may potentiate the hypotension seen with ddrug6 .",
        "triple_list": [
            [
                "ddrug5",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "immediate and extended release tablets the hypoglycemic action of ddrug0 may be potentiated by certain drugs including ddrug1 , some ddrug2 and other drugs that are highly protein bound , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 { # and # mg/kg , s , c , } inhibited the ddrug2 { # mg/kg , p , o , } - induced diarrhea in cecectomized rats .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the hypoglycemic action of ddrug0 may be potentiated by certain drugs including ddrug1 and other drugs that are highly protein bound , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , and ddrug8 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "dose reduction of ddrug0 to half the standard dose and a dose increase of ddrug1 to # mg { three 333-mg capsules } every # hours are recommended when ddrug2 and ddrug3 are coadministered .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 increases the auc for ddrug2 and ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 / ddrug1 / ddrug2 / ddrug3 : co-administration of ddrug4 with ddrug5 , ddrug6 , ddrug7 , and ddrug8 is likely to lead to an enhancement of effects .",
        "triple_list": [
            [
                "ddrug4",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "if ddrug0 is used with ddrug1 in patients with angina pectoris , additional antihypertensive effects may occur .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "hepatic enzyme inducers , inhibitors and substrates : drugs which induce cytochrome p450 3a4 { cyp 3a4 } enzyme activity { e , g , , ddrug0 , ddrug1 , ddrug2 , ddrug3 } may enhance the metabolism of ddrug4 and require that the dosage of the ddrug5 be increased .",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "therefore , co-administration of ddrug0 with drugs that are metabolized by cyp2d6 isoenzyme including certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } , ddrug8 { e , g , , ddrug9 , ddrug10 , ddrug11 } , ddrug12 { e , g , , ddrug13 } , and ddrug14 { e , g , , ddrug15 , ddrug16 } , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug16"
            ]
        ]
    },
    {
        "text": "however , because bleeding has been reported when ddrug0 and other ddrug1 have been administered to patients on ddrug2 , the physician should be cautious when administering ddrug3 to patients on ddrug4 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "the extent to which ddrug0 - ddrug1 interactions may pose clinical problems will depend on the degree of inhibition , and the pharmacokinetics of the ddrug2 involved .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "co-medications that induce cyp 3a4 { e , g , , ddrug0 , ddrug1 , ddrug2 , ddrug3 , or st , john s wort } may significantly decrease exposure to ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 : enhanced bone marrow suppression by ddrug1 and other ddrug2 has been reported among patients with neoplastic disease , except leukemia , in the presence of ddrug3 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 or ddrug1 administered with ddrug2 / ddrug3 to achieve # mac -lsb- minimum alveolar concentration -rsb- may prolong the clinically effective duration of action of initial and maintenance doses of ddrug4 and decrease the required infusion rate of ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 elicited 62 % enhancement of post - ddrug1 lipolytic activity and 100 % increase of 3h-triglyceride fractional clearance rate compared with placebo treatment .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "substances that are potent inhibitors of cyp3a4 activity { eg , ddrug0 and ddrug1 } decrease ddrug2 metabolism and increase ddrug3 plasma concentrations .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 , such as ddrug1 and ddrug2 , can inhibit renal tubular secretion of ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "the pressor effects of ddrug0 such as ddrug1 or ddrug2 are enhanced by ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "patients treated with ddrug0 and ddrug1 concomitantly may need to be monitored for increases in inr and prothrombin time .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving ddrug0 metabolized similarly to ddrug1 or on the basis of in vitro studies with ddrug2 or other ddrug3 { caution is recommended during coadministration with ddrug4 } : available data from clinical studies of ddrug5 other than ddrug6 suggest a possible drug interaction with ddrug7 for the following : ddrug8 , ddrug9 , ddrug10 such as ddrug11 and ddrug12 , and grapefruit juice .",
        "triple_list": [
            [
                "ddrug7",
                "int",
                "ddrug11"
            ]
        ]
    },
    {
        "text": "patients receiving other ddrug0 s , general ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 or other ddrug6 { including ddrug7 } concomitantly with ddrug8 may exhibit an additive cns depression .",
        "triple_list": [
            [
                "ddrug5",
                "effect",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "catecholamine-depleting drugs { eg , ddrug0 } may have an additive effect when given with ddrug1 s.",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "coadministration of ddrug0 with these drugs or other drugs that are known to be metabolized by cyp2c9 , such as ddrug1 , may result in lower plasma concentrations of these drugs .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 ddrug1 ddrug2 , like other ddrug3 , may inhibit the metabolism of ddrug4 and ddrug5 .",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of ddrug0 # % ophthalmic solution , the possibility of an additive or potentiating effect with ddrug1 { ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 } should be considered .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 use may be rarely associated with ventricular fibrillation when combined with ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "although specific drug interaction studies have not been conducted with ddrug0 , the possibility of an additive or potentiating effect with ddrug1 { ddrug2 , ddrug3 , ddrug4 , ddrug5 , or ddrug6 } should be considered .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "previous studies have demonstrated a significant reduction in the oral bioavailability of ddrug0 and ddrug1 when administered concomitantly with an intravenous ddrug2 such as ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "caution should be observed when ddrug0 is coadministered with other ddrug1 , ddrug2 , ddrug3 , or ddrug4 , as these agents may increase respiratory and circulatory depression .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "other drugs drug interactions have been reported with concomitant administration of ddrug0 and other medications , including ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "ddrug0 , including ddrug1 , may enhance the effects of oral ddrug2 , including ddrug3 or its derivatives or similar agents .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "the effect may be mediated by ddrug0 s known inhibition of hepatic cytochrome p-450 , the enzyme system responsible for the first-pass metabolism of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 , as well as a metabolite of ddrug2 , slow ddrug3 metabolism .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "also , concomitant administration of ddrug0 with products containing ddrug1 , ddrug2 containing ddrug3 , or ddrug4 { ddrug5 } chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 s : ddrug1 increases the adrenergic effect of catecholamines such as ddrug2 and ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 or oral ddrug1 : ddrug2 may enhance the blood-sugar-reducing effect of ddrug3 and oral ddrug4 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "therefore , ddrug0 and ddrug1 should not be used concomitantly .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 markedly increases the metabolic clearance of ddrug1 , and coadministration is contraindicated .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "although it has not been definitively demonstrated that ddrug0 is a potent iiia4 inhibitor , it is likely to be , given the substantial interaction of ddrug1 with ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "int",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "myocardial injury , including myocardial infarction , myocarditis , ventricular hypokinesia , and severe rhabdomyolysis appear to be increased in patients receiving ddrug0 and ddrug1 concurrently .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "when ddrug0 is added to ddrug1 therapy , ddrug2 dose should be doubled .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in clinical trials , ddrug0 was used with ddrug1 , ddrug2 , ddrug3 , oral ddrug4 , and supplemental ddrug5 , in a pharmacokinetic substudy in patients with congestive heart failure receiving ddrug6 or ddrug7 in whom therapy with ddrug8 was initiated , apparent oral clearance values for ddrug9 { n = 23 } and ddrug10 { n = 30 } were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .",
        "triple_list": [
            [
                "ddrug6",
                "mechanism",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "ddrug0 : the concomitant use of ddrug1 { ddrug2 transdermal system } with other ddrug3 , including but not limited to other ddrug4 , ddrug5 , ddrug6 , ddrug7 { e , g , , ddrug8 } , general ddrug9 , ddrug10 , ddrug11 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 } : ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 } have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with ddrug7 .",
        "triple_list": [
            [
                "ddrug6",
                "effect",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "the pressor effects of ddrug0 such as ddrug1 or ddrug2 are enhanced by ddrug3 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of ddrug0 such as ddrug1 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "nephrotoxicity has been reported following concomitant administration of ddrug0 and ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "plasma levels of several closely related ddrug0 have been reported to be increased by the concomitant administration of ddrug1 or hepatic enzyme inhibitors { e , g , , ddrug2 , ddrug3 } and decreased by the concomitant administration of hepatic enzyme inducers { e , g , , ddrug4 , ddrug5 } , and such an effect may be anticipated with ddrug6 as well .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the action of the ddrug0 may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , or other drugs that produce cns depression .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "caution should be used when administering or taking ddrug0 with ddrug1 and other strong cyp3a4 inhibitors such as , but not limited to , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { ddrug12 } , and ddrug13 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the ddrug0 of drugs may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , the ddrug6 , ddrug7 and ddrug8 , ddrug9 and the ddrug10 , and by other ddrug11 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "ddrug0 : reports indicate that ddrug1 levels may be increased during concomitant treatment with ddrug2 for injection .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "concomitant administration of ddrug0 injection and ddrug1 in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "concurrent therapy with ddrug0 and ddrug1 is not recommended .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : isolated cases of conduction disturbance { rarely with hemodynamic compromise } have been observed when ddrug1 is co-administered with ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "caution should be exercised if ddrug0 and ddrug1 are used together .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the administration of ddrug0 concomitantly with known microsomal enzyme inducer { ddrug1 or ddrug2 } to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "if intravenous ddrug0 is required to treat pneumocystis carinii pneumonia , treatment with ddrug1 should be interrupted .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 : ddrug2 and ddrug3 can reduce absorption of ddrug4 ;",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as ddrug0 include certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 } , ddrug10 salts , ddrug11 , local ddrug12 , ddrug13 , and ddrug14 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug11"
            ]
        ]
    },
    {
        "text": "drugs that induce cyp3a4 { ddrug0 } racemic ddrug1 exposure was decreased 80 % by concomitant useof ddrug2 , a potent inducer of cyp3a4 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : coadministration of a 10-mg single dose of ddrug1 with ddrug2 { 166 mg/day for # days } , a potent inhibitor of cyp2d6 , increased the auc of ddrug3 by 112 % but decreased the auc of its active metabolite , ddrug4 , by 35 % .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "compounds in these categories result in a decreased efficacy of ddrug0 : ddrug1 , ddrug2 , ddrug3 , ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "the use of ddrug0 should be considered in place of ddrug1 or ddrug2 in patients receiving ddrug3 therapy .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "in patients receiving nonselective ddrug0 { ddrug1 } { e , g , , ddrug2 } in combination with ddrug3 { e , g , , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 } , there have been reports of serious , sometimes fatal , reactions .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "- when ddrug0 or ddrug1 is used concurrently with ddrug2 { e , g , ddrug3 } , an interval of at least # hours should be maintained between the two medicines , since the absorption of ddrug4 or ddrug5 is impaired",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 is a neutralizing agent for ddrug1 that protects against renal damage .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "wait # weeks after stopping an ddrug0 before starting ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "additive adverse effects resulting from cholinergic blockade may occur when ddrug0 is administered concomitantly with other ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 or some ddrug7 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "concomitant administration with racemic ddrug0 ddrug1 - since ddrug2 is the active isomer of racemic ddrug3 { ddrug4 } , the two agents should not be coadministered .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 , and ddrug2 may increase anticholinergic effect of ddrug3 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "if ddrug0 is to be combined with other ddrug1 such as ddrug2 or ddrug3 / ddrug4 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of ddrug5 and ddrug6 { e , g , , ddrug7 or ddrug8 } are additive .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit ddrug0 binding to serum proteins or alter the concentrations of serum binding proteins : ddrug1 and related ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : ddrug1 ; ddrug2 ; ddrug3 ; certain ddrug4 , especially the ddrug5 and ddrug6 ; ddrug7 ; ddrug8 salts ; ddrug9 ; and ddrug10 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "the oral ddrug0 doses should be reduced by approximately 50 % when coadministered with ddrug1 , to achieve exposures of ddrug2 similar to those obtained when it is given without ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "since ddrug0 and ddrug1 , including ddrug2 , may each be associated with increased serum potassium levels , the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : some individuals receiving ddrug1 may experience a reversible enhancement of the pressor response to indirect-acting ddrug2 , ddrug3 or ddrug4 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 increases the metabolism of ddrug2 and some ddrug3 { ddrug4 } resulting in decreased contraceptive effectiveness and increased menstrual irregularities .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "pretreatment of rats with ddrug0 { 100 mg/kg , ip } or ddrug1 { 100 mg/kg per day , ig , for # days and a dose of # mg/kg on the 4th day } provided significant protection against the elevation of tbars levels in cerebral and hepatic tissues , induced by single high dose of oral ddrug2 administration within # h.",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the elimination half life of ddrug0 and ddrug1 also increased { ## fold } during coadministration with ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 may diminish adrenal suppression by ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : modest increases in mean trough ddrug1 concentrations were observed following initiation of ddrug2 treatment in # renal transplant patients suffering from chronic vascular rejection .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "in a single subject given one dose of ddrug0 # hours after a dose of ddrug1 - placebo tablets , a greater than 50 % reduction in the auc of ddrug2 was observed .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "concurrent use of ddrug0 with ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , and ddrug5 } may result in increased ddrug6 effects .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "although the clinical significance is not known , it is not recommended that ddrug0 be taken concomitantly with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the concomitant use of ddrug0 tablets and other ddrug1 is not recommended due to the increased possibility of gastrointestinal toxicity , with little or no increase in efficacy .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the hypotensive effect of ddrug0 is augmented by that of most other ddrug1 , including ddrug2 , negative inotropic agents , and inhaled ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "reciprocal interactions may occur with concomitant use of ddrug0 and drugs that increase or inhibit the cytochrome cyp2b6 system { e , g , , ddrug1 , ddrug2 , ddrug3 , ddrug4 } , though this has not been studied",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit ddrug0 binding to serum proteins or alter the concentrations of serum binding proteins : ddrug1 and related ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "ddrug0 , including ddrug1 , may enhance the effects of oral ddrug2 , including ddrug3 or its derivatives or similar agents .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 and oral ddrug1 : concomitant administration of ddrug2 and/or other oral ddrug3 with ddrug4 must be avoided because of the risk of hypervitaminosis a.",
        "triple_list": [
            [
                "ddrug3",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug16"
            ]
        ]
    },
    {
        "text": "ddrug0 : when ddrug1 { 50 mg tid } was administered concomitantly with ddrug2 for two weeks , ddrug3 plasma concentrations increased by 98 % and prothrombin times were prolonged .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 ddrug1 may delay or reduce the absorption of concomitant oral medication such as ddrug2 , ddrug3 , ddrug4 { acidic } or ddrug5 { basic } , as well as ddrug6 ddrug7 , ddrug8 , thyroid and ddrug9 preparations , ddrug10 and ddrug11 , and ddrug12 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug11"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 may enhance the effects of : other ddrug3 s , ddrug4 , general ddrug5 , ddrug6 such as ddrug7 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "because there is a theoretical basis that these effects may be additive , use of ddrug0 - containing or ddrug1 { like ddrug2 or ddrug3 } and ddrug4 within # hours of each other should be avoided .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 } { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 } have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with ddrug6 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 has been reported to increase the ddrug1 requirements in human subjects ingesting these agents simultaneously .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "when taken orally , ddrug0 like ddrug1 may enhance the anticoagulant effect of ddrug2 - like drugs .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "when initiating a multi-day course of ddrug0 in a patient maintained on ddrug1 , the ddrug2 maintenance dose should be halved for the period of concurrent use of ddrug3 and monitoring of serum ddrug4 concentrations should be initiated as a guide to further dosage adjustments .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit ddrug0 binding to serum proteins or alter the concentrations of serum binding proteins : ddrug1 and related ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "nevertheless , clinical studies , as well as postmarketing observations have shown that ddrug0 can reduce the natriuretic effect of ddrug1 and ddrug2 in some patients .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "concurrent administration of drugs possessing nephrotoxic { e , g , , ddrug0 , ddrug1 } , myelotoxic { e , g , , ddrug2 chemotherapy } , cardiotoxic { e , g , , ddrug3 } or hepatotoxic { e , g , , ddrug4 , ddrug5 } effects with ddrug6 may increase toxicity in these organ systems .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "the concomitant use of ddrug0 s , vasoconstricting agents { such as ddrug1 } and some ddrug2 may result in severe hypertension .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 } chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with , or within # hours of , the administration of ddrug2 , because these products may interfere with absorption resulting in lower serum and urine levels of ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "catecholamine-depleting agents : patients taking both ddrug0 and a drug that can deplete catecholamines { e , g , , ddrug1 and ddrug2 } should be observed closely for signs of hypotension and/or severe bradycardia .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "in common with other ddrug0 , ddrug1 may reduce the efficacy of oral ddrug2",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of ddrug0 such as ddrug1 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "concurrent administration of ddrug0 and ddrug1 significantly reduces the level of exposure to ddrug2 , but it is unclear how soon after ddrug3 administration ddrug4 may be given safely .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "some reports have shown that the concomitant administration of ddrug0 with ddrug1 causes hypercalcemia .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 may enhance the effects of : other ddrug3 s , ddrug4 , general ddrug5 , ddrug6 such as ddrug7 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "concomitant administration of ddrug0 { equivalent to 145mg ddrug1 } with ddrug2 { 40 mg } once daily for # days has been shown to increase the mean cmax and auc values for ddrug3 by 36 % { range from 69 % decrease to 321 % increase } and 28 % { range from 54 % decrease to 128 % increase } , respectively , and for # - hydroxy-iso-pravastatin by 55 % { range from 32 % decrease to 314 % increase } and 39 % { range from 24 % decrease to 261 % increase } , respectively in # healthy adults .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "a possible drug interaction of ddrug0 and intravenous ddrug1 has been described .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 { eg , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , and ddrug15 } may have elevated plasma concentrations when coadministered with ddrug16 ;",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug16"
            ]
        ]
    },
    {
        "text": "- the action of ddrug0 and ddrug1 may be enhanced by ddrug2 or ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 may enhance the effects of ddrug1 , ddrug2 , ddrug3 , and other ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "when used in therapeutic doses , ddrug0 had a modest effect on the pharmacokinetics of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { intravenous and oral } , ddrug12 , ddrug13 / ddrug14 or ddrug15 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "agents that induce cyp3a4 { eg , ddrug0 } could cause an increase in ddrug1 clearance and lower blood levels .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 s : ddrug1 should be administered at least # hours after or # hours before dosing with ddrug2 because plasma concentrations of ddrug3 are decreased when administered with ddrug4 containing ddrug5 , ddrug6 , or ddrug7 .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "both ddrug0 and ddrug1 block ddrug2 - induced and ddrug3 - induced dopamine release in the nucleus accumbens ;",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "concomitant administration of ddrug0 doubled the auc for ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "although it has not been established that there is an interaction between ddrug0 and ddrug1 or other ddrug2 , caution is advised when ddrug3 is initiated in patients taking a ddrug4 or any other ddrug5 .",
        "triple_list": [
            [
                "ddrug3",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 : while a synergistic relationship with ddrug1 has been reported , concomitant use may increase the toxicity of ddrug2 by possibly increasing its cellular uptake and/or impairing its renal excretion .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "inhibitors of this isoenzyme { e , g , , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , grapefruit juice , ddrug7 , ddrug8 , ddrug9 , ddrug10 } should be cautiously coadministered with ddrug11 as they can potentially increase ddrug12 levels .",
        "triple_list": [
            [
                "ddrug3",
                "advise",
                "ddrug11"
            ]
        ]
    },
    {
        "text": "interactions with ddrug0 : ddrug1 { eg , ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 } should not be administered to a patient who has received or is receiving a course of therapy with a ddrug7 such as ddrug8 .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "oral ddrug0 may potentiate the hypoglycemic action of ddrug1 , eg , ddrug2 and ddrug3 , by inhibiting their metabolism in the liver .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "certain drugs including ddrug0 , ddrug1 , ddrug2 , and ddrug3 may reduce the hypoglycemic action of ddrug4 and other oral ddrug5 .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : ddrug1 ; ddrug2 ; ddrug3 ; certain ddrug4 , especially the ddrug5 and ddrug6 ; ddrug7 ; ddrug8 salts ; ddrug9 ; and ddrug10 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "plasma levels of several closely related ddrug0 have been reported to be increased by the concomitant administration of ddrug1 or hepatic enzyme inhibitors { e , g , , ddrug2 , ddrug3 } and decreased by the concomitant administration of hepatic enzyme inducers { e , g , , ddrug4 , ddrug5 } , and such an effect may be anticipated with ddrug6 as well .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "the effects of medicinal products with similar properties such as inotropes ddrug0 , ddrug1 , ddrug2 , ddrug3 and ddrug4 may be exacerbated by ddrug5 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "- drugs whose efficacy is impaired by ddrug0 include : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , oral ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 may delay intestinal absorption of ddrug2 ;",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "since ddrug0 may reduce pulse and blood pressure , caution in using drugs such as ddrug1 { ophthalmic and systemic } , ddrug2 , and ddrug3 is advised .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "a case report of one patient taking ddrug0 # mg and ddrug1 # mg three times a day resulted in increases in ddrug2 concentrations from # mg/l to # mg/l .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 should not be administered concomitantly with potent ddrug1 such as ddrug2 and ddrug3 as the potential for ototoxicity is enhanced by the combination .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "only ddrug0 enhances ddrug1 - induced increases in accumbal dopamine .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "therefore , when ddrug0 and ddrug1 are used concomitantly , serum ddrug2 levels should be closely monitored .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in a study of # male subjects { ages # to # years } who were extensive metabolizers of the cyp2d6 isoenzyme , daily doses of ddrug0 given as # mg twice daily followed by a single dose of # mg ddrug1 increased the cmax , auc , and t1/2 of ddrug2 by an average of approximately 2 - , 5 - and 2-fold , respectively .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 injection and potassium-depleting agents : when ddrug1 are administered concomitantly with potassium-depleting agents { e , g , , ddrug2 , ddrug3 } , patients should be observed closely for development of hypokalemia .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "due to a theoretical risk of a pharmacodynamic interaction , use of ddrug0 - containing or ddrug1 { like ddrug2 or ddrug3 } and ddrug4 within # hours of each other should be avoided { see a href = frova_od , htm #ci contraindications } .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "hypotension , av conduction disturbances , and left ventricular failure have been reported in some patients receiving ddrug0 when an oral ddrug1 was added to the treatment regimen .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "additionally , higher than expected ddrug0 levels have been observed when they are begun in patients already taking ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 also has no significant effect on the intracellular phosphorylation of ddrug1 , as shown in vitro in peripheral blood mononuclear cells or in two other cell_line { u937 and molt-4 } .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose ddrug0 and ddrug1 , specifically , ddrug2 , ddrug3 , ddrug4 and ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 , a trans-3 ,4 - dimethyl-4 - { 3-hydroxyphenyl } piperidine , prevents gastrointestinal effects of intravenous ddrug1 without affecting analgesia .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "coadministration of ddrug0 with oral ddrug1 or ddrug2 has resulted in elevated plasma concentrations of the latter two drugs .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "therefore , co-administration of ddrug0 with other drugs that are metabolized by this isozyme , including ddrug1 , ddrug2 , ddrug3 , and ddrug4 { e , g , , ddrug5 , ddrug6 and ddrug7 } , or that inhibit this enzyme { e , g , , ddrug8 } , should be approached with caution .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "patients receiving other ddrug0 , ddrug1 , ddrug2 , or other ddrug3 { including ddrug4 } concomitantly with ddrug5 and ddrug6 tablets may exhibit an additive cns depression .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "the vasodilating effects of ddrug0 may be additive with those of other ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : in controlled studies in healthy volunteers , ddrug1 either had no effect { one study } or was associated with modest increases , about 30 % { two studies } in steady-state serum ddrug2 concentrations .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 , as with other ddrug1 , should be administered with extreme caution to patients being treated with ddrug2 , ddrug3 , or drugs known to prolong the qtc interval because the action of ddrug4 on the cardiovascular system may be potentiated by these agents .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 decreases ddrug2 renal clearance and increases ddrug3 plasma levels .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "should it be decided to discontinue therapy in patients receiving ddrug0 and ddrug1 concurrently , the ddrug2 should be discontinued slowly over several days before the gradual withdrawal of ddrug3 .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , certain ddrug7 , ddrug8 , ddrug9 and ddrug10 , thereby delaying elimination and increasing blood levels of these drugs .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "in some patients , the administration of a ddrug0 can reduce the diuretic , natriuretic , and antihypertensive effects of ddrug1 , ddrug2 and ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "alkalinizing agents : gastrointestinal alkalinizing agents { ddrug0 , etc , } increase absorption of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "this interaction should be given consideration in patients taking ddrug0 concomitantly with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "concurrent administration of a ddrug0 with ddrug1 has been associated with an increased risk of serious infections and no significant additional efficacy over use of the ddrug2 alone .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "results : during treatment with ddrug0 , there was a statistically significant decrease in the median of the total clearance of ddrug1 , from # ml/h to # ml/h , among the volunteers who received # mg/d .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "although neither ddrug0 nor ddrug1 affected the proliferation of prostatic epithelium in rpmi1640 containing ddrug2 alone , they modify the mitogenic effect of ddrug3 and ddrug4 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "therophylline : a recent study has shown that concomitan administration of ddrug0 and ddrug1 may cause elevated plasma levels of ddrug2 , and in some instances a slight decrease in the elimination of ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "resistance to the neuromuscular blocking action of ddrug0 has been demonstrated in patients chronically administered ddrug1 or ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "concomitant use of ddrug0 and drugs that inhibit cyp3a4 { eg , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 } may increase exposure to ddrug12 and should be avoided .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 : the concomitant use of ddrug1 { ddrug2 transdermal system } with other ddrug3 , including but not limited to other ddrug4 , ddrug5 , ddrug6 , ddrug7 { e , g , , ddrug8 } , general ddrug9 , ddrug10 , ddrug11 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug10"
            ]
        ]
    },
    {
        "text": "cytochrome p-450 inducers , such as ddrug0 , ddrug1 and ddrug2 , induce ddrug3 metabolism , causing an approximately 30 % decrease in plasma ddrug4 levels .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "inhibitors of this isoenzyme { e , g , , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , grapefruit juice , ddrug7 , ddrug8 , ddrug9 , ddrug10 } should be cautiously coadministered with ddrug11 as they can potentially increase ddrug12 levels .",
        "triple_list": [
            [
                "ddrug6",
                "advise",
                "ddrug11"
            ]
        ]
    },
    {
        "text": "ddrug0 : because of the relationship of ddrug1 to ddrug2 , patients should be advised against taking ddrug3 containing ddrug4 to avoid additive toxic effects",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "this study demonstrates that concurrent administration of ddrug0 permits at least a twofold increase in dose and total exposure to ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : in normal volunteers , concomitant administration of ddrug1 and ddrug2 resulted in an approximate 50 % increase in plasma levels of ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "in patients who have been reported to be well controlled on ddrug0 receiving concurrent ddrug1 therapy , discontinuation of ddrug2 has been reported to decrease established steady-state serum ddrug3 levels and compromise their therapeutic effects .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "protein binding in vitro , ddrug0 interferes minimally or not at all with the protein binding of ddrug1 { 20 % decrease in binding } , ddrug2 , ddrug3 { 10 % decrease in binding } , or ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "rhabdomyolysis has been observed in patients receiving ddrug0 administered alone { at recommended dosages } or concomitantly with ddrug1 including ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "there have been reports of interactions of ddrug0 with ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug25"
            ]
        ]
    },
    {
        "text": "plasma levels of several closely related ddrug0 have been reported to be increased by the concomitant administration of ddrug1 or hepatic enzyme inhibitors { e , g , , ddrug2 , ddrug3 } and decreased by the concomitant administration of hepatic enzyme inducers { e , g , , ddrug4 , ddrug5 } , and such an effect may be anticipated with ddrug6 as well .",
        "triple_list": [
            [
                "ddrug5",
                "mechanism",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "certain drugs including ddrug0 , ddrug1 , ddrug2 , and ddrug3 may reduce the hypoglycemic action of ddrug4 and other oral ddrug5 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "the absorption of ddrug0 , ddrug1 , ddrug2 , ddrug3 , and ddrug4 was significantly decreased when given simultaneously with ddrug5 ;",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ventricular tachycardia induced by ddrug0 was generally converted to sinus rhythm following administration of ddrug1 , ddrug2 , or ddrug3 but not after administration of ddrug4 alone or after ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 should not be used concomitantly with other drugs known to prolong the qt interval : certain ddrug1 , including those of class ia { such as ddrug2 and ddrug3 } and class iii { such as ddrug4 } ;",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "serious anticholinergic symptoms { i , e , , severe dry mouth , urinary retention and blurred vision } have been associated with elevations in the serum levels of ddrug0 when ddrug1 therapy is initiated .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "agents with increased levels in the presence of ddrug0 : ddrug1 increases the plasma levels of the following agents : ddrug2 , ddrug3 { 6 } , and ddrug4 thus , if a patient has been titrated to a stable dosage on one of the agents in this category , and then begins a course of the treatment with ddrug5 , it is reasonable to expect that a dose decrease for the concomitant agent may be necessary .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "caution should be exercised when ddrug0 and ddrug1 are administered concomitantly .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "there is a single case report , which suggests that ddrug0 may interfere with ddrug1 absorption .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "concomitant use of ddrug0 with ddrug1 , ddrug2 , ddrug3 , or other ddrug4 may have an additive effect .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 { 20 mg qd } increased the concentration of ddrug1 { 40 mg qd } by about 60 % , and greater degrees of inhibition are expected with higher doses of ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "with oral ddrug0 treatment , ddrug1 such as ddrug2 have been noted to possibly increase the likelihood of hematologic reactions",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "edema has been reported in patients concomitantly receiving ddrug0 and ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may have additive effects with ddrug1 and other ddrug2 , e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "concomitant use of ddrug0 and ddrug1 increases the risk of cardiac arrhythmias .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 are all metabolized by the cytochrome p450iiia4 isozyme , and it has been demonstrated that ddrug3 , a potent inhibitor of iiia4 , blocks the metabolism of these drugs , resulting in increased plasma concentrations of parent drug .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "patients using cyp3a4 metabolized ddrug0 should have cholesterol levels monitored after ddrug1 is initiated to see whether the ddrug2 dose needs adjustment .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "patients receiving high doses of ddrug0 concomitantly with ddrug1 , as in rheumatic disease , may experience ddrug2 toxicity at lower doses because of competitive renal excretory sites .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "caution should be used when ddrug0 are administered concomitantly with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : the administration of ddrug1 to normal volunteers receiving ddrug2 decreased the renal clearance and significantly increased the plasma levels of ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug18"
            ]
        ]
    },
    {
        "text": "higher concentrations of ddrug0 { 10 { -8 } - 10 { -6 } m } or ddrug1 { 3 x 10 { -8 } - 10 { -7 } m } enhance the mitogenic activity of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "prolonged recovery time may occur if ddrug0 and/or ddrug1 are used concurrently with ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the ddrug0 of drugs may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , the ddrug6 , ddrug7 and ddrug8 , ddrug9 and the ddrug10 , and by other ddrug11 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 : concurrent administration of ddrug1 and ddrug2 resulted in 50 % lower serum ddrug3 concentrations .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "caution should be used when administering or taking ddrug0 with ddrug1 and other strong cyp3a4 inhibitors such as , but not limited to , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { ddrug12 } , and ddrug13 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 , given concomitantly with ddrug2 or # minutes following ddrug3 administration , decreased ddrug4 bioavailability by approximately 25 % .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "conclusions : ddrug0 inhibit the metabolism of ddrug1 that are metabolized by cyp3a4 { i , e , , ddrug2 , ddrug3 , ddrug4 , ddrug5 } .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "the risk of using ddrug0 in combination with other drugs has not been systematically evaluated , but ddrug1 may potentiate the side effects of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "although the occurrence has not been reported with ddrug0 , nephrotoxicity has been reported following concomitant administration of other ddrug1 and ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "there have been postmarketing reports of drug interactions when ddrug0 is coadministered with ddrug1 , resulting in qt prolongation , cardiac arrythmias , ventricular tachycardia , ventricular fibrulation , and torsades de pointes , most like due to inhibition of hepatic metabolism of ddrug2 by ddrug3 .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : increased activity of both ddrug1 and ddrug2 may occur when the two are used concurrently .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "spontaneous reports of serotonin syndrome associated with co-administration of ddrug0 and ddrug1 , including ddrug2 such as ddrug3 { ddrug4 } , have been reported .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 increases the metabolism of ddrug2 and some ddrug3 { ddrug4 } resulting in decreased contraceptive effectiveness and increased menstrual irregularities .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug20"
            ]
        ]
    },
    {
        "text": "the effects of ddrug0 are antagonized by ddrug1 such as ddrug2 and ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "although specific drug interaction studies have not been conducted with ddrug0 , the possibility of an additive or potentiating effect with ddrug1 { ddrug2 , ddrug3 , ddrug4 , ddrug5 , or ddrug6 } should be considered .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 { 800 mg t , i , d , } co-administered with ddrug2 # mg resulted in a 16-fold increase in ddrug3 auc , a 7-fold increase in ddrug4 cmax and a 2-fold increase in ddrug5 half-life .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 may be taken with a light meal # h following the administration of # mg of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "interactions with other cns agents : concurrent use of ddrug0 with all ddrug1 { eg , ddrug2 , ddrug3 , ddrug4 , other ddrug5 , general ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 and ddrug12 } may result in additive central nervous system depressant effects .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug10"
            ]
        ]
    },
    {
        "text": "there have been reports of interactions of ddrug0 with ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "the concomitant use of ddrug0 with other ddrug1 may increase the frequency and/or severity of dry mouth , constipation , blurred vision and other anticholinergic pharmacological effects .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "consequently , the effect of ddrug0 on the retention of ddrug1 was lower than on absorption .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "administration of ddrug0 with other cyp3a4 inhibitors { e , g , , ddrug1 # mg bid , ddrug2 # mg qd , ddrug3 # mg tid , ddrug4 # mg qd } resulted in increases in cmax of ddrug5 ranging from # - to # - fold and auc from # - to # - fold .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "{ ddrug0 may increase the responsiveness to ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "median gastric ph was significantly higher when ddrug0 was taken after ddrug1 administration ;",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "{ see clinical pharmacology } coadministration of ddrug0 and ddrug1 # mg daily resulted in a reduction of ddrug2 plasma levels by 38 % on average .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a ddrug0 , including ddrug1 , with multivalent cation-containing products such as ddrug2 or ddrug3 ddrug4 , ddrug5 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , ddrug8 , or ddrug9 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit ddrug0 binding to serum proteins or alter the concentrations of serum binding proteins : ddrug1 and related ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug17"
            ]
        ]
    },
    {
        "text": "although not observed in this study , adverse effects could potentially arise from co-administration of ddrug0 and ddrug1 by inhibition of tubular secretion via organic cationic transporter systems .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 { e , g , ddrug1 and ddrug2 } : agents of the ddrug3 , of which ddrug4 { ddrug5 } injection , usp is a member , have been shown to interact with ddrug6 of the ddrug7 , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .",
        "triple_list": [
            [
                "ddrug4",
                "mechanism",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "if replacing ddrug0 by ddrug1 therapy , the introduction of ddrug2 should be delayed for several days after ddrug3 administration has stopped .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "blood levels of ddrug0 increased 24 % when ddrug1 was coadministered with ddrug2 { nonselective inhibitor of cytochrome p-450 } for # days , and decreased 28 % with coadministration of ddrug3 { potent inducer of cytochrome p-450 } for # days .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "patients who are applying ddrug0 gel should not concurrently use products that contain ddrug1 { n , ddrug2 } , a common component of insect repellent products .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "in a multiple-dose study , ddrug0 caused a dose-related increase in the mean elimination half-life of ddrug1 , thereby decreasing the clearance of ddrug2 by up to 80 % and leading to a five-fold increase in the auc and the half-life of ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as ddrug1 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain ddrug2 such as ddrug3 , the ddrug4 and other ddrug5 , ddrug6 , certain ddrug7 such as the ddrug8 salts , and ddrug9 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma ddrug0 concentrations include : acute ddrug1 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug10"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 has been reported to cause coronary artery vasospasm , and its effect could be additive with ddrug2 { ddrug3 } injection , usp .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "- ddrug0 or ddrug1 { with hepatotoxic potential } must not be administered together with ddrug2 or ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "effect of ddrug0 in pediatric patients there was about a 22 % increase of apparent total body clearance of ddrug1 when it was co-administered with enzyme-inducing ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 } : increase the metabolism of ddrug6 and/or some ddrug7 , leading to possible decrease in contraceptive effectiveness .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "ddrug0 : since ddrug1 is a ddrug2 , it is possible that ddrug3 , such as the ddrug4 { ddrug5 , ddrug6 , ddrug7 } or ddrug8 , may diminish the effectiveness of ddrug9 .",
        "triple_list": [
            [
                "ddrug5",
                "effect",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "therefore , coadministration of ddrug0 with drugs that strongly induce cyp3a4 activity { e , g , , ddrug1 , ddrug2 , ddrug3 } may result in reduced plasma concentrations of ddrug4 that may result in decreased efficacy of ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 has additive effects with ddrug1 and other ddrug2 { ddrug3 , ddrug4 , ddrug5 , etc } .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 supplements , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 salts may reduce the bioavailability of ddrug1 and ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "previous studies have demonstrated a significant reduction in the oral bioavailability of ddrug0 and ddrug1 when administered concomitantly with an intravenous ddrug2 such as ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "cardiac effects of ddrug0 are antagonized by ddrug1 , such as ddrug2 and ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as ddrug0 include certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 } , ddrug10 salts , ddrug11 , local ddrug12 , ddrug13 , and ddrug14 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug14"
            ]
        ]
    },
    {
        "text": "ddrug0 containing ddrug1 and ddrug2 reduce the oral absorption of ddrug3 by 75 % .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "although no studies have been conducted , concomitant administration of ddrug0 and ddrug1 may alter the metabolism of ddrug2 ;",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 } blood levels may be increased and prolonged by concurrent administration of ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : concomitant administration with ddrug1 may increase the risk of gastrointestinal ulceration and may reduce serum salicylate levels .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "because ddrug0 has not been shown to produce any additional effect beyond that obtained with ddrug1 alone and because ddrug2 increases the rate of excretion of ddrug3 , the concomitant use of ddrug4 and ddrug5 is not recommended .",
        "triple_list": [
            [
                "ddrug4",
                "advise",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "and ddrug0 , { ddrug1 } , chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of ddrug2 , resulting in systemic levels considerably lower than desired .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "conclusions : ddrug0 inhibit the metabolism of ddrug1 that are metabolized by cyp3a4 { i , e , , ddrug2 , ddrug3 , ddrug4 , ddrug5 } .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "medications can interfere with folate utilization , including : ddrug0 { such as ddrug1 , and ddrug2 } ddrug3 { sometimes prescribed to control blood sugar in type # diabetes } ddrug4 { used to control inflammation associated with crohn_disease and ulcerative colitis } ddrug5 { a ddrug6 } ddrug7 there has been concern about the interaction between ddrug8 and ddrug9 .",
        "triple_list": [
            [
                "ddrug8",
                "int",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "ddrug0 , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , certain ddrug7 , ddrug8 , ddrug9 and ddrug10 , thereby delaying elimination and increasing blood levels of these drugs .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "nephrotoxic agents : concomitant administration of ddrug0 and agents with nephrotoxic potential -lsb- e , g , , intravenous ddrug1 { e , g , , ddrug2 , ddrug3 , and ddrug4 } , ddrug5 , ddrug6 , intravenous ddrug7 , ddrug8 , and ddrug9 -rsb- is contraindicated .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "certain drugs , including ddrug0 { ddrug1 } , ddrug2 , ddrug3 , and ddrug4 may potentiate the hypoglycemic action of ddrug5 and other oral ddrug6 .",
        "triple_list": [
            [
                "ddrug4",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "hyperpyrexia has been reported when ddrug0 is administered with ddrug1 agents or with ddrug2 drugs , particularly during hot weather .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the effect of ddrug0 on the ddrug1 requirement of our patient appeared to be maximal # to # days after the initiation of ddrug2 and extended a similar length of time after ddrug3 withdrawal .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "- drugs whose efficacy is impaired by ddrug0 include : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , oral ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "concomitant use of ddrug0 and drugs that inhibit cyp3a4 { eg , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 } may increase exposure to ddrug12 and should be avoided .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "concomitant administration of ddrug0 and ddrug1 is not recommended because ddrug2 is displaced from its binding sites during the concomitant administration of ddrug3 , resulting in lower plasma concentrations and peak plasma levels .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "evidence supporting the conclusion that it is inadvisable to co-administer ddrug0 and ddrug1 is derived from a study in which healthy volunteers taking # mg/day of ddrug2 were administered a single oral dose of # mg of ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 - in a controlled study , a single dose of ddrug2 # mg co-administered with racemic ddrug3 # mg given once daily for # days was associated with a mean increase in qtc values of approximately # msec compared to ddrug4 given alone .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 , when given as # mg on day # and # mg/day on days # and 3 , decreased the auc of ddrug2 { a cyp2c9 substrate } by 23 % on day 4 , 28 % on day 8 , and 15 % on day 15 , when a single dose of ddrug3 # mg was admini , stered orally prior to the administration of the 3-day regimen of ddrug4 and on days 4,8 , and 15 .",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "it is advisable to check coagulation time within the first few days after the start and discontinuation of ddrug0 therapy , with an appropriate adjustment of the ddrug1 dose , if necessary .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "co-administration of ddrug0 at steady-state with a single dose of ddrug1 { 2 x # mg tablets } results in increased ddrug2 serum concentrations .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 , ddrug2 , etc , } increase the concentration of the ionized species of the ddrug3 molecule , thereby increasing urinary excretion .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "therefore , caution should be used when administering ddrug0 concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices , as competition for binding sites may occur { e , g , , ddrug1 } .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "before taking ddrug0 , tell your doctor if you are taking any of the following medicines : - ddrug1 or another ddrug2 such as ddrug3 { ddrug4 } , ddrug5 { ddrug6 , others } , ddrug7 { ddrug8 } , ddrug9 { ddrug10 } , or ddrug11 { ddrug12 } ;",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug10"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 should be prescribed with caution to patients on ddrug2 or other drugs that act on the central nervous system , regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : co-administration of a single dose of intravenously administered ddrug1 { 20 mg } reduced the oral absorption of a single # mg dose of ddrug2 administered following a meal , as evidenced by a 27 % decrease in mean cmax and a 22 % decrease in mean auc .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : reports suggest that ddrug1 may diminish the antihypertensive effect of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 has been shown to induce the metabolism of ddrug1 and ddrug2 , which are metabolized through cyp2c9 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "concurrent administration of ddrug0 and ddrug1 may cause severe orthostatic hypotension , ddrug2 , an inhibitor of microsomal drug metabolism , increased ddrug3 s half-life and toxicity in a rat model .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 significantly prolonged the half-life of ddrug1 to # hours .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "concomitant administration of ddrug0 and ddrug1 has been reported to result in elevated ddrug2 serum levels .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : coadministration of single doses of ddrug1 # mg and ddrug2 # mg produced additive effects on decreased alertness and impaired psychomotor performance for # to # hours after administration .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the ecg changes and/or hypokalemia that may result from the administration of ddrug0 { such as ddrug1 or ddrug2 } can be acutely worsened by ddrug3 , especially when the recommended dose of the ddrug4 is exceeded .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "this increase is due to the inhibition of ddrug0 metabolism via cyp2b6 2c9 by ddrug1 { see clinical pharmacology - pharmacokinetics : metabolism } .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "other ddrug0 { e , g , ddrug1 , ddrug2 , ddrug3 and general ddrug4 } have additive or potentiating effects with ddrug5 .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug36"
            ]
        ]
    },
    {
        "text": "ddrug0 { eg , ddrug1 } and other drugs , including ether , ddrug2 , ddrug3 , ddrug4 and ddrug5 , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with ddrug6 parenteral .",
        "triple_list": [
            [
                "ddrug5",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 may enhance the effects of : other ddrug3 s , ddrug4 , general ddrug5 , ddrug6 such as ddrug7 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "the administration of local ddrug0 containing ddrug1 or ddrug2 to patients receiving ddrug3 or ddrug4 may produce severe , prolonged hypertension .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 , including oral , injectable , transdermal , and implantable ddrug1 : an interaction study demonstrated that co-administration of ddrug2 and the oral ddrug3 ddrug4 produced average decreases of ddrug5 and ddrug6 levels of 14 % and 31 % , respectively .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "ddrug0 : clinical studies , as well as random observations , have shown that ddrug1 can reduce the natriuretic effect of ddrug2 and ddrug3 in some patients .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 ddrug2 may enhance the activity of ddrug3 or ddrug4 ;",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "patients receiving other ddrug0 s , general ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 or other ddrug6 { including ddrug7 } concomitantly with ddrug8 may exhibit an additive cns depression .",
        "triple_list": [
            [
                "ddrug4",
                "effect",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "based on adult data , lower doses of ddrug0 may be needed following coadministration of drugs which are reported to decrease ddrug1 elimination { e , g , , ddrug2 and ddrug3 } and higher ddrug4 doses may be needed following coadministration of drugs that increase ddrug5 elimination { e , g , , ddrug6 and ddrug7 } .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the concurrent use of ddrug0 and ddrug1 { ddrug2 } has been reported to result in fatal renal toxicity .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "patients who begin taking ddrug0 or who increase their ddrug1 dose or any other ddrug2 while taking ddrug3 , ddrug4 , or ddrug5 may develop toxicity characteristics for these drugs .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 , and ddrug2 decrease the half-life of ddrug3 .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "paralytic ileus may occur in patients taking ddrug0 in combination with ddrug1 - type drugs .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "other ddrug0 { e , g , ddrug1 , ddrug2 , ddrug3 and general ddrug4 } have additive or potentiating effects with ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "in a small { n = 30 } combination study of ddrug0 with ddrug1 , a 2 - to 3-fold elevation in liver enzymes was seen in # of # patients .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "concurrent use of ddrug0 with ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , and ddrug5 } may result in increased ddrug6 effects .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : concurrent administration of certain ddrug1 , such as ddrug2 and ddrug3 , would be expected to compromise the beneficial effects of ddrug4 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "because ddrug0 is a serotonin releaser and reuptake inhibitor , ddrug1 should not be used concomitantly with a ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of ddrug0 # % ophthalmic solution , the possibility of an additive or potentiating effect with ddrug1 { ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 } should be considered .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 : in a pharmacokinetic study , maximum plasma concentrations of ddrug1 were considerably lower in epileptic patients on long-term ddrug2 therapy { eg , ddrug3 , ddrug4 , or ddrug5 } than in healthy volunteers .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 significantly increased the area under the curve at steady state { auc { ss } } of ddrug1 by # - fold and the auc { ss } of ddrug2 by # - fold .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 at 10 { -10 } m or ddrug1 at about # x 10 { -9 } m inhibits proliferation stimulated by ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "increases in plasma levels of ddrug0 , and in the frequency and severity of side effects , particularly ddrug1 , have been reported when ddrug2 was added to the ddrug3 regimen .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "it is recommended that the combination of intravenous ddrug0 and ddrug1 , such as ddrug2 , not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "repeated doses of ddrug0 given prior to a single dose of ddrug1 in human trials have been reported to decrease ddrug2 absorption .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "therefore , when ddrug0 is given with ddrug1 or ddrug2 , a period of at least # hours after the last intravenous dose or # hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 } : increase the metabolism of ddrug6 and/or some ddrug7 , leading to possible decrease in contraceptive effectiveness .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "dosage adjustment of ddrug0 may be necessary when coadministered with cyp2d6 inhibitors , e , g , , ddrug1 , ddrug2 , and ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "-lsb- the gaba-ergic system and brain edema -rsb- it has been shown in rats with experimental toxic and traumatic edemas that ddrug0 { 1 mg/kg } removes the antiedematous action of ddrug1 , ddrug2 , ddrug3 and ddrug4 and reduces the action of ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "in patients receiving nonselective ddrug0 { ddrug1 } { e , g , , ddrug2 } in combination with ddrug3 { e , g , , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 } , there have been reports of serious , sometimes fatal , reactions .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 , ddrug2 , ddrug3 , and ddrug4 have been shown to decrease plasma levels of ddrug5 ;",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "the potentiating action of ddrug0 must be considered when the drug is used in conjunction with ddrug1 such as ddrug2 , ddrug3 and ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "administration of ddrug0 to patients receiving ddrug1 or ddrug2 such as ddrug3 which sensitize the myocardium , may induce cardiac arrhythmia , .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the concomitant administration of ddrug0 including ddrug1 with ddrug2 { a ddrug3 } has , on rare occasions , resulted in severe hypoglycemia .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "before taking ddrug0 , tell your doctor if you are taking any of the following medicines : - ddrug1 or another ddrug2 such as ddrug3 { ddrug4 } , ddrug5 { ddrug6 , others } , ddrug7 { ddrug8 } , ddrug9 { ddrug10 } , or ddrug11 { ddrug12 } ;",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "ddrug0 : since ddrug1 is a ddrug2 , it is possible that ddrug3 , such as the ddrug4 { ddrug5 , ddrug6 , ddrug7 } or ddrug8 , may diminish the effectiveness of ddrug9 .",
        "triple_list": [
            [
                "ddrug7",
                "effect",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "reports suggest that ddrug0 may diminish the antihypertensive effect of ddrug1 , including ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "substances that are potent inhibitors of cyp3a4 activity { eg , ddrug0 and ddrug1 } decrease ddrug2 metabolism and increase ddrug3 plasma concentrations .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 administration of ddrug2 or ddrug3 in patients { n = 13 } and volunteers { n = 96 } resulted in a rapid and significant decrease in plasma m1 { the active metabolite of ddrug4 } concentration .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 , as well as other ddrug2 , probably reduces the tubular secretion of ddrug3 based on in vitro studies in rabbit kidney slices .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "steady-state ddrug0 plasma concentrations were 3 - to 4-fold higher than in the absence of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "consequently , it is recommended not to exceed a single # mg ddrug0 dose in a 72-hour period when used in combination with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "therefore , cyp3a4 substrates known to have a narrow therapeutic index such as ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , or ddrug10 { ddrug11 , ddrug12 } should be administered with caution in patients receiving ddrug13 .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug13"
            ]
        ]
    },
    {
        "text": "ddrug0 : a recent case study has shown a possible increase in the plasma level of ddrug1 when co administered with ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 and other ddrug2 have been reported to reduce the tubular secretion of ddrug3 in an animal model , possibly increasing the toxicity of ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "although a 3-day regimen of ddrug0 given concomitantly with oral ddrug1 has not been studied , alternative or back-up methods of contraception should be used .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 - containing preparations { eg , ddrug2 } may cause hypermagnesemia and should therefore not be taken during therapy with ddrug3 by patients on chronic renal dialysis .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 anesthesia : severe hypotension has been reported during ddrug1 anesthesia with concomitant use of a ddrug2 and a ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 may have life-threatening interactions with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "as with other ddrug0 , it should be noted that ddrug1 may be capable of potentiating ddrug2 such as ddrug3 , ddrug4 , and ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "additive adverse effects resulting from cholinergic blockade may occur when ddrug0 is administered concomitantly with other ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 or some ddrug7 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "the administration of local ddrug0 containing ddrug1 or ddrug2 to patients receiving ddrug3 or ddrug4 may produce severe , prolonged hypertension .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "the potential for increased sedation when ddrug0 is given with other ddrug1 should be appreciated .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "nephrotoxic agents : concomitant administration of ddrug0 and agents with nephrotoxic potential -lsb- e , g , , intravenous ddrug1 { e , g , , ddrug2 , ddrug3 , and ddrug4 } , ddrug5 , ddrug6 , intravenous ddrug7 , ddrug8 , and ddrug9 -rsb- is contraindicated .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "ddrug0 is a novel ddrug1 that may selectively prevent ddrug2 - induced gastrointestinal effects without reversing analgesia .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "coadministration with compounds that are potent inducers of cyp3a4 { eg , ddrug0 , ddrug1 , ddrug2 , ddrug3 } may result in decreased plasma levels of ddrug4 .",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 may decrease ddrug1 response to ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "concomitant oral administration of ddrug0 { a known inhibitor of cyp3a4 activity in the liver and in the intestinal mucosa } caused an eight-fold increase of the systemic exposure to oral ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "inhibitors or substrates of cyp2d6 { i , e , , ddrug0 , ddrug1 -lsb- ddrug2 -rsb- } may increase the plasma concentration of ddrug3 when administered concomitantly .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 , as with other ddrug1 , should be administered with extreme caution to patients being treated with ddrug2 , ddrug3 , or drugs known to prolong the qtc interval because the action of ddrug4 on the cardiovascular system may be potentiated by these agents .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "since ddrug0 is coadministered with ddrug1 , the ddrug2 label should be reviewed for additional drugs that should not be coadministered .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : some individuals receiving ddrug1 may experience a reversible enhancement of the pressor response to indirect-acting ddrug2 , ddrug3 or ddrug4 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 has been reported to decrease the metabolism of certain ddrug2 by up to 60 % , leading to increased risk of ddrug3 side effects .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 injection and ddrug1 should not be administered simultaneously because both drugs are direct cardiac stimulants and their combined effects may induce serious arrhythmias .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 with ddrug1 or ddrug2 and possibly other ddrug3 cause striking and sustained increases in the concentration of ddrug4 in the brain ;",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the rate of metabolism and the leukopenic activity of ddrug0 reportedly are increased by chronic administration of high doses of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 } { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 } have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with ddrug6 .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 { 200 mg once daily } produced a 10-fold increase in ddrug1 auc and a 4-fold increase in cmax when co-administered with ddrug2 { 5 mg } in healthy volunteers .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "pharmacokinetic data from these patients demonstrated a decrease in ddrug0 clearance of approximately 33 % when ddrug1 was administered following ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit ddrug0 binding to serum proteins or alter the concentrations of serum binding proteins : ddrug1 and related ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "protein binding in vitro , ddrug0 interferes minimally or not at all with the protein binding of ddrug1 { 20 % decrease in binding } , ddrug2 , ddrug3 { 10 % decrease in binding } , or ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in patients on chronic ddrug0 therapy , the prothrombin time { inr } should be closely monitored in the 2-week period , particularly at # to # days , following initiation of the 3-day regimen of ddrug1 with each chemotherapy cycle .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 } : steady state plasma exposure { auc } of ddrug2 { 40 mg bid for # days } was decreased by 27 % when co-administered with multiple doses { 300 mg qd for # days } of ddrug3 { a ppig 3a4 inducer } .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "drugs that induce hepatic enzymes such as ddrug0 , ddrug1 and ddrug2 may increase the clearance of ddrug3 and may require increases in ddrug4 dose to achieve the desired response .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "inhibitors of this isoenzyme { e , g , , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , grapefruit juice , ddrug7 , ddrug8 , ddrug9 , ddrug10 } should be cautiously coadministered with ddrug11 as they can potentially increase ddrug12 levels .",
        "triple_list": [
            [
                "ddrug9",
                "advise",
                "ddrug11"
            ]
        ]
    },
    {
        "text": "agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 { 2 } , ddrug7 , ddrug8 , and ddrug9 thus , if a patient has been titrated to a stable dosage on ddrug10 , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for ddrug11 may be necessary .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "although there are no study data to evaluate the possibility , ddrug0 , including ddrug1 and ddrug2 , may have an additive effect with ddrug3 on the risk of developing methemoglobinemia .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 should be used with caution in those patients reveiving ddrug1 and its congeners .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 therapy urinary excretion of ddrug1 is increased , and efficacy is reduced by acidifying agents used in ddrug2 therapy .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 , an inhibitor of cyp2b6 2c9 , decreased active metabolite concentration and increased ddrug1 concentration .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "data from in vitro studies of ddrug0 other than ddrug1 suggest a possible drug interaction for the following : ddrug2 , ddrug3 , ddrug4 , ddrug5 , and ddrug6 .",
        "triple_list": [
            [
                "ddrug1",
                "int",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "in patients receiving nonselective ddrug0 { ddrug1 } { e , g , , ddrug2 } in combination with ddrug3 { e , g , , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 } , there have been reports of serious , sometimes fatal , reactions .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "- when ddrug0 or ddrug1 is used concurrently with ddrug2 { e , g , ddrug3 } , an interval of at least # hours should be maintained between the two medicines , since the absorption of ddrug4 or ddrug5 is impaired",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "immediate and extended release tablets the hypoglycemic action of ddrug0 may be potentiated by certain drugs including ddrug1 , some ddrug2 and other drugs that are highly protein bound , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "since ddrug0 in high doses has been associated with hepatotoxicity , concomitant administration of ddrug1 and ddrug2 should be used cautiously , with careful monitoring of patients .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "absorption of ddrug0 is impaired by ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , and ddrug5 - containing preparations .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "this interaction , which has not been investigated using higher doses of ddrug0 , may be more pronounced if a # mg daily dose is co-administered , particularly since ddrug1 exhibits non-linear pharmacokinetics over the dosage range 100-300 mg , if ddrug2 is co-administered with ddrug3 tablets , the initial ddrug4 dosage should be at least halved and titration to the lowest effective dose is recommended .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "aortic rings with intact endothelium from the high-dose { 4 mg/kg/day } ddrug0 group were supersensitive to ddrug1 compared to the vehicle or low-dose { 10 microg/kg/day } estradiol groups { pd2 values = # + / # , # + / # and # + / # , respectively } .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 may decrease the effects of ddrug2 , ddrug3 , and ddrug4 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 dose should not exceed a maximum of # mg in a 72 - hour period in patients receiving concomitant ddrug1 therapy .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "given the primary cns effects of ddrug0 , caution is advised in using it concomitantly with other cns-active drugs or ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "animal studies indicate that ddrug0 may be ineffective if the patient has recently received a ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "since bacteriostatic drugs may interfere with the bactericidal action of ddrug0 , it is advisable to avoid giving ddrug1 in conjunction with ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : drugs such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 and others that interfere with platelet-aggregation reactions { the main hemostatic defense of heparinized patients } may induce bleeding and should be used with caution in patients receiving ddrug8 .",
        "triple_list": [
            [
                "ddrug6",
                "effect",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "ddrug0 : when ddrug1 { 100 mg qd } and ddrug2 { 1 mg q , d , were co-administered to steady state , plasma concentration and other pharmacokinetics parameters { auc , cmax , t1/2 , } of ddrug3 were approximately twice those observed when ddrug4 was administered alone ;",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 and other ddrug1 : co-administration of ddrug2 decreased the plasma concentrations of ddrug3 { a cyp3a4 substrate } , and its active - hydroxy acid metabolite , by approximately 50 % .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "if concomitant treatment with ddrug0 and an ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } is clinically warranted , appropriate observation of the patient is advised .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "the possibility of hypotensive effects can be minimized by either discontinuing the ddrug0 or increasing salt intake prior to initiation of treatment with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug10"
            ]
        ]
    },
    {
        "text": "the mean percentage increase in the ddrug0 auc after ddrug1 administration was # % { range : # to 81 } .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "there are rare reports , however , from marketing experiences , of changes in effects of ddrug0 or oral ddrug1 in the presence of ddrug2 that necessitated changes in the doses of such agents .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "therefore , ddrug0 and ddrug1 should not be used concomitantly .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in addition , results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance { ddrug0 , ddrug1 , ddrug2 , ddrug3 , or ddrug4 } with ddrug5 may result in clinically meaningful reductions in ddrug6 concentrations .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "nevertheless , caution is indicated in the co-administration of ddrug0 with any of the ddrug1 and also in switching from one class to the other .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "effects of other antiepilepsy drugs { ddrug0 } on ddrug1 : ddrug2 : population pharmacokinetic analyses indicate that ddrug3 clearance is 60 % greater in patients taking ddrug4 with or without other enzyme - inducing ddrug5 .",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "therefore , co-administration of ddrug0 with other drugs that are metabolized by this isozyme , including ddrug1 , ddrug2 , ddrug3 , and ddrug4 { e , g , , ddrug5 , ddrug6 and ddrug7 } , or that inhibit this enzyme { e , g , , ddrug8 } , should be approached with caution .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 pretreatment attenuated the hypotensive effect of a single dose of ddrug1 but not ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "these alterations in ddrug0 pharmacokinetics produced by ddrug1 explain the increase in serum ddrug2 level that has been observed when this drug combination has been used clinically .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "although ddrug0 has a lower affinity for ddrug1 than for ddrug2 , ddrug3 should not be taken with ddrug4 - containing ddrug5 .",
        "triple_list": [
            [
                "ddrug3",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 or ddrug1 administered with ddrug2 / ddrug3 to achieve # mac -lsb- minimum alveolar concentration -rsb- may prolong the clinically effective duration of action of initial and maintenance doses of ddrug4 and decrease the required infusion rate of ddrug5 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 could exaggerate the depression of av nodal conduction observed with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "however , because bleeding has been reported when ddrug0 and other ddrug1 have been administered to patients on ddrug2 , the physician should be cautious when administering ddrug3 to patients on ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 significantly decreases clearance of ddrug1 and ddrug2 , and the combination is poorly tolerated .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "although there are no study data to evaluate the possibility , ddrug0 , including ddrug1 and ddrug2 , may have an additive effect with ddrug3 on the risk of developing methemoglobinemia .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 may add to or potentiate the therapeutic effect of other ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "other depressasnts such as ddrug0 , ddrug1 , and ddrug2 may enhance cns depression when administered with ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "serious toxicity may result if ddrug0 is coadministered with ddrug1 { ddrug2 } .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "epidemiological studies of the case-control and cohort design that have demonstrated an association between use of ddrug0 that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an ddrug1 or ddrug2 potentiated the risk of bleeding .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 , or other products containing ddrug1 or ddrug2 , ddrug3 or ddrug4 should not be administered concomitantly with , or within # hours of , the administration of ddrug5 , because they may interfere with absorption resulting in lower serum and urine levels of ddrug6 .",
        "triple_list": [
            [
                "ddrug3",
                "advise",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "dose reduction of ddrug0 to # mg every # hours is recommended when administering ddrug1 concurrently .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "concomitant administration of ddrug0 and ddrug1 is contraindicated .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in particular , convulsions have been reported when ddrug0 is administered with ddrug1 and special care should be taken when the treatment regimen includes both of these drugs .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : drugs such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 and others that interfere with platelet-aggregation reactions { the main hemostatic defense of heparinized patients } may induce bleeding and should be used with caution in patients receiving ddrug8 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and ddrug7 raise the serum ddrug8 concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that ddrug9 intoxication may result .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "ddrug0 : hallucinations have been reported when ddrug1 was used in patients taking ddrug2 { ddrug3 , ddrug4 , ddrug5 } .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug35"
            ]
        ]
    },
    {
        "text": "ddrug0 also should be used cautiously with other drugs { e , g , , ddrug1 , ddrug2 } that sensitize the myocardium to the actions of ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "inhibitors of cyp1a2 : concomitant use of ddrug0 with ddrug1 , an inhibitor of cyp1a2 , results in approximately a 6-fold increase in auc and about a # - fold increase in cmax of ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the concomitant use of other cyp3a4 inhibitors such as ddrug0 and ddrug1 with transdermal ddrug2 may also result in an increase in ddrug3 plasma concentrations , which could increase or prolong adverse drug effects and may cause serious respiratory depression .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the effects of ddrug0 were very strong and completely depressed the ddrug1 - induced hyperlocomotion .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 or ddrug1 administered with ddrug2 / ddrug3 to achieve # mac -lsb- minimum alveolar concentration -rsb- may prolong the clinically effective duration of action of initial and maintenance doses of ddrug4 and decrease the required infusion rate of ddrug5 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "when used in therapeutic doses , ddrug0 had a modest effect on the pharmacokinetics of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { intravenous and oral } , ddrug12 , ddrug13 / ddrug14 or ddrug15 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug12"
            ]
        ]
    },
    {
        "text": "in vitro mixing of an ddrug0 with beta-lactamtype ddrug1 { ddrug2 or ddrug3 } may result in a significant mutual inactivation .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "caution is advised when ddrug0 is coadministered with other medications that can prolong the qt interval { e , g , certain ddrug1 or ddrug2 } or lead to electrolyte abnormalities { such as ddrug3 or ddrug4 } .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "in a study involving healthy subjects receiving ddrug0 and ddrug1 concurrently , plasma ddrug2 levels were increased about 20 % and ddrug3 levels were increased about 30 % compared to control values .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "injection : ddrug0 injection , like other injectable ddrug1 , produces depression of the central nervous system when administered with ddrug2 , ddrug3 , ddrug4 , ddrug5 , and other ddrug6 , when ddrug7 is used concomitantly with injectable ddrug8 , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 / ddrug1 : long-term suppression of gastric acid secretion by ddrug2 or ddrug3 { eg , ddrug4 and ddrug5 } is likely to reduce ddrug6 exposure .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "the successive application of ddrug0 { 5 or # mg/kg egg weight { e , w , } and ddrug1 { 15 mg/kg e , w , } in a # min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of ddrug2 alone .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "use lowest possible dose of ddrug0 with careful monitoring , or consider ddrug1 that are not primarily metabolized by cyp3a4 , such as ddrug2 , ddrug3 , or ddrug4 in combination with ddrug5 .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 - there is one report that ddrug1 may decrease the possible effectiveness of supplemental ddrug2 for chemotherapy-induced mucositis .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 , and ddrug2 decrease the half-life of ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "we report the case of an adolescent with altered consciousness caused by ddrug0 overdose with a positive ddrug1 level to alert clinicians to the cross-reactivity of ddrug2 with a toxicology screen for ddrug3 .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "multiple-dose administration of the potent cyp3a4 inducer ddrug0 { 600 mg every # hours , q24h , for # days } , however , reduced ddrug1 cmax and auc by approximately 80 % .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma ddrug0 concentrations include : acute ddrug1 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 protects mouse tumour and normal tissues from the toxicity of oral ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "however , in a study of # normal subjects , concurrent administration of ddrug0 decreased ddrug1 protein binding and increased ddrug2 plasma clearance from # l/kg/h without ddrug3 to # l/kg/h with ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , certain ddrug7 , ddrug8 , ddrug9 and ddrug10 , thereby delaying elimination and increasing blood levels of these drugs .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug10"
            ]
        ]
    },
    {
        "text": "concurrent administration of ddrug0 and ddrug1 may cause severe orthostatic hypotension , ddrug2 , an inhibitor of microsomal drug metabolism , increased ddrug3 s half-life and toxicity in a rat model .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 may augment the hypotension caused by the ganglionic-blocking effect of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "when ddrug0 was applied to the muscle in the presence of ddrug1 , both first and second contractile responses to ddrug2 were abolished .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 s plasma half-life may be prolonged by ddrug2 , since ddrug3 and ddrug4 may compete for excretion in the renal tubule .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 } blood levels may be increased and prolonged by concurrent administration of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : ddrug1 ; ddrug2 ; ddrug3 ; certain ddrug4 , especially the ddrug5 and ddrug6 ; ddrug7 ; ddrug8 salts ; ddrug9 ; and ddrug10 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 may enhance the effects of : other ddrug3 s , ddrug4 , general ddrug5 , ddrug6 such as ddrug7 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "nephrotoxicity has been reported following concomitant administration of ddrug0 with ddrug1 or potent ddrug2 such as ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 should be used with care when ddrug1 or inhibitors of av conduction , such as certain ddrug2 { particularly of the ddrug3 -lsb- ddrug4 -rsb- and ddrug5 -lsb- ddrug6 -rsb- classes } , or ddrug7 , such as ddrug8 , are used concurrently .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "ddrug0 or ddrug1 administered with ddrug2 / ddrug3 to achieve # mac -lsb- minimum alveolar concentration -rsb- may prolong the clinically effective duration of action of initial and maintenance doses of ddrug4 and decrease the required infusion rate of ddrug5 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "concomitant administration of ddrug0 with ddrug1 resulted in a 45 % increase in systemic exposure to ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "accordingly , when ddrug0 is administered with oral ddrug1 , the prothrombin time should be closely monitored during and for several days after concomitant drug administration .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : since ddrug1 is a ddrug2 , it is possible that ddrug3 , such as the ddrug4 { ddrug5 , ddrug6 , ddrug7 } or ddrug8 , may diminish the effectiveness of ddrug9 .",
        "triple_list": [
            [
                "ddrug8",
                "effect",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "ddrug0 demonstrates some limited inhibitory activity towards cyp1a2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e , g , ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "exaggerated hypertensive responses have been reported from the combined use of ddrug0 and ddrug1 , including those contained in proprietary cold remedies and vasoconstrictive nasal drops .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "-lsb- the effect of ddrug0 on the renal excretion of ddrug1 and ddrug2 in dogs -rsb- the intravenous injection of ddrug3 in a dose of # mg/kg enhanced ddrug4 and ddrug5 excretion in chronic canine experiments .",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the ddrug0 of drugs may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , the ddrug6 , ddrug7 and ddrug8 , ddrug9 and the ddrug10 , and by other ddrug11 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "data from in vitro studies of ddrug0 other than ddrug1 suggest a possible drug interaction for the following : ddrug2 , ddrug3 , ddrug4 , ddrug5 , and ddrug6 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 } : increase the metabolism of ddrug6 and/or some ddrug7 , leading to possible decrease in contraceptive effectiveness .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "the daily dose of ddrug0 should not exceed # mg when coadministered with potent cyp3a4 inhibitors { e , g , , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 and nefazadone } .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 should be administered with caution to patients taking ddrug1 , because of the possibility of conduction disturbances .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "concurrent use of ddrug0 may render oral ddrug1 less effective .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "at 75 % recovery of fade , hoof twitch was # + / - 3 % for ddrug0 alone and # + / - 4 % for ddrug1 plus ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the iv ddrug0 dose should be reduced by approximately 25 % , and the oral ddrug1 dose should be reduced by approximately 50 % when coadministered with ddrug2 to achieve exposures of ddrug3 similar to those obtained when it is given without ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "drugs which inhibit cyp 3a4 { e , g , , ddrug0 , ddrug1 such as ddrug2 } have the potential to result in increased plasma concentrations of ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "therefore , cyp3a4 substrates known to have a narrow therapeutic index such as ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , or ddrug10 { ddrug11 , ddrug12 } should be administered with caution in patients receiving ddrug13 .",
        "triple_list": [
            [
                "ddrug7",
                "advise",
                "ddrug13"
            ]
        ]
    },
    {
        "text": "although the interactions observed in these studies do not appear to be of major clinical importance , ddrug0 should be titrated with caution in patients being treated concurrently with ddrug1 , ddrug2 , ddrug3 or ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "therefore , when ddrug0 and ddrug1 are used concomitantly , the patient should be observed closely to determine if the desired effect of the ddrug2 is obtained .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 : ddrug2 and ddrug3 can reduce absorption of ddrug4 ;",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "immediate and extended release tablets the hypoglycemic action of ddrug0 may be potentiated by certain drugs including ddrug1 , some ddrug2 and other drugs that are highly protein bound , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 } : population pharmacokinetic analyses indicate that ddrug2 clearance is 60 % greater in patients taking ddrug3 { ddrug4 } with or without other enzyme-inducing ddrug5 .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : plasma concentrations of ddrug1 decreased approximately 25 % when ddrug2 and ddrug3 were coadministered .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : since the excretion of ddrug1 is similar to that of urate , ddrug2 , which increase the excretion of urate , are also likely to increase the excretion of ddrug3 and thus lower the degree of inhibition of xanthine oxidase .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ventricular tachycardia induced by ddrug0 was generally converted to sinus rhythm following administration of ddrug1 , ddrug2 , or ddrug3 but not after administration of ddrug4 alone or after ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "clinical studies with ddrug0 have identified potentially significant interactions with ddrug1 and ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "because changes in glucose concentrations with ddrug0 coadministration were within the normal variability and individual glucose concentrations were above or near # mg/dl , dose adjustment for ddrug1 { 5 mg qd and # mg bid } with ddrug2 coadministration { up to # mg qd } is not indicated .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 { e , g , , ddrug1 } and ddrug2 containing carbohydrate-splitting enzymes { e , g , , ddrug3 , ddrug4 } may reduce the effect of ddrug5 and should not be taken concomitantly .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 { consider ddrug3 dose reduction } .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 ddrug1 may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation , the discontinuance of ddrug2 ddrug3 could pose a hazard to health if a potentially toxic drug such as ddrug4 has been filtrated to a maintenance level while the patient was taking ddrug5 ddrug6 .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 may enhance the effects of : other ddrug3 s , ddrug4 , general ddrug5 , ddrug6 such as ddrug7 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "fulminant rhabdomyolysis has been seen as early as three weeks after initiation of combined therapy with another ddrug0 and ddrug1 but may be seen after several months .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "however , in patients treated with oral ddrug0 , rare instances of drug interactions have occurred with high-dose ddrug1 therapy .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : the concomitant use of ddrug1 { ddrug2 transdermal system } with other ddrug3 , including but not limited to other ddrug4 , ddrug5 , ddrug6 , ddrug7 { e , g , , ddrug8 } , general ddrug9 , ddrug10 , ddrug11 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "certain drugs including ddrug0 , ddrug1 , ddrug2 , and ddrug3 may reduce the hypoglycemic action of ddrug4 and other oral ddrug5 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the ddrug0 of drugs may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , the ddrug6 , ddrug7 and ddrug8 , ddrug9 and the ddrug10 , and by other ddrug11 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the ddrug0 of drugs may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , the ddrug6 , ddrug7 and ddrug8 , ddrug9 and the ddrug10 , and by other ddrug11 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "other drugs drug interactions have been reported with concomitant administration of ddrug0 and other medications , including ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "in vitro , ddrug0 may displace less firmly bound drugs like ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in a multiple dose study of ddrug0 { 400 mg once daily for # days } and ddrug1 { 20 mg once daily for # days } , a 16 % decrease in the clearance of ddrug2 was observed .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "other ddrug0 { including ddrug1 } used in combination with ddrug2 may also result in similar toxicities .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "although the clinical significance of these effects is not known , caution is advised in the co-administration of ddrug0 with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the concomitant use of ddrug0 with other ddrug1 is not recommended due to the increased possibility of gastrointestinal toxicity , with little or no increase in efficacy .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the effectiveness of ddrug0 - only pills is reduced by hepatic enzyme-inducing drugs such as the ddrug1 ddrug2 , ddrug3 , and ddrug4 , and the ddrug5 ddrug6 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "cyclosporine , digoxin , methotrexate ddrug0 , like other ddrug1 , through effects on renal prostaglandins , may cause changes in the elimination of these drugs leading to elevated serum levels of ddrug2 , ddrug3 , ddrug4 , and increased toxicity .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : in a clinical pharmacology study , coadministration of an ddrug1 { ddrug2 , ddrug3 , and ddrug4 } with ddrug5 reduced serum levels and urinary excretion of ddrug6 as compared with ddrug7 administered alone , suggesting that ddrug8 may impair absorption of ddrug9 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "discussion : ddrug0 is a potent inhibitor of cyp3a4 , the major enzyme responsible for ddrug1 metabolism .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 has been shown to increase the bioavailability of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 with ddrug1 or ddrug2 and possibly other ddrug3 cause striking and sustained increases in the concentration of ddrug4 in the brain ;",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "if additional ddrug0 are to be administered by any route , they should be used with caution because the pharmacologically predictable sympathetic effects of ddrug1 may be potentiated .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "therefore , it is theoretically possible that ddrug0 may interfere with the absorption of drugs where gastric ph is an important determinant of bioavailability { e , g , ddrug1 , ddrug2 esters , ddrug3 salts , ddrug4 } .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "however , other published reports describe modest elevations { less than two-fold } of ddrug0 and metabolite concentrations when ddrug1 was taken with ddrug2 , ddrug3 , and ddrug4 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : based on reports of profound hypotension and loss of consciousness when ddrug1 was administered with ddrug2 , the concomitant use of ddrug3 with drugs of the ddrug4 { including , for example , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 } is contraindicated .",
        "triple_list": [
            [
                "ddrug3",
                "advise",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "the use of ddrug0 may result in additive cns depressant effects when coadministered with ddrug1 , ddrug2 , ddrug3 or other drugs that produce cns depression .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 enhance the adrenergic effect of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "concomitant use of ddrug0 supplements and ddrug1 may increase ddrug2 absorption",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 , as with other ddrug1 , should be administered with extreme caution to patients being treated with ddrug2 , ddrug3 , or drugs known to prolong the qtc interval because the action of ddrug4 on the cardiovascular system may be potentiated by these agents .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "tablet if a patient receiving ddrug0 is also taking ddrug1 , the effect of ddrug2 may be reduced , thus necessitating an increase in dosage .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 : ddrug2 , when given as a regimen of 125mg with ddrug3 coadministered orally as # mg on day 1 , and ddrug4 when given as # mg/day with ddrug5 coadministered orally as # mg on days # through 5 , increased the auc of ddrug6 , a cyp3a4 substrate by # - fold , on days # and 5 .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : co-administration with high doses of ddrug1 -lsb- 800 mg twice daily -rsb- increased the cmax of ddrug2 by 21 % , the auc0-120hr by 23 % and the t1/2 by 15 % .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 may reduce or reverse the pressor effect of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "also , bleeding and/or increased prothrombin time have been reported in a few patients taking ddrug0 s concomitantly with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "pharmacokinetic data indicate that oral ddrug0 inhibits the metabolism of ddrug1 , resulting in elevated plasma levels of ddrug2 and its active metabolite ddrug3 which may prolong qt intervals .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of ddrug0 such as ddrug1 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug10"
            ]
        ]
    },
    {
        "text": "following the administration of ddrug0 , the dose of other ddrug1 should be reduced .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "certain drugs , including ddrug0 { ddrug1 } , ddrug2 , ddrug3 , and ddrug4 may potentiate the hypoglycemic action of ddrug5 and other oral ddrug6 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "if treatment with inhibitors of cyp3a4 activity { such as ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , etc , } is indicated , reduction of the ddrug6 dose should be considered .",
        "triple_list": [
            [
                "ddrug3",
                "advise",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 should be used with care when ddrug1 or inhibitors of av conduction , such as certain ddrug2 { particularly of the ddrug3 -lsb- ddrug4 -rsb- and ddrug5 -lsb- ddrug6 -rsb- classes } , or ddrug7 , such as ddrug8 , are used concurrently .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "ddrug0 : since ddrug1 is a ddrug2 , it is possible that ddrug3 , such as the ddrug4 { ddrug5 , ddrug6 , ddrug7 } or ddrug8 , may diminish the effectiveness of ddrug9 .",
        "triple_list": [
            [
                "ddrug6",
                "effect",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 # mg bid for # days produced significant decreases in ddrug2 serum clearance { 25 % } and renal clearance { 30 % } with a 34 % higher serum exposure compared to ddrug3 alone .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 has a tendency to antagonize the skeletal muscle relaxing effect of ddrug1 and may potentiate the action of ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the incidence of akathisia in clinical trials of the weekly dosage schedule was greater { # % , 4/47 patients } when ddrug0 was administered on the same day as ddrug1 than when these drugs were given on separate days { # % , 1/80 patients } .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "coadministration of ddrug0 with ddrug1 has led to elevated plasma concentrations of ddrug2 , resulting in rare instances of life - threatening cardiac dysrhythmias and one death .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "however , concomitant administration of ddrug0 with ddrug1 may result in an increased rate of gi ulceration or other complications , compared to use of ddrug2 alone .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : increased serum ddrug1 levels and symptoms of ddrug2 toxicity have been reported in patients receiving concomitant ddrug3 and ddrug4 therapy .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 : the anorectic and stimulatory effects of ddrug1 may be inhibited by ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "in patients receiving ddrug0 { ddrug1 } or ddrug2 { ddrug3 } , the concomitant administration of 300-600 mg of ddrug4 per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of ddrug5 or ddrug6 .",
        "triple_list": [
            [
                "ddrug4",
                "advise",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 salts , and ddrug3 may either potentiate or weaken the blood-glucose-lowering effect of ddrug4 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 toxicity has been reported in patients receiving ddrug2 concomitantly with drugs which cause elimination of sodium , including ddrug3 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug10"
            ]
        ]
    },
    {
        "text": "ddrug0 toxicity may be aggravated by the initial release of norepinephrine caused by ddrug1 injection .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 , ddrug2 , ddrug3 } : metabolism may be inhibited by ddrug4 , increasing plasma levels of ddrug5 ;",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 is known to interact with the metabolism or renal tubular excretion of many drugs { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 agents , ddrug14 , and ddrug15 } .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug15"
            ]
        ]
    },
    {
        "text": "ddrug0 : in the fed state , ddrug1 { 40 mg/kg } increased mean maximum plasma concentration and area under the curve of ddrug2 by about 50 % in healthy subjects { n = 10 } compared with a separate group of subjects { n = 6 } given ddrug3 alone .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "data from in vitro studies of ddrug0 other than ddrug1 suggest a possible drug interaction for the following : ddrug2 , ddrug3 , ddrug4 , ddrug5 , and ddrug6 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 should be administered with caution to patients who are taking other ddrug1 or ddrug2 , including ddrug3 , ddrug4 and ddrug5 , or to those with a history of psychiatric disorder { including manic-depressive illness and schizophrenia } .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "because ddrug0 may enhance the serotonergic effects of ddrug1 , caution should be exercised when ddrug2 and ddrug3 are coadministered .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "or with ddrug0 containing ddrug1 may substantially interfere with drug absorption and result in insufficient plasma and tissue ddrug2 concentrations .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : based on reports of profound hypotension and loss of consciousness when ddrug1 was administered with ddrug2 , the concomitant use of ddrug3 with drugs of the ddrug4 { including , for example , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 } is contraindicated .",
        "triple_list": [
            [
                "ddrug3",
                "advise",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "because ddrug0 is eliminated from the body via conjugation with glutathione , use of ddrug1 prior to { # hours } or concurrent with ddrug2 may result in reduced ddrug3 clearance based upon the known property of ddrug4 to decrease glutathione levels in the blood and tissues .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "routine administration of ddrug0 or toxoids should be deferred until ddrug1 therapy is discontinued if possible .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "elevated ddrug0 serum levels have been reported with the concomitant use of ddrug1 and ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "it has been reported that results of studies in animals indicate that ddrug0 - induced ventricular arrhythmias during anesthesia can be reversed by ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "since the pharmacokinetics of ddrug0 were studied in patients treated with ddrug1 , the clearance of ddrug2 at the recommended dose may be lower and exposure { auc } higher in patients not treated with ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "at least # weeks should elapse between discontinuation of ddrug0 and initiation of treatment with a ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the ddrug0 , including ddrug1 , produce additive cns depressant effects when co-administered with other ddrug2 , ddrug3 , ddrug4 , ddrug5 , and other drugs which themselves produce cns depression .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "in a phase i trial using escalating doses of ddrug0 { 110-200 mg/m2 } and ddrug1 { 50 or # mg/m2 } given as sequential infusions , myelosuppression was more profound when ddrug2 was given after ddrug3 than with the alternate sequence { ie , ddrug4 before ddrug5 } .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "plasma levels of several closely related ddrug0 have been reported to be increased by the concomitant administration of ddrug1 or hepatic enzyme inhibitors { e , g , , ddrug2 , ddrug3 } and decreased by the concomitant administration of hepatic enzyme inducers { e , g , , ddrug4 , ddrug5 } , and such an effect may be anticipated with ddrug6 as well .",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 , and ddrug2 may increase plasma levels of ddrug3 , potentially resulting in adverse effects .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : doses of ddrug1 { ddrug2 } # g/day have been reported to increase plasma concentration of ddrug3 by ~ 47 % , possibly by inhibiting conjugation ;",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 , including oral ddrug1 : ddrug2 may decrease the hepatic metabolism of certain ddrug3 , thereby increasing their effect .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "the possibility of hypotensive effects with ddrug0 or ddrug1 can be minimized by either discontinuing the ddrug2 or increasing the salt intake prior to initiation of treatment with ddrug3 or ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 treatment should be stopped during treatment with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the clearance of ddrug0 may be increased with concurrent use of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the administration of local ddrug0 containing ddrug1 or ddrug2 to patients receiving ddrug3 or ddrug4 may produce severe , prolonged hypertension .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "by decreasing the gastrointestinal absorption of ddrug0 , ddrug1 may decrease serum concentrations of ddrug2 and its metabolites , with a consequent possible decrease in anticonvulsant effect .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the following are examples of drugs known to inhibit the metabolism of other related ddrug0 , presumably through inhibition of cyp3a : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , and some ddrug6 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "coadministration with compounds that are potent inducers of cyp3a4 { eg , ddrug0 , ddrug1 , ddrug2 , ddrug3 } may result in decreased plasma levels of ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "avoid the use of preparations such as ddrug0 and local ddrug1 which contain any ddrug2 { e , g , , ddrug3 , ddrug4 } , since it has been reported that ddrug5 can potentiate the effects of catecholamines .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 increased the auc of ddrug1 by 25 % on day # and decreased the auc of ddrug2 by 19 % on day # relative to the dosing of ddrug3 on days # through 3 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug44"
            ]
        ]
    },
    {
        "text": "the safety and efficacy of concomitant use of ddrug0 and ddrug1 is unknown , and the concomitant use of two potentially hepatotoxic medications is not ordinarily recommended unless the probable benefits outweigh the known risks .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the following are examples of drugs known to inhibit the metabolism of other related ddrug0 , presumably through inhibition of cyp3a : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , and some ddrug6 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "concomitant use of ddrug0 with ddrug1 , ddrug2 , ddrug3 , or other ddrug4 may have an additive effect .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with ddrug1 , ddrug2 s , ddrug3 { allergy , cold , and sinus medicines } , diabetic drugs , ddrug4 , ddrug5 , ddrug6 like ddrug7 or ddrug8 , and high blood pressure medications .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "concomitant administration of ddrug0 and moderate cyp1a2 inhibitors , including ddrug1 and ddrug2 , has not been evaluated , but should be avoided unless clinically necessary because of similar potential drug interactions .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "if ddrug0 is to be combined with other ddrug1 such as ddrug2 or ddrug3 / ddrug4 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of ddrug5 and ddrug6 { e , g , , ddrug7 or ddrug8 } are additive .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "protein binding in vitro , ddrug0 interferes minimally or not at all with the protein binding of ddrug1 { 20 % decrease in binding } , ddrug2 , ddrug3 { 10 % decrease in binding } , or ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : coadministration of ddrug1 , a p_glycoprotein substrate , with oral ddrug2 resulted in a reduction in clearance and an increase in ddrug3 cmax and auc values .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "although the interactions observed in these studies do not appear to be of major clinical importance , ddrug0 should be titrated with caution in patients being treated concurrently with ddrug1 , ddrug2 , ddrug3 or ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "although the interactions observed in these studies do not appear to be of major clinical importance , ddrug0 should be titrated with caution in patients being treated concurrently with ddrug1 , ddrug2 , ddrug3 or ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 - and/or ddrug1 - containing ddrug2 , products containing ddrug3 { ddrug4 } , ddrug5 containing ddrug6 or other metal cations , or ddrug7 { ddrug8 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after ddrug9 .",
        "triple_list": [
            [
                "ddrug4",
                "advise",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "hypertensive crises have resulted when ddrug0 have been used concomitantly within14 days following use of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 can interact with ddrug1 or other ddrug2 { may potentiate the cns depressant effects of either these medications or ddrug3 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and ddrug6 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "in addition , ddrug0 alone can inhibit adrenal ddrug1 synthesis and may cause adrenal_insufficiency during corticosteroid withdrawal .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 , as with other ddrug1 , should be administered with extreme caution to patients being treated with ddrug2 , ddrug3 , or drugs known to prolong the qtc interval because the action of ddrug4 on the cardiovascular system may be potentiated by these agents .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "the mean qt c interval { msec } was # with ddrug0 alone and # with ddrug1 plus ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "since ddrug0 may reduce pulse and blood pressure , caution in using drugs such as ddrug1 { ophthalmic and systemic } , ddrug2 , and ddrug3 is advised .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "concomitant administration of ddrug0 and ddrug1 in dogs , but not in rats , at approximately # times the recommended maximum human therapeutic dose of each { 40 to # mg/kg/day of ddrug2 / ddrug3 } resulted in greater gastrointestinal toxicity than when either drug was administered alone .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : decreases ddrug1 effectiveness by enzyme induction .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "since ddrug0 { ddrug1 } may interact with concurrently administered ddrug2 , periodic serum level determinations of these drugs may be necessary { eg , ddrug3 may elevate ddrug4 serum levels and ddrug5 has been reported to both increase and decrease ddrug6 levels } .",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 also significantly decreased the incidence of lymphatic invasion of adenocarcinomas , which was enhanced by ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the concurrent use of ddrug0 injection with other ddrug1 or medications with anticholinergic activity , such as ddrug2 , ddrug3 , or ddrug4 , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "urinary alkalinizing agents { ddrug0 , some ddrug1 } increase the concentration of the non-ionized species of the ddrug2 molecule , thereby decreasing urinary excretion .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 or other ddrug1 { concurrent use with ddrug2 may result in uterine hypertonus , possibly causing uterine rupture or cervical laceration , especially in the absence of adequate cervical dilatation ;",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "an increase in serum ddrug0 concentration has been reported during concomitant administration of ddrug1 with ddrug2 , so careful monitoring of serum ddrug3 levels is recommended during concomitant use .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "{ ddrug0 may decrease arterial responsiveness to ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "caution should be used when ddrug0 and ddrug1 are administered concomitantly .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 dosage must be determined with care in patients undergoing treatment with ddrug2 , as hypercalcemia in such patients may precipitate cardiac arrhythmias .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 may reduce the antihypertensive effects of ddrug1 , ddrug2 , ddrug3 and ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : patients on ddrug1 , especially those with intravascular volume depletion , may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 : drugs such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 and others that interfere with platelet-aggregation reactions { the main hemostatic defense of heparinized patients } may induce bleeding and should be used with caution in patients receiving ddrug8 .",
        "triple_list": [
            [
                "ddrug7",
                "effect",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "both ddrug0 and ddrug1 slow av conduction .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 is also expected to reduce plasma concentrations of other ddrug1 that have significant metabolism by cyp3a4 , such as ddrug2 and ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "nephrotoxic agents : concomitant administration of ddrug0 and agents with nephrotoxic potential -lsb- e , g , , intravenous ddrug1 { e , g , , ddrug2 , ddrug3 , and ddrug4 } , ddrug5 , ddrug6 , intravenous ddrug7 , ddrug8 , and ddrug9 -rsb- is contraindicated .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "increased hepatotoxicity of ddrug0 by concomitant administration of ddrug1 in the rat .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "drugs decreasing ddrug0 effect : ddrug1 , ddrug2 , ddrug3 , or ddrug4 may partially counteract the anticoagulant action of ddrug5 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "a pharmacokinetic interaction between ddrug0 and ddrug1 has been observed during studies involving renal and cardiac transplant patients .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as ddrug1 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain ddrug2 such as ddrug3 , the ddrug4 and other ddrug5 , ddrug6 , certain ddrug7 such as the ddrug8 salts , and ddrug9 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "although ddrug0 used alone has little or no effect on pupil size , mydriasis resulting from concomitant therapy with ddrug1 and ddrug2 may occur .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 may enhance the cns-depressive effects of ddrug1 , ddrug2 or other ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : serum ddrug1 levels may be increased by ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "because the ddrug0 have been shown to depress plasma prothrombin activity , patients who are on ddrug1 therapy may require downward adjustment of their ddrug2 dosage .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 ddrug1 are inhibited by ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "specific effects of ddrug0 on other ddrug1 ddrug2 : ddrug3 causes an increase in steady-state ddrug4 plasma concentrations .",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "when used in therapeutic doses , ddrug0 had a modest effect on the pharmacokinetics of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { intravenous and oral } , ddrug12 , ddrug13 / ddrug14 or ddrug15 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "hepatic enzyme inducers , inhibitors and substrates : drugs which induce cytochrome p450 3a4 { cyp 3a4 } enzyme activity { e , g , , ddrug0 , ddrug1 , ddrug2 , ddrug3 } may enhance the metabolism of ddrug4 and require that the dosage of the ddrug5 be increased .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 : in vitro and/or in vivo data indicate that ddrug1 , ddrug2 , and oral ddrug3 markedly inhibit the metabolism of ddrug4 , which can result in an increase in plasma ddrug5 levels and prolongation of the qt interval on the ecg .",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "because prostaglandins play an important role in hemostasis , and ddrug0 affect platelet function as well , concurrent therapy with all ddrug1 , including ddrug2 , and ddrug3 requires close monitoring of patients to be certain that no change in their ddrug4 dosage is required .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "the physician should be cautious when administering ddrug0 to patients taking ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "serum ddrug0 concentrations increase when ddrug1 is initiated in a patient maintained on ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "therefore , extreme caution should be exercised when administering ddrug0 to patients receiving ddrug1 or ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "if leprosy-associated inflammatory reactions develop in patients being treated with ddrug0 and ddrug1 , it is still advisable to continue treatment with both drugs .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may also interfere with the absorption of oral ddrug1 supplements and ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "therefore , the combined use of ddrug0 with ddrug1 should generally be avoided .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "additive cns depression may occur when ddrug0 are administered concomitantly with other ddrug1 including ddrug2 , ddrug3 , and ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "therefore , prothrombin time should be carefully monitored in patients receiving ddrug0 and ddrug1 - like drugs simultaneously .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 and foods fortified with ddrug1 concomitant administration of ddrug2 with a therapeutic ddrug3 containing # mg of elemental ddrug4 { as feso4 } or ddrug5 supplemented with # mg of elemental ddrug6 reduced extent of absorption by 80 % and 31 % , respectively .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "the ddrug0 - induced neuronal damage produced a tolerance to the disruptive effects of ddrug1 and a supersensitivity to the disruptive effects of ddrug2 in rats responding in a schedule controlled paradigm .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "when ddrug0 and ddrug1 are used together , the signs of atropinization { flushing , mydriasis , tachycardia , dryness of the mouth and nose } may occur earlier than might be expected than when ddrug2 is used alone because ddrug3 may potentiate the effect of ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 increases the clearance of ddrug1 by 15 % or more , possibly due to the induction of glutathione-s-transferase .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 alone had no effect on platelet aggregation , but did slightly enhance the inhibition of platelet aggregation by ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "drugs that reportedly may increase oral ddrug0 response , ie , increased prothrombin response , in man include : ddrug1 * ;",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "lethargy and somnolence have been reported following doses of ddrug0 and ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "consequently , concomitant administration of ddrug0 with strong cyp3a4 inhibitors { e , g , , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } should be approached with caution .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "therefore , when ddrug0 and ddrug1 are used concomitantly , patients should be observed to determine whether the desired effect on blood pressure is obtained .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "before taking ddrug0 , tell your doctor if you are taking any of the following medicines : - ddrug1 or another ddrug2 such as ddrug3 { ddrug4 } , ddrug5 { ddrug6 , others } , ddrug7 { ddrug8 } , ddrug9 { ddrug10 } , or ddrug11 { ddrug12 } ;",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 { 2 } , ddrug7 , ddrug8 , and ddrug9 thus , if a patient has been titrated to a stable dosage on ddrug10 , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for ddrug11 may be necessary .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 { ddrug2 , ddrug3 , ddrug4 , ddrug5 , fruit juices , etc , } lower absorption of ddrug6 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 may decrease arterial responsiveness to ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 reduce the renal clearance of ddrug1 and add a high risk of ddrug2 toxicity .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 prolong and intensify the effects of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 has a tendency to antagonize the skeletal muscle relaxing effect of ddrug1 and may potentiate the action of ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "co-administration of ddrug0 and ddrug1 resulted in a reduction of ddrug2 plasma levels by 27 % compared with those achieved with ddrug3 alone .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "if a ddrug0 is also used , the risk of ddrug1 toxicity may be increased .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in single and multiple dose studies in healthy subjects receiving both ddrug0 and ddrug1 , prothrombin time { measured as inr } was increased by approximately 8 % to 11 % .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : ddrug1 ; ddrug2 ; ddrug3 ; certain ddrug4 , especially the ddrug5 and ddrug6 ; ddrug7 ; ddrug8 salts ; ddrug9 ; and ddrug10 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 , ddrug2 , ddrug3 , or ddrug4 may interfere with the bactericidal effect of ddrug5 .",
        "triple_list": [
            [
                "ddrug4",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "when administered concurrently , the following drugs may interact with ddrug0 : ddrug1 , general : exaggeration of the hypotension induced by general ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 has been shown to be antagonistic to ddrug1 , including ddrug2 , based on in vitro studies and time kill curves with enteric gram-negative bacilli .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 used concurrently with ddrug1 may also result in increased cardiotoxicity .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "plasma concentrations { auc 0-24 hrs } of ddrug0 decreased 15 % with coadministration of ddrug1 relative to that observed with ddrug2 alone .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "concomitant use of ddrug0 and other ddrug1 is generally not recommended because of possible potentiating effects .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "a # { 17 } % decrease in the steady-state auc of ddrug0 was observed when ddrug1 was administered # hours prior to ddrug2 , but not when the two drugs were administered simultaneously { n = 12 } .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the onset of neuromuscular blockade by ddrug0 was unaffected by ddrug1 , but the duration of neuromuscular blockade was prolonged from # minutes to # minutes .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 should not be used in patients receiving ddrug1 , .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "oral ddrug0 : ddrug1 , when given once daily for # days as a 100-mg capsule with an oral ddrug2 containing # mcg of ddrug3 and # mg of ddrug4 , decreased the auc of ddrug5 by 43 % , and decreased the auc of ddrug6 by 8 % ;",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "absorption of ddrug0 is impaired by ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , and ddrug5 - containing preparations .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 may enhance the effects of : other ddrug3 s , ddrug4 , general ddrug5 , ddrug6 such as ddrug7 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "- ddrug0 { e , g , , ddrug1 } use of ddrug2 with ddrug3 may increase the chance of side effects affecting the liver and/or the side effects of ddrug4",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "when used in therapeutic doses , ddrug0 had a modest effect on the pharmacokinetics of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { intravenous and oral } , ddrug12 , ddrug13 / ddrug14 or ddrug15 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug14"
            ]
        ]
    },
    {
        "text": "ddrug0 , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , certain ddrug7 , ddrug8 , ddrug9 and ddrug10 , thereby delaying elimination and increasing blood levels of these drugs .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "results : the geometric mean { 90 % confidence interval } whole blood ddrug0 area under the plasma concentration time-curve increased 60 % { 35 % -90 % } , from # to # ng x h/ml , and maximum concentration increased 43 % { 14 % -81 % } , from # to # ng/ml , with ddrug1 coadministration , whereas the mean elimination half-life of ddrug2 decreased slightly , from # to # hours .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "when ddrug0 was coadministered with ddrug1 , ddrug2 , or h2antagonists , reduced plasma concentrations of ddrug3 were reported .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : studies in normal volunteers have shown that ddrug1 like other ddrug2 , can interfere with the effects of ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : as with other ddrug1 , renal excretion of ddrug2 is inhibited by ddrug3 and resulted in an approximate 80 % increase in the auc for ddrug4 .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 decreases ddrug2 renal clearance and increases ddrug3 plasma levels .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 may enhance the effects of : other ddrug3 s , ddrug4 , general ddrug5 , ddrug6 such as ddrug7 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "as with other ddrug0 , it should be noted that ddrug1 may be capable of potentiating ddrug2 such as ddrug3 , ddrug4 , and ddrug5 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 , porpranolol , ddrug2 } may exacerbate rebound hypertension when ddrug3 is withdrawn .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : the concomitant use of ddrug1 { ddrug2 transdermal system } with other ddrug3 , including but not limited to other ddrug4 , ddrug5 , ddrug6 , ddrug7 { e , g , , ddrug8 } , general ddrug9 , ddrug10 , ddrug11 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "the results of a study of coadministration of ddrug0 { 50 mg/kg } with an ddrug1 containing ddrug2 to # patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ddrug3 of approximately 20 % and 13 % , respectively , suggesting that the oral absorption of ddrug4 may be reduced by these ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 - ddrug1 may protect against the ototoxic effects of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : while studies have not shown ddrug1 to interact with ddrug2 , caution should be exercised , nonetheless , since interactions have been seen with other ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 salts , and ddrug3 may either potentiate or weaken the blood-glucose-lowering effect of ddrug4 .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 in combination with other ddrug1 , general ddrug2 , ddrug3 , ddrug4 , ddrug5 , or other ddrug6 { including ddrug7 } has additive depressant effects .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "ddrug0 , or other products containing ddrug1 or ddrug2 , ddrug3 or ddrug4 should not be administered concomitantly with , or within # hours of , the administration of ddrug5 , because they may interfere with absorption resulting in lower serum and urine levels of ddrug6 .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a ddrug0 , including ddrug1 , with multivalent cation-containing products such as ddrug2 or ddrug3 ddrug4 , ddrug5 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , ddrug8 , or ddrug9 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "ddrug0 - and/or ddrug1 - containing ddrug2 , products containing ddrug3 { ddrug4 } , ddrug5 containing ddrug6 or other metal cations , or ddrug7 { ddrug8 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after ddrug9 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "concurrent administration of ddrug0 and ddrug1 can produce clinically significant increases in the plasma levels of the ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the hypoglycemic action of ddrug0 may be potentiated by certain drugs including ddrug1 and other drugs that are highly protein bound , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , and ddrug8 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 { eg , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , and ddrug15 } may have elevated plasma concentrations when coadministered with ddrug16 ;",
        "triple_list": [
            [
                "ddrug13",
                "mechanism",
                "ddrug16"
            ]
        ]
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of ddrug0 such as ddrug1 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug13"
            ]
        ]
    },
    {
        "text": "before taking ddrug0 , tell your doctor if you are taking any of the following medicines : - ddrug1 or another ddrug2 such as ddrug3 { ddrug4 } , ddrug5 { ddrug6 , others } , ddrug7 { ddrug8 } , ddrug9 { ddrug10 } , or ddrug11 { ddrug12 } ;",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "both ddrug0 and ddrug1 block ddrug2 - induced and ddrug3 - induced dopamine release in the nucleus accumbens ;",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 reduces urinary excretion of ddrug1 and may enhance its effect .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 should be used with care when ddrug1 or inhibitors of av conduction , such as certain ddrug2 { particularly of the ddrug3 -lsb- ddrug4 -rsb- and ddrug5 -lsb- ddrug6 -rsb- classes } , or ddrug7 , such as ddrug8 , are used concurrently .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 should be used with caution in patients who are receiving a ddrug1 orally because of the potential for additive effects on systemic beta-blockade .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in a study in which patients with active ra were treated for up to # weeks with concurrent ddrug0 and ddrug1 therapy , a 7 % rate of serious infections was observed , which was higher than that observed with ddrug2 alone { 0 % } .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 may increase the serum concentration of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "this may occur because ddrug0 competitively displaces ddrug1 from protein binding sites .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in the presence of ddrug0 { 10 { -5 } m } , ddrug1 { 10 { -8 } m } failed to cause the first contraction ;",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug14"
            ]
        ]
    },
    {
        "text": "as with other ddrug0 , it should be noted that ddrug1 may be capable of potentiating ddrug2 such as ddrug3 , ddrug4 , and ddrug5 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "patients on ddrug0 treatment should be closely monitored when ddrug1 is introduced or withdrawn .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 , as well as a metabolite of ddrug2 , slow ddrug3 metabolism .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "in post-marketing experience , bleeding events have been reported , predominantly in the elderly , in association with increases in prothrombin time in patients receiving ddrug0 concurrently with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "coadministration of ddrug0 with ddrug1 tablets is therefore contraindicated .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "however , co administration of ddrug0 with either ddrug1 or ddrug2 led to increased plasma concentrations of ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 , and ddrug2 decrease the half-life of ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "the uptake inhibitors ddrug0 and ddrug1 { 3 mumol/liter } potentiated the positive inotropic effects of ddrug2 in nonfailing myocardium { p < # } but not in functional class iv myocardium .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "concomitant administration of ddrug0 and ddrug1 , ddrug2 , ddrug3 , or an ddrug4 / ddrug5 oral ddrug6 produced minor changes in the pharmacokinetics of ddrug7 , which were considered to be without clinical significance .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "the absorption of oral ddrug0 is significantly reduced by the concomitant administration of an ddrug1 containing ddrug2 and ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as ddrug0 include certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 } , ddrug10 salts , ddrug11 , local ddrug12 , ddrug13 , and ddrug14 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "coadministration of single , oral doses of ddrug0 with ddrug1 { 10 mg and # mg , respectively } , a strong , selective cyp3a4 inhibitor produced a 34 % increase in ddrug2 s maximal plasma concentrations and a 20 % increase in the area under the plasma concentration-time curve .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "coadministration of ddrug0 and ddrug1 1/35 increased the exposure of ddrug2 and ddrug3 by 20 % and 34 % , respectively .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 or ddrug1 increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered ddrug2 , such as ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "it is , however , possible that concomitant use of other known ddrug0 such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 might increase the photosensitivity reaction of actinic_keratosis treated with the ddrug7 for topical solution .",
        "triple_list": [
            [
                "ddrug6",
                "effect",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "there have been reports of interactions of ddrug0 with ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "in combination with other ddrug0 , ddrug1 may still kill even experienced users , particularly if their tolerance to the drug has reduced or the strength of their usual dose has increased .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a ddrug0 , including ddrug1 , with multivalent cation-containing products such as ddrug2 or ddrug3 ddrug4 , ddrug5 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , ddrug8 , or ddrug9 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "interactions with ddrug0 : ddrug1 { eg , ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 } should not be administered to a patient who has received or is receiving a course of therapy with a ddrug7 such as ddrug8 .",
        "triple_list": [
            [
                "ddrug5",
                "advise",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "capsules ddrug0 # mg t , i , d , produced a clinically relevant elevation of plasma ddrug1 and reduction in renal ddrug2 clearance in psychiatric patients and normal subjects with steady state plasma ddrug3 concentrations .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of ddrug0 # % ophthalmic solution , the possibility of an additive or potentiating effect with ddrug1 { ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 } should be considered .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 : in a pharmacokinetic study , maximum plasma concentrations of ddrug1 were considerably lower in epileptic patients on long-term ddrug2 therapy { eg , ddrug3 , ddrug4 , or ddrug5 } than in healthy volunteers .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 in combination with other ddrug1 , general ddrug2 , ddrug3 , ddrug4 , ddrug5 , or other ddrug6 { including ddrug7 } has additive depressant effects .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "this may indicate that ddrug0 could enhance the toxicity of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the ddrug0 of drugs may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , the ddrug6 , ddrug7 and ddrug8 , ddrug9 and the ddrug10 , and by other ddrug11 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug11"
            ]
        ]
    },
    {
        "text": "blood levels of ddrug0 increased 24 % when ddrug1 was coadministered with ddrug2 { nonselective inhibitor of cytochrome p-450 } for # days , and decreased 28 % with coadministration of ddrug3 { potent inducer of cytochrome p-450 } for # days .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "another oral ddrug0 , ddrug1 , inhibits the metabolism of ddrug2 , resulting in elevated plasma concentrations of ddrug3 and its active metabolite ddrug4 which may prolong qt intervals .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "for example , since ddrug0 may reduce the gastrointestinal absorption of both the oral ddrug1 and ddrug2 , the net effects are unpredictable .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "this interaction should be given consideration in patients taking ddrug0 concomitantly with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "previous studies have demonstrated a significant reduction in the oral bioavailability of ddrug0 and ddrug1 when administered concomitantly with an intravenous ddrug2 such as ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "caution should be exercised when considering the use of ddrug0 and ddrug1 in patients with depressed myocardial function .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "thus in order to avoid bleeding , reduced dosage of ddrug0 is recommended during treatment with ddrug1 { human } .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "exert particular caution in combining ddrug0 with other ddrug1 { ddrug2 and ddrug3 } : particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "in addition , results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance { ddrug0 , ddrug1 , ddrug2 , ddrug3 , or ddrug4 } with ddrug5 may result in clinically meaningful reductions in ddrug6 concentrations .",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "the concurrent use of two or more drugs with anticholinergic activity -- such as an ddrug0 { eg , ddrug1 } , an ddrug2 { eg , ddrug3 } , and/or a ddrug4 { eg , ddrug5 } -- commonly results in excessive anticholinergic effects , including dry mouth and associated dental complications , blurred vision , and , in patients exposed to high temperature and humidity , hyperpyrexia .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "drugs such as ddrug0 and ddrug1 may inhibit the metabolism of ddrug2 and thus decrease their clearance .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of ddrug0 such as ddrug1 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 may enhance the effects of : other ddrug3 s , ddrug4 , general ddrug5 , ddrug6 such as ddrug7 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with ddrug1 , ddrug2 s , ddrug3 { allergy , cold , and sinus medicines } , diabetic drugs , ddrug4 , ddrug5 , ddrug6 like ddrug7 or ddrug8 , and high blood pressure medications .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "the lower rate of absorption in the groups receiving # mg ddrug0 instead of # mg of ddrug1 per kg diet resulted in a decreased renal excretion of ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "in a study in normal volunteers , concomitant administration of ddrug0 and ddrug1 resulted in increased serum ddrug2 concentrations .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 concentrations should be monitored at the initiation of ddrug3 therapy and frequently thereafter , and the dose of these three drug products adjusted appropriately .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "administration of ddrug0 to hypoparathyroid patients who are concurrently being treated with ddrug1 may cause hypercalcemia .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "however , there has been one report of prolonged prothrombin time when ddrug0 was added to the regimen of a patient treated with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "when ddrug0 or ddrug1 is used at the same time as other medicines or substances the following interactions must be taken into account : - ddrug2 and ddrug3 may enhance the action of ddrug4 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "nevertheless , caution is indicated in the coadministration of ddrug0 with any of the ddrug1 and also in switching from one class to the other .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in patients receiving nonselective ddrug0 { ddrug1 } { e , g , , ddrug2 } in combination with ddrug3 { e , g , , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 } , there have been reports of serious , sometimes fatal , reactions .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "when ddrug0 and ddrug1 are used together , the signs of atropinization { flushing , mydriasis , tachycardia , dryness of the mouth and nose } may occur earlier than might be expected than when ddrug2 is used alone because ddrug3 may potentiate the effect of ddrug4 .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 : as with other ddrug1 , concomitant administration of ddrug2 and ddrug3 is not generally recommended because of the potential of increased adverse effects .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 can be used with low dose ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "because severe hypoglycemia has been reported in patients concomitantly receiving oral ddrug0 { an ddrug1 } and oral ddrug2 , such a potential interaction involving the latter agents when used concomitantly with ddrug3 tablets { an ddrug4 } can not be ruled out .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 generally should not be given with ddrug1 because they reduce ddrug2 s renal clearance and add a high risk of ddrug3 toxicity .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 interferes with the absorption of ddrug1 , including ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "clinically significant effects have been reported with the ddrug0 when used concomitantly with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "interactions with other ddrug0 : significant decreases in the auc of ddrug1 { 20 % } and ddrug2 { 84 % } occurred following simultaneous administration of these agents with ddrug3 .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "the possibility of hypotensive effects with ddrug0 or ddrug1 can be minimized by either discontinuing the ddrug2 or increasing the salt intake prior to initiation of treatment with ddrug3 or ddrug4 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "with combined use , clinicians should be aware , when ddrug0 is added , of the potential for reexacerbation of pulmonary symptomatology due to lowered serum ddrug1 concentrations .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may decrease the effect of ddrug1 , ddrug2 , and ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "while no in vivo drug-drug interaction studies were conducted between ddrug0 and inducers of cyp3a , compounds that are potent cytochrome_p450_family_3_subfamily_a inducers { such as ddrug1 , ddrug2 , ddrug3 , and ddrug4 } would be expected to decrease ddrug5 concentrations .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "inhibitors of this isoenzyme { e , g , , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , grapefruit juice , ddrug7 , ddrug8 , ddrug9 , ddrug10 } should be cautiously coadministered with ddrug11 as they can potentially increase ddrug12 levels .",
        "triple_list": [
            [
                "ddrug10",
                "advise",
                "ddrug11"
            ]
        ]
    },
    {
        "text": "with simultaneous dosing of ddrug0 # mg and ddrug1 # mg , # of # subjects experienced a standing systolic blood pressure of less than # mm hg .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 } and ddrug2 may interfere with the effect of each other when administered concurrently .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "although the mechanism of interaction between ddrug0 and ddrug1 is not totally known , enzyme induction and displacement of ddrug2 from plasma alb binding sites are possibilities .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug28"
            ]
        ]
    },
    {
        "text": "it is known that cyp1a2 is inhibited by several medicinal products , including ddrug0 , and such medicinal products could theoretically adversely influence the clearance of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of ddrug0 , ddrug1 and ddrug2 should not be co-administered .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 may interfere with the absorption of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "therefore , co-administration of ddrug0 with drugs that are metabolized by cyp2d6 isoenzyme including certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } , ddrug8 { e , g , , ddrug9 , ddrug10 , ddrug11 } , ddrug12 { e , g , , ddrug13 } , and ddrug14 { e , g , , ddrug15 , ddrug16 } , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug10"
            ]
        ]
    },
    {
        "text": "ddrug0 : hallucinations have been reported when ddrug1 was used in patients taking ddrug2 { ddrug3 , ddrug4 , ddrug5 } .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "these results would seem to dictate against the clinical use of ddrug0 with ddrug1 , or during the period following ddrug2 therapy when plasma asparagine levels are below normal .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 should be administered with caution to patients who are taking other ddrug1 or ddrug2 , including ddrug3 , ddrug4 and ddrug5 , or to those with a history of psychiatric disorder { including manic-depressive illness and schizophrenia } .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "certain drugs , including ddrug0 { ddrug1 } , ddrug2 , ddrug3 , and ddrug4 may potentiate the hypoglycemic action of ddrug5 and other oral ddrug6 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 - and/or ddrug1 - containing ddrug2 , products containing ddrug3 { ddrug4 } , ddrug5 containing ddrug6 or other metal cations , or ddrug7 { ddrug8 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after ddrug9 .",
        "triple_list": [
            [
                "ddrug8",
                "advise",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "therefore , co-administration of ddrug0 with other drugs that are metabolized by this isozyme , including ddrug1 , ddrug2 , ddrug3 , and ddrug4 { e , g , , ddrug5 , ddrug6 and ddrug7 } , or that inhibit this enzyme { e , g , , ddrug8 } , should be approached with caution .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "the anticoagulant effect of ddrug0 is enhanced by concurrent treatment with ddrug1 { human } in patients with hereditary antithrombin iii deficiency .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "dose adjustment of ddrug0 may be required and pth and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong cyp3a4 inhibitor { e , g , , ddrug1 , ddrug2 , ddrug3 ;",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of ddrug0 such as ddrug1 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug12"
            ]
        ]
    },
    {
        "text": "increases in prothrombin time have been noted in patients receiving long - term ddrug0 therapy after ddrug1 was initiated .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "it is , however , possible that concomitant use of other known ddrug0 such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 might increase the photosensitivity reaction of actinic_keratosis treated with the ddrug7 for topical solution .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "these results suggest that the hepatoxicity of ddrug0 in alcoholic beverages is enhanced by interaction with its congeners and ddrug1 ;",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "before taking ddrug0 , tell your doctor if you are taking any of the following medicines : - ddrug1 or another ddrug2 such as ddrug3 { ddrug4 } , ddrug5 { ddrug6 , others } , ddrug7 { ddrug8 } , ddrug9 { ddrug10 } , or ddrug11 { ddrug12 } ;",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 similarly inhibit and stimulate ddrug2 - or ddrug3 - induced proliferation of prostatic epithelium .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of ddrug0 such as ddrug1 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug11"
            ]
        ]
    },
    {
        "text": "ddrug0 : population pharmacokinetic analyses indicate that ddrug1 clearance is 60 % greater in patients taking ddrug2 with or without other enzyme - inducing ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "therefore you may need to take a ddrug0 supplement while taking ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "until data on possible interactions between ddrug0 and ddrug1 are obtained , ddrug2 should not be administered within # hours before or # hours after ddrug3 administration .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "it is , however , possible that concomitant use of other known ddrug0 such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 might increase the photosensitivity reaction of actinic_keratosis treated with the ddrug7 for topical solution .",
        "triple_list": [
            [
                "ddrug4",
                "effect",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "other ddrug0 { e , g , ddrug1 , ddrug2 , ddrug3 and general ddrug4 } have additive or potentiating effects with ddrug5 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "there have been greater than two-fold increases of previously stable plasma levels of ddrug0 when ddrug1 has been administered in combination with these agents .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "drugs that lower seizure threshold : concurrent administration of ddrug0 and agents { e , g , , ddrug1 , other ddrug2 , ddrug3 , systemic ddrug4 , etc , } that lower seizure threshold should be undertaken only with extreme caution .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 } : increase the metabolism of ddrug6 and/or some ddrug7 , leading to possible decrease in contraceptive effectiveness .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "the cns effects of ddrug0 may be enhanced by ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 can inhibit the metabolism of ddrug2 , increasing its plasma level .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "therefore , ddrug0 or other ddrug1 { as used for management of angina } or other drugs having vasodilator activity should , if possible , be discontinued before starting ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 should not be administered concomitantly with ddrug1 , ddrug2 , ddrug3 , ddrug4 , or ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "dose-response curves { derived from the results of using the tablets as well as pure powders } showed that ddrug0 was responsible for the inhibitory activity , which was partially antagonized by ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "if it is necessary to continue the ddrug0 , initiate therapy with ddrug1 at a dose of # mg daily , and provide close medical supervision after the initial dose until blood pressure has stabilized .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "patients receiving other ddrug0 , ddrug1 , ddrug2 , or other ddrug3 { including ddrug4 } concomitantly with ddrug5 and ddrug6 tablets may exhibit an additive cns depression .",
        "triple_list": [
            [
                "ddrug4",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "because prostaglandins play an important role in hemostasis , and ddrug0 affect platelet function as well , concurrent therapy with all ddrug1 , including ddrug2 , and ddrug3 requires close monitoring of patients to be certain that no change in their ddrug4 dosage is required .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "accordingly , careful patient monitoring and dose adjustment of ddrug0 is recommended in patients concomitantly taking ddrug1 and ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "these results suggest that exposure to environmental ddrug0 may alter the biological and behavioral responsiveness of an animal to ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the concurrent use of two or more drugs with anticholinergic activity -- such as an ddrug0 { eg , ddrug1 } , an ddrug2 { eg , ddrug3 } , and/or a ddrug4 { eg , ddrug5 } -- commonly results in excessive anticholinergic effects , including dry mouth and associated dental complications , blurred vision , and , in patients exposed to high temperature and humidity , hyperpyrexia .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "in vitro studies indicate that , at therapeutic concentrations of ddrug0 { 300 m g/ml } , the binding of ddrug1 was reduced from approximately # % to # % , representing a potential twofold increase in unbound ddrug2 plasma levels .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : clinical studies , as well as post-marketing observations , have shown that ddrug1 can reduce the natriuretic effect of ddrug2 and ddrug3 in some patients .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 : ddrug2 and ddrug3 containing ddrug4 or ddrug5 , as well as formulations containing divalent and trivalent cations such as ddrug6 { ddrug7 } , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with ddrug8 and interfere with its bioavailability .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "caution should be exercised if an ddrug0 is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones , such as ddrug1 , ddrug2 , and ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 , ddrug2 , and possibly ddrug3 } : concomitant administration with ddrug4 may increase the risk of gastrointestinal ulceration .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 , and ddrug2 : drugs such as ddrug3 , ddrug4 , and ddrug5 may increase the risk of developing peripheral_neuropathies or other ddrug6 - associated adverse events by interfering with the renal clearance of ddrug7 { thereby raising systemic exposure } .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "in renal and cardiac transplant recipients , a reduction of ddrug0 dose ranging from 15 % to 48 % was necessary to maintain ddrug1 trough concentrations similar to those seen prior to the addition of ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "other ddrug0 { including ddrug1 } used in combination with ddrug2 may also result in similar toxicities .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "drugs that lower seizure threshold : concurrent administration of ddrug0 and agents { e , g , , ddrug1 , other ddrug2 , ddrug3 , systemic ddrug4 , etc , } that lower seizure threshold should be undertaken only with extreme caution .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 ddrug1 # , 25 , and # mg administered once daily for # days increased plasma ddrug2 concentrations { auc { 0 - } } by # to 60 % in healthy subjects administered a single 300-mg dose of ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 like other ddrug2 , has been shown to affect bleeding parameters in patients receiving ddrug3 , and serious clinical bleeding has been reported .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "drug interactions with ddrug0 administration of # mg of ddrug1 { 2 x # mg capsule } within # minutes of an ddrug2 and ddrug3 containing ddrug4 { ddrug5 } decreased ddrug6 auc by 41 % and cmax by 43 % .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "caution should be used when administering or taking ddrug0 with ddrug1 and other strong cyp3a4 inhibitors such as , but not limited to , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { ddrug12 } , and ddrug13 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug12"
            ]
        ]
    },
    {
        "text": "in # other schizophrenic patients treated with oral ddrug0 and ddrug1 , discontinuation of ddrug2 produced a mean # - fold increase in ddrug3 concentrations .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : concomitant administration of ddrug1 and ddrug2 is not recommended because ddrug3 is displaced from its binding sites during the concomitant administration of ddrug4 , resulting in lower plasma concentrations , peak plasma levels , and auc values .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "similarly , ddrug0 decreased the rate of elimination of ddrug1 { by approximately 50 % } by the same mechanism .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "of particular importance , sufficient time must elapse before initiating ddrug0 treatment in a patient being withdrawn from ddrug1 , given the long half-life of the parent and active metabolite { at least # weeks may be necessary } .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : sporadic cases of seizures have been reported during concomitant use of ddrug1 and ddrug2 { ddrug3 , ddrug4 } .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : the concomitant administration of ddrug1 with the ddrug2 ddrug3 has , on rare occasions , resulted in severe hypoglycemia .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "thus , careful monitoring of clinical status is warranted when ddrug0 is administered or discontinued in ddrug1 - treated patients .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 tablets may alter the metabolism of ddrug1 , ddrug2 , and ddrug3 , resulting in elevated plasma concentrations of the latter drugs .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "- the action of ddrug0 and ddrug1 may be enhanced by ddrug2 or ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of ddrug0 such as ddrug1 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "therefore , co-administration of ddrug0 with drugs that are metabolized by cyp2d6 isoenzyme including certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } , ddrug8 { e , g , , ddrug9 , ddrug10 , ddrug11 } , ddrug12 { e , g , , ddrug13 } , and ddrug14 { e , g , , ddrug15 , ddrug16 } , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 - there have been rare postmarketing reports describing patients with weakness , hyperreflexia , and incoordination following the use of a ddrug1 { ddrug2 } and ddrug3 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "therefore , if ddrug0 is administered with ddrug1 , the clinician should be alert to the possibility of increases in ddrug2 levels .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "when combined with ddrug0 , ddrug1 exhibited strong synergistic activity while only additive effects were observed with the combination of ddrug2 { or ddrug3 } and ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "therefore , ddrug0 may interfere with the absorption of drugs where gastric ph is an important determinant of bioavailability { eg , ddrug1 , ddrug2 salts and ddrug3 } .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "concurrent use of ddrug0 with ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , and ddrug5 } may result in increased ddrug6 effects .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "a dose increase of ddrug0 / ddrug1 to 533/133 mg twice daily with food isrecommended in combination with ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "before taking ddrug0 , tell your doctor if you are taking any of the following medicines : - ddrug1 or another ddrug2 such as ddrug3 { ddrug4 } , ddrug5 { ddrug6 , others } , ddrug7 { ddrug8 } , ddrug9 { ddrug10 } , or ddrug11 { ddrug12 } ;",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 , and ddrug2 may decrease ddrug3 plasma levels , resulting in a decrease in effectiveness of a previously effective ddrug4 dose .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "conclusions : ddrug0 inhibit the metabolism of ddrug1 that are metabolized by cyp3a4 { i , e , , ddrug2 , ddrug3 , ddrug4 , ddrug5 } .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 increases ddrug1 auc values by 14 % .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "for adult-onset diabetics , dosage adjustment of ddrug0 may be necessary during and after ddrug1 therapy ;",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : it has been reported that ddrug1 prolongs the half-life of the ddrug2 , ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : potential interaction of ddrug1 and ddrug2 may exist .",
        "triple_list": [
            [
                "ddrug1",
                "int",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "nephrotoxic agents : concomitant administration of ddrug0 and agents with nephrotoxic potential -lsb- e , g , , intravenous ddrug1 { e , g , , ddrug2 , ddrug3 , and ddrug4 } , ddrug5 , ddrug6 , intravenous ddrug7 , ddrug8 , and ddrug9 -rsb- is contraindicated .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 can interact with ddrug1 or other ddrug2 { may potentiate the cns depressant effects of either these medications or ddrug3 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and ddrug6 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "in uninfected volunteers , 46 % developed rash while receiving ddrug0 and ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "additive adverse effects resulting from cholinergic blockade may occur when ddrug0 is administered concomitantly with other ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 or some ddrug7 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "agents increasing serum potassium : ddrug0 and ddrug1 iv attenuate potassium loss caused by ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : sporadic cases of seizures have been reported during concomitant use of ddrug1 and ddrug2 { ddrug3 , ddrug4 } .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "concurrent administration of low-dose ddrug0 and ddrug1 may produce an additive or potentiating effect on urine flow .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "drugs which inhibit cyp 3a4 { e , g , , ddrug0 , ddrug1 such as ddrug2 } have the potential to result in increased plasma concentrations of ddrug3 .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : when used in the perioperative period , ddrug1 has been implicated in the prolongation of the neuromuscular blockade of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 } : increase the metabolism of ddrug6 and/or some ddrug7 , leading to possible decrease in contraceptive effectiveness .",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 concentrations in bile and cystic fluid were increased { about 2-fold } in hydatid cyst patients treated with ddrug2 { 10 mg/kg/day } { n = 7 } compared with ddrug3 { 20 mg/kg/day } alone { n = 12 } .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "in vitro , ddrug0 appears to be displaced from its binding sites by ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the concurrent administration of ddrug0 and ddrug1 increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ddrug2 alone .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "caution should be exercised if an ddrug0 is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones , such as ddrug1 , ddrug2 , and ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "however , another ddrug0 has been found to produce a less than two-second increase in prothrombin time in healthy volunteers receiving low doses of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in addition , drugs that are actively secreted via this route { e , g , , ddrug0 , ddrug1 and ddrug2 } should be co-administered with care as they might increase ddrug3 levels .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "studies with ddrug0 in combination with ddrug1 indicate that the dose of the ddrug2 can be reduced when it is given with a ddrug3 .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "other drugs drug interactions have been reported with concomitant administration of ddrug0 and other medications , including ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "higher concentrations of ddrug0 { 10 { -8 } - 10 { -6 } m } or ddrug1 { 3 x 10 { -8 } - 10 { -7 } m } enhance the mitogenic activity of ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the actions of the ddrug0 may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 or other ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "data suggest that coadministration of oral ddrug0 and ddrug1 can result in prolongation of the qt interval on the ecg .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "although not studied with ddrug0 , inhibition of n-acetyltransferase may have clinically relevant consequences for drugs such as ddrug1 , ddrug2 , and ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug22"
            ]
        ]
    },
    {
        "text": "co-medications that induce cyp 3a4 { e , g , , ddrug0 , ddrug1 , ddrug2 , ddrug3 , or st , john s wort } may significantly decrease exposure to ddrug4 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "interactions with other cns agents : concurrent use of ddrug0 with all ddrug1 { eg , ddrug2 , ddrug3 , ddrug4 , other ddrug5 , general ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 and ddrug12 } may result in additive central nervous system depressant effects .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "caution should be exercised if an ddrug0 is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones , such as ddrug1 , ddrug2 , and ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : as with other ddrug1 , ddrug2 inhibits the renal excretion of ddrug3 , resulting in an approximate doubling in a , c , a 54 % increase in peak ddrug4 plasma levels , and a 50 % prolongation in the apparent elimination half-life .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 : ddrug2 and ddrug3 containing ddrug4 or ddrug5 , as well as formulations containing divalent and trivalent cations such as ddrug6 { ddrug7 } , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with ddrug8 and interfere with its bioavailability .",
        "triple_list": [
            [
                "ddrug4",
                "mechanism",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "on the basis of the metabolism of ddrug0 by cytochrome p450 3a4 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , grapefruit juice , and other inhibitors of cyp3a4 would be expected to lead to an increase in plasma ddrug5 concentrations .",
        "triple_list": [
            [
                "ddrug4",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "careful observation is required when ddrug0 is administered concurrently with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma ddrug0 concentrations include : acute ddrug1 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug19"
            ]
        ]
    },
    {
        "text": "concurrent use of ddrug0 may antagonize the anorectic effect of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 should be avoided by patients with a history of serious reaction to any ddrug1 , including ddrug2 and ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "the serum estrogen concentrations of ddrug0 + ddrug1 - treated rats decreased by 50 % , while those of the ddrug2 - treated rats increased { 2 - to 5-fold } .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "potential drug interactions for ddrug0 include , increased sedation if ddrug1 is combined with other ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 formulations containing buffer should be administered at least one hour apart on an empty stomach .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "renal function should be monitored carefully if high doses of ddrug0 are to be administered with ddrug1 because of the increased potential of nephrotoxicity and ototoxicity of ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 - concomitant intake of ddrug1 and ddrug2 may reduce the absorption of ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "these results suggest that the analgesic effect of ddrug0 may be diminished when it is administered shortly after ddrug1 nasal spray , but by # minutes any such reduction in effect should be minimal .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 toxicity was usually reversible upon discontinuation of ddrug1 and the ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "in simultaneous treatment with ddrug0 and ddrug1 , the anticoagulant effect should be carefully titrated and monitored .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "these increased exposures of ddrug0 and ddrug1 should be taken into consideration when selecting an oral ddrug2 for women taking ddrug3 .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "inhibitors of cyp3a4 { eg , ddrug0 } or cyp2d6 { eg , ddrug1 , ddrug2 , or ddrug3 } can inhibit ddrug4 elimination and cause increased blood levels .",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 produced significantly increased vasoconstriction after a single administration of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "nephrotoxic agents : concomitant administration of ddrug0 and agents with nephrotoxic potential -lsb- e , g , , intravenous ddrug1 { e , g , , ddrug2 , ddrug3 , and ddrug4 } , ddrug5 , ddrug6 , intravenous ddrug7 , ddrug8 , and ddrug9 -rsb- is contraindicated .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "this appears to be the only clinically relevant interaction of this kind with ddrug0 , although theoretically , coadministration of other drugs known to alter cardiac conduction { eg , ddrug1 or ddrug2 , ddrug3 , ddrug4 or ddrug5 , ddrug6 and ddrug7 } might also contribute to a prolongation of the qtc interval .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "caution is advised when ddrug0 is coadministered with other medications that can prolong the qt interval { e , g , certain ddrug1 or ddrug2 } or lead to electrolyte abnormalities { such as ddrug3 or ddrug4 } .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "drugs that may alter ddrug0 plasma concentrations drugs that may increase ddrug1 plasma concentrations : caution is recommended when administering ddrug2 with inhibitors of the cyp3a4 family { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 } .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 may interact with ddrug2 in studies with male rats , ddrug3 was found to inhibit the hepatic microsomal enzyme system at a dose of # mg/kg/day .",
        "triple_list": [
            [
                "ddrug1",
                "int",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "nephrotoxic agents : concomitant administration of ddrug0 and agents with nephrotoxic potential -lsb- e , g , , intravenous ddrug1 { e , g , , ddrug2 , ddrug3 , and ddrug4 } , ddrug5 , ddrug6 , intravenous ddrug7 , ddrug8 , and ddrug9 -rsb- is contraindicated .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 - and/or ddrug1 - containing ddrug2 , products containing ddrug3 { ddrug4 } , ddrug5 containing ddrug6 or other metal cations , or ddrug7 { ddrug8 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after ddrug9 .",
        "triple_list": [
            [
                "ddrug5",
                "advise",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "refer to the package insert for ddrug0 preparations before use of such preparations with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "it is , therefore , advisable to monitor ddrug0 concentrations in patients receiving ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : based on reports of profound hypotension and loss of consciousness when ddrug1 was administered with ddrug2 , the concomitant use of ddrug3 with drugs of the ddrug4 { including , for example , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 } is contraindicated .",
        "triple_list": [
            [
                "ddrug3",
                "advise",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "plasma exposure { auc } to ddrug0 was increased 62 % when coadministered with ddrug1 and 38 % when coadministered with ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "- although not a true drug interaction , ddrug0 may precipitate seizures in susceptible patients and ddrug1 dosage may need to be adjusted",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in addition to this pharmacological interaction , this report describes a novel chemical reaction between ddrug0 { a ddrug1 } and ddrug2 under acidic conditions similar to those found in vivo , resulting in a 3-ethoxylated product .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "there is thus an enhancement effect of ddrug0 upon the reaction of placental vessels to ddrug1 in vitro .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : when a single 375-mg dose of ddrug1 was administered on day9 of a 14-day regimen of # mg/day of ddrug2 , a strong cyp3a4 inducer , the auc of ddrug3 decreased approximately 11-fold and the mean terminal half-life decreased approximately 3-fold .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the immediate release , but not the coat-core formulation of ddrug0 increased plasma ddrug1 concentrations by about 20 % .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 potentiate the analgesic effect of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "possible drug interactions of ddrug0 with ddrug1 or with other ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "concomitant administration of ddrug0 and moderate cyp1a2 inhibitors , including ddrug1 and ddrug2 , has not been evaluated , but should be avoided unless clinically necessary because of similar potential drug interactions .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 with ddrug1 or ddrug2 and possibly other ddrug3 cause striking and sustained increases in the concentration of ddrug4 in the brain ;",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 or ddrug1 increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered ddrug2 , such as ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 used at doses of # mg/kg and # mg/kg decreased the antinociceptive effect of ddrug1 , ddrug2 { only in the tail-flick test } and ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as ddrug0 include certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 } , ddrug10 salts , ddrug11 , local ddrug12 , ddrug13 , and ddrug14 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 : combination ddrug1 may decrease the clearance of some ddrug2 { ddrug3 , ddrug4 , ddrug5 } and increase the clearance of others { ddrug6 , ddrug7 , ddrug8 } .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 { e , g , , ddrug1 } and ddrug2 containing carbohydrate-splitting enzymes { e , g , , ddrug3 , ddrug4 } may reduce the effect of ddrug5 and should not be taken concomitantly .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 has been shown to have an additive cns depressant effect when given with either ddrug1 , ddrug2 , ddrug3 or ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 : in vitro data indicate that ddrug1 inhibits the metabolism of ddrug2 , which can result in an increase in plasma ddrug3 levels and prolongation of the qt interval on the ecg .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : concomitant administration of ddrug1 oral and ddrug2 resulted in decreased clearance of ddrug3 and significant increases in ddrug4 plasma levels { total auc increased approximately threefold from # to # m g/h/ml } and terminal half-life increased approximately twofold from # to # hours .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : although the results of a clinical study did not indicate a safe problem associated with the administration of ddrug1 { ddrug2 } injection , usp to subjects already receiving ddrug3 , there have been reports that ddrug4 may potentiate the vasoconstrictive action of ddrug5 by blocking the vasodilating property of epinephrine .",
        "triple_list": [
            [
                "ddrug4",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "therefore , co-administration of ddrug0 with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index , including certain ddrug1 { ddrug2 -lsb- ddrug3 -rsb- , such as ddrug4 , ddrug5 , and ddrug6 } , ddrug7 and ddrug8 { e , g , , ddrug9 , ddrug10 } , should be approached with caution .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "pharmacokinetic interaction between single oral doses of ddrug0 and ddrug1 in healthy volunteers .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "interactions may occur between ddrug0 supplements and ddrug1 and other ddrug2 and herbs such as garlic { allium sativum } and ddrug3 { ddrug4 } .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the hypoglycemic action of ddrug0 may be potentiated by certain drugs including ddrug1 and other drugs that are highly protein bound , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , and ddrug8 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "furthermore , ddrug0 , ddrug1 , ddrug2 , and other inducers of cyp3a4 may cause a reduction in plasma ddrug3 concentrations .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 concentrations should be monitored at the initiation of ddrug3 therapy and frequently thereafter , and the dose of these three drug products adjusted appropriately .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 should not be used concomitantly with ddrug1 because of the possibility of ototoxicity .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 similarly inhibit and stimulate ddrug2 - or ddrug3 - induced proliferation of prostatic epithelium .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of ddrug0 such as ddrug1 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug13"
            ]
        ]
    },
    {
        "text": "the use of ddrug0 in patients who are receiving ddrug1 may potentiate renal disease states .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 , such as ddrug1 and ddrug2 , can inhibit renal tubular secretion of ddrug3 .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "nephrotoxic agents : concomitant administration of ddrug0 and agents with nephrotoxic potential -lsb- e , g , , intravenous ddrug1 { e , g , , ddrug2 , ddrug3 , and ddrug4 } , ddrug5 , ddrug6 , intravenous ddrug7 , ddrug8 , and ddrug9 -rsb- is contraindicated .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "prolonged recovery time may occur if ddrug0 and/or ddrug1 are used concurrently with ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "use of ddrug0 in a patient who has previously received ddrug1 increases the risk of cardiotoxicity .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 - although ddrug1 did not potentiate the cognitive and motor effects of ddrug2 in a clinical trial , as with other ddrug3 , the use of ddrug4 by patients taking ddrug5 is not recommended .",
        "triple_list": [
            [
                "ddrug4",
                "advise",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "in a study of # schizophrenic patients coadministered oral ddrug0 and ddrug1 , plasma ddrug2 levels were decreased by a mean of 70 % and mean scores on the brief psychiatric rating scale were increased from baseline .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 prolong and intensify the anticholinergic { drying } effects of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "oral ddrug0 : coadministration of ddrug1 and an oral ddrug2 increased auc values for ddrug3 and ddrug4 by approximately 30 % and 20 % .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 toxicity has been reported in patients receiving ddrug2 concomitantly with drugs which cause elimination of sodium , including ddrug3 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "this small decrease in excretion of ddrug0 by ddrug1 is not expected to be of clinical importance .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "animal experience indicates that ddrug0 prolongs the sleeping time after ddrug1 or after ddrug2 , increases the inhibitory effects of ddrug3 , but does not exhibit maoa inhibition .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 may enhance the effects of : other ddrug3 s , ddrug4 , general ddrug5 , ddrug6 such as ddrug7 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "enhanced ddrug0 clearance secondary to ddrug1 therapy .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 decreased the hyperuricemic effect of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "there is one report suggesting that the concomitant use of ddrug0 { ddrug1 } and ddrug2 may have caused 3 - to 6-fold elevations on sgpt { alt } in a few patients .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "population pharmacokinetic studies showed higher concentrations of ddrug0 among patients concurrently treated with ddrug1 , an inhibitor of c , p , a , .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may decrease the effect of ddrug1 , ddrug2 , and ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "patients receiving catecholamine-depleting drugs , such as ddrug0 or ddrug1 , should be closely monitored , because the added beta-adrenergic blocking action of ddrug2 may produce excessive reduction of sympathetic activity .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "adequate monitoring of ddrug0 plasma concentrations should be considered when therapy with ddrug1 is initiated or changed in patients receiving ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 could exaggerate the prolongation of the qt interval observed with ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "there are rare reports , however , from marketing experiences , of changes in effects of ddrug0 or oral ddrug1 in the presence of ddrug2 that necessitated changes in the doses of such agents .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 and related drugs may increase the responsiveness to ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "both ddrug0 and ddrug1 block ddrug2 - induced and ddrug3 - induced dopamine release in the nucleus accumbens ;",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "to avoid this interaction , ddrug0 or ddrug1 should be given # hour prior to dosing with ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 salts , and ddrug3 may either potentiate or weaken the blood-glucose-lowering effect of ddrug4 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "a rare , but serious , constellation of symptoms , termed serotonin syndrome , has been reported with the concomitant use of ddrug0 { ddrug1 } and agents for migraine therapy , such as ddrug2 { ddrug3 } and ddrug4 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma ddrug0 concentrations include : acute ddrug1 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug20"
            ]
        ]
    },
    {
        "text": "in one survey , # % of patients taking ddrug0 in combination with ddrug1 experienced tremor , as compared to # % reported to occur with ddrug2 alone .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "consequently , it is recommended that ddrug0 not be used in combination with either ddrug1 , ddrug2 , or ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 , like other ddrug2 , may cause changes in the elimination of ddrug3 leading to elevated serum levels of the drug and increased toxicity .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : concurrent administration of # mg or # mg ddrug1 with # mg ddrug2 increased ddrug3 exposure and ddrug4 { active metabolite } exposure by approximately 20 % in cyp2d6 extensive metabolizers .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the effects of concomitant administration of ddrug0 and ddrug1 on the pr interval were less than additive .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : co-administration of # mg twice-daily ddrug1 with ddrug2 resulted in an approximate 80 % increase in plasma levels of ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ingestion of ddrug0 may increase serum concentrations of ddrug1 and ddrug2 and increase ddrug3 s nephrotoxicity .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "absorption of ddrug0 is impaired by ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , and ddrug5 - containing preparations .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "interactions with ddrug0 : ddrug1 { eg , ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 } should not be administered to a patient who has received or is receiving a course of therapy with a ddrug7 such as ddrug8 .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "avoid the use of preparations such as ddrug0 and local ddrug1 which contain any ddrug2 { e , g , , ddrug3 , ddrug4 } , since it has been reported that ddrug5 can potentiate the effects of catecholamines .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "after multiple dosing , ddrug0 { ddrug1 # mcg im once weekly } reduced ddrug2 clearance by approximately 30 % .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "presumably , ddrug0 acts as a stimulator of ddrug1 metabolism and has been reported to cause decreased serum levels of the ddrug2 and increased prothrombin-proconvertin concentrations .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "use of ddrug0 with ddrug1 { e , g , , ddrug2 , ddrug3 , or ddrug4 } , ddrug5 supplements , or potassium-containing salt substitutes may lead to significant increases in serum potassium .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "however , the peak plasma level of ddrug0 was reduced by approximately 20 % when taking ddrug1 due to a slight delay in the absorption of ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 is a potential inhibitor of the cyp2c9 isoenzyme in vivo as indicated by its ability to inhibit the in vitro metabolism of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 should not be administered concomitantly with other ddrug1 { such as ddrug2 } because of possible additive effects and increased toxicity .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "therefore , cyp3a4 substrates known to have a narrow therapeutic index such as ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , or ddrug10 { ddrug11 , ddrug12 } should be administered with caution in patients receiving ddrug13 .",
        "triple_list": [
            [
                "ddrug10",
                "advise",
                "ddrug13"
            ]
        ]
    },
    {
        "text": "elevated plasma levels of ddrug0 have been reported with concomitant ddrug1 use .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 may enhance the effects of : other ddrug3 s , ddrug4 , general ddrug5 , ddrug6 such as ddrug7 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "ddrug0 or ddrug1 excess may decrease the effect of ddrug2 , and an ddrug3 deficiency can increase the effect of ddrug4 .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "interactions with ddrug0 : ddrug1 { eg , ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 } should not be administered to a patient who has received or is receiving a course of therapy with a ddrug7 such as ddrug8 .",
        "triple_list": [
            [
                "ddrug7",
                "advise",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug18"
            ]
        ]
    },
    {
        "text": "consider additive sedative effects and confusional states to emerge , if ddrug0 is given with ddrug1 or ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 salts , and ddrug3 may either potentiate or weaken the blood-glucose-lowering effect of ddrug4 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 : since both ddrug1 and ddrug2 can cause increased intracranial pressure , their combined use is contraindicated .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "recovery from 50 % twitch to 75 % fade recovery took # + / - # min for ddrug0 alone and # + / - # min for ddrug1 plus ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "ddrug0 reduced the antitumour activity of oral ddrug1 by dose modifying factors { dmf } of ## .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the in vitro interaction between ddrug0 and the ddrug1 ddrug2 is complex .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "this appears to be the only clinically relevant interaction of this kind with ddrug0 , although theoretically , coadministration of other drugs known to alter cardiac conduction { eg , ddrug1 or ddrug2 , ddrug3 , ddrug4 or ddrug5 , ddrug6 and ddrug7 } might also contribute to a prolongation of the qtc interval .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of ddrug0 such as ddrug1 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "it is , however , possible that concomitant use of other known ddrug0 such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 might increase the photosensitivity reaction of actinic_keratosis treated with the ddrug7 for topical solution .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "ddrug0 altered coagulation parameters and/or bleeding have been reported in patients taking ddrug1 concomitantly with ddrug2 such as ddrug3 and ddrug4 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit ddrug0 binding to serum proteins or alter the concentrations of serum binding proteins : ddrug1 and related ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug14"
            ]
        ]
    },
    {
        "text": "if concomitant treatment with ddrug0 and an ddrug1 is clinically warranted , appropriate observation of the patient is advised .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 significantly increased the area under the curve at steady state { auc { ss } } of ddrug1 by # - fold and the auc { ss } of ddrug2 by # - fold .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : ddrug1 ;",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "interactions with ddrug0 : ddrug1 { eg , ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 } should not be administered to a patient who has received or is receiving a course of therapy with a ddrug7 such as ddrug8 .",
        "triple_list": [
            [
                "ddrug4",
                "advise",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "ddrug0 prolong and intensify the anticholinergic effects of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may have additive effects with ddrug1 and other ddrug2 , e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "therefore , co-administration of ddrug0 with drugs that are metabolized by cyp2d6 isoenzyme including certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } , ddrug8 { e , g , , ddrug9 , ddrug10 , ddrug11 } , ddrug12 { e , g , , ddrug13 } , and ddrug14 { e , g , , ddrug15 , ddrug16 } , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "in patients receiving another ddrug0 in combination with ddrug1 { ddrug2 } , there have been reports of serious , sometimes fatal , reactions including hyperthermia , rigidity , myoclonus , autonomic instability with possible rapid fluctuations of vital signs , and mental status changes that include extreme agitation progressing to delirium and coma .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 : in normal volunteers { n = 9 } , pretreatment with ddrug2 or ddrug3 did not affect ddrug4 pharmacokinetics except that a small { 13 % } but statistically significant increase in the area under the serum concentration curve of ddrug5 resulted with ddrug6 .",
        "triple_list": [
            [
                "ddrug5",
                "mechanism",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "with simultaneous dosing of ddrug0 # mg and ddrug1 # mg , # of # subjects experienced a standing systolic blood pressure of less than # mm hg .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 , ddrug2 , ddrug3 } : metabolism may be inhibited by ddrug4 , increasing plasma levels of ddrug5 ;",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 should be administered with caution to patients receiving ddrug1 { ddrug2 , wyeth-ayerst laboratories } .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with ddrug1 , ddrug2 , and certain other agents .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 should not beadministered concomitantly becausedecreases in ddrug2 plasmaconcentrations may reduce the efficacy ofthe drug .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "injection : ddrug0 injection , like other injectable ddrug1 , produces depression of the central nervous system when administered with ddrug2 , ddrug3 , ddrug4 , ddrug5 , and other ddrug6 , when ddrug7 is used concomitantly with injectable ddrug8 , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 will increase plasmaconcentration of other cyp3a4 metabolized drugs { e , g , , triazolo - ddrug1 , ddrug2 , certain ddrug3 , etc , } .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 - ddrug1 may increase the absorption of ddrug2 if taken concomitantly .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "however , due to possible pharmacodynamic interactions , when co-administered with ddrug0 , a reduction in dosage of ddrug1 on the concomitant ddrug2 , ddrug3 , ddrug4 or ddrug5 may be required .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 , including ddrug1 , may enhance the effects of oral ddrug2 , including ddrug3 or its derivatives or similar agents .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 used at doses of # mg/kg and # mg/kg decreased the antinociceptive effect of ddrug1 , ddrug2 { only in the tail-flick test } and ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of ddrug0 # % ophthalmic solution , the possibility of an additive or potentiating effect with ddrug1 { ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 } should be considered .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 , such as ddrug1 and ddrug2 , can inhibit renal tubular secretion of ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "concurrent administration of drugs possessing nephrotoxic { e , g , , ddrug0 , ddrug1 } , myelotoxic { e , g , , ddrug2 chemotherapy } , cardiotoxic { e , g , , ddrug3 } or hepatotoxic { e , g , , ddrug4 , ddrug5 } effects with ddrug6 may increase toxicity in these organ systems .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "during administration of multiple oral doses of ddrug0 to healthy subjects stabilized on a maintenance dose of ddrug1 , a 13 % -19 % increase in plasma ddrug2 levels occurred at six hours postdose .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 , ddrug2 , ddrug3 } : metabolism may be inhibited by ddrug4 , increasing plasma levels of ddrug5 ;",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "the plasma concentration of ddrug0 may increase when the drug is given concomitantly with hepatic enzyme inhibitors { e , g , , ddrug1 , ddrug2 } and decrease by concomitant administration of hepatic enzyme inducers { e , g , , ddrug3 , ddrug4 } , and adjustment of the dosage of ddrug5 may therefore be necessary .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 supplements and ddrug1 benazepril can attenuate potassium loss caused by ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 { # and # mg/kg , s , c , } inhibited the ddrug2 { # mg/kg , p , o , } - induced diarrhea in cecectomized rats .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "we conclude that ddrug0 prevents ddrug1 - induced increases in gastrointestinal transit time by means of selective peripheral opioid anitagonism without affecting central opioid analgesia .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in vitro studies have shown that the metabolism of ddrug0 may be modified by the concomitant administration of compounds that induce , inhibit , or are metabolized by cytochrome p450 3a4 , such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , and ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "additionally , ddrug0 should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as ddrug1 , ddrug2 , and ddrug3 because of the danger of blocking cardiac contractility when systemic vascular resistance is high .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "administration of ddrug0 to patients receiving ddrug1 has been reported to lead to hypotension and bradycardia .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "interactions attributed to the combined use of ddrug0 injection and epidural ddrug1 include hypotension and dyspnea .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "it was concluded that , although ddrug0 did augment the neuromuscular blockade of ddrug1 , the effect was minimal .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "it is recommended that ddrug0 not be used concomitantly with ddrug1 because the effects of concomitant administration of ddrug2 with most other ddrug3 have not been studied , the concomitant use of ddrug4 with other cns-active drugs should be approached with caution .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the following are examples of drugs known to inhibit the metabolism of other related ddrug0 , presumably through inhibition of cyp3a : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , and some ddrug6 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "{ 1968 , 1970 } , the higher serum concentrations of ddrug0 and ddrug1 reached after administration of ddrug2 are due not only to slower renal elimination but also to an altered distribution in the body .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "conversely , decreases in plasma levels of the ddrug0 have been reported upon discontinuation of ddrug1 which may result in the loss of the therapeutic efficacy of the ddrug2 6 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "drugs that reduce the number of blood platelets by causing bone marrow depression { such as ddrug0 } or drugs which inhibit platelet function { eg , ddrug1 and other ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 } may increase the bleeding tendency produced by ddrug7 without altering prothrombin time determinations .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "since bacteriostatic drugs , such as the ddrug0 of ddrug1 , may interfere with the bactericidal action of ddrug2 , it is not advisable to administer these drugs concomitantly .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "intraventricular injection of ddrug0 at doses of # to # micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular ddrug1 and ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "twelve strains of staphylococcus aureus { a frequent cause of infection in ddrug0 , but not in ddrug1 and ddrug2 , addicts } were completely inhibited by the drug combination .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "coadministration with compounds that are potent inducers of cyp3a4 { eg , ddrug0 , ddrug1 , ddrug2 , ddrug3 } may result in decreased plasma levels of ddrug4 .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 may accentuate the electrolyte loss associated with ddrug1 therapy .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : in a study in healthy volunteers , a six-day course of ddrug1 at # mg/day followed by a single # mg dose of ddrug2 resulted in a reduction in ddrug3 levels to below detectable limits .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "coadministration of ddrug0 decreased the maximum plasma concentration of ddrug1 by 6 % , decreased clearance by 38 % , and increased half-life by 58 % .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "if possible , ddrug0 should be withdrawn at least # hours before initiating ddrug1 therapy .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and ddrug7 raise the serum ddrug8 concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that ddrug9 intoxication may result .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with ddrug1 , ddrug2 , and certain other agents .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as ddrug0 include certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 } , ddrug10 salts , ddrug11 , local ddrug12 , ddrug13 , and ddrug14 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 { eg , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , and ddrug15 } may have elevated plasma concentrations when coadministered with ddrug16 ;",
        "triple_list": [
            [
                "ddrug7",
                "mechanism",
                "ddrug16"
            ]
        ]
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a ddrug0 , including ddrug1 , with multivalent cation-containing products such as ddrug2 or ddrug3 ddrug4 , ddrug5 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , ddrug8 , or ddrug9 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma ddrug0 concentrations include : acute ddrug1 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "cytochrome p-450 inducers , such as ddrug0 , ddrug1 and ddrug2 , induce ddrug3 metabolism , causing an approximately 30 % decrease in plasma ddrug4 levels .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 s plasma half-life may be prolonged by ddrug2 , since ddrug3 and ddrug4 may compete for excretion in the renal tubule .",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "resistance to the neuromuscular blocking action of ddrug0 has been demonstrated in patients chronically administered ddrug1 or ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "in patients , the concomitant administration of ddrug0 with ddrug1 was associated with a higher occurrence of torsade de pointes .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : based on reports of profound hypotension and loss of consciousness when ddrug1 was administered with ddrug2 , the concomitant use of ddrug3 with drugs of the ddrug4 { including , for example , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 } is contraindicated .",
        "triple_list": [
            [
                "ddrug3",
                "advise",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "oral ddrug0 : coadministration of ddrug1 and an oral ddrug2 increased auc values for ddrug3 and ddrug4 by approximately 30 % and 20 % .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "coadministration of ddrug0 with ddrug1 lowered the ddrug2 plasma concentrations to undetectable levels .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : combination ddrug1 may decrease the clearance of some ddrug2 { ddrug3 , ddrug4 , ddrug5 } and increase the clearance of others { ddrug6 , ddrug7 , ddrug8 } .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "the concomitant use of transdermal ddrug0 with ddrug1 or other potent 3a4 inhibitors such as ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and nefazadone may result in an increase in ddrug7 plasma concentrations .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "concomitant administration of ddrug0 with ddrug1 is contraindicated .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the ddrug0 of drugs may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , the ddrug6 , ddrug7 and ddrug8 , ddrug9 and the ddrug10 , and by other ddrug11 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug10"
            ]
        ]
    },
    {
        "text": "ddrug0 has been shown to change the bioavailabillty ddrug1 when they are co-administered , which may require ddrug2 dose adjustment .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "therefore , co-administration of ddrug0 with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index , including certain ddrug1 { ddrug2 -lsb- ddrug3 -rsb- , such as ddrug4 , ddrug5 , and ddrug6 } , ddrug7 and ddrug8 { e , g , , ddrug9 , ddrug10 } , should be approached with caution .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "there have been reports of interactions of ddrug0 with ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug12"
            ]
        ]
    },
    {
        "text": "consequently , it is recommended that ddrug0 not be used in combination with either ddrug1 , ddrug2 , or ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 administration to a digitalized , hypothyroid patient may increase the dose requirement of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "interactions of ddrug0 and ddrug1 in absorption and retention .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 : a drug interaction .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "patients currently receiving ddrug0 therapy should be carefully monitored for a change in pharmacological effect when initiating and discontinuing therapy with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 , including ddrug1 , may enhance the effects of the oral ddrug2 ddrug3 or its derivatives .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "when used in therapeutic doses , ddrug0 had a modest effect on the pharmacokinetics of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { intravenous and oral } , ddrug12 , ddrug13 / ddrug14 or ddrug15 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug10"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 { consider ddrug3 dose reduction } .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "these results suggest that both ddrug0 and ddrug1 , and possibly other ddrug2 and ddrug3 , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of ddrug4 and ddrug5 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "however , due to possible pharmacodynamic interactions , when co-administered with ddrug0 , a reduction in dosage of ddrug1 on the concomitant ddrug2 , ddrug3 , ddrug4 or ddrug5 may be required .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "the gastrointestinal absorption of ddrug0 and ddrug1 is accelerated when they are coadministered with ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 with ddrug1 or ddrug2 and possibly other ddrug3 cause striking and sustained increases in the concentration of ddrug4 in the brain ;",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "the results raise the possibility that the ethanolysis reaction may occur in the stomach of people who consume ddrug0 and ddrug1 on a regular basis .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 , ddrug2 , ddrug3 , or ddrug4 may interfere with the bactericidal effect of ddrug5 .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of ddrug0 such as ddrug1 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "ddrug0 has been reported to decrease the clearance of ddrug1 and ddrug2 and thus may increase the pharmacologic effect of these ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "international normalized ratio { inr } elevations and/or bleeding events have been reported in some patients taking ddrug0 while on ddrug1 therapy .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "because their vasospastic effects may be additive , coadministration of ddrug0 and other ddrug1 within # hours of each other is not recommended .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug21"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 supplements , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "in a study in normal volunteers , it was found that chronic concurrent administration of # g of ddrug0 per day decreases ddrug1 blood levels approximately 20 % .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may decrease the effectiveness of oral ddrug1 , certain ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and ddrug7 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "a # to 45 % increase in auc and cmax of ddrug0 was observed with concomitant administration of ddrug1 twice daily .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "immediate and extended release tablets the hypoglycemic action of ddrug0 may be potentiated by certain drugs including ddrug1 , some ddrug2 and other drugs that are highly protein bound , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "because ddrug0 reduces the clearance of both ddrug1 and its active metabolite , ddrug2 , there is a strong likelihood of substantial accumulation of both species during chronic co-administration .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "therefore , concomitant use of ddrug0 and ddrug1 is contraindicated .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "administration of ddrug0 with other cyp3a4 inhibitors { e , g , , ddrug1 # mg bid , ddrug2 # mg qd , ddrug3 # mg tid , ddrug4 # mg qd } resulted in increases in cmax of ddrug5 ranging from # - to # - fold and auc from # - to # - fold .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 may reduce the antihypertensive effects of ddrug1 , ddrug2 , ddrug3 and ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "clinical implications of ddrug0 interactions with five ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 should not be administered concomitantly with ddrug1 , ddrug2 , ddrug3 , ddrug4 , or ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "certain drugs , including ddrug0 { ddrug1 } , ddrug2 , ddrug3 , and ddrug4 may potentiate the hypoglycemic action of ddrug5 and other oral ddrug6 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 - pectin , ddrug2 , ddrug3 , ddrug4 , certain anticancer drugs , and ddrug5 may interfere with intestinal ddrug6 absorption , resulting in unexpectedly low serum concentrations .",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 should be used with care when ddrug1 or inhibitors of av conduction , such as certain ddrug2 { particularly of the ddrug3 -lsb- ddrug4 -rsb- and ddrug5 -lsb- ddrug6 -rsb- classes } , or ddrug7 , such as ddrug8 , are used concurrently .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 decreased the binding of ddrug1 by a net change of # % { percentage increase in fdf , # % } at # micromol/l ;",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "oral ddrug0 : ddrug1 , when given once daily for # days as a 100-mg capsule with an oral ddrug2 containing # mcg of ddrug3 and # mg of ddrug4 , decreased the auc of ddrug5 by 43 % , and decreased the auc of ddrug6 by 8 % ;",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "injection : ddrug0 injection , like other injectable ddrug1 , produces depression of the central nervous system when administered with ddrug2 , ddrug3 , ddrug4 , ddrug5 , and other ddrug6 , when ddrug7 is used concomitantly with injectable ddrug8 , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "in patients given very high doses { 3900 mg } of ddrug0 daily , increases in serum ddrug1 levels were seen when ddrug2 , # mg b , i , d , , was administered concurrently .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "deaths from severe enterocolitis , diarrhea , and dehydration have been reported in elderly patients receiving weekly ddrug0 and ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "although ddrug0 may increase the bioavailability of ddrug1 by increasing gastric emptying , ddrug2 may also adversely affect disease control by its dopamine receptor antagonistic properties .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in eight hiv-infected patients , the steady-state auc of ddrug0 was decreased an average of 26 % { 95 % ci = 14 % , 37 % } when ddrug1 was administered # hours prior to a marketed chewable/dispersible tablet formulation of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : elevated ddrug1 levels have been reported in postmarketing experience when ddrug2 is administered concomitantly .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a ddrug0 , including ddrug1 , with multivalent cation-containing products such as ddrug2 or ddrug3 ddrug4 , ddrug5 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , ddrug8 , or ddrug9 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "it is recommended to avoid concurrent administration of ddrug0 with ddrug1 containing ddrug2 for at least # hours following ddrug3 administration .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 may potentiate the toxic effects of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ddrug0 is administered in combination with other ddrug1 such as ddrug2 , ddrug3 , ddrug4 , or inhalation general ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 should not be used together with ddrug1 { ddrug2 , ddrug3 } , another arthritis medication .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "interactions for ddrug0 { ddrug1 } : ddrug2 therapy : ddrug3 may potentiate the effects of ddrug4 and vasoactive drugs resulting in postural hypotension .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 : enteric coated ddrug1 should not be given concurrently with ddrug2 , since an increase in the ph of the stomach may effect the enteric coating of the tablets .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "however , the systemic administration of some ddrug0 has been shown to elevate plasma concentrations of ddrug1 , interfere with the metabolism of ddrug2 , and enhance the effects of the oral ddrug3 ddrug4 and its derivatives , and has been associated with transient elevations in serum creatinine in patients receiving systemic ddrug5 concomitantly .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "studies in rats have shown that ddrug0 administration attenuates certain types of ddrug1 dependent hypertension , including ddrug2 hypertension .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "therefore , cyp3a4 substrates known to have a narrow therapeutic index such as ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , or ddrug10 { ddrug11 , ddrug12 } should be administered with caution in patients receiving ddrug13 .",
        "triple_list": [
            [
                "ddrug6",
                "advise",
                "ddrug13"
            ]
        ]
    },
    {
        "text": "tablets simultaneous administration of ddrug0 and ddrug1 tablets may reduce the natriuretic and antihypertensive effects of ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 have also been shown to interfere with the metabolism of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "therefore , co-administration of ddrug0 with drugs that are metabolized by cyp2d6 isoenzyme including certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } , ddrug8 { e , g , , ddrug9 , ddrug10 , ddrug11 } , ddrug12 { e , g , , ddrug13 } , and ddrug14 { e , g , , ddrug15 , ddrug16 } , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug14"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 } : increase the metabolism of ddrug6 and/or some ddrug7 , leading to possible decrease in contraceptive effectiveness .",
        "triple_list": [
            [
                "ddrug5",
                "mechanism",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "concurrent use with ddrug0 or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 is known to interact with the metabolism or renal tubular excretion of many drugs { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 agents , ddrug14 , and ddrug15 } .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 , and ddrug2 decrease the ed50 of ddrug3 by 30 % to 45 % .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 - related adverse effects have occurred in patients consuming ddrug1 while on therapy with ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "- ddrug0 : in some patients , the administration of a ddrug1 can reduce the diuretic , natriuretic , and antihypertensive effects of ddrug2 , ddrug3 and ddrug4 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "administration of ddrug0 to patients who are receiving ddrug1 or ddrug2 may result in an additive pressor effect .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the concomitant use of transdermal ddrug0 with ddrug1 or other potent 3a4 inhibitors such as ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and nefazadone may result in an increase in ddrug7 plasma concentrations .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "however , a crossover study in healthy subjects receiving either ddrug0 # mg q , i , d , or # mg h , s , concomitantly with a # mg b , i , d , dosage of ddrug1 { ddrug2 , key pharmaceuticals , inc , } demonstrated less alteration in steady-state ddrug3 peak serum levels with the # mg h , s , regimen , particularly in subjects aged # years and older .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "a dose increase of ddrug0 / ddrug1 to 533/133 mg { 4 capsules or # ml } twice daily taken with food is recommended when used in combination with ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the hypoglycemic action of ddrug0 may be potentiated by certain drugs including ddrug1 and other drugs that are highly protein bound , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , and ddrug8 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit ddrug0 binding to serum proteins or alter the concentrations of serum binding proteins : ddrug1 and related ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug10"
            ]
        ]
    },
    {
        "text": "ddrug0 - administration of # mg/day ddrug1 for # days in healthy volunteers resulted in a 50 % increase in cmax and 82 % increase in auc of the ddrug2 ddrug3 { given in a single dose of # mg } .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "these pharmacokinetic effects seen during ddrug0 coadministration can result in increased clinical effects { e , g , , prolonged sodation } of both ddrug1 and ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : the co-administration of ddrug1 tablets and ddrug2 is generally not advisable .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 / nutrition / herb interactions : food : cns effects of ddrug1 may be enhanced if ddrug2 are used concurrently with ddrug3 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "concomitant administration of ddrug0 { equivalent to # mg ddrug1 } with ddrug2 { 20 mg } once daily for # days resulted in approximately 17 % decrease { range from 67 % decrease to 44 % increase } in ddrug3 auc values in # healthy males .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "since ddrug0 { ddrug1 } may interact with concurrently administered ddrug2 , periodic serum level determinations of these drugs may be necessary { eg , ddrug3 may elevate ddrug4 serum levels and ddrug5 has been reported to both increase and decrease ddrug6 levels } .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 in combination with other ddrug1 , general ddrug2 , ddrug3 , ddrug4 , ddrug5 , or other ddrug6 { including ddrug7 } has additive depressant effects .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "however , appropriate monitoring of blood glucose should be performed when initiating ddrug0 in diabetic patients and ddrug1 dosage should be adjusted if needed .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "a number of drugs , including ddrug0 , have been shown to displace ddrug1 from plasma protein ;",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 caused a statistically significant increase in plasma exposures of ddrug1 and ddrug2 { 12 % and 15 % , respectively } , and in the pharmacodynamic effects { prothrombin time , measured as inr } of ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 has been found to temporarily raise serum concentrations of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "drugs that induce hepatic enzymes such as ddrug0 , ddrug1 and ddrug2 may increase the clearance of ddrug3 and may require increases in ddrug4 dose to achieve the desired response .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "plasma concentrations of ddrug0 are reduced when given concurrently with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "several ddrug0 have been reported to block the pharmacologic effects of ddrug1 , ddrug2 , or similar agents , and such an effect may be anticipated with ddrug3 because of its structural similarity to other ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the hypoglycemic action of ddrug0 may be potentiated by certain drugs including ddrug1 and other drugs that are highly protein bound , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , and ddrug8 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "ddrug0 blunts the reflex tachycardia produced by ddrug1 without preventing its hypotensive effect .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "accordingly , ddrug0 and ddrug1 should not ordinarily be co-administered .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "agents causing renin release ddrug0 's effect will be augmented by ddrug1 that cause renin release .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "conversely , ddrug0 may interfere with ddrug1 { i , e , , ddrug2 , ddrug3 } .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "therefore , patients on ddrug0 should be observed when ddrug1 tablets are either added or deleted from a therapeutic regimen .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the gastrointestinal absorption of ddrug0 and ddrug1 is accelerated when they are coadministered with ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 may increase sensitivity to the ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 generally should not be given with ddrug1 because they reduce its renal clearance and add a high risk of ddrug2 toxicity .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "close observation of the patient is recommended when a ddrug0 is administered to patients receiving catecholamine-depleting drugs such as ddrug1 , because of possible additive effects and the production of hypotension and/or marked bradycardia , which may produce vertigo , syncope or postural hypotension .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "co-administration with ddrug0 or ddrug1 had a modest effect on the pharmacokinetics of ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 : increased prothrombin time , with or without clinical bleeding , has been reported when ddrug2 is administered concomitantly .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "when used in therapeutic doses , ddrug0 had a modest effect on the pharmacokinetics of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { intravenous and oral } , ddrug12 , ddrug13 / ddrug14 or ddrug15 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug15"
            ]
        ]
    },
    {
        "text": "drugs that have been reported to diminish oral ddrug0 response , ie , decreased prothrom-bin time response , in man significantly include : ddrug1 ;",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may potentiate the hypotensive effects of ddrug1 and the anticholinergic effects of ddrug2 - type drugs .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 supplements , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "ddrug0 { eg , ddrug1 } and other drugs , including ether , ddrug2 , ddrug3 , ddrug4 and ddrug5 , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with ddrug6 parenteral .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "rhabdomyolysis secondary to a drug interaction between ddrug0 and ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the extent to which ddrug0 - ddrug1 interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the ddrug2 involved .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the absorption of ddrug0 may be affected by the simultaneous administration of indigestion remedies , ddrug1 or ddrug2 supplements .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 could exaggerate the prolongation of the qt interval observed with ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the following precautions should be kept in mind in the treatment of anticholinesterase poisoning although they do not bear directly on the use of ddrug0 and ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 has additive effects with ddrug1 and other ddrug2 { ddrug3 , ddrug4 , ddrug5 , etc } .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 : concurrent administration of ddrug1 { an ddrug2 } and another ddrug3 has been associated with an increased risk of serious infections , an increased risk of neutropenia and no additional benefit compared to these medicinal products alone .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 may have additive effects with ddrug1 and other ddrug2 , e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 decreases ddrug1 clearance by up to 25 % , and may produce aucs # m min in some patients .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "drugs whose absorption can be affected by the level of acidity in the stomach : drugs such as ddrug0 and ddrug1 should be administered at least # hours prior to dosing with ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "therefore , increased monitoring of ddrug0 is recommended when initiating , adjusting , or discontinuing ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 should be avoided by patients with a history of serious reaction to any ddrug1 , including ddrug2 and ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "{ in some patients , the ddrug0 can reduce the diuretic , natriuretic , and antihypertensive effects of ddrug1 , ddrug2 , and ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the hypoglycemic action of ddrug0 may be potentiated by certain drugs including ddrug1 and other drugs that are highly protein bound , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , and ddrug8 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the absorption of ddrug0 , ddrug1 , ddrug2 , ddrug3 , and ddrug4 was significantly decreased when given simultaneously with ddrug5 ;",
        "triple_list": [
            [
                "ddrug4",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "when concomitant treatment with ddrug0 and ddrug1 is to be terminated , the ddrug2 should be discontinued first .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of ddrug0 such as ddrug1 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 have been reported to blunt the hypotensive effect of systemic ddrug1 , it is not known whether the concurrent use of these agents with ddrug2 in humans can lead to resulting interference with the iop lowering effect .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 - and ddrug1 - containing ddrug2 , administered concomitantly with ddrug3 , significantly decreased the bioavailability { 48 % } of ddrug4 .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "inhibitors or substrates of cyp2d6 { i , e , , ddrug0 , ddrug1 -lsb- ddrug2 -rsb- } may increase the plasma concentration of ddrug3 when administered concomitantly .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "use of ddrug0 with ddrug1 { e , g , , ddrug2 , ddrug3 , or ddrug4 } , ddrug5 supplements , or potassium-containing salt substitutes may lead to significant increases in serum potassium .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "simultaneous administration of ddrug0 with ddrug1 should be avoided .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "if ddrug0 therapy is initiated in a patient currently receiving ddrug1 , cautious titration is advised .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "there have been reports of interactions of ddrug0 with ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with ddrug1 , ddrug2 s , ddrug3 { allergy , cold , and sinus medicines } , diabetic drugs , ddrug4 , ddrug5 , ddrug6 like ddrug7 or ddrug8 , and high blood pressure medications .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "coadministration of ddrug0 with ddrug1 or any known cyp3a4 inducer should be avoided when possible , and alternative therapy considered .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "thus patients receiving oral ddrug0 and ddrug1 tablets should have their prothrombin time monitored and their ddrug2 dose adjusted accordingly .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "concomitant use of ddrug0 usually depresses ddrug1 activity and may necessitate raising the dosage .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "however , # mg of ddrug0 q12h for # days increased the ddrug1 c max by 23 % and ddrug2 auc by 16 % .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 , including ddrug1 , may enhance the effects of oral ddrug2 , such as ddrug3 or its derivatives .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "compounds in these categories result in a decreased efficacy of ddrug0 : ddrug1 , ddrug2 , ddrug3 , ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "serum concentration of ddrug0 and ddrug1 may increase when patients take ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 including coumarin derivatives , indandione derivatives , and ddrug1 such as ddrug2 { ddrug3 } , and ddrug4 may increase the risk of bleeding when administered concomitantly with ddrug5 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 use in patients who are receiving high doses of ddrug1 may be associated with an increase in serum ddrug2 levels and potential ddrug3 toxicity .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "limited data in patients receiving known enzyme inducers { ddrug0 , ddrug1 , ddrug2 } indicate only a 30 % increase in the rate of ddrug3 elimination .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 toxicity has been reported to have occurred in a patient on chronic ddrug1 treatment following the initiation of ddrug2 therapy .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 { 2 } , ddrug7 , ddrug8 , and ddrug9 thus , if a patient has been titrated to a stable dosage on ddrug10 , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for ddrug11 may be necessary .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "ddrug0 / ddrug1 : the coadministration of ddrug2 or ddrug3 will not affect plasma concentrations of ddrug4 , but may reduce endogenous plasma levels of ddrug5 / ergocalcitriol by accelerating metabolism .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 { 500 mg t , i , d } produced a 4-fold increase in ddrug1 auc and a 3-fold increase in cmax when co-administered with ddrug2 # mg in healthy volunteers .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "particular caution is necessary when using ddrug0 in cases of mixed drug overdosage since the toxic effects { such as convulsions and cardiac dysrhythmias } of other drugs taken in overdose { especially ddrug1 } may emerge with the reversal of the ddrug2 effect by ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may increase the action of ddrug1 , ddrug2 , ddrug3 , and ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 and other ddrug1 can reduce the antihypertensive effect of ddrug2 and other ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 may displace acidic drugs such as ddrug1 or ddrug2 from their binding sites .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 increases the auc for ddrug2 and ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 - concomitant intake of ddrug1 and ddrug2 may reduce the absorption of ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "in some patients , the administration of a ddrug0 can reduce the diuretic , natriuretic , and antihypertensive effects of ddrug1 , ddrug2 and ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "however , because some ddrug0 have been reported to enhance the anticoagulant effects of ddrug1 or its derivatives in patients , the prothrombin time or other suitable coagulation test should be closely monitored if a ddrug2 is administered concomitantly with ddrug3 or its derivatives .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : ddrug1 ; ddrug2 ; ddrug3 ; certain ddrug4 , especially the ddrug5 and ddrug6 ; ddrug7 ; ddrug8 salts ; ddrug9 ; and ddrug10 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "prior administration of ddrug0 { 90 mg kg { -1 } body weight } was shown to prevent the conversion of ddrug1 { 100 mg kg { -1 } body weight } to ddrug2 in vivo and to eliminate the fluoride and citrate elevations seen in ddrug3 - intoxicated animals .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "patients receiving concomitant ddrug0 and ddrug1 should be carefully monitored ;",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "two percent of patients treated concurrently with ddrug0 and ddrug1 developed neutropenia { anc # x 109/l } .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and ddrug7 raise the serum ddrug8 concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that ddrug9 intoxication may result .",
        "triple_list": [
            [
                "ddrug7",
                "mechanism",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of ddrug0 such as ddrug1 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug10"
            ]
        ]
    },
    {
        "text": "ddrug0 may exacerbate the hypertensive response seen with ddrug1 withdrawl .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "since there have been conflicting results regarding the effect of ddrug0 levels , it is recommended that ddrug1 levels be monitored when initiating , adjusting , and discontinuing ddrug2 therapy to avoid possible over - or under-digitalization .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 reduce the renal clearance of ddrug1 and add a high risk of ddrug2 toxicity .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "upon administration of # mg of ddrug0 with # mg tid ddrug1 , the cmax and auc of ddrug2 were reduced by 40 % and 30 % , respectively .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : coadministration of once daily doses of ddrug1 , as a tablet formulation comparable to # mg or # mg of the capsule formulation , with ddrug2 # mg once daily , resulted in a decrease in auc by approximately 25 % and cmax , by approximately 20 % of both ddrug3 and ddrug4 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 may inhibit the metabolism of ddrug2 , leading to increased plasma concentrations .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "- ddrug0 , oral { diabetes medicine you take by mouth } use of oral ddrug1 with ddrug2 may increase the chance of side effects affecting the blood and/or the side effects or oral ddrug3",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : reports suggest that ddrug1 may diminish the antihypertensive effect of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 therapy : urinary excretion of ddrug1 is increased , and efficacy is reduced , by ddrug2 used in ddrug3 therapy .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "therefore , co-administration of ddrug0 with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index , including certain ddrug1 { ddrug2 -lsb- ddrug3 -rsb- , such as ddrug4 , ddrug5 , and ddrug6 } , ddrug7 and ddrug8 { e , g , , ddrug9 , ddrug10 } , should be approached with caution .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "human pharmacokinetics data indicate that oral ddrug0 potently inhibits the metabolism of ddrug1 resulting in an eight-fold increase in the mean auc of ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may enhance the effects of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "interaction of ddrug0 and ddrug1 in vitro .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 may reduce or reverse the pressor effect of ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 iv/im reduced the ddrug2 response to ddrug3 in normovolemic healthy subjects by approximately 20 % { mean sodium and urinary output decreased 17 % } .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "the vasodilating effects of ddrug0 may be additive with those of other ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : may decrease ddrug1 anti-inflammatory action by competing for the same receptors .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "interactions with other cns agents : concurrent use of ddrug0 with all ddrug1 { eg , ddrug2 , ddrug3 , ddrug4 , other ddrug5 , general ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 and ddrug12 } may result in additive central nervous system depressant effects .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "when other ddrug0 or ddrug1 are used concomitantly , there is the potential for ddrug2 to increase the risk of bleeding .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 may enhance the effects of : other ddrug3 s , ddrug4 , general ddrug5 , ddrug6 such as ddrug7 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "patients receiving ddrug0 should be advised against the concurrent use of other ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 - and ddrug1 - containing ddrug2 , administered concomitantly with ddrug3 , significantly decreased the bioavailability { 48 % } of ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "- ddrug0 and ddrug1 ddrug2 : ddrug3 and ddrug4 ddrug5 have the potential of binding ddrug6 and reducing ddrug7 absorption from the gastrointestinal tract",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "therefore , when ddrug0 and ddrug1 are used concomitantly , the patient should be observed closely to determine if the desired effect of the ddrug2 is obtained .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in addition to bleeding associated with ddrug0 and ddrug1 , drugs that alter platelet function { such as ddrug2 , ddrug3 and ddrug4 } may increase the risk of bleeding if administered prior to , during , or after ddrug5 therapy .",
        "triple_list": [
            [
                "ddrug4",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 may enhance the metabolic clearance of ddrug2 , resulting in decreased blood levels and lessened physiologic activity , thus requiring an increase in ddrug3 dosage .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "- in isolated cases , a pronounced though reversible , impairment of renal function { accompanied by a corresponding increase in the serum creatinine level } has been reported in organ transplant patients receiving ddrug0 therapy and concomitant ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "results of preliminary studies in humans and rats suggest that nonabsorbable ddrug0 given concurrently with ddrug1 may inhibit the desired ddrug2 - induced drop in colonic ph.",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "concomitant administration of ddrug0 { 10 mg } and ddrug1 { 800 mg } produced an 85 % increase in the mean cmax and auc of ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "- drugs that may decrease plasma ddrug0 concentrations include : ddrug1 , chronic ddrug2 abuse , ddrug3",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "consequently , concomitant administration of ddrug0 with strong cyp3a4 inhibitors { e , g , , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } should be approached with caution .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "additional reductions in blood pressure may occur when ddrug0 is administered with ddrug1 , ddrug2 , or other ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 : ddrug2 may enhance the activity of ddrug3 or ddrug4 ;",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "due to its nephrotoxicity , ddrug0 may cause abnormal renal uptake to be seen on ddrug1 bone scintigraphy .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 will increase plasmaconcentration of other cyp3a4 metabolized drugs { e , g , , triazolo - ddrug1 , ddrug2 , certain ddrug3 , etc , } .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : immediate release capsules : there have been rare reports of an interaction between ddrug1 and ddrug2 { with a decreased plasma level of ddrug3 } .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the hypoglycemic effect of ddrug0 has been reported to increase when ddrug1 is given concurrently .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 should not be used concomitantly with other drugs known to prolong the qt interval : certain ddrug1 , including those of class ia { such as ddrug2 and ddrug3 } and class iii { such as ddrug4 } ;",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "these pharmacokinetic effects seen during ddrug0 coadministration can result in increased clinical effects { e , g , , prolonged sodation } of both ddrug1 and ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "if concomitant treatment with ddrug0 and an ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } is clinically warranted , appropriate observation of the patient is advised .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 may decrease the effects of ddrug2 , ddrug3 , and ddrug4 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "the elimination half life of ddrug0 and ddrug1 also increased { ## fold } during coadministration with ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 caused a decrease in ddrug2 phosphorylation { 50 % inhibition of total phosphate formation } in u937/molt # cells .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 { hypertension } - in clinical studies of patients with hypertension , the addition of ddrug2 # to # mg to ddrug3 and ddrug4 increased mean serum potassium slightly { about ## meq/l } .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "in patients taking an ddrug0 { eg , ddrug1 , ddrug2 , ddrug3 or ddrug4 } , the concomitant use of ddrug5 may reduce seizure control by lowering the plasma levels of the ddrug6 .",
        "triple_list": [
            [
                "ddrug4",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "clinical studies with ddrug0 have identified potentially significant interactions with ddrug1 and ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "a dose adjustment is not needed when ddrug0 is administered with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "due to wide interindividual variability in the dose adjustment required , it is recommended that ddrug0 concentrations be monitored closely after initiation of ddrug1 therapy and that the dose of ddrug2 be adjusted as appropriate .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 - induced oxidative stress in rat brain and liver is prevented by ddrug1 or ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the concomitant administration of ddrug0 and ddrug1 is contraindicated .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 salts , and ddrug3 may either potentiate or weaken the blood-glucose-lowering effect of ddrug4 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 : concomitant use of ddrug1 and ddrug2 may produce severe weakness in patients with myasthenia gravis .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "therefore , ddrug0 , including oral , injectable , transdermal , and implantable forms , may not be reliable when ddrug1 is co-administered .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "patients who are treated with ddrug0 and concomitant ddrug1 should be closely observed for signs and symptoms of serotonin syndrome { e , g , , cognitive dysfunction , hyperpyrexia , hyperreflexia , incoordination } .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the concurrent use of two or more drugs with anticholinergic activity -- such as an ddrug0 { eg , ddrug1 } , an ddrug2 { eg , ddrug3 } , and/or a ddrug4 { eg , ddrug5 } -- commonly results in excessive anticholinergic effects , including dry mouth and associated dental complications , blurred vision , and , in patients exposed to high temperature and humidity , hyperpyrexia .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "therefore , co-administration of ddrug0 with drugs that are metabolized by cyp2d6 isoenzyme including certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } , ddrug8 { e , g , , ddrug9 , ddrug10 , ddrug11 } , ddrug12 { e , g , , ddrug13 } , and ddrug14 { e , g , , ddrug15 , ddrug16 } , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "reciprocal interactions may occur with concomitant use of ddrug0 and drugs that increase or inhibit the cytochrome cyp2b6 system { e , g , , ddrug1 , ddrug2 , ddrug3 , ddrug4 } , though this has not been studied",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as ddrug1 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain ddrug2 such as ddrug3 , the ddrug4 and other ddrug5 , ddrug6 , certain ddrug7 such as the ddrug8 salts , and ddrug9 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 may potentiate the effects of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 ddrug1 may delay or reduce the absorption of concomitant oral medication such as ddrug2 , ddrug3 , ddrug4 { acidic } or ddrug5 { basic } , as well as ddrug6 ddrug7 , ddrug8 , thyroid and ddrug9 preparations , ddrug10 and ddrug11 , and ddrug12 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug23"
            ]
        ]
    },
    {
        "text": "the use of ddrug0 may result in additive cns depressant effects when coadministered with ddrug1 , ddrug2 , ddrug3 or other drugs that produce cns depression .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "drugs that induce hepatic enzymes such as ddrug0 , ddrug1 and ddrug2 may increase the clearance of ddrug3 and may require increases in ddrug4 dose to achieve the desired response .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "systemic exposure to ddrug0 is expected to be increased when coadministered with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 attenuates , but ddrug1 potentiates , the acute locomotor effects of ddrug2 ;",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 s : after repeated co-administration of ddrug1 , the auc of ddrug2 was lowered by 28 % -lsb- 90 % ci : 20-33 -rsb- .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "in a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy , free ddrug0 may be decreased when ddrug1 are started thus increasing ddrug2 requirements .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : seizures have been reported in patients taking ddrug1 concomitantly with the ddrug2 ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 or ddrug1 : the risk of myopathy/rhabdomyolysis is increased when either ddrug2 or ddrug3 is used concomitantly with a closely related member of the ddrug4 { see warnings , myopathy/rhabdomyolysis } .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "plasma concentrations of ddrug0 are decreased when administered with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the action of the ddrug0 may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , or other drugs that produce cns depression .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "literature reports indicate that coadministration of ddrug0 may reduce the natriuretic and antihypertensive effects of ddrug1 in some patients by inhibiting prostaglandin synthesis .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "- ddrug0 may enhance the cns depressive effects of ddrug1 , ddrug2 and other ddrug3",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "however , ddrug0 has the potential to increase the hypotensive effect of ddrug1 and ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 - although ddrug1 did not potentiate the cognitive and motor effects of ddrug2 in a clinical trial , as with other ddrug3 , the use of ddrug4 by patients taking ddrug5 is not recommended .",
        "triple_list": [
            [
                "ddrug3",
                "advise",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "the ddrug0 , including ddrug1 , produce additive cns depressant effects when co-administered with other ddrug2 , ddrug3 , ddrug4 , ddrug5 , and other drugs which themselves produce cns depression .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 } : population pharmacokinetic analyses indicate that ddrug2 clearance is 60 % greater in patients taking ddrug3 { ddrug4 } with or without other enzyme-inducing ddrug5 .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 : the concomitant use of ddrug1 { ddrug2 transdermal system } with other ddrug3 , including but not limited to other ddrug4 , ddrug5 , ddrug6 , ddrug7 { e , g , , ddrug8 } , general ddrug9 , ddrug10 , ddrug11 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "ddrug0 : anticoagulant activity should be monitored , particularly in the first few days after initiating or changing ddrug1 therapy in patients receiving ddrug2 or similar agents , since these patients are at an increased risk of bleeding complications .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 { e , g , , ddrug1 , ddrug2 , ddrug3 } and ddrug4 may reduce the therapeutic effects of ddrug5 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "the pressor effects of ddrug0 such as ddrug1 or ddrug2 are enhanced by ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 , and ddrug2 decrease the ed50 of ddrug3 by 30 % to 45 % .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "cardiac effects of ddrug0 are antagonized by ddrug1 , such as ddrug2 and ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 } : increase the metabolism of ddrug6 and/or some ddrug7 , leading to possible decrease in contraceptive effectiveness .",
        "triple_list": [
            [
                "ddrug4",
                "mechanism",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "experience with ddrug0 { ddrug1 } suggests the potential for interactions with ddrug2 and ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "int",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "because moderate cyp3a4 inhibitors { e , g , , ddrug0 } result in 2-fold increase in plasma concentrations of ddrug1 , concomitant administration should also be approached with caution .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "trough plasma ddrug0 levels were also 20 % higher when ddrug1 and ddrug2 were administered concomitantly .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "cns-active drugs ddrug0 : ddrug1 # mg potentiated the cns-impairing effects of ddrug2 # g/kg on balance testing and reaction time for # hour after ddrug3 administration and on the digit symbol substitution test { dsst } , symbol copying test , and the variability component of the divided attention test for # hours after ddrug4 administration .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : interferes with the contraceptive effect of microdosed ddrug1 - containing minipill preparations .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "coadministration of ddrug0 and strong cyp3a4 inhibitors , such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , and ddrug5 has not been evaluated but should be undertaken with caution because of similar potential drug interactions .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 has the potential to decrease plasma concentrations of ddrug1 and ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 may enhance the effects of : other ddrug3 s , ddrug4 , general ddrug5 , ddrug6 such as ddrug7 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "in patients receiving ddrug0 alone , ddrug1 auc increased by 27 % and cmax by 21 % .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "pharmacokinetic studies have demonstrated that ddrug0 and ddrug1 significantly increased the systemic exposure of ddrug2 and/or its major metabolites .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "- ddrug0 : ddrug1 blunts the increases in urine volume and sodium excretion seen during ddrug2 treatment and inhibits the ddrug3 - induced increase in plasma renin activity .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 agents decrease blood levels and increase excretion of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 may inhibit the metabolism of ddrug2 , leading to increased plasma concentrations .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 , including ddrug2 , decrease the clearance of ddrug3 , the less active isomer of racemic ddrug4 .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 may decrease the effectiveness of oral ddrug1 , certain ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and ddrug7 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "ddrug0 at # mg bid { the usual prescription dose } co-administered with ddrug1 { 500 mcg bid } for # days has been shown to increase ddrug2 plasma levels by 58 % .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "concomitant use of ddrug0 and drugs that inhibit cyp3a4 { eg , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 } may increase exposure to ddrug12 and should be avoided .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "use of ddrug0 with ddrug1 { e , g , , ddrug2 , ddrug3 , or ddrug4 } , ddrug5 supplements , or potassium-containing salt substitutes may lead to significant increases in serum potassium .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "- ddrug0 { e , g , , ddrug1 } use of ddrug2 with ddrug3 may increase the chance of side effects affecting the liver and/or the side effects of ddrug4",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "close observation of the patient is recommended when a ddrug0 is administered to patients receiving catecholamine-depleting drugs such as ddrug1 , because of possible additive effects and the production of hypotension and/or marked bradycardia , which may produce vertigo , syncope , or postural hypotension .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "before taking ddrug0 , tell your doctor if you are taking any of the following medicines : - ddrug1 or another ddrug2 such as ddrug3 { ddrug4 } , ddrug5 { ddrug6 , others } , ddrug7 { ddrug8 } , ddrug9 { ddrug10 } , or ddrug11 { ddrug12 } ;",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "caution should be used when administering or taking ddrug0 with ddrug1 and other strong cyp3a4 inhibitors such as , but not limited to , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { ddrug12 } , and ddrug13 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug11"
            ]
        ]
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of ddrug0 such as ddrug1 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "urinary acidifying agents these agents { ddrug0 , ddrug1 , etc , } increase the concentration of the ionized species of the ddrug2 molecule , thereby increasing urinary excretion .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 at # mg bid decreased the bioavailability { auc } of ddrug1 by 26 % , but not the peak concentration .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in addition , the beneficial effects of ddrug0 in parkinsons disease have been reported to be reversed by ddrug1 and ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "because there is a theoretical basis that these effects may be additive , use of ddrug0 - containing or ddrug1 { like ddrug2 or ddrug3 } and ddrug4 within # hours is contraindicated .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "because there is a theoretical basis that these effects may be additive , use of ddrug0 - containing or ddrug1 { like ddrug2 or ddrug3 } and ddrug4 within # hours is contraindicated .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "a dose increase of ddrug0 / ddrug1 to 533/133 mg { 4 capsules or # ml } twice daily taken with food is recommended when used in combination with ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "in patients receiving nonselective ddrug0 { ddrug1 } { e , g , , ddrug2 } in combination with ddrug3 { e , g , , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 } , there have been reports of serious , sometimes fatal , reactions .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "caution should be used when administering or taking ddrug0 with ddrug1 and other strong cyp3a4 inhibitors such as , but not limited to , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { ddrug12 } , and ddrug13 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "for these reasons , it is felt that , in most subjects who have had an unsatisfactory lipid response to either drug alone , the possible benefits of combined therapy with ddrug0 and a ddrug1 do not outweigh the risks of severe myopathy , rhabdomyolysis , and acute renal failure .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 concentrations were equivocally higher when given with ddrug1 , but this is not likely to be clinically important .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug20"
            ]
        ]
    },
    {
        "text": "vasospastic reactions have been reported with therapeutic doses of ddrug0 - containing drugs when co-administered with these ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "hormonal ddrug0 co-administration of ddrug1 with an oral ddrug2 has been shown to influence the plasma concentrations of the two hormonal components , ddrug3 { ee } and ddrug4 { lng } .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the adverse effects of ddrug0 , such as myelosuppression and diarrhea , would be expected to be exacerbated by other ddrug1 having similar adverse effects .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 , ddrug2 , and possibly ddrug3 } : concomitant administration with ddrug4 may increase the risk of gastrointestinal ulceration .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "in addition to bleeding associated with ddrug0 and ddrug1 , drugs that alter platelet function { such as ddrug2 , ddrug3 and ddrug4 } may increase the risk of bleeding if administered prior to , during , or after ddrug5 therapy .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 : coadministration of ddrug1 { 200 mg/day for # days } with a 15-mg single dose of ddrug2 increased the auc of ddrug3 and its active metabolite by 63 % and 77 % , respectively .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : animal studies wshow that ddrug1 given with ddrug2 , including ddrug3 , yields a net decrease in anti-inflammatory activity with lowered blood levels of the non-aspirin drug .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as ddrug1 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain ddrug2 such as ddrug3 , the ddrug4 and other ddrug5 , ddrug6 , certain ddrug7 such as the ddrug8 salts , and ddrug9 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "all ddrug0 should be used cautiously in patients taking ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "drugs decreasing ddrug0 effect : ddrug1 , ddrug2 , ddrug3 , or ddrug4 may partially counteract the anticoagulant action of ddrug5 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 , ddrug2 , etc , } increase the concentration of the ionized species of the ddrug3 molecule , thereby increasing urinary excretion .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "avoid the use of preparations such as ddrug0 and local ddrug1 which contain any ddrug2 { e , g , , ddrug3 , ddrug4 } , since it has been reported that ddrug5 can potentiate the effects of catecholamines .",
        "triple_list": [
            [
                "ddrug3",
                "advise",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 may enhance the effects of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "concomitant administration of ddrug0 and ddrug1 , ddrug2 , ddrug3 , or an ddrug4 / ddrug5 oral ddrug6 produced minor changes in the pharmacokinetics of ddrug7 , which were considered to be without clinical significance .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "plasma concentrations of ddrug0 are decreased when administered with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with ddrug1 , ddrug2 s , ddrug3 { allergy , cold , and sinus medicines } , diabetic drugs , ddrug4 , ddrug5 , ddrug6 like ddrug7 or ddrug8 , and high blood pressure medications .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "hepatic enzyme inducers , inhibitors and substrates : drugs which induce cytochrome p450 3a4 { cyp 3a4 } enzyme activity { e , g , , ddrug0 , ddrug1 , ddrug2 , ddrug3 } may enhance the metabolism of ddrug4 and require that the dosage of the ddrug5 be increased .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 { eg , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , and ddrug15 } may have elevated plasma concentrations when coadministered with ddrug16 ;",
        "triple_list": [
            [
                "ddrug5",
                "mechanism",
                "ddrug16"
            ]
        ]
    },
    {
        "text": "single doses of either ddrug0 or ddrug1 ddrug2 bind the ddrug3 and reduce its absorption from the gastrointestinal tract by up to # and # percent , respectively .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "after stopping ddrug0 tablets , at least # weeks should be allowed before starting a ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 { such as ddrug1 } and ddrug2 can suppress the ddrug3 rgic renal and mesenteric vasodilation induced with low dose dopamine infusion .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 may enhance the cns-depressive effects of ddrug1 , ddrug2 or other ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "with oral ddrug0 treatment , ddrug1 such as ddrug2 have been noted to possibly increase the likelihood of hematologic reactions",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "this interaction should be given consideration in patients taking ddrug0 concomitantly with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "there is a significant increase in exposure to ddrug0 when ddrug1 is coadministered with ddrug2 { cyp3a4 inhibitor } .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 : ddrug2 should be administered with extreme caution in patients being treated with ddrug3 or ddrug4 because the action of ddrug5 on the cardiovascular system may be potentiated by these agents .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "products containing ddrug0 and other multivalent cations { such as ddrug1 , ddrug2 , ddrug3 } are likely to interfere with absorption of ddrug4 .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 have produced an elevation of plasma ddrug2 levels and a reduction in renal ddrug3 clearance .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of ddrug0 such as ddrug1 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug15"
            ]
        ]
    },
    {
        "text": "drugs that reduce the number of blood platelets by causing bone marrow depression { such as ddrug0 } or drugs which inhibit platelet function { eg , ddrug1 and other ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 } may increase the bleeding tendency produced by ddrug7 without altering prothrombin time determinations .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "in a study in which patients with active ra were treated for up to # weeks with concurrent ddrug0 and ddrug1 therapy , a 7 % rate of serious infections was observed , which was higher than that observed with ddrug2 alone { 0 % } .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 with ddrug1 or ddrug2 and possibly other ddrug3 cause striking and sustained increases in the concentration of ddrug4 in the brain ;",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 in combination with other ddrug1 , general ddrug2 , ddrug3 , ddrug4 , ddrug5 , or other ddrug6 { including ddrug7 } has additive depressant effects .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "plasma levels of several closely related ddrug0 have been reported to be increased by the concomitant administration of ddrug1 or hepatic enzyme inhibitors { e , g , , ddrug2 , ddrug3 } and decreased by the concomitant administration of hepatic enzyme inducers { e , g , , ddrug4 , ddrug5 } , and such an effect may be anticipated with ddrug6 as well .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the ddrug0 of drugs may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , the ddrug6 , ddrug7 and ddrug8 , ddrug9 and the ddrug10 , and by other ddrug11 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 : altered serum levels of ddrug1 { increased and decreased } have been reported in patients receiving concomitant ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 - ddrug1 may potentiate the tardive dyskinesia side reactions of ddrug2 if used concomitantly with them .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 may delay intestinal absorption of ddrug2 ;",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "after the coadministration of # mg oral ddrug0 twice daily and one # mg dose of ddrug1 to # subjects , the auc and cmax of ddrug2 averaged 302 % { # s , d , } and 251 % { # s , d , } , respectively , of those obtained after co-treatment with placebo .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "drug-drug interactions given the primary cns effects of ddrug0 , caution should be used when ddrug1 is taken in combination with other ddrug2 and ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : coadministration of ddrug1 and ddrug2 resulted in a 24 % increase in plasma concentrations of ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 may antagonize the hypotensive effects of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "injection : ddrug0 injection , like other injectable ddrug1 , produces depression of the central nervous system when administered with ddrug2 , ddrug3 , ddrug4 , ddrug5 , and other ddrug6 , when ddrug7 is used concomitantly with injectable ddrug8 , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "caution should be used when administering or taking ddrug0 with ddrug1 and other strong cyp3a4 inhibitors such as , but not limited to , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { ddrug12 } , and ddrug13 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug13"
            ]
        ]
    },
    {
        "text": "drugs which inhibit cyp 3a4 { e , g , , ddrug0 , ddrug1 such as ddrug2 } have the potential to result in increased plasma concentrations of ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 , ddrug2 , ddrug3 , and ddrug4 have been shown to decrease plasma levels of ddrug5 ;",
        "triple_list": [
            [
                "ddrug4",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "although these results do not indicate a significant interaction between ddrug0 and ddrug1 or ddrug2 , the administration of ddrug3 to patients taking ddrug4 should be done extremely cautiously , and patients should be closely monitored .",
        "triple_list": [
            [
                "ddrug3",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 and oral ddrug1 : concomitant administration of ddrug2 and/or other oral ddrug3 with ddrug4 must be avoided because of the risk of hypervitaminosis a.",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "agents causing renin release : the antihypertensive effect of ddrug0 and ddrug1 iv is augmented by ddrug2 that cause renin release { e , g , , ddrug3 } .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of ddrug0 # % ophthalmic solution , the possibility of an additive or potentiating effect with ddrug1 { ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 } should be considered .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 } : increase the metabolism of ddrug6 and/or some ddrug7 , leading to possible decrease in contraceptive effectiveness .",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "when ddrug0 was administered { at a dose of # mg bid } in conjunction with a single 50-mg dose of ddrug1 , a cyp2d6 substrate , the auc of ddrug2 increased 3-fold .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "marked symptomatic orthostatic hypotension has been reported when ddrug0 and ddrug1 were used in combination .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "however , interactions may be expected , and ddrug0 should not be used in combination with other ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "therefore , cyp3a4 substrates known to have a narrow therapeutic index such as ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , or ddrug10 { ddrug11 , ddrug12 } should be administered with caution in patients receiving ddrug13 .",
        "triple_list": [
            [
                "ddrug9",
                "advise",
                "ddrug13"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 is known to interact with the metabolism or renal tubular excretion of many drugs { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 agents , ddrug14 , and ddrug15 } .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "patients receiving ddrug0 along with either oral or intravenous ddrug1 should be monitored for possible atrioventricular conduction disturbances , left ventricular failure and hypotension .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 should not be administered to patients receiving ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 should not be coadministered .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "however , the systemic administration of some ddrug0 has been shown to elevate plasma concentrations of ddrug1 , interfere with the metabolism of ddrug2 , and enhance the effects of the oral ddrug3 ddrug4 and its derivatives , and has been associated with transient elevations in serum creatinine in patients receiving systemic ddrug5 concomitantly .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "consequently , it is recommended that ddrug0 not be used in combination with either ddrug1 , ddrug2 , or ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "data suggest that coadministration of oral ddrug0 and ddrug1 can result in prolongation of the qt interval on the ecg .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 has additive effects with ddrug1 and other ddrug2 { ddrug3 , ddrug4 , ddrug5 , etc } .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : although ddrug1 is minimally absorbed into the systemic circulation , there is some potential for an additive interaction with concomitantly used ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as ddrug0 include certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 } , ddrug10 salts , ddrug11 , local ddrug12 , ddrug13 , and ddrug14 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug12"
            ]
        ]
    },
    {
        "text": "hypersensitivity reactions : patients with a history of severe hypersensitivity reactions to products containing cremophor el { eg , ddrug0 for injection concentrate and ddrug1 for injection concentrate } should not be treated with ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 , and ddrug2 : drugs such as ddrug3 , ddrug4 , and ddrug5 may increase the risk of developing peripheral_neuropathies or other ddrug6 - associated adverse events by interfering with the renal clearance of ddrug7 { thereby raising systemic exposure } .",
        "triple_list": [
            [
                "ddrug5",
                "mechanism",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "drug interactions with ddrug0 administration of # mg of ddrug1 { 2 x # mg capsule } within # minutes of an ddrug2 and ddrug3 containing ddrug4 { ddrug5 } decreased ddrug6 auc by 41 % and cmax by 43 % .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "the concurrent use of two or more drugs with anticholinergic activity -- such as an ddrug0 { eg , ddrug1 } , an ddrug2 { eg , ddrug3 } , and/or a ddrug4 { eg , ddrug5 } -- commonly results in excessive anticholinergic effects , including dry mouth and associated dental complications , blurred vision , and , in patients exposed to high temperature and humidity , hyperpyrexia .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 salts , and ddrug3 may either potentiate or weaken the blood-glucose-lowering effect of ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , ddrug2 , ddrug3 { ddrug4 may decrease the effects of these medicines } , ddrug5 { using these medicines with ddrug6 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral ddrug10 containing ddrug11 { ddrug12 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "triple_list": [
            [
                "ddrug12",
                "effect",
                "ddrug13"
            ]
        ]
    },
    {
        "text": "ddrug0 may augment the activity of other ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may enhance the cns-depressive effects of ddrug1 , ddrug2 or other ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "in em individuals treated with ddrug0 or ddrug1 , the auc of ddrug2 is approximately 6 - to 8-fold and css , max is about 3 - to 4-fold greater than ddrug3 alone .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "injection : ddrug0 injection , like other injectable ddrug1 , produces depression of the central nervous system when administered with ddrug2 , ddrug3 , ddrug4 , ddrug5 , and other ddrug6 , when ddrug7 is used concomitantly with injectable ddrug8 , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 interact pharmacologically with orally administered ddrug2 , but the effect is not clinically significant .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "in patients taking an ddrug0 { eg , ddrug1 , ddrug2 , ddrug3 or ddrug4 } , the concomitant use of ddrug5 may reduce seizure control by lowering the plasma levels of the ddrug6 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 } { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 } have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with ddrug6 .",
        "triple_list": [
            [
                "ddrug5",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "drugs which induce cyp3a4 activity { eg , ddrug0 , ddrug1 , ddrug2 } would be expected to increase the clearance of ddrug3 resulting in lowered plasma concentrations .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "however , other published reports describe modest elevations { less than two-fold } of ddrug0 and metabolite concentrations when ddrug1 was taken with ddrug2 , ddrug3 , and ddrug4 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "we propose these pharmacokinetic changes to be the underlying mechanism for the reduction of oral ddrug0 cytotoxicity by ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the administration of local ddrug0 containing ddrug1 or ddrug2 to patients receiving ddrug3 , ddrug4 or ddrug5 may produce severe , prolonged hypotension or hypertension .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "the action of the ddrug0 may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , or other drugs that produce cns depression .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "- ddrug0 : ddrug1 should generally not be given with ddrug2 { such as ddrug3 } because they reduce its renal clearance and add a high risk of ddrug4 toxicity .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : in some patients , the administration of a ddrug1 can reduce the diuretic , natriuretic , and antihypertensive effects of ddrug2 , ddrug3 and ddrug4 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 may decrease the effectiveness of oral ddrug1 , certain ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and ddrug7 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "in the presence of these ddrug0 , larger doses of ddrug1 may be required or ddrug2 may not be effective .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 / ddrug1 : the coadministration of ddrug2 or ddrug3 will not affect plasma concentrations of ddrug4 , but may reduce endogenous plasma levels of ddrug5 / ergocalcitriol by accelerating metabolism .",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "caution should be exercised when administering ddrug0 with drugs that are known to inhibit phosphatase activities { e , g , , ddrug1 } .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the absorption of ddrug0 , ddrug1 , ddrug2 , ddrug3 , and ddrug4 was significantly decreased when given simultaneously with ddrug5 ;",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "it has been reported that ddrug0 enhances the anticoagulant effect of ddrug1 - like drugs .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "inhibitors of endogenous prostaglandin synthesis it has been reported that ddrug0 may reduce the antihypertensive effect of ddrug1 , especially in cases of low renin hypertension .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 is known to slow the metabolism of ddrug2 and increase its serum levels ddrug3 levels should be determined prior to concurrent administration with ddrug4 , signs and symptoms of ddrug5 toxicity should be monitored closely , and appropriate dosage adjustment of the ddrug6 should be made .",
        "triple_list": [
            [
                "ddrug3",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 : when a single 125-mg dose of ddrug1 was administered on day5 of a 10-day regimen of # mg/day of ddrug2 , a strong cyp3a4 inhibitor , the auc of ddrug3 increased approximately 5-fold and the mean terminal half-life of ddrug4 increased approximately 3-fold .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : ddrug1 ; ddrug2 ; ddrug3 ; certain ddrug4 , especially the ddrug5 and ddrug6 ; ddrug7 ; ddrug8 salts ; ddrug9 ; and ddrug10 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "if concomitant treatment with ddrug0 and an ddrug1 is clinically warranted , appropriate observation of the patient is advised .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "before taking ddrug0 , tell your doctor if you are taking any of the following medicines : - ddrug1 or another ddrug2 such as ddrug3 { ddrug4 } , ddrug5 { ddrug6 , others } , ddrug7 { ddrug8 } , ddrug9 { ddrug10 } , or ddrug11 { ddrug12 } ;",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug11"
            ]
        ]
    },
    {
        "text": "ddrug0 : concomitant administration of ddrug1 with ddrug2 may result in an increased risk of gi ulceration and complications compared to ddrug3 alone .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "additional reductions in blood pressure may occur when ddrug0 is administered with ddrug1 , ddrug2 , or other ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 ddrug1 may delay or reduce the absorption of concomitant oral medication such as ddrug2 , ddrug3 , ddrug4 { acidic } or ddrug5 { basic } , as well as ddrug6 ddrug7 , ddrug8 , thyroid and ddrug9 preparations , ddrug10 and ddrug11 , and ddrug12 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug10"
            ]
        ]
    },
    {
        "text": "therefore , co-administration of ddrug0 with other drugs that are metabolized by this isozyme , including ddrug1 , ddrug2 , ddrug3 , and ddrug4 { e , g , , ddrug5 , ddrug6 and ddrug7 } , or that inhibit this enzyme { e , g , , ddrug8 } , should be approached with caution .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 have produced an elevation of plasma ddrug2 levels and a reduction in renal ddrug3 clearance .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : in healthy subjects receiving the cyp3a4 inducer , ddrug1 , at # mg twice daily for # days and # mg twice daily for # days , systemic exposure { auc } to ddrug2 was decreased approximately 72 % .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : following concomitant administration of a single dose of ddrug1 to subjects receiving multiple doses of ddrug2 , m1 peak levels were increased { ~ 40 % } over those seen when ddrug3 was given alone .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "although no clinical studies have been conducted , it is likely that the metabolism of ddrug0 may be affected by the known cyp3a4 inducers { such as ddrug1 , ddrug2 , ddrug3 } , cyp3a4 inhibitors { azole antimycotics e , g , , ddrug4 ;",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "injection : ddrug0 injection , like other injectable ddrug1 , produces depression of the central nervous system when administered with ddrug2 , ddrug3 , ddrug4 , ddrug5 , and other ddrug6 , when ddrug7 is used concomitantly with injectable ddrug8 , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 in large amounts may counteract the antiepileptic effect of ddrug1 , ddrug2 and ddrug3 , and increase the frequency of seizures in susceptible pediatric patients .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 used at doses of # mg/kg and # mg/kg decreased the antinociceptive effect of ddrug1 , ddrug2 { only in the tail-flick test } and ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "renal clearance measurements of ddrug0 can not be made with any significant accuracy in patients receiving ddrug1 , ddrug2 , or ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 : ddrug2 should be administered with extreme caution in patients being treated with ddrug3 or ddrug4 because the action of ddrug5 on the cardiovascular system may be potentiated by these agents .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "patients stabilized on oral ddrug0 who are found to require ddrug1 replacement therapy should be watched very closely when thyroid is started .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "absorption of ddrug0 is impaired by ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , and ddrug5 - containing preparations .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 , ddrug2 , ddrug3 , and ddrug4 have been shown to decrease plasma levels of ddrug5 ;",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 may increase the ototoxic potential of ddrug1 , especially in the presence of impaired renal function .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 , and ddrug2 may increase anticholinergic effect of ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "concurrent administration of ddrug0 and ddrug1 may result in elevated serum levels of ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 potentiate the analgesic effect of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "furthermore , ddrug0 , ddrug1 , ddrug2 , and other inducers of cyp3a4 may cause a reduction in plasma ddrug3 concentrations .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "considerable caution should be exercised if ddrug0 is administered concurrently with ddrug1 { ddrug2 } since paranoid symptoms have been reported during therapy with this combination .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "therefore , close monitoring of prothrombin time is recommended and adjustment of the ddrug0 dose may be necessary when ddrug1 capsules are administered concomitantly with ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 causes a slight decrease { about 10 % } in steady-state ddrug2 concentrations .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the concurrent use of two or more drugs with anticholinergic activity -- such as an ddrug0 { eg , ddrug1 } , an ddrug2 { eg , ddrug3 } , and/or a ddrug4 { eg , ddrug5 } -- commonly results in excessive anticholinergic effects , including dry mouth and associated dental complications , blurred vision , and , in patients exposed to high temperature and humidity , hyperpyrexia .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "when ddrug0 is co-administered with inducers of drug clearance , such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , or ddrug5 , use of a daily dose of # mg of ddrug6 should be considered",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "- when ddrug0 or ddrug1 is used concurrently with ddrug2 { e , g , ddrug3 } , an interval of at least # hours should be maintained between the two medicines , since the absorption of ddrug4 or ddrug5 is impaired",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 should be used with care when ddrug1 or inhibitors of av conduction , such as certain ddrug2 { particularly of the ddrug3 -lsb- ddrug4 -rsb- and ddrug5 -lsb- ddrug6 -rsb- classes } , or ddrug7 , such as ddrug8 , are used concurrently .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 , when given as a regimen of # mg on day # and # mg/day on days # and 3 , increased the auc of ddrug1 , a cyp3a4 substrate , by # - fold on day # and by # - fold on day 3 , when ddrug2 was coadministered intravenously as # mg on day # and orally as # mg on days # and 3 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "it is recommended that the combination of intravenous ddrug0 and ddrug1 , such as ddrug2 , not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "immediate and extended release tablets the hypoglycemic action of ddrug0 may be potentiated by certain drugs including ddrug1 , some ddrug2 and other drugs that are highly protein bound , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "a direct causal relationship has not been established , but physicians should consider the possibility that ddrug0 may alter a diabetic patient s response to ddrug1 or oral ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the extent to which ddrug0 - ddrug1 interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the ddrug2 involved .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 in large amounts may counteract the antiepileptic effect of ddrug1 , ddrug2 and ddrug3 , and increase the frequency of seizures in susceptible pediatric patients .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : in healthy subjects receiving ddrug1 , a cyp3a4 inhibitor , at # mg twice daily for # days , systemic exposure { auc } to ddrug2 was increased to approximately # - fold of control and half-life increased to # - fold of control .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "if ddrug0 is to be combined with other ddrug1 such as ddrug2 or ddrug3 / ddrug4 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of ddrug5 and ddrug6 { e , g , , ddrug7 or ddrug8 } are additive .",
        "triple_list": [
            [
                "ddrug5",
                "effect",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "however , caution should be used when administering ddrug0 with ddrug1 since these patients are at increased risk of bleeding complications .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "- ddrug0 may enhance the effects of ddrug1 therapy",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "clearance of ddrug0 decreased by about 27 % when ddrug1 was administered intravenously concomitantly with ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 : increased prothrombin time , with or without clinical bleeding , has been reported when ddrug2 is administered concomitantly .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a ddrug0 , including ddrug1 , with multivalent cation-containing products such as ddrug2 or ddrug3 ddrug4 , ddrug5 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , ddrug8 , or ddrug9 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : ddrug1 ; ddrug2 ; ddrug3 ; certain ddrug4 , especially the ddrug5 and ddrug6 ; ddrug7 ; ddrug8 salts ; ddrug9 ; and ddrug10 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "the administration of local ddrug0 containing ddrug1 or ddrug2 to patients receiving ddrug3 , ddrug4 or ddrug5 may produce severe , prolonged hypotension or hypertension .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "therefore , co-administration of ddrug0 with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index , including certain ddrug1 { ddrug2 -lsb- ddrug3 -rsb- , such as ddrug4 , ddrug5 , and ddrug6 } , ddrug7 and ddrug8 { e , g , , ddrug9 , ddrug10 } , should be approached with caution .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "interactions with ddrug0 : ddrug1 { eg , ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 } should not be administered to a patient who has received or is receiving a course of therapy with a ddrug7 such as ddrug8 .",
        "triple_list": [
            [
                "ddrug3",
                "advise",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "also , due to the potential for additive effects such as bradycardia and av block , caution is warranted in patients receiving ddrug0 with agents known to affect sinus node function or av nodal conduction { e , g , , ddrug1 , ddrug2 , and ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "it is recommended that the dose of ddrug0 be reduced to one-half the usual dose when administered with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "there was a small decrease in the clearance of ddrug0 caused by a 400-mg dose of ddrug1 ;",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "drug interactions with ddrug0 : concomitant use of ddrug1 with ddrug2 should be avoided .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "in patients receiving nonselective ddrug0 { ddrug1 } { e , g , , ddrug2 } in combination with ddrug3 { e , g , , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 } , there have been reports of serious , sometimes fatal , reactions .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "nevertheless , the possibility of additive negative inotropic effects of ddrug0 and ddrug1 should be recognized .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "interactions with other cns agents : concurrent use of ddrug0 with all ddrug1 { eg , ddrug2 , ddrug3 , ddrug4 , other ddrug5 , general ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 and ddrug12 } may result in additive central nervous system depressant effects .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "coadministration of ddrug0 and strong cyp3a4 inhibitors , such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , and ddrug5 has not been evaluated but should be undertaken with caution because of similar potential drug interactions .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 - and ddrug1 - containing ddrug2 , administered concomitantly with ddrug3 , significantly decreased the bioavailability { 48 % } of ddrug4 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "there have been reports of ddrug0 - related side effects in patients on concomitant therapy with ddrug1 and ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : the combined use of ddrug1 and ddrug2 should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 , by decreasing gut motility , may increase ddrug2 absorption .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "when ddrug0 or ddrug1 is used at the same time as other medicines or substances the following interactions must be taken into account : - ddrug2 and ddrug3 may enhance the action of ddrug4 .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "there is one reported case of a patient with acute delirium associated with the simultaneous use of ddrug0 and oral ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "human pharmacokinetics data indicate that oral ddrug0 potently inhibits the metabolism of ddrug1 resulting in a mean eight-fold increase in auc of ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "inhibitors of this isoenzyme { e , g , , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , grapefruit juice , ddrug7 , ddrug8 , ddrug9 , ddrug10 } should be cautiously coadministered with ddrug11 as they can potentially increase ddrug12 levels .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug11"
            ]
        ]
    },
    {
        "text": "ddrug0 has been shown to have an additive cns depressant effect when given with either ddrug1 , ddrug2 , ddrug3 or ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "blunting of the antihypertensive effect of ddrug0 by ddrug1 has been reported .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 steady-state cmax , a , c , and cmin were increased 21 % , decreased 19 % , and decreased 48 % , respectively , by concomitant ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "additive adverse effects resulting from cholinergic blockade may occur when ddrug0 is administered concomitantly with other ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 or some ddrug7 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 } : ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 } have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with ddrug7 .",
        "triple_list": [
            [
                "ddrug4",
                "effect",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma ddrug0 concentrations include : acute ddrug1 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma ddrug0 concentrations include : acute ddrug1 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "in vitro studies have shown ddrug0 can displace ddrug1 s , such as ddrug2 , from their protein-binding sites .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 interferes with the metabolism of ddrug1 resulting in a 42 % to 74 % dose-related decrease in ddrug2 clearance and a subsequent 260 % to 350 % increase in serum theophylline levels .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "therefore , close monitoring of prothrombin time is recommended , and adjustment of the ddrug0 dose may be necessary when ddrug1 is administered concomitantly .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "caution should be observed when ddrug0 is coadministered with other ddrug1 , ddrug2 , ddrug3 , or ddrug4 , as these agents may increase respiratory and circulatory depression .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "due to wide interindividual variability in the dose adjustment required , it is recommended that ddrug0 concentrations be monitored closely after initiation of ddrug1 therapy and that the dose of ddrug2 be adjusted as appropriate .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "intrathecal injection of ddrug0 at doses of # to # micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of ddrug1 , and a high dose of ddrug2 { 40 micrograms } completely blocked the tail-flick inhibition induced by intraventricular ddrug3 { 16 micrograms } .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug32"
            ]
        ]
    },
    {
        "text": "particular caution should be observed with ddrug0 since there are conflicting results for the effect of ddrug1 on the availability of ddrug2 and ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : coadministration of ddrug1 with ddrug2 resulted in a 35 % increase in ddrug3 plasma a , c.",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 supplements , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug10"
            ]
        ]
    },
    {
        "text": "ddrug0 : concurrent administration of certain ddrug1 , such as ddrug2 and ddrug3 , would be expected to compromise the beneficial effects of ddrug4 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "caution is advised in patients receiving concomitant high-dose ddrug0 and ddrug1 , as anorexia , tachypnea , lethargy and coma have been rarely reported due to a possible drug interaction .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with any of the following : - ddrug1 { e , g , , ddrug2 } { with long-term , high-dose use } or",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "similarly , the effects of ddrug0 on ddrug1 , ddrug2 and sodium plasma ddrug3 concentrations are unpredictable",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "these results suggest that both ddrug0 and ddrug1 , and possibly other ddrug2 and ddrug3 , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of ddrug4 and ddrug5 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "effects of ddrug0 are increased with ddrug1 and ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 , including ddrug1 , may enhance the effects of the oral ddrug2 ddrug3 or its derivatives .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : when ddrug1 and ddrug2 suspension were coadministered , plasma concentrations of ddrug3 decreased approximately 35 % .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "exert particular caution in combining ddrug0 with other ddrug1 { ddrug2 and ddrug3 } : particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "it is recommended that plasma ddrug0 levels be monitored when ddrug1 is coadministered with ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 - ddrug1 can antagonize the effect of ddrug2",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "if ddrug0 or other hepatic enzyme inducers are taken concurrently with ddrug1 or ddrug2 , lower plasma levels of ddrug3 may occur .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "additionally , ddrug0 , such as ddrug1 and ddrug2 , may antagonize the activity of ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 should be prescribed with caution to patients on ddrug2 or other drugs that act on the central nervous system , regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the concomitant use of transdermal ddrug0 with ddrug1 or other potent 3a4 inhibitors such as ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and nefazadone may result in an increase in ddrug7 plasma concentrations .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "patients should be warned of the potential danger of the intravenous self-administration of ddrug0 while under treatment with ddrug1 or ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "additive cns depression may occur when ddrug0 are administered concomitantly with other ddrug1 including ddrug2 , ddrug3 , and ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "concomitant treatment with ddrug0 { ddrug1 , ddrug2 } , ddrug3 , or ddrug4 may potentiate any hypokalemic effect of ddrug5 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 or ddrug1 : concomitant administration of ddrug2 or ddrug3 decreases the elimination of ddrug4 , most likely by inhibition of renal tubular secretion of ddrug5 .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 may increase serum levels of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "administration of ddrug0 tablets to patients receiving either ddrug1 or ddrug2 concurrently should be undertaken with caution , using small initial doses and small gradual dose increases .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "as a consequence , when ddrug0 and ddrug1 are given concomitantly , the patient should be carefully observed for signs of ddrug2 toxicity .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 should not beadministered concomitantly becausedecreases in ddrug2 plasmaconcentrations may reduce the efficacy of the drug .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 - ddrug1 may counteract the antinaturetic effect of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "drugs that inhibit both aldehyde oxidase and cyp3a4 ddrug0 : ddrug1 inhibits both aox1 { in vitro } and cyp3a4 { in vitro and in vivo } , the primary and secondary enzymes , respectively , responsible for ddrug2 metabolism .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 is known to interact with the metabolism or renal tubular excretion of many drugs { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 agents , ddrug14 , and ddrug15 } .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of ddrug0 such as ddrug1 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug11"
            ]
        ]
    },
    {
        "text": "a study in six healthy volunteers has shown a significant increase in peak ddrug0 plasma levels { 58 % } and auc { 53 % } after a 1-week course of ddrug1 # mg/day and a single dose of ddrug2 60mg .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "refer to the package insert for ddrug0 preparations before use of such preparations with ddrug1",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "an encephalopathic syndrome { characterized by weakness , lethargy , fever , tremulousness and confusion , extrapyramidal symptoms , leukocytosis , elevated serum enzymes , bun , and fbs } followed by irreversible brain damage has occurred in a few patients treated with ddrug0 plus ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 and related drugs may decrease arterial responsiveness to ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 should not be used in patients who have previously received the recommended maximum cumulative doses of ddrug1 or ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "taking ddrug0 after drinking ddrug1 may worsen side effects and may cause severe hypotension and cardiovascular collapse .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : co-administration of ddrug1 with ddrug2 # mg daily , a potent inducer of hepatic metabolism , produced an approximate 50 % decrease in ddrug3 plasma concentrations .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a ddrug0 , including ddrug1 , with multivalent cation-containing products such as ddrug2 or ddrug3 ddrug4 , ddrug5 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , ddrug8 , or ddrug9 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "ddrug0 has also been shown to inhibit cyp2b6 1a2 , an isoform also involved in ddrug1 metabolism .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "when ddrug0 is added to or withdrawn from treatment , dosage adjustment of ddrug1 may be required .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "caution should be used when administering or taking ddrug0 with ddrug1 and other strong cyp3a4 inhibitors such as , but not limited to , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { ddrug12 } , and ddrug13 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 : the concomitant use of ddrug1 { ddrug2 transdermal system } with other ddrug3 , including but not limited to other ddrug4 , ddrug5 , ddrug6 , ddrug7 { e , g , , ddrug8 } , general ddrug9 , ddrug10 , ddrug11 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug12"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 concentrations should be monitored at the initiation of ddrug3 therapy and frequently thereafter , and the dose of these three drug products adjusted appropriately .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 should not be administered concurrently with d2-antagonists , such as ddrug1 , ddrug2 , ddrug3 , or ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 is also expected to reduce plasma concentrations of other ddrug1 that have significant metabolism by cyp3a4 , such as ddrug2 and ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 increased mean ddrug1 plasma concentrations { auc } by 29 % .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in some patients , the administration of ddrug0 can reduce the diuretic , natriuretic , and antihypertensive effects of ddrug1 , ddrug2 , and ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "concomitant use of ddrug0 and ddrug1 is not recommended .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "a drug-drug interaction study with ddrug0 in healthy volunteers has shown a 30 % decrease in ddrug1 trough concentrations .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "there have been greater than 2-fold increases in previously stable plasma levels of other ddrug0 , including ddrug1 , when ddrug2 has been administered in combination with these agents .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "during controlled hypotensive anesthesia using ddrug0 in association with ddrug1 , high concentrations { 3 % or above } of ddrug2 should not be used because the degree of hypotension will be increased and because of the possibility of a large reduction in cardiac output and an increase in central venous pressure .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the concurrent use of ddrug0 injection with other ddrug1 or medications with anticholinergic activity , such as ddrug2 , ddrug3 , or ddrug4 , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 : limited clinical data suggest a higher incidence of adverse experiences in patients receiving ddrug2 concurrently with either ddrug3 or ddrug4 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 has been shown to have neuromuscular blocking properties that may enhance the action of other ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "interactions with ddrug0 : ddrug1 { eg , ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 } should not be administered to a patient who has received or is receiving a course of therapy with a ddrug7 such as ddrug8 .",
        "triple_list": [
            [
                "ddrug6",
                "advise",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "ddrug0 / ddrug1 : long-term suppression of gastric acid secretion by ddrug2 or ddrug3 { eg , ddrug4 and ddrug5 } is likely to reduce ddrug6 exposure .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "endothelium-intact aortic rings from high - ddrug0 rats were supersensitive to ddrug1 when compared to vehicle - , ddrug2 - and ddrug3 + high - ddrug4 - treated rats { pd2 values = # + / # , # + / # , # + / # and # + / # , respectively } .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "phase ii clinical trial data , where ddrug0 and ddrug1 have been used concomitantly , indicate that ddrug2 may exacerbate the neutropenic effect of ddrug3 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "for example , when ddrug0 are administered concomitantly with ddrug1 , prothrombin time should be carefully monitored and if necessary , the dosage of ddrug2 should be reduced .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 or ddrug1 excess may decrease the effect of ddrug2 , and an ddrug3 deficiency can increase the effect of ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit ddrug0 binding to serum proteins or alter the concentrations of serum binding proteins : ddrug1 and related ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "using in situ hybridization , we observed that ddrug0 caused a rapid and transient dose-dependent increase in arc mrna level in the striatum and cortex that was abolished by pretreatment with the specific drd1 antagonist ddrug1 but not by an ddrug2 ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "if ddrug0 is given concomitantly with ddrug1 , the ddrug2 dose should be reduced { by approx , 50 % } , because ddrug3 amplifies the therapeutic actions and side-effects of ddrug4 massively .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "the reddish color is due to the formation of a nonabsorbable complex between ddrug0 or its breakdown products and ddrug1 in the gastrointestinal tract .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in another drug interaction study , co-administration of orally inhaled ddrug0 and oral ddrug1 , a potent inhibitor of cytochrome p450 3a4 , increased the exposure { auc } of ddrug2 by approximately # - fold at steady state , while levels of ddrug3 remained unchanged .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 { such as ddrug1 } and ddrug2 can suppress the ddrug3 rgic renal and mesenteric vasodilation induced with low dose dopamine infusion .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "agents causing renin release : the antihypertensive effect of ddrug0 and ddrug1 iv is augmented by ddrug2 that cause renin release { e , g , , ddrug3 } .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "intrathecal injection of ddrug0 at doses of # to # micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of ddrug1 , and a high dose of ddrug2 { 40 micrograms } completely blocked the tail-flick inhibition induced by intraventricular ddrug3 { 16 micrograms } .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "data from in vitro studies of ddrug0 other than ddrug1 suggest a possible drug interaction for the following : ddrug2 , ddrug3 , ddrug4 , ddrug5 , and ddrug6 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "in patients receiving nonselective ddrug0 { ddrug1 } { e , g , , ddrug2 } in combination with ddrug3 { e , g , , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 } , there have been reports of serious , sometimes fatal , reactions .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug25"
            ]
        ]
    },
    {
        "text": "oral ddrug0 may enhance the effect of ddrug1 in ddrug2 by decreasing vitamin k availability .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in well-controlled patients undergoing concurrent therapy with ddrug0 , a decrease in the steady-state serum concentrations of ddrug1 may occur when cime-tidine therapy is discontinued .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "therefore , co-administration of ddrug0 with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index , including certain ddrug1 { ddrug2 -lsb- ddrug3 -rsb- , such as ddrug4 , ddrug5 , and ddrug6 } , ddrug7 and ddrug8 { e , g , , ddrug9 , ddrug10 } , should be approached with caution .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "co-administration of ddrug0 with ddrug1 resulted in increases in ddrug2 peak plasma levels of 42 % , although overall exposure to ddrug3 was not significantly increased .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "since higher doses of ddrug0 { 400 mg daily } may result in higher increases in cmax and auc , a single # mg dose of ddrug1 should not be exceeded in a 24-hour period when used in combination with ddrug2 # mg daily .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : in some patients , the administration of a ddrug1 can reduce the diuretic , natriuretic , and antihypertensive effects of ddrug2 , ddrug3 and ddrug4 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 in combination with ddrug1 enhances the manifestation of corneal lesions in rats epidural injection ddrug2 may potentiate the cns-depressive effect of ddrug3 , ddrug4 or other ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the plasma concentration of ddrug0 may increase when the drug is given concomitantly with hepatic enzyme inhibitors { e , g , , ddrug1 , ddrug2 } and decrease by concomitant administration of hepatic enzyme inducers { e , g , , ddrug3 , ddrug4 } , and adjustment of the dosage of ddrug5 may therefore be necessary .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "hypotension : patients on diuretic therapy : patients on ddrug0 and especially those in whom diuretic therapy was recently instituted , may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ddrug1 or ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may increase the ototoxic potential of other drugs such as ddrug1 and some ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "drug-drug interactions ddrug0 - ddrug1 should be administered with caution to patients being treated with systemically-administered { oral or intravenous } ddrug2 { or other ddrug3 } because the action of ddrug4 on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "patients taking ddrug0 and ddrug1 concomitantly may develop increased serum concentrations of ddrug2 resulting in excessive widening of the qrs complex and/or prolongation of the q-t interval .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : combination ddrug1 may decrease the clearance of some ddrug2 { ddrug3 , ddrug4 , ddrug5 } and increase the clearance of others { ddrug6 , ddrug7 , ddrug8 } .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "- ddrug0 : pretreatment with ddrug1 reduces both the natriuresis and hyperreninemia produced by ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of ddrug0 such as ddrug1 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug15"
            ]
        ]
    },
    {
        "text": "monitoring of liver enzymes is recommended when ddrug0 is used in combination with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may decrease thyroidal uptake of ddrug1 , a rebound in uptake may occur up to # days after sudden withdrawal of ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 not only block the therapeutic effects of ddrug1 , but may produce severe bronchospasm in copd patients .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "therefore , ddrug0 should be administered with caution with intranasal ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "there is one report suggesting that the concomitant use of ddrug0 { ddrug1 } and ddrug2 may have caused 3 - to 6-fold elevations on sgpt { alt } in a few patients .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma ddrug0 concentrations include : acute ddrug1 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug18"
            ]
        ]
    },
    {
        "text": "ddrug0 may also have an additive effect when given with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "interactions with other cns agents : concurrent use of ddrug0 with all ddrug1 { eg , ddrug2 , ddrug3 , ddrug4 , other ddrug5 , general ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 and ddrug12 } may result in additive central nervous system depressant effects .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "therefore , co-administration of ddrug0 with other drugs that are metabolized by this isoenzyme , including other ddrug1 , ddrug2 , ddrug3 , and ddrug4 { eg , ddrug5 , ddrug6 , and ddrug7 } , or that inhibit this enzyme { eg , ddrug8 } , should be approached with caution .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 { eg , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , and ddrug15 } may have elevated plasma concentrations when coadministered with ddrug16 ;",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug16"
            ]
        ]
    },
    {
        "text": "because of ddrug0 s tendency to cause renal impairment , the use of ddrug1 should be avoided in combination with potentially nephrotoxic drugs such as ddrug2 , ddrug3 and intravenous ddrug4 unless the potential benefits outweigh the risks to the patient .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug13"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug13"
            ]
        ]
    },
    {
        "text": "ddrug0 had no significant impact on the cmax and auc of ddrug1 , although it significantly decreased the ddrug2 tmax by 44 % and increased the intracellular exposure to phosphorylated ddrug3 by 110 % .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 prolonged gastrointestinal transit time from # to # minutes { p = # } ; this was prevented by ddrug1 { p = # } .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : coadministration of ddrug1 with ddrug2 resulted in a 152 % increase in ddrug3 plasma auc and very little change in ddrug4 plasma a , c.",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : a report of severe ddrug1 toxicity was reported in a patient receiving ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the effects of ddrug0 may be potentiated by ddrug1 which inhibits the metabolism of ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the iv ddrug0 dose should be reduced by approximately 25 % , and the oral ddrug1 dose should be reduced by approximately 50 % when coadministered with ddrug2 to achieve exposures of ddrug3 similar to those obtained when it is given without ddrug4 .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 : concomitant treatment with ddrug3 , ddrug4 , or ddrug5 may potentiate a possible hypokalemic effect of ddrug6",
        "triple_list": [
            [
                "ddrug5",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "other drugs drug interactions have been reported with concomitant administration of ddrug0 and other medications , including ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 pretreatment augmented the depressant effect of ddrug1 on the early components p1 and n1 , while attenuating ddrug2 's influence on components p2 and p3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in a study in diabetics with microalbuminuria ddrug0 # mg combined with the ddrug1 ddrug2 # mg increased the frequency of hyperkalemia { serum potassium # meq/l } from 17 % on ddrug3 alone to 38 % .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the pressor effects of ddrug0 and other ddrug1 can combine to cause dangerous hypertension .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 is known to interact with the metabolism or renal tubular excretion of many drugs { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 agents , ddrug14 , and ddrug15 } .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug12"
            ]
        ]
    },
    {
        "text": "in the case that you are taking ddrug0 while taking ddrug1 , higher doses of ddrug2 may be needed .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "when ddrug0 is co-administered with inducers of drug clearance , such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , or ddrug5 , use of a daily dose of # mg of ddrug6 should be considered",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and ddrug7 raise the serum ddrug8 concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that ddrug9 intoxication may result .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "the clinical significance of this reduction is not known , hence ddrug0 is not recommended to be ingested simultaneously with ddrug1 / ddrug2 - containing ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "these results suggest that both ddrug0 and ddrug1 , and possibly other ddrug2 and ddrug3 , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of ddrug4 and ddrug5 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 { and possibly other ddrug2 } and ddrug3 may increase ddrug4 absorption in patients who inactivate ddrug5 by bacterial metabolism in the lower intestine , so that ddrug6 intoxication may result .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "serious anticholinergic symptoms { severe dry mouth , urinary retention , blurred vision } have been associated with elevations in the serum levels of ddrug0 when ddrug1 is added to the drug regimen .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "injection : ddrug0 injection , like other injectable ddrug1 , produces depression of the central nervous system when administered with ddrug2 , ddrug3 , ddrug4 , ddrug5 , and other ddrug6 , when ddrug7 is used concomitantly with injectable ddrug8 , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 , or other products containing ddrug1 or ddrug2 , ddrug3 or ddrug4 should not be administered concomitantly with , or within # hours of , the administration of ddrug5 , because they may interfere with absorption resulting in lower serum and urine levels of ddrug6 .",
        "triple_list": [
            [
                "ddrug4",
                "advise",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "treatment with ddrug0 can directly interfere with blood glucose levels or may interact with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 has the potential to decrease plasma concentrations of ddrug1 and ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "patients taking ddrug0 may not benefit from ddrug1 containing medicines , such as cough and cold preparations , antidiarrheal preparations , and ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "if a patient requires ddrug0 and ddrug1 therapy , it is suggested that ddrug2 , ddrug3 , or ddrug4 { ddrug5 and ddrug6 } be used as alternatives to ddrug7 , as these agents have no effect on the pharmacokinetic profile of ddrug8 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "ddrug0 has been reported to decrease the clearance of ddrug1 and ddrug2 and thus may increase the pharmacologic effect of these ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 may also potentiate the replication of some organisms contained in ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the hypoglycemic action of ddrug0 may be potentiated by certain drugs including ddrug1 and other drugs that are highly protein bound , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , and ddrug8 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "drugs that cause significant sustained elevation in gastric ph { ddrug0 such as ddrug1 or ddrug2 } may reduce plasma concentrations of ddrug3 and therefore potentially may reduce efficacy .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 - there have been rare postmarketing reports describing patients with weakness , hyperreflexia , and incoordination following the use of a ddrug1 { ddrug2 } and ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 ddrug1 , as well as a metabolite of ddrug2 , slow ddrug3 metabolism .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "administration of ddrug0 to patients receiving ddrug1 or ddrug2 such as ddrug3 which sensitize the myocardium , may induce cardiac arrhythmia , .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "since ddrug0 and ddrug1 , including ddrug2 , may each be associated with increased serum potassium levels , the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 : ddrug2 and ddrug3 containing ddrug4 or ddrug5 , as well as formulations containing divalent and trivalent cations such as ddrug6 { ddrug7 } , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with ddrug8 and interfere with its bioavailability .",
        "triple_list": [
            [
                "ddrug6",
                "mechanism",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "these results suggest that both ddrug0 and ddrug1 , and possibly other ddrug2 and ddrug3 , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of ddrug4 and ddrug5 .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "although no interaction between ddrug0 and ddrug1 has been observed , it is not recommended for use with ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "plasma exposure of ddrug0 { 10 mg bid } was increased by 28 % following administration of ddrug1 { 40 mg bid } for # days , while plasma exposure of ddrug2 { 40 mg bid } was not substantially increased following administration of ddrug3 { 10 mg bid } for # days .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : drugs such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 and others that interfere with platelet-aggregation reactions { the main hemostatic defense of heparinized patients } may induce bleeding and should be used with caution in patients receiving ddrug8 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "administration of ddrug0 has been reported to increase the plasma levels of ddrug1 , if given concomitantly .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in a comparison of ddrug0 tolerance in dogs anesthetized with ddrug1 , ddrug2 , or ddrug3 , the dosage of ddrug4 needed to cause ventricular tachycardia was significantly higher , as was the ld50 of ddrug5 , with ddrug6 or ddrug7 than with ddrug8 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 supplements , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug12"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 } : ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 } have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with ddrug7 .",
        "triple_list": [
            [
                "ddrug5",
                "effect",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "ddrug0 should not be combined with other ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in addition , results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance { ddrug0 , ddrug1 , ddrug2 , ddrug3 , or ddrug4 } with ddrug5 may result in clinically meaningful reductions in ddrug6 concentrations .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 { ddrug2 , ddrug3 , ddrug4 , ddrug5 , fruit juices , etc , } lower absorption of ddrug6 .",
        "triple_list": [
            [
                "ddrug5",
                "mechanism",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "similarly , ddrug0 decreased the antinociceptive effect of ddrug1 { only in the tail-flick test } and ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 steady-state cmax , a , c , and cmin were increased by 12 % , 15 % , and 14 % , respectively , by concomitant ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 - ddrug1 may decrease the absorption of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 concentrations are increased by about 15 % when ddrug2 and ddrug3 are administered concomitantly .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "blood glucose concentrations should be carefully monitored when ddrug0 and oral ddrug1 are coadministered .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "if ddrug0 is to be combined with other ddrug1 such as ddrug2 or ddrug3 / ddrug4 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of ddrug5 and ddrug6 { e , g , , ddrug7 or ddrug8 } are additive .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "profound hypotensive episodes may occur when ddrug0 infection and ddrug1 are used concomitantly .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug31"
            ]
        ]
    },
    {
        "text": "although the interaction between ddrug0 and other potent cyp3a4 inhibitors { e , g , , ddrug1 , ddrug2 , and ddrug3 } has not been studied , increased exposures to ddrug4 may be expected when ddrug5 is used concomitantly with these medications .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "it is recommended that ddrug0 be taken at least # hours following ddrug1 administration .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the effectiveness of ddrug0 - only pills is reduced by hepatic enzyme-inducing drugs such as the ddrug1 ddrug2 , ddrug3 , and ddrug4 , and the ddrug5 ddrug6 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "administration of ddrug0 to patients receiving ddrug1 or ddrug2 such as ddrug3 which sensitize the myocardium , may induce cardiac arrhythmia , .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "administration of ddrug0 to patients who are receiving ddrug1 or ddrug2 may result in an additive pressor effect .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 caused a statistically significant increase in plasma exposures of ddrug1 and ddrug2 { 12 % and 15 % , respectively } , and in the pharmacodynamic effects { prothrombin time , measured as inr } of ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "ddrug0 - taking ddrug1 and a ddrug2 together may increase the risk of convulsions { seizures } .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "in patients receiving nonselective ddrug0 { ddrug1 } { e , g , , ddrug2 } in combination with ddrug3 { e , g , , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 } , there have been reports of serious , sometimes fatal , reactions .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 - prior ingestion of ddrug1 may decrease the ddrug2 response to ddrug3 in the treatment of poisoning .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "oral ddrug0 may potentiate the hypoglycemic action of ddrug1 , eg , ddrug2 and ddrug3 , by inhibiting their metabolism in the liver .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "co-administration of ddrug0 and ddrug1 or other agents interfering with neuromuscular transmission { e , g , , ddrug2 } should only be performed with caution as the effect of the ddrug3 may be potentiated .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "in addition , there have been cases reported in which concomitant use of ddrug0 and ddrug1 was followed by cardiac enlargement and congestive heart failure .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 { eg , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , and ddrug15 } may have elevated plasma concentrations when coadministered with ddrug16 ;",
        "triple_list": [
            [
                "ddrug12",
                "mechanism",
                "ddrug16"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 } : increase the metabolism of ddrug6 and/or some ddrug7 , leading to possible decrease in contraceptive effectiveness .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "patients receiving catecholamine-depleting drugs , such as ddrug0 or ddrug1 , should be closely monitored , because the added beta-adrenergic blocking action of ddrug2 may produce excessive reduction of sympathetic activity .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 : in a study of healthy volunteers , ddrug1 significantly reduced the bioavailability of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "therefore , ddrug0 has the potential for interaction with ddrug1 and ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 , ddrug2 , and possibly ddrug3 } : concomitant administration with ddrug4 may increase the risk of gastrointestinal ulceration .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 : in normal volunteers , concomitant administration of ddrug1 and ddrug2 resulted in significantly increased plasma levels of ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 may antagonize the neuron blockade produced by ddrug1 resulting in decreased antihypertensive effect and requiring increased dosage of the latter .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in addition , other ddrug0 have been reported to decrease the cyp3a4-mediated metabolism of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "injection : ddrug0 injection , like other injectable ddrug1 , produces depression of the central nervous system when administered with ddrug2 , ddrug3 , ddrug4 , ddrug5 , and other ddrug6 , when ddrug7 is used concomitantly with injectable ddrug8 , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .",
        "triple_list": [
            [
                "ddrug7",
                "effect",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "ddrug0 { eg , ddrug1 } and other drugs , including ether , ddrug2 , ddrug3 , ddrug4 and ddrug5 , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with ddrug6 parenteral .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "concurrent use of ddrug0 with ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , and ddrug5 } may result in increased ddrug6 effects .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 : if ddrug1 is given concurrently with ddrug2 , the protein binding of ddrug3 may be reduced .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : steady-state trough concentrations of ddrug1 were about 56 % higher when # mg ddrug2 was coadministered with each dose of ddrug3 { 15 mg/kg/day } in eight neurocysticercosis patients .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : combination ddrug1 may decrease the clearance of some ddrug2 { ddrug3 , ddrug4 , ddrug5 } and increase the clearance of others { ddrug6 , ddrug7 , ddrug8 } .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 : upon concomitant administration of # mg of ddrug2 with # mg bid ddrug3 , the cmax and auc of ddrug4 were reduced by approximately 20 % .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ddrug0 is administered in combination with other ddrug1 such as ddrug2 , ddrug3 , ddrug4 , or inhalation general ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 in combination with ddrug1 enhances the manifestation of corneal lesions in rats epidural injection ddrug2 may potentiate the cns-depressive effect of ddrug3 , ddrug4 or other ddrug5 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : clinical studies , as well as post-marketing observations , have shown that ddrug1 can reduce the natriuretic effect of ddrug2 and ddrug3 in some patients .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "other ddrug0 have demonstrated moderate to marked interference with the metabolism of ddrug1 , resulting in a reduced clearance , a prolongation of plasma half-life , and an increase in symptoms that accompany high levels of ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 , and ddrug2 decrease the ed50 of ddrug3 by 30 % to 45 % .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "however , because some ddrug0 have been reported to enhance the effects of ddrug1 or its derivatives , prothrombin time or other suitable anticoagulation test should be monitored closely if a ddrug2 is administered with ddrug3 or its derivatives .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "in a single-dose crossover study examining ddrug0 # mg and ddrug1 # mg each administered alone and concomitantly with ddrug2 # gram , absorption of the ddrug3 was delayed and their bioavailability was reduced by 17 % and 16 % , respectively , when administered concomitantly with ddrug4 .",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit ddrug0 binding to serum proteins or alter the concentrations of serum binding proteins : ddrug1 and related ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug13"
            ]
        ]
    },
    {
        "text": "concomitant use of ddrug0 and drugs that inhibit cyp3a4 { eg , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 } may increase exposure to ddrug12 and should be avoided .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 may reduce or reverse the pressor effect of ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 should not be used with other ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "therefore , the efficacy of oral ddrug0 during administration of ddrug1 may be reduced .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 sometimes proves to be fatal when used in combination with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 { eg , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , and ddrug15 } may have elevated plasma concentrations when coadministered with ddrug16 ;",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug16"
            ]
        ]
    },
    {
        "text": "ddrug0 ddrug1 may delay or reduce the absorption of concomitant oral medication such as ddrug2 , ddrug3 , ddrug4 { acidic } or ddrug5 { basic } , as well as ddrug6 ddrug7 , ddrug8 , thyroid and ddrug9 preparations , ddrug10 and ddrug11 , and ddrug12 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "ddrug0 has been reported to decrease the tubular secretion of ddrug1 and to potentiate its toxicity .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the antihypertensive effects of ddrug0 , ddrug1 , ddrug2 , and ddrug3 may be reduced by ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 interact pharmacologically with orally administered ddrug2 , but the effect is not clinically significant .",
        "triple_list": [
            [
                "ddrug1",
                "int",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 enhance the adrenergic effect of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 given concurrently increases ddrug1 anion plasma levels and extends its plasma half-life significantly .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "lymphocytopenia has been reported in patients receiving ddrug0 , and it is possible that the administration of ddrug1 as antiemetic prophylaxis may have enhanced the likelihood of this effect .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "there have been a number of reports in the post-marketing experience of coma and death associated with the concomitant intravenous misuse of ddrug0 and ddrug1 by addicts .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "data from in vitro studies of ddrug0 suggest a possible drug interaction with ddrug1 for the following : ddrug2 and ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "int",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "there have been reports of interactions of ddrug0 with ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 , or other products containing ddrug1 or ddrug2 , ddrug3 or ddrug4 should not be administered concomitantly with , or within # hours of , the administration of ddrug5 , because they may interfere with absorption resulting in lower serum and urine levels of ddrug6 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 , an inducer of drug metabolism , decreased the concentrations of ddrug1 and its active metabolite .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 should be administered with caution to patients who are taking other ddrug1 or ddrug2 , including ddrug3 , ddrug4 and ddrug5 , or to those with a history of psychiatric disorder { including manic-depressive illness and schizophrenia } .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "the cmax of ddrug0 was 13 % higher when it was coadministered with ddrug1 ;",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug24"
            ]
        ]
    },
    {
        "text": "ddrug0 should not be used with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : in vitro and/or in vivo data show that ddrug1 , ddrug2 , and ddrug3 markedly inhibit the metabolism of ddrug4 , which can result in an increase in plasma ddrug5 levels and prolongation of the qt interval on the ecg .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 : ddrug2 and ddrug3 containing ddrug4 or ddrug5 , as well as formulations containing divalent and trivalent cations such as ddrug6 { ddrug7 } , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with ddrug8 and interfere with its bioavailability .",
        "triple_list": [
            [
                "ddrug5",
                "mechanism",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 may enhance the effects of the oral ddrug2 , ddrug3 , or its derivatives .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "if concomitant treatment with ddrug0 and an ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } is clinically warranted , appropriate observation of the patient is advised .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "therefore , cyp3a4 substrates known to have a narrow therapeutic index such as ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , or ddrug10 { ddrug11 , ddrug12 } should be administered with caution in patients receiving ddrug13 .",
        "triple_list": [
            [
                "ddrug12",
                "advise",
                "ddrug13"
            ]
        ]
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma ddrug0 concentrations include : acute ddrug1 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug13"
            ]
        ]
    },
    {
        "text": "ddrug0 : coadministration of ddrug1 with ddrug2 causes an increase in ddrug3 plasma concentrations , in # otherwise healthy male volunteers ingesting ddrug4 , the steady-state trough { cmin } ddrug5 concentration was # micrograms/ml .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a ddrug0 , including ddrug1 , with multivalent cation-containing products such as ddrug2 or ddrug3 ddrug4 , ddrug5 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , ddrug8 , or ddrug9 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 absorption : the following agents may bind and decrease absorption of ddrug1 from the gastrointestinal tract : ddrug2 , ddrug3 resin , ddrug4 , ddrug5 , ddrug6 , soybean flour { e , g , , infant formula } , ddrug7 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "ddrug0 should be used cautiously in conjunction with ddrug1 in patients suffering from hypopro-thrombinemia .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : drugs such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 and others that interfere with platelet-aggregation reactions { the main hemostatic defense of heparinized patients } may induce bleeding and should be used with caution in patients receiving ddrug8 .",
        "triple_list": [
            [
                "ddrug4",
                "effect",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 inhibit the hypotensive effect of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "inducers and inhibitors of hepatic metabolism : ddrug0 reduced plasma concentrations of ddrug1 by about 70 % .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "concurrent administration of ddrug0 { another tnf - blocking agent } and ddrug1 { an ddrug2 } has been associated with an increased risk of serious infections , and increased risk of neutropenia and no additional benefit compared to these medicinal products alone .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "therefore , ddrug0 has the potential for interaction with ddrug1 and ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "pharmacologic studies indicate that there may be additive effects in prolonging av conduction when using ddrug0 or ddrug1 concomitantly with ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "therefore , co-administration of ddrug0 with other drugs that are metabolized by this isozyme , including ddrug1 , ddrug2 , ddrug3 , and ddrug4 { e , g , , ddrug5 , ddrug6 and ddrug7 } , or that inhibit this enzyme { e , g , , ddrug8 } , should be approached with caution .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "use in conjunction with other ddrug0 : the addition of ddrug1 to ddrug2 { ddrug3 } affects the steady-state plasma concentrations of ddrug4 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "therefore , the combination of ddrug0 and ddrug1 is not recommended .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "this might be explained by a blockade by ddrug0 of the elimination of ddrug1 by the liver .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in patients receiving nonselective ddrug0 { ddrug1 } { e , g , , ddrug2 } in combination with ddrug3 { e , g , , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 } , there have been reports of serious , sometimes fatal , reactions .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "ddrug0 should be used with care when ddrug1 or inhibitors of av conduction , such as certain ddrug2 { particularly of the ddrug3 -lsb- ddrug4 -rsb- and ddrug5 -lsb- ddrug6 -rsb- classes } , or ddrug7 , such as ddrug8 , are used concurrently .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "interactions may occur between ddrug0 supplements and ddrug1 and other ddrug2 and herbs such as garlic { allium sativum } and ddrug3 { ddrug4 } .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "before taking ddrug0 , tell your doctor if you are taking any of the following medicines : - ddrug1 or another ddrug2 such as ddrug3 { ddrug4 } , ddrug5 { ddrug6 , others } , ddrug7 { ddrug8 } , ddrug9 { ddrug10 } , or ddrug11 { ddrug12 } ;",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "if treatment with inhibitors of cyp3a4 activity { such as ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , etc , } is indicated , reduction of the ddrug6 dose should be considered .",
        "triple_list": [
            [
                "ddrug4",
                "advise",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 may increase slightly the effect of ddrug1 , e , g , , ddrug2 , ddrug3 , ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 accelerates the metabolism of ddrug1 ;",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 should not be administered concomitantly with potent ddrug1 such as ddrug2 and ddrug3 as the potential for ototoxicity is enhanced by the combination .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "drugs which require a dose reduction when coadminstered with ddrug0 ddrug1 : ddrug2",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "- ddrug0 may enhance the cns depressive effects of ddrug1 , ddrug2 and other ddrug3",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "patients receiving other ddrug0 s , general ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 or other ddrug6 { including ddrug7 } concomitantly with ddrug8 may exhibit an additive cns depression .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "ddrug0 : concomitant administration of ddrug1 at # mg qd resulted in a two-fold increase in ddrug2 plasma concentration .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "it has been reported that the addition of ddrug0 to a maintenance schedule of ddrug1 resulted in reversible acute renal failure in two of four healthy volunteers .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : in a pharmacokinetic study , maximum plasma concentrations of ddrug1 were considerably lower in epileptic patients on long-term ddrug2 therapy { eg , ddrug3 , ddrug4 , or ddrug5 } than in healthy volunteers .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 , and ddrug2 : drugs such as ddrug3 , ddrug4 , and ddrug5 may increase the risk of developing peripheral_neuropathies or other ddrug6 - associated adverse events by interfering with the renal clearance of ddrug7 { thereby raising systemic exposure } .",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "the intake of ddrug0 and ddrug1 should be separated by at least two hours .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : elevated serum levels of ddrug1 have been reported with concomitant use of ddrug2 with other members of the ddrug3 .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as ddrug0 include certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 } , ddrug10 salts , ddrug11 , local ddrug12 , ddrug13 , and ddrug14 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug13"
            ]
        ]
    },
    {
        "text": "ddrug0 may decrease the effectiveness of oral ddrug1 , certain ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and ddrug7 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "immediate and extended release tablets the hypoglycemic action of ddrug0 may be potentiated by certain drugs including ddrug1 , some ddrug2 and other drugs that are highly protein bound , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "serious cardiac dysrhythmias , some resulting in death , have occurred in patients receiving ddrug0 concomitantly with other ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 { and possibly other ddrug2 } and ddrug3 may increase ddrug4 absorption in patients who inactivate ddrug5 by bacterial metabolism in the lower intestine , so that ddrug6 intoxication may result .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 or oral ddrug1 : ddrug2 may enhance the blood-sugar-reducing effect of ddrug3 and oral ddrug4 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "concomitant use of ddrug0 with ddrug1 is not recommended .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "- ddrug0 may enhance the cns depressive effects of ddrug1 , ddrug2 and other ddrug3",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "plasma levels of ddrug0 may become subtherapeutic during ddrug1 therapy .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "some reports have shown that the concomitant administration of ddrug0 with ddrug1 causes hypercalcemia .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "therefore , patients without a functioning ddrug0 gland who are on thyroid replacement therapy may need to increase their thyroid dose if ddrug1 or ddrug2 - containing oral ddrug3 are given .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "therefore , plasma concentrations of ddrug0 should also be monitored when it is given concurrently with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 , like other ddrug1 , has had less than additive effects with ddrug2 , presumably because both drugs lower blood pressure by inhibiting parts of the renin-angiotensin system",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "therefore , co-administration of ddrug0 with drugs that are metabolized by cyp2d6 isoenzyme including certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } , ddrug8 { e , g , , ddrug9 , ddrug10 , ddrug11 } , ddrug12 { e , g , , ddrug13 } , and ddrug14 { e , g , , ddrug15 , ddrug16 } , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug15"
            ]
        ]
    },
    {
        "text": "in some patients , the administration of ddrug0 can reduce the diuretic , natriuretic , and antihypertensive effects of ddrug1 , ddrug2 , and ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "increasing the ddrug0 dose to # mg every # hours does not compensate for the increased ddrug1 metabolism due to ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "therefore , co-administration of ddrug0 with drugs that are metabolized by cyp2d6 isoenzyme including certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } , ddrug8 { e , g , , ddrug9 , ddrug10 , ddrug11 } , ddrug12 { e , g , , ddrug13 } , and ddrug14 { e , g , , ddrug15 , ddrug16 } , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug11"
            ]
        ]
    },
    {
        "text": "ddrug0 : coadministration of ddrug1 and ddrug2 suspension results in a significant decrease in average steady - state plasma ddrug3 concentrations .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 : ddrug2 and ddrug3 containing ddrug4 or ddrug5 , as well as formulations containing divalent and trivalent cations such as ddrug6 { ddrug7 } , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with ddrug8 and interfere with its bioavailability .",
        "triple_list": [
            [
                "ddrug7",
                "mechanism",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "therefore , co-administration of ddrug0 with drugs that are metabolized by cyp2d6 isoenzyme including certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } , ddrug8 { e , g , , ddrug9 , ddrug10 , ddrug11 } , ddrug12 { e , g , , ddrug13 } , and ddrug14 { e , g , , ddrug15 , ddrug16 } , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 or other ddrug1 { concurrent use with ddrug2 may result in uterine hypertonus , possibly causing uterine rupture or cervical laceration , especially in the absence of adequate cervical dilatation ;",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 reports suggest that ddrug1 may diminish the antihypertensive effect of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 may have additive effects with ddrug1 and other ddrug2 , e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 had no significant impact on the cmax and auc of ddrug1 , although it significantly decreased the ddrug2 tmax by 44 % and increased the intracellular exposure to phosphorylated ddrug3 by 110 % .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 - containing preparations { eg , ddrug2 } may cause hypermagnesemia and should therefore not be taken during therapy with ddrug3 by patients on chronic renal dialysis .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 ddrug1 , as well as a metabolite of ddrug2 , slow ddrug3 metabolism .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : in a clinical pharmacology study , coadministration of an ddrug1 { ddrug2 , ddrug3 , and ddrug4 } with ddrug5 reduced serum levels and urinary excretion of ddrug6 as compared with ddrug7 administered alone , suggesting that ddrug8 may impair absorption of ddrug9 .",
        "triple_list": [
            [
                "ddrug4",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 : studies in animals demonstrate that the acute toxicity of ddrug1 is enhanced by the ddrug2 ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "the plasma concentration of ddrug0 may increase when the drug is given concomitantly with hepatic enzyme inhibitors { e , g , , ddrug1 , ddrug2 } and decrease by concomitant administration of hepatic enzyme inducers { e , g , , ddrug3 , ddrug4 } , and adjustment of the dosage of ddrug5 may therefore be necessary .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug41"
            ]
        ]
    },
    {
        "text": "ddrug0 absorption : the following agents may bind and decrease absorption of ddrug1 from the gastrointestinal tract : ddrug2 , ddrug3 resin , ddrug4 , ddrug5 , ddrug6 , soybean flour { e , g , , infant formula } , ddrug7 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "because there is a theoretical basis that these effects may be additive , use of ddrug0 - containing or ddrug1 { like ddrug2 or ddrug3 } and ddrug4 within # hours is contraindicated .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "the action of the ddrug0 may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , or other drugs that produce cns depression .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma ddrug0 concentrations include : acute ddrug1 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "in europe , ddrug0 was observed to occasionally intensify the effect of ddrug1 taken concomitantly by patients suffering from hypertension ;",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "consequently , ddrug0 should be avoided in patients receiving ddrug1 and ddrug2 , which are very potent inhibitors of cyp3a .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "in patients receiving ddrug0 , the addition of ddrug1 to therapy could prolong the prothrombin time .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 also should be used cautiously with other drugs { e , g , , ddrug1 , ddrug2 } that sensitize the myocardium to the actions of ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "short-term pharmacokinetic studies have demonstrated that concomitant administration of ddrug0 and ddrug1 { ddrug2 capsules and tablets } results in reduced protein binding of ddrug3 , but there was no change in the clearance of free ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "some ddrug0 , including ddrug1 , have also been shown to interfere with the metabolism of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 interferes with the therapeutic action of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 ddrug1 ddrug2 , like other ddrug3 , may inhibit the metabolism of ddrug4 and ddrug5 .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving ddrug0 metabolized similarly to ddrug1 or on the basis of in vitro studies with ddrug2 or other ddrug3 { caution is recommended during coadministration with ddrug4 } : available data from clinical studies of ddrug5 other than ddrug6 suggest a possible drug interaction with ddrug7 for the following : ddrug8 , ddrug9 , ddrug10 such as ddrug11 and ddrug12 , and grapefruit juice .",
        "triple_list": [
            [
                "ddrug7",
                "int",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "ddrug0 may displace acidic drugs such as ddrug1 or ddrug2 from their binding sites .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "in a study in which the # mg ddrug0 orally disintegrating tablet was administered with and without ddrug1 { an ddrug2 with multiple effects on the gi tract } to healthy volunteers , the auc of ddrug3 was 10 % lower and the cmax of ddrug4 was 20 % lower when the orally disintegrating tablet was given with ddrug5 compared to when it was given alone .",
        "triple_list": [
            [
                "ddrug4",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 - pectin , ddrug2 , ddrug3 , ddrug4 , certain anticancer drugs , and ddrug5 may interfere with intestinal ddrug6 absorption , resulting in unexpectedly low serum concentrations .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "caution is warranted and therapeutic concentration monitoring is recommended for ddrug0 when coadministered with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 / ddrug1 : an increase in the frequency of skin rash has been reported among patients receiving ddrug2 or ddrug3 concurrently with ddrug4 compared to patients who are not receiving both drugs .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "- drugs whose efficacy is impaired by ddrug0 include : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , oral ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may decrease the amount of ddrug1 { ddrug2 , ddrug3 } that gets absorbed into your body .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "seizures have been reported in patients taking another ddrug0 and the ddrug1 ddrug2 concurrently .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of ddrug0 such as ddrug1 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "oral ddrug0 inhibits the gastrointestinal absorption of ddrug1 , oral ddrug2 , ddrug3 and ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "interaction of ddrug0 and ddrug1 in rats .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "patients taking both ddrug0 and a ddrug1 should be monitored to ensure that a satisfactory hypotensive effect is achieved .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : the stimulatory effects of ddrug1 may be inhibited by ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : the concomitant use of ddrug1 { ddrug2 transdermal system } with other ddrug3 , including but not limited to other ddrug4 , ddrug5 , ddrug6 , ddrug7 { e , g , , ddrug8 } , general ddrug9 , ddrug10 , ddrug11 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "there have been isolated reports of patients experiencing increases in their prothrombin times when ddrug0 was added to ddrug1 therapy .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 , like ddrug1 , produced depletions of striatal dopamine but these actions were potentiated by ddrug2 pretreatment .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the concomitant administration of ddrug0 and ddrug1 has been associated with a decrease in the excretion of oxypurines { hypoxanthine and xanthine } and an increase in urinary uric_acid excretion compared with that observed with ddrug2 alone .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 diminished the binding of ddrug1 to human serum by a net change of # % { percentage increase in free drug fraction -lsb- fdf -rsb- , # % } at # micromol/l and by a net change of # % { percentage increase in fdf , # % } at # micromol/l .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "although clinical studies have not been performed , based on the involvement of the cytochrome p-450 3a family in ddrug0 metabolism , inhibitors of this enzyme system , notably oral ddrug1 , should be used cautiously in patients receiving ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "therefore , ddrug0 should not be used in any condition in which a ddrug1 is being employed .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : in a clinical pharmacology study , coadministration of an ddrug1 { ddrug2 , ddrug3 , and ddrug4 } with ddrug5 reduced serum levels and urinary excretion of ddrug6 as compared with ddrug7 administered alone , suggesting that ddrug8 may impair absorption of ddrug9 .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with ddrug1 , ddrug2 s , ddrug3 { allergy , cold , and sinus medicines } , diabetic drugs , ddrug4 , ddrug5 , ddrug6 like ddrug7 or ddrug8 , and high blood pressure medications .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 or ddrug1 administered with ddrug2 / ddrug3 to achieve # mac -lsb- minimum alveolar concentration -rsb- may prolong the clinically effective duration of action of initial and maintenance doses of ddrug4 and decrease the required infusion rate of ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "if you are also using a ddrug0 inhaler , take ddrug1 first and then wait about # minutes before using the ddrug2 inhaler .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "agents increasing serum potassium : ddrug0 attenuates potassium loss caused by ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : the mixing of ddrug1 with an ddrug2 in vitro can result in substantial inactivation of the ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the concomitant use of ddrug0 with ddrug1 and ddrug2 s may have additive effects on prolonging atrioventricular conduction time .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "- ddrug0 : ddrug1 may potentiate the effect of various ddrug2 , necessitating a reduction in the dosage of these drugs .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 should not be administered concurrently with d2-antagonists , such as ddrug1 , ddrug2 , ddrug3 , or ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of ddrug0 such as ddrug1 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "concurrent use of ddrug0 and ddrug1 in clinical practice has been associated with increased anticoagulant effects .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "these ddrug0 should be used in the myasthenic patient only where definitely indicated , and then careful adjustment should be made of adjunctive ddrug1 dosage .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 modifies ddrug1 metabolism with increased serum levels of ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 administration to rachitic chicks was effective in significantly elevating duodenal ddrug1 absorption , acting primarily to enhance serosal transport .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a ddrug0 , including ddrug1 , with multivalent cation-containing products such as ddrug2 or ddrug3 ddrug4 , ddrug5 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , ddrug8 , or ddrug9 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug33"
            ]
        ]
    },
    {
        "text": "ddrug0 levels may be decreased ; increased dosages may be required to prevent symptoms of ddrug1 withdrawal , ddrug2 maintained patients beginning ddrug3 therapy should be monitored forevidence of withdrawal and ddrug4 dose should be adjusted accordingly .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 may reduce the antihypertensive effects of ddrug1 , ddrug2 , ddrug3 and ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 : limited clinical data suggest a higher incidence of adverse experiences in patients receiving ddrug2 concurrently with either ddrug3 or ddrug4 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 : patients on ddrug1 , especially those in whom diuretic therapy was recently instituted , may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "consequently , the combination of ddrug0 with ddrug1 is also contraindicated .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 absorption : the following agents may bind and decrease absorption of ddrug1 from the gastrointestinal tract : ddrug2 , ddrug3 resin , ddrug4 , ddrug5 , ddrug6 , soybean flour { e , g , , infant formula } , ddrug7 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "this study demonstrated that the potent cytochrome p450 enzyme-inducer ddrug0 did indeed have a marked effect on the metabolism of ddrug1 , resulting in a 5-fold increase in clearance when administered concomitantly to patients with dsm-iv-diagnosed schizophrenia , schizoaffective disorder , or bipolar disorder .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the concomitant use of transdermal ddrug0 with ddrug1 or other potent 3a4 inhibitors such as ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and nefazadone may result in an increase in ddrug7 plasma concentrations .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "the benefits and risks of using ddrug0 with ddrug1 and other potentially nephrotoxic agents should be carefully considered , and the lowest effective dose employed",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 , and ddrug2 may increase anticholinergic effect of ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "during ddrug0 administration , systemic clearance of ddrug1 was reduced from # + / - # ml/min { mean + / - standard deviation } to # + / - # ml/min { p less than # } .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "concomitant administration of ddrug0 with ddrug1 capsules is not recommended .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "coadministration with ddrug0 increased exposure of ddrug1 { auc } by 46 % .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : as with some other ddrug1 , concurrent administration of ddrug2 with ddrug3 may lead to elevated serum concentrations of ddrug4 and prolongation of its elimination half-life .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 decreased the cmax and auc of sustained-release ddrug1 { ddrug2 } by approximately 31 % and 11 % , respectively .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "separating the doses of ddrug0 and ddrug1 minimizes this decrease in bioavailability ;",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : as with other ddrug1 , co-administration of ddrug2 with ddrug3 resulted in an increase in the plasma exposure of ddrug4 , with a 49 % increase in mean cmax , a 122 % increase in mean auc , and a 53 % increase in half-life .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "on the basis of the metabolism of ddrug0 by cytochrome p450 3a4 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , grapefruit juice , and other inhibitors of cyp3a4 would be expected to lead to an increase in plasma ddrug5 concentrations .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 has been shown to have neuromuscular blocking properties that may enhance the action of other ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the mean clearances of ddrug0 were 16 % and 15 % lower in patients on ddrug1 and inhibitors of tubular organic cation transport , respectively .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 { 2 } , ddrug7 , ddrug8 , and ddrug9 thus , if a patient has been titrated to a stable dosage on ddrug10 , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for ddrug11 may be necessary .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and ddrug7 raise the serum ddrug8 concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that ddrug9 intoxication may result .",
        "triple_list": [
            [
                "ddrug6",
                "mechanism",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 { hypertension } - in clinical studies of patients with hypertension , the addition of ddrug2 # to # mg to ddrug3 and ddrug4 increased mean serum potassium slightly { about ## meq/l } .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "renal clearance measurements of ddrug0 can not be made with any significant accuracy in patients receiving ddrug1 , ddrug2 , or ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "thus , when ddrug0 and ddrug1 are administered concurrently , subjects should be observed carefully for signs of ddrug2 toxicity .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : patients on ddrug1 therapy may exhibit a diminished response to toxoids and ddrug2 or ddrug3 due to inhibition of antibody response .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "during concomitant therapy of ddrug0 with ddrug1 , the patient should be observed closely for signs of renal failure , as well as to assure diuretic efficacy .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "although neither ddrug0 nor ddrug1 affected the proliferation of prostatic epithelium in rpmi1640 containing ddrug2 alone , they modify the mitogenic effect of ddrug3 and ddrug4 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 : in a clinical pharmacology study , coadministration of an ddrug1 { ddrug2 , ddrug3 , and ddrug4 } with ddrug5 reduced serum levels and urinary excretion of ddrug6 as compared with ddrug7 administered alone , suggesting that ddrug8 may impair absorption of ddrug9 .",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "although concomitant use of ddrug0 and ddrug1 is not recommended , it should be noted that discontinuation of concomitant ddrug2 administration may result in an increase in ddrug3 plasma levels .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "the concomitant use of ddrug0 or ddrug1 with ddrug2 is not recommended .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 diminishes the effect of ddrug1 and ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the possibility of hypotensive effects with ddrug0 can be minimized by either discontinuing the ddrug1 or increasing the salt intake prior to initiation of treatment with ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "- ddrug0 and ddrug1 ddrug2 : ddrug3 and ddrug4 ddrug5 have the potential of binding ddrug6 and reducing ddrug7 absorption from the gastrointestinal tract",
        "triple_list": [
            [
                "ddrug4",
                "mechanism",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 may enhance the effects of ddrug1 , ddrug2 , ddrug3 , and other ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 { e , g , , ddrug1 , ddrug2 , ddrug3 } and ddrug4 may reduce the therapeutic effects of ddrug5 .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "the steady state plasma concentrations of ddrug0 and ddrug1 have been reported to be increased an average of 31 % and 20 % , respectively , by the concomitant administration of ddrug2 tablets in doses up to # mg/day .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "products containing ddrug0 and other ddrug1 likely will interfere with absorption of ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "plasma levels of several closely related ddrug0 have been reported to be increased by the concomitant administration of ddrug1 or hepatic enzyme inhibitors { e , g , , ddrug2 , ddrug3 } and decreased by the concomitant administration of hepatic enzyme inducers { e , g , , ddrug4 , ddrug5 } , and such an effect may be anticipated with ddrug6 as well .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "the concomitant use of other cyp3a4 inhibitors such as ddrug0 and ddrug1 with transdermal ddrug2 may also result in an increase in ddrug3 plasma concentrations , which could increase or prolong adverse drug effects and may cause serious respiratory depression .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "both ddrug0 and ddrug1 block ddrug2 - induced and ddrug3 - induced dopamine release in the nucleus accumbens ;",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug23"
            ]
        ]
    },
    {
        "text": "in patients receiving nonselective ddrug0 { ddrug1 } { e , g , , ddrug2 } in combination with ddrug3 { e , g , , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 } , there have been reports of serious , sometimes fatal , reactions .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug24"
            ]
        ]
    },
    {
        "text": "in patients receiving ddrug0 and a ddrug1 concomitantly , any reduction in ddrug2 dosage should be gradual in order to avoid the possible complications of sudden ddrug3 withdrawal .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "{ in some patients , the ddrug0 can reduce the diuretic , natriuretic , and antihypertensive effects of ddrug1 , ddrug2 , and ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ingestion of ddrug0 may increase serum concentrations of ddrug1 and ddrug2 and increase ddrug3 s nephrotoxicity .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "recovery of hoof twitch from 50 % to 75 % took # + / - # min for ddrug0 alone and # + / - # min for ddrug1 plus ddrug2 { p = # } .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 { ddrug2 } injection , usp should not be used with ddrug3 because the combination may cause synergistic elevation of blood pressure .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "if ddrug0 is given concomitantly with ddrug1 , the ddrug2 dose should be reduced { by approx , 50 % } , because ddrug3 amplifies the therapeutic actions and side-effects of ddrug4 massively .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "concomitant administration of ddrug0 and ddrug1 resulted in slight increases in plasma ddrug2 levels and slight decreases in plasma ddrug3 levels .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "based on anecdotal reports , there may be an interaction between ddrug0 and ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : clinical evidence has shown that ddrug1 can be formed with concurrent ingestion of ddrug2 and ddrug3 .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "hypotension : patients on diuretic therapy : patients on ddrug0 and especially those in whom diuretic therapy was recently instituted , may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ddrug1 or ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "although clinical studies have not established a cause and effect relationship , physicians should be aware that variable effects an blood coagulation have been reported very rarely in patients receiving oral ddrug0 and ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "- drugs whose efficacy is impaired by ddrug0 include : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , oral ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug11"
            ]
        ]
    },
    {
        "text": "ddrug0 may increase the action of ddrug1 , ddrug2 , ddrug3 , and ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 has been shown to be antagonistic to ddrug1 , including ddrug2 , based on in vitro studies and time kill curves with enteric gram-negative bacilli .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "steady-state serum concentrations of ddrug0 are reported to fluctuate significantly when ddrug1 is either added or deleted from the drug regimen .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : a relationship of functional antagonism exists between ddrug1 , which promote calcium absorption , and ddrug2 , which inhibit calcium absorption .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "if these agents are to be administered concurrently , ddrug0 concentrations should be monitored , especially when ddrug1 therapy is initiated , adjusted , or discontinued .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "as with other ddrug0 , if ddrug1 is to be administered orally with ddrug2 of the ddrug3 or ddrug4 type , it is recommended that ecg and blood pressure be monitored .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "when used in therapeutic doses , ddrug0 had a modest effect on the pharmacokinetics of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { intravenous and oral } , ddrug12 , ddrug13 / ddrug14 or ddrug15 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 salts , and ddrug3 may either potentiate or weaken the blood-glucose-lowering effect of ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 can interact with ddrug1 or other ddrug2 { may potentiate the cns depressant effects of either these medications or ddrug3 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and ddrug6 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "if you are also using a ddrug0 inhaler , take ddrug1 first and then wait about # minutes before using the ddrug2 inhaler .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may potentiate the hypotensive effects of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 : coadministration of ddrug2 with ddrug3 resulted in a 47 % decrease in ddrug4 and an 18 % decrease in ddrug5 plasma concentrations .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "in addition , several ddrug0 s that are cytochrome cyp2b6 inducers can decrease plasma concentrations of ddrug1 and ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the administration of local ddrug0 containing ddrug1 or ddrug2 to patients receiving ddrug3 or ddrug4 may produce severe , prolonged hypertension .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 interferes with the absorption of ddrug1 , including ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : the concomitant use of ddrug1 { ddrug2 transdermal system } with other ddrug3 , including but not limited to other ddrug4 , ddrug5 , ddrug6 , ddrug7 { e , g , , ddrug8 } , general ddrug9 , ddrug10 , ddrug11 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "pretreatment of megakaryocytes with extracellular ddrug0 { 50 microm } also inhibited ddrug1 - induced responses .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "there have been reports of interactions of ddrug0 with ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug11"
            ]
        ]
    },
    {
        "text": "the concurrent use of two or more drugs with anticholinergic activity -- such as an ddrug0 { eg , ddrug1 } , an ddrug2 { eg , ddrug3 } , and/or a ddrug4 { eg , ddrug5 } -- commonly results in excessive anticholinergic effects , including dry mouth and associated dental complications , blurred vision , and , in patients exposed to high temperature and humidity , hyperpyrexia .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "co-administration : concomitant use of ddrug0 with ddrug1 , ddrug2 , and other ddrug3 may increase the risk of bleeding .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug26"
            ]
        ]
    },
    {
        "text": "other potentially important drug interactions : ddrug0 : ddrug1 metabolized by hepatic oxidation { e , g , , ddrug2 , ddrug3 , ddrug4 elc , } should be used with caution because the clearance of these drugs is likely to be reduced by ddrug5 .",
        "triple_list": [
            [
                "ddrug4",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 in combination with other ddrug1 , general ddrug2 , ddrug3 , ddrug4 , ddrug5 , or other ddrug6 { including ddrug7 } has additive depressant effects .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the risk of hypoglycemia secondary to this mechanism may be increased if ddrug0 and ddrug1 are given concomitantly in the presence of renal insufficiency .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 has been reported to produce clinically significant fluctuations in steady-state serum concentrations of various ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 - containing therapies should not be used with ddrug1 as they may diminish its pharmacologic action .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 will increase plasmaconcentration of other cyp3a4 metabolized drugs { e , g , , triazolo - ddrug1 , ddrug2 , certain ddrug3 , etc , } .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug10"
            ]
        ]
    },
    {
        "text": "ddrug0 - related adverse effects have occurred in patients when ddrug1 and ddrug2 were coadministered .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "thus , when ddrug0 and ddrug1 are administered concurrently , subjects should be observed carefully for signs of ddrug2 toxicity .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "as with other ddrug0 , if ddrug1 is to be administered orally with ddrug2 of the ddrug3 or ddrug4 type , it is recommended that ecg and blood pressure be monitored .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "in a placebo-controlled trial in normal volunteers , the administration of a single # mg dose of ddrug0 on day # of a four-day regimen of oral ddrug1 { 400 mg twice daily } resulted in a 10 % increase in mean auc of ddrug2 { p = # } , and a slight but not statistically significant increase in mean cmax and mean half-life of ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as ddrug1 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain ddrug2 such as ddrug3 , the ddrug4 and other ddrug5 , ddrug6 , certain ddrug7 such as the ddrug8 salts , and ddrug9 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "avoid the use of preparations such as ddrug0 and local ddrug1 which contain any ddrug2 { e , g , , ddrug3 , ddrug4 } , since it has been reported that ddrug5 can potentiate the effects of catecholamines .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 ddrug1 may delay or reduce the absorption of concomitant oral medication such as ddrug2 , ddrug3 , ddrug4 { acidic } or ddrug5 { basic } , as well as ddrug6 ddrug7 , ddrug8 , thyroid and ddrug9 preparations , ddrug10 and ddrug11 , and ddrug12 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "ddrug0 : doses of ddrug1 { ddrug2 } # g/day have been reported to increase plasma concentration of ddrug3 by ~ 47 % , possibly by inhibiting conjugation ;",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 , or ddrug2 increased metabolic clearance of ddrug3 because of the induction of hepatic enzymes .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 is known to interact with the metabolism or renal tubular excretion of many drugs { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 agents , ddrug14 , and ddrug15 } .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug11"
            ]
        ]
    },
    {
        "text": "the response to ddrug0 may be blunted by ddrug1 and ddrug2 which cause a rise in prolactin .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug12"
            ]
        ]
    },
    {
        "text": "if ddrug0 are required during ddrug1 therapy , ddrug2 should be taken at least # hours before or after the supplement .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "if concomitant treatment with ddrug0 and an ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } is clinically warranted , appropriate observation of the patient is advised .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "data from a randomized trial of ddrug0 and ddrug1 plus or minus ddrug2 in ovarian_cancer indicated that ddrug3 significantly reduced neurotoxicity ;",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : coadministration of ddrug1 with ddrug2 resulted in an 83 % increase in ddrug3 plasma auc and a 51 % increase in ddrug4 plasma a , c.",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "concomitant use of ddrug0 and drugs that inhibit cyp3a4 { eg , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 } may increase exposure to ddrug12 and should be avoided .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 { ddrug2 , ddrug3 , ddrug4 , ddrug5 , fruit juices , etc , } lower absorption of ddrug6 .",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "therefore , concurrent use of ddrug0 with ddrug1 may render these ddrug2 less effective .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : co-administration of ddrug1 # mg b , i , d , for # days decreased the plasma concentrations of both ddrug2 { a cyp2c9 substrate } and ddrug3 { a cyp3a4 substrate } by # and 38 % , respectively .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 may increase the ototoxic potential of other drugs such as ddrug1 and some ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the concurrent use of two or more drugs with anticholinergic activity -- such as an ddrug0 { eg , ddrug1 } , an ddrug2 { eg , ddrug3 } , and/or a ddrug4 { eg , ddrug5 } -- commonly results in excessive anticholinergic effects , including dry mouth and associated dental complications , blurred vision , and , in patients exposed to high temperature and humidity , hyperpyrexia .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : the concomitant use of ddrug1 { ddrug2 transdermal system } with other ddrug3 , including but not limited to other ddrug4 , ddrug5 , ddrug6 , ddrug7 { e , g , , ddrug8 } , general ddrug9 , ddrug10 , ddrug11 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a ddrug0 , including ddrug1 , with multivalent cation-containing products such as ddrug2 or ddrug3 ddrug4 , ddrug5 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , ddrug8 , or ddrug9 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 : enhanced bone marrow suppression by ddrug1 and other ddrug2 has been reported among patients with neoplastic disease , except leukemia , in the presence of ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ddrug0 is administered in combination with other ddrug1 such as ddrug2 , ddrug3 , ddrug4 , or inhalation general ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with any of the following : - ddrug1 { e , g , , ddrug2 } { with long-term , high-dose use } or",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 may decrease serum ddrug1 concentration , especially in patients with renal dysfunction , by increasing the non-renal clearance of ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 , ddrug2 , ddrug3 , and ddrug4 have been shown to decrease plasma levels of ddrug5 ;",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "if concomitant treatment with ddrug0 and an ddrug1 is clinically warranted , appropriate observation of the patient is advised .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "caution is advised when beginning , discontinuing , or changing the dose of ddrug0 in patients receiving ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "oral doses of ddrug0 { 10-20 mg/kg } , via akr1a1 inhibition , significantly reduced the rate of elimination of ddrug1 { by approximately 40 % } given to healthy volunteers in moderate doses .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "caution should be exercised during the administration of ddrug0 to patients anaesthetised with ddrug1 as arrhythmias may be precipitated .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : some individuals receiving ddrug1 may experience a reversible enhancement of the pressor response to indirect-acting ddrug2 , ddrug3 or ddrug4 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug43"
            ]
        ]
    },
    {
        "text": "because a similar interaction is likely , ddrug0 should also not be administered concurrently with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : the effects of ddrug1 and ddrug2 on gi bleeding are synergistic , such that users of both drugs together have a risk of serious gi bleeding higher than users of either drug alone .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "in both species , ddrug0 , but not ddrug1 , antagonized the rate-decreasing effects of ddrug2 on fi and fr responding .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 { e , g , , ddrug1 , ddrug2 , ddrug3 } and ddrug4 may reduce the therapeutic effects of ddrug5 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 : the concomitant use of ddrug1 { ddrug2 transdermal system } with other ddrug3 , including but not limited to other ddrug4 , ddrug5 , ddrug6 , ddrug7 { e , g , , ddrug8 } , general ddrug9 , ddrug10 , ddrug11 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "the hypoglycemic action of ddrug0 may be potentiated by certain drugs including ddrug1 and other drugs that are highly protein bound , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , and ddrug8 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug19"
            ]
        ]
    },
    {
        "text": "it is recommended not to exceed a single # mg ddrug0 dose in a 24-hour period when used in combination with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 should not be administered concomitantly with other ddrug1 { such as ddrug2 } because of possible additive effects and increased toxicity .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "other ddrug0 { e , g , ddrug1 , ddrug2 , ddrug3 and general ddrug4 } have additive or potentiating effects with ddrug5 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "combined treatment with ddrug0 and ddrug1 enhances the degree of apoptosis assessed using morphological markers that identify chromatin and nuclear matrix protein condensation .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 potentiates other ddrug1 such as ddrug2 or ddrug3 and ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 { ddrug2 , ddrug3 , ddrug4 , ddrug5 , fruit juices , etc , } lower absorption of ddrug6 .",
        "triple_list": [
            [
                "ddrug4",
                "mechanism",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 may block the antihypertensive action of ddrug1 and similarly acting compounds .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in an emergency situation when opioid analgesia must be administered to a patient receiving ddrug0 , the amount of ddrug1 required may be greater than usual , and the resulting respiratory_failure may be deeper and more prolonged .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "administration of ddrug0 during therapy with a ddrug1 has been shown to produce a stimulating effect in some depressed patients .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in patients receiving nonselective ddrug0 { ddrug1 } { e , g , , ddrug2 } in combination with ddrug3 { e , g , , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 } , there have been reports of serious , sometimes fatal , reactions .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 may also decrease the absorption of ddrug1 , which can lead to a deficiency .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "therefore , co-administration of ddrug0 with drugs that are metabolized by cyp2d6 isoenzyme including certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } , ddrug8 { e , g , , ddrug9 , ddrug10 , ddrug11 } , ddrug12 { e , g , , ddrug13 } , and ddrug14 { e , g , , ddrug15 , ddrug16 } , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "ddrug0 : in a pharmacokinetic study , maximum plasma concentrations of ddrug1 were considerably lower in epileptic patients on long-term ddrug2 therapy { eg , ddrug3 , ddrug4 , or ddrug5 } than in healthy volunteers .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 interferes with renal tubular secretion of ddrug2 and produces an increase in the level of ddrug3 in serum .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the action of the ddrug0 may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , or other drugs that produce cns depression .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "since ddrug0 are potentiated by the ddrug1 , they should be used cautiously in the treatment of convulsions .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the action of ddrug0 is potentiated by ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 potentiates the muscle relaxant effect of all ddrug1 , most notably ddrug2 , and mac { minimum alveolar concentration } is reduced by concomitant administration of n 2o .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "coingestion of ddrug0 with ddrug1 , ddrug2 with ddrug3 , and ddrug4 with ddrug5 at high to toxic concentrations decreases the binding of the target drug .",
        "triple_list": [
            [
                "ddrug4",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 dose should not exceed a maximum of # mg in a 48 - hour period in patients receiving concomitant ddrug1 therapy .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "because ddrug0 have been shown to depress plasma prothrombin activity , patients who are on ddrug1 therapy may require downward adjustment of their ddrug2 dosage .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "inhibitors of this isoenzyme { e , g , , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , grapefruit juice , ddrug7 , ddrug8 , ddrug9 , ddrug10 } should be cautiously coadministered with ddrug11 as they can potentially increase ddrug12 levels .",
        "triple_list": [
            [
                "ddrug5",
                "advise",
                "ddrug11"
            ]
        ]
    },
    {
        "text": "poor metabolizers of ddrug0 : interactions of ddrug1 with strong inhibitors of cyp2d6 { such as ddrug2 , ddrug3 , ddrug4 , and ddrug5 } have not been studied , but these drugs would be expected to increase blood levels of the r { + } enantiomer of ddrug6 .",
        "triple_list": [
            [
                "ddrug5",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "while no in vivo drug-drug interaction studies were conducted between ddrug0 and inducers of cyp3a , compounds that are potent cytochrome_p450_family_3_subfamily_a inducers { such as ddrug1 , ddrug2 , ddrug3 , and ddrug4 } would be expected to decrease ddrug5 concentrations .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "however , the antagonism of the ddrug0 - induced anxiogenic effects by ddrug1 was only observed in the time spent in the light zone , and ddrug2 - induced anxiogenic effects were neither reversed by ddrug3 nor by ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "because ddrug0 reduces the clearance of both ddrug1 and its active metabolite , ddrug2 , there is a strong likelihood of substantial accumulation of both species during chronic co-administration .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "since ddrug0 inhibits platelet function , there is a potential for increased risk of bleeding , particularly in patients maintained on ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "although there are no study data to evaluate the possibility , ddrug0 , including ddrug1 and ddrug2 , may have an additive effect with ddrug3 on the risk of developing methemoglobinemia .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 should be used with care when ddrug1 or inhibitors of av conduction , such as certain ddrug2 { particularly of the ddrug3 -lsb- ddrug4 -rsb- and ddrug5 -lsb- ddrug6 -rsb- classes } , or ddrug7 , such as ddrug8 , are used concurrently .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 should not be taken closely in time with ddrug1 and ddrug2 containing ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "toxicology studies of ddrug0 - related deaths reveal frequent involvement of other ddrug1 , including ddrug2 , ddrug3 such as ddrug4 { ddrug5 } , and , to a rising degree , ddrug6 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "furthermore it has been proposed that ddrug0 resulted in induction of p-450iie1 in the patients liver which , in turn , resulted in a greater proportion of the ingested ddrug1 being converted to the toxic metabolites .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "co-administration : concomitant use of ddrug0 with ddrug1 , ddrug2 , and other ddrug3 may increase the risk of bleeding .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : in healthy individuals , plasma concentrations of ddrug1 increased approximately 40 % with coadministration of ddrug2 and ddrug3 , a known inhibitor of cytochrome p450 3a4 .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "plasma ddrug0 concentration should be monitored when ddrug1 and ddrug2 are co administered , and appropriate dosage adjustments of ddrug3 should be made .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "increasing the ddrug0 dose to # mg every # hours does not compensate for the increased ddrug1 metabolism due to ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "if ddrug0 is to be combined with other ddrug1 such as ddrug2 or ddrug3 / ddrug4 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of ddrug5 and ddrug6 { e , g , , ddrug7 or ddrug8 } are additive .",
        "triple_list": [
            [
                "ddrug5",
                "effect",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 may reduce or reverse the pressor effect of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "based on adult data , lower doses of ddrug0 may be needed following coadministration of drugs which are reported to decrease ddrug1 elimination { e , g , , ddrug2 and ddrug3 } and higher ddrug4 doses may be needed following coadministration of drugs that increase ddrug5 elimination { e , g , , ddrug6 and ddrug7 } .",
        "triple_list": [
            [
                "ddrug4",
                "advise",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 dosage must be determined with care in patients undergoing treatment with ddrug2 , as hypercalcemia in such patients may precipitate cardiac arrhythmias .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the antihypertensive effects of ddrug0 , ddrug1 , ddrug2 , and ddrug3 may be reduced by ddrug4 .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "combination ddrug0 may also decrease the plasma concentration of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "concomitant single dose administration of ddrug0 # mg with multiple doses of ddrug1 and ddrug2 produced a significant increase in exposure of ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 at doses of # mg bid { otc dose } resulted in a 13 % increase in ddrug1 plasma levels { 500 mcg single dose } .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 increased the auc of ddrug1 by 25 % on day # and decreased the auc of ddrug2 by 19 % on day # relative to the dosing of ddrug3 on days # through 3 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "however , a crossover study in healthy subjects receiving either ddrug0 # mg q , i , d , or # mg h , s , concomitantly with a # mg b , i , d , dosage of ddrug1 { ddrug2 , key pharmaceuticals , inc , } demonstrated less alteration in steady-state ddrug3 peak serum levels with the # mg h , s , regimen , particularly in subjects aged # years and older .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "patients taking ddrug0 when ddrug1 is given should be observed for the appearance of unsteady gait or marked changes in mental status ;",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "although in vivo studies have not been done to see if ddrug0 clearance is changed by coadministration of ddrug1 , it is not recommended that they be coadministered .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 reduce the renal clearance of ddrug1 and add a high risk of ddrug2 toxicity .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "caution should be used when administering or taking ddrug0 with ddrug1 and other strong cyp3a4 inhibitors such as , but not limited to , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { ddrug12 } , and ddrug13 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 - pectin , ddrug2 , ddrug3 , ddrug4 , certain anticancer drugs , and ddrug5 may interfere with intestinal ddrug6 absorption , resulting in unexpectedly low serum concentrations .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "certain drugs including ddrug0 , ddrug1 , ddrug2 , and ddrug3 may reduce the hypoglycemic action of ddrug4 and other oral ddrug5 .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "the concomitant use of ddrug0 with ddrug1 and ddrug2 s may have additive effects on prolonging atrioventricular conduction time .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 { eg , ddrug1 } and other drugs , including ether , ddrug2 , ddrug3 , ddrug4 and ddrug5 , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with ddrug6 parenteral .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 { 2 } , ddrug7 , ddrug8 , and ddrug9 thus , if a patient has been titrated to a stable dosage on ddrug10 , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for ddrug11 may be necessary .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "-lsb- the effect of ddrug0 on the renal excretion of ddrug1 and ddrug2 in dogs -rsb- the intravenous injection of ddrug3 in a dose of # mg/kg enhanced ddrug4 and ddrug5 excretion in chronic canine experiments .",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 are inhibited by ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : increased serum ddrug1 levels and symptoms of ddrug2 toxicity have been reported in patients receiving ddrug3 during therapy with ddrug4 .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "products containing ddrug0 and other ddrug1 likely will interfere with absorption of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "therefore , cyp3a4 substrates known to have a narrow therapeutic index such as ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , or ddrug10 { ddrug11 , ddrug12 } should be administered with caution in patients receiving ddrug13 .",
        "triple_list": [
            [
                "ddrug4",
                "advise",
                "ddrug13"
            ]
        ]
    },
    {
        "text": "the ddrug0 steady-state cmin decreased 31 % to # 1 micrograms/ml when ddrug1 { 3000 mg/day , divided into three doses } was coadministered .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in a single study , rats given high intraperitoneal doses of an ddrug0 plus ddrug1 experienced severe toxicity , including convulsions and death .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "therefore , ddrug0 should be taken at least # hour before or 4-6 hours after a ddrug1 to avoid impeding its absorption .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "concomitant use of ddrug0 with ddrug1 , ddrug2 , ddrug3 , or other ddrug4 may have an additive effect .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 may enhance the seizure risk in patients taking ddrug1",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : because ddrug1 may increase blood glucose concentrations , dosage adjustments of ddrug2 may be required .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "tablets : the ddrug0 , including ddrug1 , produce cns-depressant effects when administered with such medications as ddrug2 or ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as ddrug1 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain ddrug2 such as ddrug3 , the ddrug4 and other ddrug5 , ddrug6 , certain ddrug7 such as the ddrug8 salts , and ddrug9 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 or ddrug1 increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered ddrug2 , such as ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 including coumarin derivatives , indandione derivatives , and ddrug1 such as ddrug2 { ddrug3 } , and ddrug4 may increase the risk of bleeding when administered concomitantly with ddrug5 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "nevertheless , caution is indicated in the co-administration of ddrug0 with any of the ddrug1 and also in switching from one class to the other .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 is known to interact with the metabolism or renal tubular excretion of many drugs { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 agents , ddrug14 , and ddrug15 } .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug10"
            ]
        ]
    },
    {
        "text": "catecholamine-depleting drugs { e , g , , ddrug0 } may have an additive effect when given with ddrug1 agents .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "if signs and symptoms suggestive of ddrug0 toxicity occur when ddrug1 and ddrug2 are given concomitantly , physicians are advised to obtain serum ddrug3 levels and adjust ddrug4 doses appropriately .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the potential effects of ddrug0 and ddrug1 on potassium kinetics and renal function should be considered when these agents are administered concurrently .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "drugs that inhibit cytochrome p450iid6 , such as ddrug0 , might increase the plasma concentrations of ddrug1 in patients that are on chronic ddrug2 therapy ;",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 produced an elevation of plasma ddrug2 levels and a reduction in renal ddrug3 clearance in a study of eleven normal volunteers .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 similarly inhibit and stimulate ddrug2 - or ddrug3 - induced proliferation of prostatic epithelium .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 is known to interact with the metabolism or renal tubular excretion of many drugs { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 agents , ddrug14 , and ddrug15 } .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug14"
            ]
        ]
    },
    {
        "text": "ddrug0 should not be used concomitantly with other drugs known to prolong the qt interval : certain ddrug1 , including those of class ia { such as ddrug2 and ddrug3 } and class iii { such as ddrug4 } ;",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "additional ddrug0 significantly inhibited the absorption of ddrug1 in both dietary ddrug2 treatments .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 { eg , ddrug1 } and other drugs , including ether , ddrug2 , ddrug3 , ddrug4 and ddrug5 , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with ddrug6 parenteral .",
        "triple_list": [
            [
                "ddrug4",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "the administration of local ddrug0 containing ddrug1 or ddrug2 to patients receiving ddrug3 , ddrug4 or ddrug5 may produce severe , prolonged hypotension or hypertension .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "patients on ddrug0 therapy may require dosage adjustment of the anticoagulant during and after ddrug1 therapy .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 administration of ddrug2 or ddrug3 in patients { n = 13 } and volunteers { n = 96 } resulted in a rapid and significant decrease in plasma m1 { the active metabolite of ddrug4 } concentration .",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 : bioavailability is mildly reduced { approximately 10 % } when ddrug1 and ddrug2 are coadministered .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "thus , when ddrug0 and ddrug1 are administered concurrently , subjects should be observed carefully for signs of ddrug2 toxicity .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : disturbances of blood glucose , including hyperglycemia and hypoglycemia , have been reported in patients treated concomitantly with ddrug1 and an ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : coadministration of single doses of ddrug1 # mg and ddrug2 # mg produced additive effects on decreased alertness and impaired psychomotor performance for # to # hours after administration .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma ddrug0 concentrations include : acute ddrug1 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug12"
            ]
        ]
    },
    {
        "text": "however , there are limited in vivo data suggesting a modest cyp2d6 inhibitory effect for ddrug0 , i , e , , coadministration of ddrug1 { 20 mg/day for # days } with the ddrug2 ddrug3 { single dose of # mg } , a substrate for cyp2d6 , resulted in a 40 % increase in cmax and a 100 % increase in auc of ddrug4 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "plasma levels of several closely related ddrug0 have been reported to be increased by the concomitant administration of ddrug1 or hepatic enzyme inhibitors { e , g , , ddrug2 , ddrug3 } and decreased by the concomitant administration of hepatic enzyme inducers { e , g , , ddrug4 , ddrug5 } , and such an effect may be anticipated with ddrug6 as well .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "in patients receiving another ddrug0 in combination with ddrug1 { ddrug2 } , there have been reports of serious , sometimes fatal , reactions including hyperthermia , rigidity , myoclonus , autonomic instability with possible rapid fluctuations of vital signs , and mental status changes that include extreme agitation progressing to delirium and coma .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as ddrug1 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain ddrug2 such as ddrug3 , the ddrug4 and other ddrug5 , ddrug6 , certain ddrug7 such as the ddrug8 salts , and ddrug9 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "when ddrug0 and ddrug1 were concomitantly administered intravenously to normal volunteers , there was a 10-20 % increase in ddrug2 blood levels at some time points .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "tablets : the ddrug0 , including ddrug1 , produce cns-depressant effects when administered with such medications as ddrug2 or ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "some ddrug0 have also been shown to interfere with the metabolism of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the effect of ddrug0 on plasma ddrug1 has not been studied , but cases of increased ddrug2 plasma levels during ddrug3 therapy have been reported .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "the hypoglycemic action of ddrug0 may be potentiated by certain drugs including ddrug1 and other drugs that are highly protein bound , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , and ddrug8 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "however , in another study in healthy volunteers , the pharmacokinetics of ddrug0 were significantly altered { 29 % decrease in auc and 38 % decrease in cmax } when a 1-mg dose of ddrug1 was administered # minute after a 20-mg dose of ddrug2 nasal spray .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "use of ddrug0 with ddrug1 { e , g , , ddrug2 , ddrug3 , or ddrug4 } , ddrug5 supplements , or potassium-containing salt substitutes may lead to significant increases in serum potassium .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : when multiple doses of ddrug1 and ddrug2 were coadministered , steady-state plasma ddrug3 concentrations increased by approximately 20 % .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "in order to maintain ddrug0 levels , limit adverse experiences , and achieve the ddrug1 dose of # mg/day , a ddrug2 dose reduction of approximately 40 % was necessary for eight of these # subjects .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 may interfere with the anti-glaucoma action of ddrug1 or ddrug2 ;",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 } { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 } have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with ddrug6 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 : there have been reports of increased anticoagulant effects when ddrug1 and oral ddrug2 were used concomitantly .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "patients who begin taking ddrug0 or who increase their ddrug1 dose or any other ddrug2 while taking ddrug3 , ddrug4 , or ddrug5 may develop toxicity characteristics for these drugs .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "the ddrug0 , including ddrug1 , produce additive cns depressant effects when co-administered with other ddrug2 , ddrug3 , ddrug4 , ddrug5 , and other drugs which themselves produce cns depression .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "inhibitors of this isoenzyme { e , g , , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , grapefruit juice , ddrug7 , ddrug8 , ddrug9 , ddrug10 } should be cautiously coadministered with ddrug11 as they can potentially increase ddrug12 levels .",
        "triple_list": [
            [
                "ddrug4",
                "advise",
                "ddrug11"
            ]
        ]
    },
    {
        "text": "ddrug0 : the concomitant administration of ddrug1 with the ddrug2 ddrug3 has , on rare occasions , resulted in severe hypoglycemia .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug11"
            ]
        ]
    },
    {
        "text": "ddrug0 may partially counteract the anticoagulation effects of ddrug1 or ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "toxicology studies of ddrug0 - related deaths reveal frequent involvement of other ddrug1 , including ddrug2 , ddrug3 such as ddrug4 { ddrug5 } , and , to a rising degree , ddrug6 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "before taking ddrug0 , tell your doctor if you are taking any of the following medicines : - ddrug1 or another ddrug2 such as ddrug3 { ddrug4 } , ddrug5 { ddrug6 , others } , ddrug7 { ddrug8 } , ddrug9 { ddrug10 } , or ddrug11 { ddrug12 } ;",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as ddrug1 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain ddrug2 such as ddrug3 , the ddrug4 and other ddrug5 , ddrug6 , certain ddrug7 such as the ddrug8 salts , and ddrug9 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 { and possibly other ddrug2 } and ddrug3 may increase ddrug4 absorption in patients who inactivate ddrug5 by bacterial metabolism in the lower intestine , so that ddrug6 intoxication may result .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "drugs that induce hepatic enzymes such as ddrug0 , ddrug1 and ddrug2 may increase the clearance of ddrug3 and may require increases in ddrug4 dose to achieve the desired response .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of ddrug0 such as ddrug1 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug14"
            ]
        ]
    },
    {
        "text": "some reports have shown that the concomitant administration of ddrug0 with ddrug1 causes hypercalcemia .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "patients who begin taking ddrug0 or who increase their ddrug1 dose or any other ddrug2 while taking ddrug3 , ddrug4 , or ddrug5 may develop toxicity characteristics for these drugs .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "coingestion of ddrug0 with ddrug1 , ddrug2 with ddrug3 , and ddrug4 with ddrug5 at high to toxic concentrations decreases the binding of the target drug .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "patients receiving other ddrug0 s , general ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 or other ddrug6 { including ddrug7 } concomitantly with ddrug8 may exhibit an additive cns depression .",
        "triple_list": [
            [
                "ddrug7",
                "effect",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "coadministration of ddrug0 tablets with ddrug1 or ddrug2 has resulted in elevated plasma concentrations of the latter two drugs .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "these increases should be considered when selecting an oral ddrug0 for a woman taking ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : concomitant ddrug1 may decrease the metabolic clearance of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the effects of medicinal products with similar properties such as inotropes ddrug0 , ddrug1 , ddrug2 , ddrug3 and ddrug4 may be exacerbated by ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "although it has not been established that there is an interaction between ddrug0 and ddrug1 or other ddrug2 , caution is advised when ddrug3 is initiated in patients taking a ddrug4 or any other ddrug5 .",
        "triple_list": [
            [
                "ddrug3",
                "advise",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a ddrug0 , including ddrug1 , with multivalent cation-containing products such as ddrug2 or ddrug3 ddrug4 , ddrug5 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , ddrug8 , or ddrug9 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "elevated serum levels of ddrug0 have been reported with the concomitant use of some ddrug1 and ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "it was shown that ddrug0 antagonized evidently the antinociceptive effect of ddrug1 and their analogue .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in common with other ddrug0 , ddrug1 may reduce the efficacy of oral ddrug2",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : co-administration of ddrug1 # mg b , i , d , and ddrug2 , a potent cyp3a4 inhibitor , increased the plasma concentrations of ddrug3 by approximately 2-fold .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 may counteract the anticholinesterase effect of ddrug2 , thereby potentially aggravating myasthenia gravis .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "if ddrug0 therapy is required , ddrug1 concentrations and therapeutic effects are likely to be markedly reduced or abolished as a consequence of increased metabolism and higher clearance of ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 } : ddrug2 may decrease plasma levels of ddrug3 ;",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 { e , g , , ddrug1 , ddrug2 , ddrug3 } and ddrug4 may reduce the therapeutic effects of ddrug5 .",
        "triple_list": [
            [
                "ddrug4",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "drug interactions : ddrug0 may interact with some drugs , like ddrug1 { ddrug2 } : ddrug3 could theoretically affect ddrug4 pharmacodynamics - ddrug5 - jzqyavbxjcqsok_uhfffaoysa_n - ddrug6 : ddrug7 and ddrug8 cause additive cns depression - ddrug9 : ddrug10 increases the effect of ddrug11",
        "triple_list": [
            [
                "ddrug7",
                "effect",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "it is recommended that serum ddrug0 levels be monitored frequently if ddrug1 is administered concomitantly with ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "use lowest possible dose of ddrug0 with careful monitoring , or consider ddrug1 that are not primarily metabolized by cyp3a4 , such as ddrug2 , ddrug3 , or ddrug4 in combination with ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 alone had no effect on tyrosine phosphorylation in t24 cells , but dose-dependently inhibits the effects of ddrug1 when both are added simultaneously .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "oral ddrug0 caution should be exercised when ddrug1 are given in conjunction with ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 increase the rate of absorption of ddrug1 , while ddrug2 decreases it .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "concomitant use of ddrug0 and drugs that inhibit cyp3a4 { eg , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 } may increase exposure to ddrug12 and should be avoided .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug11"
            ]
        ]
    },
    {
        "text": "ddrug0 should not be administered concomitantly with ddrug1 , ddrug2 , ddrug3 , ddrug4 , or ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "if ddrug0 is to be combined with other ddrug1 such as ddrug2 or ddrug3 / ddrug4 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of ddrug5 and ddrug6 { e , g , , ddrug7 or ddrug8 } are additive .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "the concurrent use of ddrug0 with ddrug1 may produce paralytic ileus .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "although not studied with ddrug0 , inhibition of n-acetyltransferase may have clinically relevant consequences for drugs such as ddrug1 , ddrug2 , and ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 have been reported to decrease the tubular secretion of ddrug1 and to potentiate its toxicity .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the therapeutic efficacy of ddrug0 may be compromised in these patients when ddrug1 is discontinued .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "other potentially important drug interactions : ddrug0 : ddrug1 metabolized by hepatic oxidation { e , g , , ddrug2 , ddrug3 , ddrug4 elc , } should be used with caution because the clearance of these drugs is likely to be reduced by ddrug5 .",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 , including ddrug1 , may enhance the effects of oral ddrug2 , including ddrug3 or its derivatives or similar agents .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "when used in therapeutic doses , ddrug0 had a modest effect on the pharmacokinetics of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { intravenous and oral } , ddrug12 , ddrug13 / ddrug14 or ddrug15 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "ddrug0 tablets may alter the metabolism of ddrug1 , ddrug2 , and ddrug3 , resulting in elevated plasma concentrations of the latter drugs .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "patients receiving other ddrug0 s , general ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 or other ddrug6 { including ddrug7 } concomitantly with ddrug8 may exhibit an additive cns depression .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "the administration of local ddrug0 containing ddrug1 or ddrug2 to patients receiving ddrug3 , ddrug4 or ddrug5 may produce severe , prolonged hypotension or hypertension .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "the effects of medicinal products with similar properties such as inotropes ddrug0 , ddrug1 , ddrug2 , ddrug3 and ddrug4 may be exacerbated by ddrug5 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "concomitant administration of ddrug0 { equivalent to 145mg ddrug1 } with ddrug2 { 40 mg } once daily for # days has been shown to increase the mean cmax and auc values for ddrug3 by 36 % { range from 69 % decrease to 321 % increase } and 28 % { range from 54 % decrease to 128 % increase } , respectively , and for # - hydroxy-iso-pravastatin by 55 % { range from 32 % decrease to 314 % increase } and 39 % { range from 24 % decrease to 261 % increase } , respectively in # healthy adults .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : co-administration of ddrug1 # mg b , i , d , for # days decreased the plasma concentrations of both ddrug2 { a cyp2c9 substrate } and ddrug3 { a cyp3a4 substrate } by # and 38 % , respectively .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "however , caution should be exercised because there have been a few spontaneous reports of prolonged prothrombin times , with or without bleeding , in ddrug0 - treated patients receiving concomitant ddrug1 therapy .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 did not affect the pharmacokinetic profile of either drug , and the mechanism under lying the interference with ddrug1 s hypotensive effect is unknown .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 - or ddrug2 - containing } : concomitant administration of 300-mg ddrug3 capsules with # ml ddrug4 suspension reduces the rate { cmax } and extent { auc } of absorption by approximately 40 % .",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "since ddrug0 may reduce pulse and blood pressure , caution in using drugs such as ddrug1 { ophthalmic and systemic } , ddrug2 , and ddrug3 is advised .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 increases the metabolism of ddrug2 and some ddrug3 { ddrug4 } resulting in decreased contraceptive effectiveness and increased menstrual irregularities .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 } : the concomitant administration of a ddrug2 with a ddrug3 may increase the risks of cns stimulation and convulsions .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 may enhance the effects of ddrug1 , ddrug2 , ddrug3 , and other ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with the ddrug1 preparation causing a gritty substance to form or may interact with the preservative in the ddrug2 preparation causing a toxic effect in the eye .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may increase the effects of other ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "on the contrary , ddrug0 and ddrug1 were agonists in induction of analgesia .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "it may be necessary to adjust the dosage of oral ddrug0 upon beginning or stopping ddrug1 , since ddrug2 may prolong prothrombin time .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "drugs that may have their plasma concentration altered by ddrug0 ddrug1 increases the mean cmax and auc of ddrug2 { cyp3a4 substrate } 2 - and # - fold , respectively , suggesting an inhibition of the cyp3a4 by ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma ddrug0 concentrations include : acute ddrug1 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 should be used cautiously in conjunction with ddrug1 in hypoprothrombinemia .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "increased nephrotoxicity has been reported following concomitant administration of ddrug0 and ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 - concomitant use of ddrug1 and ddrug2 may ameliorate increased intestinal permeability caused by ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "in vitro studies have shown that the metabolism of ddrug0 may be modified by the concomitant administration of compounds that induce , inhibit , or are metabolized by cytochrome p450 3a4 , such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , and ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "- drugs whose efficacy is impaired by ddrug0 include : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , oral ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "therefore , co-administration of ddrug0 with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index , including certain ddrug1 { ddrug2 -lsb- ddrug3 -rsb- , such as ddrug4 , ddrug5 , and ddrug6 } , ddrug7 and ddrug8 { e , g , , ddrug9 , ddrug10 } , should be approached with caution .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "interaction between ddrug0 and ddrug1 in the development of spontaneous motility in chick embryos .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "co-medications that induce cyp 3a4 { e , g , , ddrug0 , ddrug1 , ddrug2 , ddrug3 , or st , john s wort } may significantly decrease exposure to ddrug4 .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "in addition , drugs that are actively secreted via this route { e , g , , ddrug0 , ddrug1 and ddrug2 } should be co-administered with care as they might increase ddrug3 levels .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a ddrug0 , including ddrug1 , with multivalent cation-containing products such as ddrug2 or ddrug3 ddrug4 , ddrug5 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , ddrug8 , or ddrug9 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 { eg , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , and ddrug15 } may have elevated plasma concentrations when coadministered with ddrug16 ;",
        "triple_list": [
            [
                "ddrug15",
                "mechanism",
                "ddrug16"
            ]
        ]
    },
    {
        "text": "consequently , concomitant administration of ddrug0 with strong cyp3a4 inhibitors { e , g , , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } should be approached with caution .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "the concomitant use of ddrug0 or ddrug1 with ddrug2 is not recommended .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the potentiating action of ddrug0 must be considered when the drug is used in conjunction with ddrug1 such as ddrug2 , ddrug3 and ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 { such as ddrug1 } and ddrug2 can suppress the ddrug3 rgic renal and mesenteric vasodilation induced with low dose dopamine infusion .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "coingestion of ddrug0 with ddrug1 , ddrug2 with ddrug3 , and ddrug4 with ddrug5 at high to toxic concentrations decreases the binding of the target drug .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 can interact with ddrug1 or other ddrug2 { may potentiate the cns depressant effects of either these medications or ddrug3 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and ddrug6 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "renal clearance measurements of ddrug0 can not be made with any significant accuracy in patients receiving ddrug1 , ddrug2 , or ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "concomitant administration of ddrug0 tablets with ddrug1 may alter the metabolism of one or both of the drugs .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "nevertheless , the effects of ddrug0 on travelers receiving comedication , particularly diabetics or patients using ddrug1 , should be checked before departure .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "diminished urinary excretion of ddrug0 has been reported during the concomitant administration of ddrug1 and ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "in patients receiving nonselective ddrug0 { ddrug1 } { e , g , , ddrug2 } in combination with ddrug3 { e , g , , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 } , there have been reports of serious , sometimes fatal , reactions .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "coadministration of ddrug0 with other ddrug1 , ddrug2 , and ddrug3 may cause hypokalemia .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "co-administration of ddrug0 decreased the plasma concentrations of ddrug1 by approximately 40 % .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "seizures have been reported in patients taking another ddrug0 and the ddrug1 ddrug2 concurrently .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : clinical studies , as well as post marketing observations , have shown that ddrug1 can reduce the natriuretic effect of ddrug2 and ddrug3 in some patients .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "drugs that cause significant sustained elevation in gastric ph { ddrug0 such as ddrug1 or ddrug2 } may reduce plasma concentrations of ddrug3 and therefore potentially may reduce efficacy .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "the ddrug0 , including ddrug1 , produce additive cns depressant effects when co-administered with other ddrug2 , ddrug3 , ddrug4 , ddrug5 , and other drugs which themselves produce cns depression .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "however , # mg of ddrug0 q12h for # days increased the ddrug1 c max by 23 % and ddrug2 auc by 16 % .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "response to ddrug0 may be enhanced by ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "caution should be taken when ddrug0 is used concomitantly with medications that are predominantly metabolized by cyp2d6 and which have a narrow therapeutic window , such as ddrug1 , ddrug2 and ddrug3 { see clinical pharmacology } .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 should not be administered during ddrug3 treatment .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "products containing ddrug0 and other multivalent cations { such as ddrug1 , ddrug2 , ddrug3 } are likely to interfere with absorption of ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "these studies indicate that ddrug0 or ddrug1 co-administration enhances ddrug2 gastrointestinal absorption .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "although a dose adjustment of ddrug0 is not recommended when administered in combination with ddrug1 , close monitoring for known side effects of ddrug2 , such as liver enzyme abnormalities and hearing impairment , is warranted .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "the use of ddrug0 should be considered in place of ddrug1 or ddrug2 in patients receiving ddrug3 therapy .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "however , due to possible pharmacodynamic interactions , when co-administered with ddrug0 , a reduction in dosage of ddrug1 on the concomitant ddrug2 , ddrug3 , ddrug4 or ddrug5 may be required .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "- the action of ddrug0 and ddrug1 may be enhanced by ddrug2 or ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 { consider ddrug3 dose reduction } .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "if the two drugs are coadministered , the ddrug0 should be withdrawn several days before the gradual withdrawal of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "close supervision and careful adjustment of dosage are required when ddrug0 is administered with ddrug1 or ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 is known to raise serum ddrug1 levels .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 { e , g , ddrug1 and ddrug2 } : agents of the ddrug3 , of which ddrug4 { ddrug5 } injection , usp is a member , have been shown to interact with ddrug6 of the ddrug7 , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .",
        "triple_list": [
            [
                "ddrug5",
                "mechanism",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "the administration of local ddrug0 containing ddrug1 or ddrug2 to patients receiving ddrug3 or ddrug4 may produce severe , prolonged hypertension .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug11"
            ]
        ]
    },
    {
        "text": "also , concomitant administration of ddrug0 with products containing ddrug1 , ddrug2 containing ddrug3 , or ddrug4 { ddrug5 } chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma ddrug0 concentrations include : acute ddrug1 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug21"
            ]
        ]
    },
    {
        "text": "in vitro data suggest that ddrug0 , when compared to ddrug1 , has a less pronounced effect on the biotransformation system responsible for the metabolism of ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 have been shown to interfere with the metabolism of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : the reports that the concomitant use of ddrug1 and ddrug2 may contribute to the enhancement of ddrug3 toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "therefore concomitant administration of ddrug0 with ddrug1 is contraindicated .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 may enhance the effects of : other ddrug3 s , ddrug4 , general ddrug5 , ddrug6 such as ddrug7 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 has been reported to significantly alter the metabolism of nonsedating ddrug1 ddrug2 and ddrug3 when taken concomitantly .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "when ddrug0 was coadministered with ddrug1 , ddrug2 , or h2antagonists , reduced plasma concentrations of ddrug3 were reported .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : the auc of ddrug1 was increased about 4-fold when ddrug2 at # mg/day was coadministered with a single 200-mg dose of ddrug3 to two patients with renal impairment { clcr = 15 and # ml/min } .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "however , ddrug0 stimulated , but did not significantly inhibit , proliferation in the presence of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may also interact with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 or ddrug1 : the risk of myopathy/rhabdomyolysis is increased when either ddrug2 or ddrug3 is used concomitantly with a closely related member of the ddrug4 { see warnings , myopathy/rhabdomyolysis } .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "the drug interaction between ddrug0 and ddrug1 is not well known .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 in combination with ddrug1 enhances the manifestation of corneal lesions in rats epidural injection ddrug2 may potentiate the cns-depressive effect of ddrug3 , ddrug4 or other ddrug5 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "serum concentration of ddrug0 and ddrug1 may increase when patients take ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "using ddrug0 with ddrug1 { heart medicine } may cause hypercalcemia { too much ddrug2 in the blood } , which could increase the chance of developing an irregular heartbeat .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "concomitant administration of ddrug0 { equivalent to # mg ddrug1 } with ddrug2 { 20 mg } once daily for # days resulted in approximately 17 % decrease { range from 67 % decrease to 44 % increase } in ddrug3 auc values in # healthy males .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 should not be administered during ddrug3 treatment .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 } is also reported to affect ddrug2 concentrations adversely .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the potentiating action of ddrug0 must be considered when the drug is used in conjunction with ddrug1 such as ddrug2 , ddrug3 and ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 is known to interact with the metabolism or renal tubular excretion of many drugs { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 agents , ddrug14 , and ddrug15 } .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "when used in therapeutic doses , ddrug0 had a modest effect on the pharmacokinetics of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { intravenous and oral } , ddrug12 , ddrug13 / ddrug14 or ddrug15 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug13"
            ]
        ]
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug21"
            ]
        ]
    },
    {
        "text": "a possible interaction between ddrug0 and ddrug1 , a ddrug2 , has been reported , resulting in a potentiation of the hypoglycemic action of ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "wait # weeks after stopping ddrug0 before starting a ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "therefore , when ddrug0 and ddrug1 are used concomitantly , the patient should be observed closely to determine if the desired effect of the ddrug2 is obtained .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "intravenous ddrug0 was shown to double the bioavailability of oral ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : reports suggest that ddrug1 may diminish the antihypertensive effect of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug12"
            ]
        ]
    },
    {
        "text": "protein binding in vitro , ddrug0 interferes minimally or not at all with the protein binding of ddrug1 { 20 % decrease in binding } , ddrug2 , ddrug3 { 10 % decrease in binding } , or ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 , ddrug2 , ddrug3 } : metabolism may be inhibited by ddrug4 , increasing plasma levels of ddrug5 ;",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "blunting of the antihypertensive effect of ddrug0 by ddrug1 including ddrug2 has been reported .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "it is suggested to monitor both ddrug0 and ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 - and/or ddrug1 - containing ddrug2 , products containing ddrug3 { ddrug4 } , ddrug5 containing ddrug6 or other metal cations , or ddrug7 { ddrug8 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after ddrug9 .",
        "triple_list": [
            [
                "ddrug6",
                "advise",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "microdosed minipill ddrug0 preparations are not recommended for use with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "reports in the literature suggest that plasma levels of ddrug0 { and its active metabolite ddrug1 } may be increased when ddrug2 and ddrug3 are used in combination .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit ddrug0 binding to serum proteins or alter the concentrations of serum binding proteins : ddrug1 and related ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug16"
            ]
        ]
    },
    {
        "text": "however , when any additional drug , including ddrug0 , is added to the treatment of patients on ddrug1 therapy , the patients should be observed for alterations of the prothrombin time .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may decrease the hypotensive effect of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may increase the clearance of chronic high dose ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "therefore , ddrug0 should be administered { with food } one hour after or more than two hours before ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "- drugs that may either increase or decrease plasma ddrug0 concentrations include : ddrug1 , vaiproic acid , and ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : concomitant administration of ddrug1 and ddrug2 has been reported to result in elevated ddrug3 serum levels .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "administration of ddrug0 concomitantly with ddrug1 in five normal volunteers resulted in increased ddrug2 levels in all subjects and bioavailability of ddrug3 was increased approximately 50 % .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug22"
            ]
        ]
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the ddrug0 of drugs may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , the ddrug6 , ddrug7 and ddrug8 , ddrug9 and the ddrug10 , and by other ddrug11 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit ddrug0 binding to serum proteins or alter the concentrations of serum binding proteins : ddrug1 and related ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 are a major contributing factor to ddrug1 toxicity .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : the concomitant use of ddrug1 { ddrug2 transdermal system } with other ddrug3 , including but not limited to other ddrug4 , ddrug5 , ddrug6 , ddrug7 { e , g , , ddrug8 } , general ddrug9 , ddrug10 , ddrug11 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "- drugs with ototoxic potential : especially in the presence of impaired renal function , the use of parenterally administered ddrug0 in patients to whom ddrug1 are also being given should be avoided , except in life-threatening conditions .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "plasma levels of several closely related ddrug0 have been reported to be increased by the concomitant administration of ddrug1 or hepatic enzyme inhibitors { e , g , , ddrug2 , ddrug3 } and decreased by the concomitant administration of hepatic enzyme inducers { e , g , , ddrug4 , ddrug5 } , and such an effect may be anticipated with ddrug6 as well .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "co-administration of ddrug0 and ddrug1 resulted in markedly increased plasma concentrations of ddrug2 in animals .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "there have been reports of interactions of ddrug0 with ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 , and ddrug2 may increase plasma levels of ddrug3 , potentially resulting in adverse effects .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with ddrug1 , ddrug2 s , ddrug3 { allergy , cold , and sinus medicines } , diabetic drugs , ddrug4 , ddrug5 , ddrug6 like ddrug7 or ddrug8 , and high blood pressure medications .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "if treatment with inhibitors of cyp3a4 activity { such as ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , etc , } is indicated , reduction of the ddrug6 dose should be considered .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 : a case of severe hypoglycemia has been reported in a type ii diabetic patient maintained on ddrug1 { 1 gm/day } # days after the addition of ddrug2 { 75 mg/day } .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "co-administration of ddrug0 decreased the plasma concentrations of ddrug1 { a cyp3a4 substrate } by approximately 50 % .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "administration of ddrug0 with other cyp3a4 inhibitors { e , g , , ddrug1 # mg bid , ddrug2 # mg qd , ddrug3 # mg tid , ddrug4 # mg qd } resulted in increases in cmax of ddrug5 ranging from # - to # - fold and auc from # - to # - fold .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "co-administration : concomitant use of ddrug0 with ddrug1 , ddrug2 , and other ddrug3 may increase the risk of bleeding .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : as with some other ddrug1 , concurrent administration of ddrug2 with ddrug3 may lead to elevated serum concentrations of ddrug4 and prolongation of its elimination half-life .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 binds both ddrug2 and ddrug3 in the intestine , thus impairing absorption of these ddrug4 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "therefore , co-administration of ddrug0 with other drugs that are metabolized by this isoenzyme , including other ddrug1 , ddrug2 , ddrug3 , and ddrug4 { eg , ddrug5 , ddrug6 , and ddrug7 } , or that inhibit this enzyme { eg , ddrug8 } , should be approached with caution .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "cns-active drugs ddrug0 an additive effect on psychomotor performance was seen with coadministration of ddrug1 and ddrug2 # g/kg for up to # hours after ddrug3 administration .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "however , patients on ddrug0 may show elevations of ddrug1 concentrations after initiation of therapy with ddrug2 , which may be clinically significant in patients prone to ddrug3 toxicity .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the ddrug0 , including ddrug1 , produce additive cns depressant effects when co-administered with other ddrug2 , ddrug3 , ddrug4 , ddrug5 , and other drugs which themselves produce cns depression .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "limited data in patients receiving known enzyme inducers { ddrug0 , ddrug1 , ddrug2 } indicate only a 30 % increase in the rate of ddrug3 elimination .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 supplements , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "experience with co-administration of ddrug0 and ddrug1 in patients is limited , therefore , consideration should be given to temporarily suspending use of ddrug2 in patients receiving ddrug3 .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "the effects of medicinal products with similar properties such as inotropes ddrug0 , ddrug1 , ddrug2 , ddrug3 and ddrug4 may be exacerbated by ddrug5 .",
        "triple_list": [
            [
                "ddrug4",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 should be introduced at the lowest recommended dose in patients receiving ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 should not be administered to patients receiving ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 may decrease the effectiveness of oral ddrug1 , certain ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and ddrug7 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "thus , smaller doses of ddrug0 may be effective in the presence of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 absorption : the following agents may bind and decrease absorption of ddrug1 from the gastrointestinal tract : ddrug2 , ddrug3 resin , ddrug4 , ddrug5 , ddrug6 , soybean flour { e , g , , infant formula } , ddrug7 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the ddrug0 of drugs may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , the ddrug6 , ddrug7 and ddrug8 , ddrug9 and the ddrug10 , and by other ddrug11 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "patients receiving both ddrug0 and ddrug1 should be observed closely to determine if the desired diuretic and/or antihypertensive effect of ddrug2 is achieved .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ventricular tachycardia induced by ddrug0 was generally converted to sinus rhythm following administration of ddrug1 , ddrug2 , or ddrug3 but not after administration of ddrug4 alone or after ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 - induced hypokalemia may enhance the curariform effect of ddrug2 { e , g , , ddrug3 } .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "oral ddrug0 and other hormonalmethods of birth control should not be usedas the sole method of contraception inwomen taking ddrug1 , since nevirapinemay lower the plasma levels of thesemedications .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "drugs that reduce the number of blood platelets by causing bone marrow depression { such as ddrug0 } or drugs which inhibit platelet function { eg , ddrug1 and other ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 } may increase the bleeding tendency produced by ddrug7 without altering prothrombin time determinations .",
        "triple_list": [
            [
                "ddrug5",
                "effect",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "substances that are potent inhibitors of cyp3a4 activity { eg , ddrug0 and ddrug1 } decrease ddrug2 metabolism and increase ddrug3 plasma concentrations .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "the administration of local ddrug0 containing ddrug1 or ddrug2 to patients receiving ddrug3 , ddrug4 or ddrug5 may produce severe , prolonged hypotension or hypertension .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 should not be administered concomitantly with ddrug1 , ddrug2 , ddrug3 , ddrug4 , or ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 } and ddrug2 may interfere with the effect of each other when administered concurrently .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "however , in a study of # normal subjects , concurrent administration of ddrug0 decreased ddrug1 protein binding and increased ddrug2 plasma clearance from # l/kg/h without ddrug3 to # l/kg/h with ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : coadministration of ddrug1 { 200 mg bid } , a potent cyp3a4 inducer , with ddrug2 { 30 mg qd } resulted in an approximate 70 % decrease in cmax and auc values of both ddrug3 and its active metabolite , ddrug4 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 - induced hypokalemia may enhance the curariform effect of ddrug2 { e , g , , ddrug3 } .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "this allows ddrug0 to open air passages , increasing the effectiveness of the ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the prior administration of ddrug0 does not enhance the duration , but quickens the onset and may increase the depth , of neuromuscular block induced by ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "compounds in these categories result in a decreased efficacy of ddrug0 : ddrug1 , ddrug2 , ddrug3 , ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "on administration of oral ddrug0 , the need for ddrug1 therapy should be reviewed and the dose reduced by approximately 50 % or discontinued .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "if treatment with inhibitors of cyp3a4 activity { such as ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , etc , } is indicated , reduction of the ddrug6 dose should be considered .",
        "triple_list": [
            [
                "ddrug5",
                "advise",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 : may decrease renal tubular secretion of ddrug1 resulting in increased blood levels and/or ddrug2 toxicity .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "concurrent use of ddrug0 with oral ddrug1 may render oral ddrug2 less effective .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 should be used with care when ddrug1 or inhibitors of av conduction , such as certain ddrug2 { particularly of the ddrug3 -lsb- ddrug4 -rsb- and ddrug5 -lsb- ddrug6 -rsb- classes } , or ddrug7 , such as ddrug8 , are used concurrently .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 attenuates , but ddrug1 potentiates , the acute locomotor effects of ddrug2 ;",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : in vitro and/or in vivo data indicate that ddrug1 , ddrug2 , and oral ddrug3 markedly inhibit the metabolism of ddrug4 , which can result in an increase in plasma ddrug5 levels and prolongation of the qt interval on the ecg .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "in addition , results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance { ddrug0 , ddrug1 , ddrug2 , ddrug3 , or ddrug4 } with ddrug5 may result in clinically meaningful reductions in ddrug6 concentrations .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 , oral : co-administration of ddrug1 and ddrug2 usually results in inhibition of response to ddrug3 , although there have been some conflicting reports .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "therefore , co-administration of ddrug0 with other drugs that are metabolized by this isoenzyme , including other ddrug1 , ddrug2 , ddrug3 , and ddrug4 { eg , ddrug5 , ddrug6 , and ddrug7 } , or that inhibit this enzyme { eg , ddrug8 } , should be approached with caution .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "single doses of either ddrug0 or ddrug1 ddrug2 bind the ddrug3 and reduce its absorption from the gastrointestinal tract by up to # and # percent , respectively .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "in post-marketing experience , bleeding has been reported in patients on concomitant treatment with ddrug0 and ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the doses of ddrug0 required to antagonize the effects of ddrug1 were more than # times higher than those required to antagonize the effects of ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "nephrotoxicity has been reported following concomitant administration of ddrug0 with ddrug1 or potent ddrug2 such as ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "hypotension - patients on diuretic therapy : patients on ddrug0 , and especially those in whom diuretic therapy was recently instituted , may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma ddrug0 concentrations include : acute ddrug1 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug14"
            ]
        ]
    },
    {
        "text": "ddrug0 : when ddrug1 is administered with ddrug2 , its protein binding is reduced , although the clearance of free ddrug3 is not altered .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 potentiates other ddrug1 such as ddrug2 or ddrug3 and ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 binds both ddrug2 and ddrug3 in the intestine , thus impairing absorption of these ddrug4 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "caution is therefore advised in the coadministration of ddrug0 inhalation aerosol with other ddrug1 - containing drugs .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "therefore the , combination of ddrug0 with other ddrug1 , including ddrug2 , may also result i n similar toxicities .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : there have been rare reports of increased prothrombin time in patients taking ddrug1 to whom ddrug2 was administered .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 may increase the action of ddrug1 , ddrug2 , ddrug3 , and ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a ddrug0 , including ddrug1 , with multivalent cation-containing products such as ddrug2 or ddrug3 ddrug4 , ddrug5 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , ddrug8 , or ddrug9 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "ddrug0 : concomitant administration of ddrug1 with ddrug2 may potentiate blood-pressure - and heart-rate-lowering effects .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 caused a statistically significant increase in plasma exposures of ddrug1 and ddrug2 { 12 % and 15 % , respectively } , and in the pharmacodynamic effects { prothrombin time , measured as inr } of ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "plasma ddrug0 concentrations may need to be monitored and the dose of the ddrug1 may need to be reduced if a ddrug2 is co-administered with ddrug3 .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : since ddrug1 is a ddrug2 , it is possible that ddrug3 , such as the ddrug4 { ddrug5 , ddrug6 , ddrug7 } or ddrug8 , may diminish the effectiveness of ddrug9 .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "{ concurrent use with ddrug0 may enhance the possibility of ddrug1 toxicity associated with hypokalemia .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 ddrug2 can antagonize the in vitro antiviral activity of ddrug3 and ddrug4 against hiv .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "caution should be exercised when ddrug0 are given in conjunction with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "these studies indicate that ddrug0 or ddrug1 co-administration enhances ddrug2 gastrointestinal absorption .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : in some patients with compromised renal function who are being treated with ddrug1 , the co-administration of ddrug2 may result in a further deterioration of renal function .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "laboratory tests : the combination of ddrug0 and low-dose ddrug1 has been associated with elevations of cholesterol and triglycerides , sgot { ast } , and sgpt { alt } in some patients .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "because oral ddrug0 may interfere with the hepatic metabolism of ddrug1 , toxic levels of the ddrug2 may occur when an oral ddrug3 and ddrug4 are administered concurrently .",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "inhibitors of this isoenzyme { e , g , , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , grapefruit juice , ddrug7 , ddrug8 , ddrug9 , ddrug10 } should be cautiously coadministered with ddrug11 as they can potentially increase ddrug12 levels .",
        "triple_list": [
            [
                "ddrug7",
                "advise",
                "ddrug11"
            ]
        ]
    },
    {
        "text": "the extent to which ddrug0 - ddrug1 interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the ddrug2 involved .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 can reduce the antihypertensive effects of ddrug1 and ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the use of ddrug0 may result in additive cns depressant effects when coadministered with ddrug1 , ddrug2 , ddrug3 or other drugs that produce cns depression .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : immediate release capsules : since there have been isolated reports of patients with elevated ddrug1 levels , and there is a possible interaction between ddrug2 and ddrug3 , it is recommended that ddrug4 levels be monitored when initiating , adjusting , and discontinuing ddrug5 to avoid possible over - or under-digitalization .",
        "triple_list": [
            [
                "ddrug2",
                "int",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "it is , however , possible that concomitant use of other known ddrug0 such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 might increase the photosensitivity reaction of actinic_keratosis treated with the ddrug7 for topical solution .",
        "triple_list": [
            [
                "ddrug5",
                "effect",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 blocks dopamine receptors , thus inhibiting the central stimulant effects of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "based on clinical and pharmacokinetic results from the atac trial , ddrug0 should not be administered with ddrug1 { see clinical pharmacology drug interactions and clinical pharmacology - clinical studies - adjuvant treatment of breast_cancer in postmenopausal women subsections } .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "additive adverse effects resulting from cholinergic blockade may occur when ddrug0 is administered concomitantly with other ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 or some ddrug7 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "injection : ddrug0 injection , like other injectable ddrug1 , produces depression of the central nervous system when administered with ddrug2 , ddrug3 , ddrug4 , ddrug5 , and other ddrug6 , when ddrug7 is used concomitantly with injectable ddrug8 , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "thus , the results suggest that ddrug0 exposure of rats results in free radical-mediated tissue damage , as indicated by elevated cerebral and hepatic lipid peroxidation , which was prevented by ddrug1 and ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 has been reported to increase the plasma levels and cardiovascular effects of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 ddrug1 ddrug2 , like other ddrug3 , may inhibit the metabolism of ddrug4 and ddrug5 .",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 or ddrug1 substantially interfere with the absorption of some ddrug2 , resulting in low urine levels .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "cytochrome p-450 inducers , such as ddrug0 , ddrug1 and ddrug2 , induce ddrug3 metabolism , causing an approximately 30 % decrease in plasma ddrug4 levels .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "acid-catalyzed ethanolysis of ddrug0 in anhydrous and aqueous ddrug1 solutions .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 has a complex effect on oral ddrug1 pharmacokinetics .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit ddrug0 binding to serum proteins or alter the concentrations of serum binding proteins : ddrug1 and related ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : the concomitant use of ddrug1 { ddrug2 transdermal system } with other ddrug3 , including but not limited to other ddrug4 , ddrug5 , ddrug6 , ddrug7 { e , g , , ddrug8 } , general ddrug9 , ddrug10 , ddrug11 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug11"
            ]
        ]
    },
    {
        "text": "in rats , simultaneous ingestion of ddrug0 and ddrug1 in the diet for # weeks has been reported to cause tumors , and it has been suggested that ddrug2 may react with ddrug3 in the rat stomach to form a nitrosamine , which is tumorigenic .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 should be used with caution in patients taking ddrug1 , and renal function should be carefully monitored .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "data from in vitro studies of ddrug0 other than ddrug1 suggest a possible drug interaction for the following : ddrug2 , ddrug3 , ddrug4 , ddrug5 , and ddrug6 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "because of ddrug0 s tendency to cause renal impairment , the use of ddrug1 should be avoided in combination with potentially nephrotoxic drugs such as ddrug2 , ddrug3 and intravenous ddrug4 unless the potential benefits outweigh the risks to the patient .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as ddrug1 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain ddrug2 such as ddrug3 , the ddrug4 and other ddrug5 , ddrug6 , certain ddrug7 such as the ddrug8 salts , and ddrug9 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "ddrug0 ddrug1 may delay or reduce the absorption of concomitant oral medication such as ddrug2 , ddrug3 , ddrug4 { acidic } or ddrug5 { basic } , as well as ddrug6 ddrug7 , ddrug8 , thyroid and ddrug9 preparations , ddrug10 and ddrug11 , and ddrug12 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "concomitant use of prostaglandin synthase inhibiting drugs , eg , ddrug0 , may decrease the hypotensive effects of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 reversible increases in serum ddrug1 concentrations and toxicity have been reported during concomitant administration of ddrug2 with ddrug3 , and with some ddrug4 .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "while no in vivo drug-drug interaction studies were conducted between ddrug0 and inducers of cyp3a , compounds that are potent cytochrome_p450_family_3_subfamily_a inducers { such as ddrug1 , ddrug2 , ddrug3 , and ddrug4 } would be expected to decrease ddrug5 concentrations .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "plasma concentrations of ddrug0 are decreased when administered with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 : concomitant administration of low-dose ddrug1 with ddrug2 may result in an increased rate of gi ulceration or other complications , compared to use of ddrug3 alone .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "drugs that cause significant sustained elevation in gastric ph { ddrug0 such as ddrug1 or ddrug2 } may reduce plasma concentrations of ddrug3 and therefore potentially may reduce efficacy .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "because there is a theoretical basis that these effects may be additive , use of ddrug0 - containing or ddrug1 { like ddrug2 or ddrug3 } and ddrug4 within # hours is contraindicated .",
        "triple_list": [
            [
                "ddrug3",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "toxicology studies of ddrug0 - related deaths reveal frequent involvement of other ddrug1 , including ddrug2 , ddrug3 such as ddrug4 { ddrug5 } , and , to a rising degree , ddrug6 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "-lsb- the gaba-ergic system and brain edema -rsb- it has been shown in rats with experimental toxic and traumatic edemas that ddrug0 { 1 mg/kg } removes the antiedematous action of ddrug1 , ddrug2 , ddrug3 and ddrug4 and reduces the action of ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "this appears to be the only clinically relevant interaction of this kind with ddrug0 , although theoretically , coadministration of other drugs known to alter cardiac conduction { eg , ddrug1 or ddrug2 , ddrug3 , ddrug4 or ddrug5 , ddrug6 and ddrug7 } might also contribute to a prolongation of the qtc interval .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 may decrease the effect of ddrug1 , ddrug2 , and ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug11"
            ]
        ]
    },
    {
        "text": "conversely , the ddrug0 have been reported to increase the serum levels and prolong the serum half-life of ddrug1 by inhibiting its metabolism .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "milk , milk products , and ddrug0 - rich foods or drugs may impair the absorption of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 s : ddrug1 should be administered at least # hours after or # hours before dosing with ddrug2 because plasma concentrations of ddrug3 are decreased when administered with ddrug4 containing ddrug5 , ddrug6 , or ddrug7 .",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "therefore , patients without a functioning ddrug0 gland who are on thyroid replacement therapy may need to increase their thyroid dose if ddrug1 or ddrug2 - containing oral ddrug3 are given .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 { eg , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , and ddrug15 } may have elevated plasma concentrations when coadministered with ddrug16 ;",
        "triple_list": [
            [
                "ddrug6",
                "mechanism",
                "ddrug16"
            ]
        ]
    },
    {
        "text": "ddrug0 : weakness hyperreflexia , and incoordination have been reported rarely when ddrug1 have been co-administered with ddrug2 { e , g.",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : clinical studies , as well as post-marketing observations , have shown that ddrug1 can reduce the natriuretic effect of ddrug2 and ddrug3 in some patients .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the administration of other ddrug0 with ddrug1 has been shown to reduce the antihypertensive effect in some patients and result in severe hyperkalemia in patients with impaired renal function .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "because of reports of prolongation of the prothrombin time beyond the therapeutic range in patients taking concurrent ddrug0 and ddrug1 , it is suggested that the prothrombin time be monitored carefully , and the dose of ddrug2 or other ddrug3 - like drugs should be adjusted accordingly , in patients taking both drugs .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "however , the peak plasma level of ddrug0 was reduced by approximately 20 % when taking ddrug1 due to a slight delay in the absorption of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : use of ddrug1 with ddrug2 and other ddrug3 may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 blocks dopamine and norepinephrine reuptake , thus inhibiting the central stimulant effects of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "injection : ddrug0 injection , like other injectable ddrug1 , produces depression of the central nervous system when administered with ddrug2 , ddrug3 , ddrug4 , ddrug5 , and other ddrug6 , when ddrug7 is used concomitantly with injectable ddrug8 , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 has been reported to decrease the clearance of ddrug2 and , thus , may increase the pharmacologic effect of ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "tissue culture and animal studies indicate that ddrug0 can diminish or abolish the effect of ddrug1 on malignant cells # this effect on ddrug2 activity persists as long as plasma asparagine levels are suppressed .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 have been reported to increase steadystate plasma ddrug2 levels .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "discontinuation of ddrug0 in well-controlled patients receiving ddrug1 and ddrug2 may decrease the plasma levels and efficacy of the ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "however , it adversely affected response duration suggesting that ddrug0 should not be administered with ddrug1 and/or ddrug2 #",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "patients on oral ddrug0 receiving ddrug1 treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : the concomitant use of ddrug1 { ddrug2 transdermal system } with other ddrug3 , including but not limited to other ddrug4 , ddrug5 , ddrug6 , ddrug7 { e , g , , ddrug8 } , general ddrug9 , ddrug10 , ddrug11 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 use may be rarely associated with ventricular fibrillation when combined with ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "drugs which induce cyp3a4 activity { eg , ddrug0 , ddrug1 , ddrug2 } would be expected to increase the clearance of ddrug3 resulting in lowered plasma concentrations .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "a 5-mg ddrug0 dose should not be exceeded when used in combination with # mg once daily ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "a potential interaction between oral ddrug0 and oral ddrug1 leading to severe hypoglycemia has been reported .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "{ 1968 , 1970 } , the higher serum concentrations of ddrug0 and ddrug1 reached after administration of ddrug2 are due not only to slower renal elimination but also to an altered distribution in the body .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "there have been reports of ddrug0 - related side effects in patients on concomitant therapy with ddrug1 and ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 s and ddrug1 : the following adverse events were experienced more commonly in patients receiving concomitant ddrug2 or ddrug3 { n = 94 } compared to patients not receiving these concomitant drugs { n = 456 } : hypotension 10 % vs 4 % , myocardial infarction 3 % vs 1 % , serious pneumonias 5 % vs 3 % , serious falls 9 % vs 3 % , and bone and joint injuries 6 % vs 2 % .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : some ddrug1 may increase the concentration of ddrug2 in the blood .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "concomitant use of ddrug0 with ddrug1 , ddrug2 , ddrug3 , or other ddrug4 may have an additive effect .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in a similar study with ddrug0 in healthy volunteers , # of # subjects dosed with ddrug1 # mg and ddrug2 # mg separated by # hours experienced a standing systolic blood pressure below # mm hg .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "patients treated with ddrug0 plus ddrug1 should , therefore , be observed closely for evidence of marked bradycardia or hypotension which may present as vertigo , syncope/presyncope , or orthostatic changes in blood pressure without compensatory tachycardia .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "therefore , such combined treatment should be approached with caution and patients should be monitored closely when ddrug0 is combined with these drugs , particularly with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "short-term pharmacokinetic studies have demonstrated that concomitant administration of ddrug0 and ddrug1 { ddrug2 capsules and tablets } results in reduced protein binding of ddrug3 , but there was no change in the clearance of free ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "therefore , extreme caution should be exercised when administering ddrug0 to patients receiving ddrug1 or ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the effect of ddrug0 on oral ddrug1 is variable .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : in normal volunteers , a small decrease in ddrug1 levels was observed when multiple doses of ddrug2 and ddrug3 were administered concomitantly .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "in diabetic patients , the metabolic effects of ddrug0 may decrease blood glucose and therefore , ddrug1 requirements .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "some ddrug0 , including ddrug1 , have been associated with transient elevations in serum creatinine in patients receiving ddrug2 concomitantly .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 interferes with renal tubular secretion of ddrug2 and produces an increase in the level of ddrug3 in serum .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "patients should be warned of the potential danger of the intravenous self-administration of ddrug0 while under treatment with ddrug1 or ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 ddrug1 and heavy ddrug2 intake for longer than # weeks may produce malabsorption of ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "toxicology studies of ddrug0 - related deaths reveal frequent involvement of other ddrug1 , including ddrug2 , ddrug3 such as ddrug4 { ddrug5 } , and , to a rising degree , ddrug6 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "rhabdomyolysis has been observed in patients receiving ddrug0 administered alone { at recommended dosages } or concomitantly with ddrug1 including ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may decrease the effectiveness of oral ddrug1 , certain ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and ddrug7 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 , including ddrug1 , may enhance the effects of oral ddrug2 , such as ddrug3 or its derivatives .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 - ddrug1 was observed to enhance { in tissue culture } the effect of ddrug2 in reducing the number of human breast_cancer cells that were in the s phase .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "dose adjustment of ddrug0 may be required and pth and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong cyp3a4 inhibitor { e , g , , ddrug1 , ddrug2 , ddrug3 ;",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "cyclosporine , digoxin , methotrexate ddrug0 , like other ddrug1 , through effects on renal prostaglandins , may cause changes in the elimination of these drugs leading to elevated serum levels of ddrug2 , ddrug3 , ddrug4 , and increased toxicity .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "because prostaglandina play an important role in hemostasis and ddrug0 has an effect on platelet function as well , concurent therapy with ddrug1 and ddrug2 requires close monitoring of patients on both drugs .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "patients taking ddrug0 may not benefit from ddrug1 containing medicines , such as cough and cold preparations , antidiarrheal preparations , and ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "at higher than recommended doses , ddrug0 # mg administered once daily for # days increased plasma concentrations by 23 % as measured by auc0-24hr in patients receiving ddrug1 # to # mg/week for rheumatoid arthritis .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 is inhibited by ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "an intravenous injection of ddrug0 given later also produces a complete and immediately beginning depletion of ddrug1 already accumulated in the thyroid , within a period of # min after 99m-tco-4-injection with a corresponding increase in blood levels .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 has been reported to decrease the clearance of ddrug2 and , thus , may increase the pharmacologic effect of ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : when administered to patients on a ddrug1 , this parenteral ddrug2 may cause hypertension and tachycardia .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 - although not reported , ddrug2 , via its metabolism to histamine , might decrease the efficacy of ddrug3 and ddrug4 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "risk of anaphylactic reaction : although it is known that patients on ddrug0 may be refractory to ddrug1 in the treatment of anaphylactic shock , ddrug2 can , in addition , interfere with the modulation of allergic reaction and lead to an increased severity and/or frequency of attacks .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : hallucinations have been reported when ddrug1 was used in patients taking ddrug2 { ddrug3 , ddrug4 , ddrug5 } .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "immediate and extended release tablets the hypoglycemic action of ddrug0 may be potentiated by certain drugs including ddrug1 , some ddrug2 and other drugs that are highly protein bound , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may enhance the effects of ddrug1 , ddrug2 , and other ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "also , due to the potential for additive effects such as bradycardia and av block , caution is warranted in patients receiving ddrug0 with agents known to affect sinus node function or av nodal conduction { e , g , , ddrug1 , ddrug2 , and ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : caution should be used if ddrug1 is administered concomitantly with ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "therefore , the concomitant administration of ddrug0 and ddrug1 is contraindicated , and alternative ddrug2 should be considered .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "urinary alkalinizing agents { ddrug0 , some ddrug1 } increase the concentration of the non-ionized species of the ddrug2 molecule , thereby decreasing urinary excretion .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 may decrease renal tubular secretion of ddrug1 when used concurrently , resulting in increased and more prolonged ddrug2 blood levels .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "patients receiving ddrug0 and ddrug1 concomitantly should have a dose reduction of ddrug2 , to approximately 1/3 to 1/4 the usual dose .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 may enhance the effects of : other ddrug3 s , ddrug4 , general ddrug5 , ddrug6 such as ddrug7 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "therefore , concurrent use of ddrug0 and ddrug1 is not recommended .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "- ddrug0 { e , g , , ddrug1 } use of ddrug2 with ddrug3 may increase the chance of side effects affecting the liver and/or the blood",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 , such as ddrug1 , may have an additive effect when given with ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "in the presence of these ddrug0 , larger doses of ddrug1 may be required or ddrug2 may not be effective .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 { ddrug2 , ddrug3 , ddrug4 , ddrug5 , fruit juices , etc , } lower absorption of ddrug6 .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "administering ddrug0 together with ddrug1 { 100-500 microm } inhibited insp { 3 } - induced responses { both ca { 2 + } and current responses } in a dose-dependent fashion .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "when used in therapeutic doses , ddrug0 had a modest effect on the pharmacokinetics of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { intravenous and oral } , ddrug12 , ddrug13 / ddrug14 or ddrug15 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 { e , g , , ddrug1 } - taking ddrug2 and ddrug3 together may decrease the effects of ddrug4 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose ddrug0 and ddrug1 , specifically , ddrug2 , ddrug3 , ddrug4 and ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "drugs which require a dose reduction when coadminstered with ddrug0 ddrug1 : ddrug2",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "interactions may occur between ddrug0 supplements and ddrug1 and other ddrug2 and herbs such as garlic { allium sativum } and ddrug3 { ddrug4 } .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "other potentially important drug interactions : ddrug0 : ddrug1 metabolized by hepatic oxidation { e , g , , ddrug2 , ddrug3 , ddrug4 elc , } should be used with caution because the clearance of these drugs is likely to be reduced by ddrug5 .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , certain ddrug7 , ddrug8 , ddrug9 and ddrug10 , thereby delaying elimination and increasing blood levels of these drugs .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 may inhibit both synthetic and catabolic enzymes of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 / ddrug1 : long-term suppression of gastric acid secretion by ddrug2 or ddrug3 { eg , ddrug4 and ddrug5 } is likely to reduce ddrug6 exposure .",
        "triple_list": [
            [
                "ddrug4",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 { ddrug2 } : may potentiate ddrug3 - induced hypokalemia which may predispose the patient to cardiac dysfunction .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 } { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 } have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with ddrug6 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "since ddrug0 is extensively metabolized by cyp4f3 isoenzymes , caution should be exercised when ddrug1 is coadministered with inhibitors of c , p , a , such as ddrug2 and ddrug3 or inhibitors of cyp2c19 such as ddrug4 .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "spontaneous reports of serotonin syndrome associated with co-administration of ddrug0 and ddrug1 , including ddrug2 such as ddrug3 { ddrug4 } , have been reported .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the beneficial effects on arterial thrombus formation from combined therapy with ddrug0 and ddrug1 must be weighed against an increased risk of inducing hemorrhage .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : when ddrug1 was co-administered with ddrug2 , the auc and cmax of ddrug3 were reduced by about 30 % and 50 % , respectively .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "an additive hypotensive effect has been reported with the combination of systemic ddrug0 and ddrug1 therapy .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "drug interactions : ddrug0 may interact with some drugs , like ddrug1 { ddrug2 } : ddrug3 could theoretically affect ddrug4 pharmacodynamics - ddrug5 - jzqyavbxjcqsok_uhfffaoysa_n - ddrug6 : ddrug7 and ddrug8 cause additive cns depression - ddrug9 : ddrug10 increases the effect of ddrug11",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 has been shown to have an additive cns depressant effect when given with either ddrug1 , ddrug2 , ddrug3 or ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug16"
            ]
        ]
    },
    {
        "text": "because of its primary cns effect , caution should be used when ddrug0 is taken with other ddrug1 and ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "because of its primary cns effect , caution should be used when ddrug0 is taken with other ddrug1 and ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 } : increase the metabolism of ddrug6 and/or some ddrug7 , leading to possible decrease in contraceptive effectiveness .",
        "triple_list": [
            [
                "ddrug4",
                "mechanism",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "limited data in patients receiving known enzyme inducers { ddrug0 , ddrug1 , ddrug2 } indicate only a 30 % increase in the rate of ddrug3 elimination .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 ddrug1 ddrug2 , like other ddrug3 , may inhibit the metabolism of ddrug4 and ddrug5 .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "ddrug0 and ddrug1 - ddrug2 may decrease hepatic toxicity in those with ddrug3 overdosage or in those taking ddrug4 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "total body clearance of ddrug0 was reduced by an average 22 % and 51 % when ddrug1 and ddrug2 , respectively , were added to a regimen consisting of ddrug3 , usp { modified } and ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "coadministration of ddrug0 { 40 mg bid { day 1 } and # mg qd { days 2-7 } } with ddrug1 { 10 mg ddrug2 bid } resulted in 21 % increase in ddrug3 auc0-12 and a 16 % increase in ddrug4 cmax leading to a 16 % decrease in glucose auc0-24 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "there are reports of enhanced as well as diminished effects of ddrug0 when given concurrently with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the effects of ddrug0 are antagonized by ddrug1 such as ddrug2 and ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : in the presence of ddrug1 at # mg qid { n = 12 } the mean apparent oral clearance of ddrug2 fell by 14 % and creatinine clearance fell by 10 % .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 ddrug1 may delay or reduce the absorption of concomitant oral medication such as ddrug2 , ddrug3 , ddrug4 { acidic } or ddrug5 { basic } , as well as ddrug6 ddrug7 , ddrug8 , thyroid and ddrug9 preparations , ddrug10 and ddrug11 , and ddrug12 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "if treatment with inhibitors of cyp3a4 activity { such as ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , etc , } is indicated , reduction of the ddrug6 dose should be considered .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "if concomitant treatment with ddrug0 and an ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } is clinically warranted , appropriate observation of the patient is advised .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "co-treatment with the potent cyp3a4 inhibitor ddrug0 increases ddrug1 auc by 2/3 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the effect of concomitant administration of ddrug0 and ddrug1 has been demonstrated in a placebo-controlled crossover study in normal volunteers .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 should either be temporarily discontinued or decreased by 50 % when coadministered with ddrug1 on the day of ddrug2 infusion .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 potentiates other ddrug1 such as ddrug2 or ddrug3 and ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "in addition , the beneficial effects of ddrug0 in parkinsons disease have been reported to be reversed by ddrug1 and ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "certain drugs , including ddrug0 { ddrug1 } , ddrug2 , ddrug3 , and ddrug4 may potentiate the hypoglycemic action of ddrug5 and other oral ddrug6 .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 } : ddrug2 reduced the bioavailability of ddrug3 { n = 16 } by about 20 % .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "it is , however , possible that concomitant use of other known ddrug0 such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 might increase the photosensitivity reaction of actinic_keratosis treated with the ddrug7 for topical solution .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "concomitant use of ddrug0 and drugs that inhibit cyp3a4 { eg , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 } may increase exposure to ddrug12 and should be avoided .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "additive adverse effects resulting from cholinergic blockade may occur when ddrug0 is administered concomitantly with other ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 or some ddrug7 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "if concomitant treatment with ddrug0 and an ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } is clinically warranted , appropriate observation of the patient is advised .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "when other potent parental ddrug0 , such as ddrug1 , are used in combination with ddrug2 , patients should be continuously observed for several hours for any excessive fall in blood pressure .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "immediate and extended release tablets the hypoglycemic action of ddrug0 may be potentiated by certain drugs including ddrug1 , some ddrug2 and other drugs that are highly protein bound , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "cyclosporine , digoxin , methotrexate ddrug0 , like other ddrug1 , through effects on renal prostaglandins , may cause changes in the elimination of these drugs leading to elevated serum levels of ddrug2 , ddrug3 , ddrug4 , and increased toxicity .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "in some patients , the administration of ddrug0 can reduce the diuretic , natriuretic , and antihypertensive effects of ddrug1 , ddrug2 , and ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in a comparison of ddrug0 tolerance in dogs anesthetized with ddrug1 , ddrug2 , or ddrug3 , the dosage of ddrug4 needed to cause ventricular tachycardia was significantly higher , as was the ld50 of ddrug5 , with ddrug6 or ddrug7 than with ddrug8 .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of ddrug0 such as ddrug1 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "ddrug0 may partially counteract the anticoagulation effects of ddrug1 or ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "previous studies have demonstrated a significant reduction in the oral bioavailability of ddrug0 and ddrug1 when administered concomitantly with an intravenous ddrug2 such as ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "a dose increase of ddrug0 / ddrug1 to 533/133 mg twice daily with food isrecommended in combination with ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 tablets may alter the metabolism of ddrug1 , ddrug2 , and ddrug3 , resulting in elevated plasma concentrations of the latter drugs .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "when ddrug0 is co-administered with inducers of drug clearance , such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , or ddrug5 , use of a daily dose of # mg of ddrug6 should be considered",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "concomitant administration of ddrug0 and ddrug1 is not recommended because ddrug2 is displaced from its binding sites during the concomitant administration of ddrug3 , resulting in lower plasma concentrations and peak plasma levels .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 can interact with ddrug1 or other ddrug2 { may potentiate the cns depressant effects of either these medications or ddrug3 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and ddrug6 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "other ddrug0 that inhibit prostaglandin synthesis have been shown to interfere with ddrug1 in some studies and with ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 is also expected to reduce plasma concentrations of other oral ddrug1 that are predominantly metabolized by cyp2c9 or cyp3a4 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of ddrug0 such as ddrug1 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "certain drugs , including ddrug0 { ddrug1 } , ddrug2 , ddrug3 , and ddrug4 may potentiate the hypoglycemic action of ddrug5 and other oral ddrug6 .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "combinations of ddrug0 and ddrug1 were indifferent for # strains and synergistic for # strains .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 anesthesia : severe hypotension has been reported during ddrug1 anesthesia with concomitant use of a ddrug2 and a ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "it is not known if the effects of ddrug0 are altered by concomitant medications that affect hepatic metabolism of drugs { ddrug1 , etc , } , but physicians should be alert to the possibility that a smaller initial dose and longer intervals between doses may be needed .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "however , patients with moderate to severe cardiovascular disease or those taking ddrug0 therapy are at increased risk for potentially serious cardiovascular adverse effects with ddrug1 therapy .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "pretreatment of rats with ddrug0 { 100 mg/kg , ip } or ddrug1 { 100 mg/kg per day , ig , for # days and a dose of # mg/kg on the 4th day } provided significant protection against the elevation of tbars levels in cerebral and hepatic tissues , induced by single high dose of oral ddrug2 administration within # h.",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug17"
            ]
        ]
    },
    {
        "text": "ddrug0 serum levels should be monitored and appropriate dose adjustments considered for patients given both ddrug1 and ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "additionally , ddrug0 , such as ddrug1 and ddrug2 , may antagonize the activity of ddrug3 .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "the following are examples of drugs known to inhibit the metabolism of other related ddrug0 , presumably through inhibition of cyp3a : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , and some ddrug6 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "thus , ddrug0 should not be administered concurrently with ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as ddrug0 include certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 } , ddrug10 salts , ddrug11 , local ddrug12 , ddrug13 , and ddrug14 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "apparent oral clearance and volume of distribution of ddrug0 decreased with 38 % and 45 % , respectively , when ddrug1 was given with ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "use with ddrug0 : the principal pathway for detoxification of ddrug1 is inhibited by ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the concomitant use of ddrug0 is not recommended since ddrug1 may antagonize the antibacterial effect of ddrug2 in the urinary tract .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a ddrug0 , including ddrug1 , with multivalent cation-containing products such as ddrug2 or ddrug3 ddrug4 , ddrug5 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , ddrug8 , or ddrug9 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "additive adverse effects resulting from cholinergic blockade may occur when ddrug0 is administered concomitantly with other ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 or some ddrug7 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 should not be administered with other ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "additionally , ddrug0 should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as ddrug1 , ddrug2 , and ddrug3 because of the danger of blocking cardiac contractility when systemic vascular resistance is high .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "synergism between ddrug0 { e , g , , ddrug1 } , ddrug2 , and other ddrug3 has been reported .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "in healthy subjects receiving ddrug0 { 1 gm daily } for one week , plasma ddrug1 levels increased by about 30 % and half-life increased by about 10 % .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "antagonism has been demonstrated between ddrug0 and ddrug1 in vitro .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 supplements , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "oral ddrug0 inhibits the gastrointestinal absorption of ddrug1 , oral ddrug2 , ddrug3 and ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : marked hypertension and tachycardia have been reported in association with concomitant administration of ddrug1 and ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : administration of ddrug1 # hours prior to or concurrent with oral ddrug2 was associated with a # { 114 } % increase in the steady-state auc of ddrug3 { n = 12 } .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "concomitant use of ddrug0 and drugs that inhibit cyp3a4 { eg , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 } may increase exposure to ddrug12 and should be avoided .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug10"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 is known to interact with the metabolism or renal tubular excretion of many drugs { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 agents , ddrug14 , and ddrug15 } .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 : combination ddrug1 may increase the clearance of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "because there is a theoretical basis that these effects may be additive , use of ddrug0 - containing or ddrug1 { like ddrug2 or ddrug3 } and ddrug4 within # hours of each other should be avoided .",
        "triple_list": [
            [
                "ddrug3",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "to avoid this interaction , ddrug0 or ddrug1 should be given # hour prior to dosing with ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "drugs that induce hepatic enzymes such as ddrug0 , ddrug1 and ddrug2 may increase the clearance of ddrug3 and may require increases in ddrug4 dose to achieve the desired response .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 may increase slightly the effect of ddrug1 , e , g , , ddrug2 , ddrug3 , ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma ddrug0 concentrations include : acute ddrug1 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug17"
            ]
        ]
    },
    {
        "text": "the ddrug0 , including ddrug1 , produce additive cns depressant effects when co-administered with other ddrug2 , ddrug3 , ddrug4 , ddrug5 , and other drugs which themselves produce cns depression .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 ddrug1 may delay or reduce the absorption of concomitant oral medication such as ddrug2 , ddrug3 , ddrug4 { acidic } or ddrug5 { basic } , as well as ddrug6 ddrug7 , ddrug8 , thyroid and ddrug9 preparations , ddrug10 and ddrug11 , and ddrug12 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "the hypoglycemic action of ddrug0 may be potentiated by certain drugs including ddrug1 and other drugs that are highly protein bound , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , and ddrug8 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "however , because bleeding has been reported when ddrug0 and other ddrug1 have been administered to patients on ddrug2 , the physician should be cautious when administering ddrug3 to patients on ddrug4 .",
        "triple_list": [
            [
                "ddrug3",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 { eg , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , and ddrug15 } may have elevated plasma concentrations when coadministered with ddrug16 ;",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug16"
            ]
        ]
    },
    {
        "text": "ddrug0 { ddrug1 } has been reported to produce antabuse-like side effects when given concomitantly with ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the depression of cardiac contractility , conductivity , and automaticity as well as the vascular dilation associated with ddrug0 may be potentiated by ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "drug-drug interactions given the primary cns effects of ddrug0 , caution should be used when ddrug1 is taken in combination with other ddrug2 and ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "if ddrug0 therapy is initiated in a patient currently receiving ddrug1 careful monitoring for adverse reactions is advised and downward dose adjustment may be required .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "as with other ddrug0 , it should be noted that ddrug1 may be capable of potentiating ddrug2 such as ddrug3 , ddrug4 , and ddrug5 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the concomitant administration of ddrug0 and ddrug1 resulted in the need for an unusually high maintenance dose of ddrug2 { 20 mg per day } in order to produce a therapeutic effect .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "as with some other ddrug0 , the time of onset of neuromuscular block induced by ddrug1 is lengthened and the duration of block is shortened in patients receiving ddrug2 or ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "tablets : the ddrug0 , including ddrug1 , produce cns-depressant effects when administered with such medications as ddrug2 or ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : drugs such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 and others that interfere with platelet-aggregation reactions { the main hemostatic defense of heparinized patients } may induce bleeding and should be used with caution in patients receiving ddrug8 .",
        "triple_list": [
            [
                "ddrug3",
                "effect",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "interactions with other cns agents : concurrent use of ddrug0 with all ddrug1 { eg , ddrug2 , ddrug3 , ddrug4 , other ddrug5 , general ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 and ddrug12 } may result in additive central nervous system depressant effects .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug14"
            ]
        ]
    },
    {
        "text": "concurrent use of ddrug0 with ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , and ddrug5 } may result in increased ddrug6 effects .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "it is suggested that in patients receiving ddrug0 , alternatives to ddrug1 should be used if ddrug2 therapy is needed .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "because both of these drugs have negative inotropic properties and the effects of coadministration with ddrug0 are unknown , neither ddrug1 nor ddrug2 should be administered concurrently with ddrug3 unless , in the judgment of the physician , the benefits of this combination outweigh the risks .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "- ddrug0 : ddrug1 should generally not be given with ddrug2 { such as ddrug3 } because they reduce its renal clearance and add a high risk of ddrug4 toxicity .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug34"
            ]
        ]
    },
    {
        "text": "agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 { 2 } , ddrug7 , ddrug8 , and ddrug9 thus , if a patient has been titrated to a stable dosage on ddrug10 , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for ddrug11 may be necessary .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "we conclude that the prophylactic and antidotal properties of ddrug0 seen in animals treated with ddrug1 derive from its capacity to inhibit the nad + - dependent oxidation responsible for converting ddrug2 to ddrug3 in the committed step of the toxic pathway .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "intraventricular injection of ddrug0 at doses of # to # micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular ddrug1 and ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the action of the ddrug0 may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , or other drugs that produce cns depression .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "ddrug0 plasma concentrations should be monitored when ddrug1 and ddrug2 are coadministered .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "experience with ddrug0 { ddrug1 } suggests the potential for interactions with ddrug2 and ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "however , it adversely affected response duration suggesting that ddrug0 should not be administered with ddrug1 and/or ddrug2 #",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "concurrent administration of drugs possessing nephrotoxic { e , g , , ddrug0 , ddrug1 } , myelotoxic { e , g , , ddrug2 chemotherapy } , cardiotoxic { e , g , , ddrug3 } or hepatotoxic { e , g , , ddrug4 , ddrug5 } effects with ddrug6 may increase toxicity in these organ systems .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "ddrug0 : increased serum ddrug1 levels and symptoms of ddrug2 toxicity have been reported in patients receiving ddrug3 during therapy with ddrug4 .",
        "triple_list": [
            [
                "ddrug3",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 , like other ddrug1 , has had less than additive effects with ddrug2 , presumably because both drugs lower blood pressure by inhibiting parts of the renin-angiotensin system",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "since animal studies suggest that the action of ddrug0 may be prolonged by therapy with ddrug1 , ddrug2 should be employed with caution .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 may delay intestinal absorption of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "additive cns depression may occur when ddrug0 are administered concomitantly with other ddrug1 including ddrug2 , ddrug3 , and ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "ddrug0 and foods fortified with ddrug1 concomitant administration of ddrug2 with a therapeutic ddrug3 containing # mg of elemental ddrug4 { as feso4 } or ddrug5 supplemented with # mg of elemental ddrug6 reduced extent of absorption by 80 % and 31 % , respectively .",
        "triple_list": [
            [
                "ddrug2",
                "mechanism",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "this appears to be the only clinically relevant interaction of this kind with ddrug0 , although theoretically , coadministration of other drugs known to alter cardiac conduction { eg , ddrug1 or ddrug2 , ddrug3 , ddrug4 or ddrug5 , ddrug6 and ddrug7 } might also contribute to a prolongation of the qtc interval .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug12"
            ]
        ]
    },
    {
        "text": "- drugs whose efficacy is impaired by ddrug0 include : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , oral ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "therefore , # to # hours should elapse between administration of ddrug0 and ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : based on reports of profound hypotension and loss of consciousness when ddrug1 was administered with ddrug2 , the concomitant use of ddrug3 with drugs of the ddrug4 { including , for example , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 } is contraindicated .",
        "triple_list": [
            [
                "ddrug3",
                "advise",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "- drugs that may decrease plasma ddrug0 concentrations include : ddrug1 , chronic ddrug2 abuse , ddrug3",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "- drugs whose efficacy is impaired by ddrug0 include : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , oral ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug12"
            ]
        ]
    },
    {
        "text": "ddrug0 : concomitant administration of ddrug1 containing ddrug2 or ddrug3 with ddrug4 chewable/dispersible buffered tablets or pediatric powder for oral solution may potentiate adverse events associated with the ddrug5 components .",
        "triple_list": [
            [
                "ddrug2",
                "effect",
                "ddrug4"
            ]
        ]
    },
    {
        "text": "in patients receiving nonselective ddrug0 { ddrug1 } { e , g , , ddrug2 } in combination with ddrug3 { e , g , , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 } , there have been reports of serious , sometimes fatal , reactions .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug6"
            ]
        ]
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma ddrug0 concentrations include : acute ddrug1 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "ddrug0 : based on reports of profound hypotension and loss of consciousness when ddrug1 was administered with ddrug2 , the concomitant use of ddrug3 with drugs of the ddrug4 { including , for example , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 } is contraindicated .",
        "triple_list": [
            [
                "ddrug3",
                "advise",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "ddrug0 may enhance the toxicity of ddrug1 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "elevated serum levels of ddrug0 have been reported with concomitant use of ddrug1 with ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 : experience in over # patients in a non-comparative clinical trial has shown that concomitant administration of ddrug1 and ddrug2 is usually well tolerated , but there have been occasional literature reports suggesting that the combination may increase the likelihood of congestive heart failure , severe hypotension or exacerbation of angina .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "the plasma concentration of ddrug0 has been reported to be increased by the concomitant administration of ddrug1 ;",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 are all metabolized by the cytochrome p450iiia4 isozyme , and it has been demonstrated that ddrug3 , a potent inhibitor of iiia4 , blocks the metabolism of these drugs , resulting in increased plasma concentrations of parent drug .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "however , because some ddrug0 have been reported to enhance the anticoagulant effects of ddrug1 or its derivatives in patients , the prothrombin time or other suitable coagulation test should be closely monitored if a ddrug2 is administered concomitantly with ddrug3 or its derivatives .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 may enhance the effects of : other ddrug3 s , ddrug4 , general ddrug5 , ddrug6 such as ddrug7 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug9"
            ]
        ]
    },
    {
        "text": "the extent to which ddrug0 - ddrug1 interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the ddrug2 involved .",
        "triple_list": [
            [
                "ddrug0",
                "int",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : an increased risk of hepatitis has been reported to result from combined use of ddrug1 and ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "it would be expected that ddrug0 use during therapy with ddrug1 would worsen the incidence or severity of diarrhea , but this has not been studied .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "in patients receiving nonselective ddrug0 { ddrug1 } { e , g , , ddrug2 } in combination with ddrug3 { e , g , , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 } , there have been reports of serious , sometimes fatal , reactions .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug7"
            ]
        ]
    },
    {
        "text": "ddrug0 : combination ddrug1 may increase or decrease the effects of ddrug2 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 may potentiate the adverse effects of other ddrug1 administered concomitantly .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 may raise serum ddrug2 levels in some individuals .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 ddrug1 and heavy ddrug2 intake for longer than # weeks may produce malabsorption of ddrug3 .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "ddrug0 : ddrug1 - containing preparations { eg , ddrug2 } may cause hypermagnesemia and should therefore not be taken during therapy with ddrug3 by patients on chronic renal dialysis .",
        "triple_list": [
            [
                "ddrug1",
                "advise",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug8"
            ]
        ]
    },
    {
        "text": "ddrug0 may interact with ddrug1 or other ddrug2 , causing increased sedative effects .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "pharmacokinetic studies have demonstrated that ddrug0 and ddrug1 significantly increased the systemic exposure of ddrug2 and/or its major metabolites .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "a rare , but serious , constellation of symptoms , termed serotonin syndrome , has been reported with the concomitant use of ddrug0 { ddrug1 } and agents for migraine therapy , such as ddrug2 { ddrug3 } and ddrug4 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 { eg , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , and ddrug15 } may have elevated plasma concentrations when coadministered with ddrug16 ;",
        "triple_list": [
            [
                "ddrug8",
                "mechanism",
                "ddrug16"
            ]
        ]
    },
    {
        "text": "although the interaction between ddrug0 and other potent cyp3a4 inhibitors { e , g , , ddrug1 , ddrug2 , and ddrug3 } has not been studied , increased exposures to ddrug4 may be expected when ddrug5 is used concomitantly with these medications .",
        "triple_list": [
            [
                "ddrug2",
                "advise",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "on the basis of the metabolism of ddrug0 by cytochrome p450 3a4 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , grapefruit juice , and other inhibitors of cyp3a4 would be expected to lead to an increase in plasma ddrug5 concentrations .",
        "triple_list": [
            [
                "ddrug1",
                "mechanism",
                "ddrug5"
            ]
        ]
    },
    {
        "text": "care should be taken if ddrug0 is used concomitantly with ddrug1 s of the ddrug2 type .",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "other ddrug0 that inhibit prostaglandin synthesis have been shown to interfere with ddrug1 in some studies and with ddrug2 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "when ddrug0 is co-administered with inducers of drug clearance , such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , or ddrug5 , use of a daily dose of # mg of ddrug6 should be considered",
        "triple_list": [
            [
                "ddrug0",
                "advise",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "the hypotensive effect of ddrug0 is augmented by that of most other ddrug1 , including ddrug2 , negative inotropic agents , and inhaled ddrug3 .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug1"
            ]
        ]
    },
    {
        "text": "ddrug0 , ddrug1 , or ddrug2 increased metabolic clearance of ddrug3 because of the induction of hepatic enzymes .",
        "triple_list": [
            [
                "ddrug0",
                "mechanism",
                "ddrug3"
            ]
        ]
    },
    {
        "text": "when other potent parental ddrug0 , such as ddrug1 , are used in combination with ddrug2 , patients should be continuously observed for several hours for any excessive fall in blood pressure .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "ddrug0 altered coagulation parameters and/or bleeding have been reported in patients taking ddrug1 concomitantly with ddrug2 such as ddrug3 and ddrug4 .",
        "triple_list": [
            [
                "ddrug1",
                "effect",
                "ddrug2"
            ]
        ]
    },
    {
        "text": "this appears to be the only clinically relevant interaction of this kind with ddrug0 , although theoretically , coadministration of other drugs known to alter cardiac conduction { eg , ddrug1 or ddrug2 , ddrug3 , ddrug4 or ddrug5 , ddrug6 and ddrug7 } might also contribute to a prolongation of the qtc interval .",
        "triple_list": [
            [
                "ddrug0",
                "effect",
                "ddrug6"
            ]
        ]
    }
]